Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00001	CT_32222119	Clinical analysis of pregnant women with 2019 novel coronavirus pneumonia.	32222119		https://pubmed.ncbi.nlm.nih.gov/32222119	5	Other			20-Jan-2020	10-Feb-2020	22	No	Case report		Hubei, China	28-Mar-2020	
#00002	CT_32220650	Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study.	32220650		https://pubmed.ncbi.nlm.nih.gov/32220650	36				17-Jan-2020	01-Mar-2020	45	No	Observational cohort study	Retrospective	Zhejiang, China	25-Mar-2020	
#00003	CT_32220574	Featuring COVID-19 cases via screening symptomatic patients with epidemiologic link during flu season in a medical center of central Taiwan.	32220574		https://pubmed.ncbi.nlm.nih.gov/32220574	43	Other			20-Jan-2020	19-Feb-2020	31	No		Retrospective	Taichung, Taiwan	13-Mar-2020	
#00004	CT_32220284	Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study.	32220284		https://pubmed.ncbi.nlm.nih.gov/32220284	7	Other			01-Jan-2020	08-Feb-2020	39	No	Single-Centre study	Retrospective	Wuhan, China	24-Mar-2020	
#00005	CT_32220276	Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia	32220276		https://pubmed.ncbi.nlm.nih.gov/32220276	7	Other			04-Feb-2020	15-Feb-2020	12	No	Single-Centre study	Retrospective	Beijing, China	28-Mar-2020	
#00006	CT_32220033	Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19).	32220033		https://pubmed.ncbi.nlm.nih.gov/32220033	280	Drug(s)	Lopinavir | Ritonavir | Ribavirin	- 59 Remained in hospital. - 221 Discharged.	20-Jan-2020	20-Feb-2020	32	No		Retrospective	Jiangsu and Anhui, China	27-Mar-2020	
#00007	CT_32222986	Clinical characteristics of 54 medical staff with COVID-19: A retrospective study in a single center in Wuhan, China.	32222986		https://pubmed.ncbi.nlm.nih.gov/32222986	54	IgG | Drugs	Interferon | Thymosin | Immunoglobulin | Antimicrobial agent | Empirical Antivirals | Low dose of corticosteroid | Big dose of corticosteroid		07-Jan-2020	11-Feb-2020	36	No	Single-Centre case series	Retrospective	Wuhan, China	29-Mar-2020	
#00008	CT_32219885	Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19.	32219885		https://pubmed.ncbi.nlm.nih.gov/32219885	610	Other			02-Feb-2020	17-Feb-2020	16	No		Retrospective	Wuhan, China	26-Mar-2020	
#00009	CT_32219356	Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19).	32219356		https://pubmed.ncbi.nlm.nih.gov/32219356	187				23-Jan-2020	23-Feb-2020	32	No	Single-center case series	Retrospective	Wuhan, China	27-Mar-2020	
#00010	CT_32217835	Clinical and immunological features of severe and moderate coronavirus disease 2019.	32217835		https://pubmed.ncbi.nlm.nih.gov/32217835	21		Methylprednisolone | Empirical antibiotics | Oseltamivir | Ganciclovir					No	Observational study	Retrospective	Wuhan, China	27-Mar-2020	
#00011	CT_32217650	Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis.	32217650		https://pubmed.ncbi.nlm.nih.gov/32217650	1,590				11-Dec-2019	31-Jan-2020	52	Yes	Case study	Retrospective	China	26-Mar-2020	
#00012	CT_32217649	Clinical and CT features of early-stage patients with COVID-19: a retrospective analysis of imported cases in Shanghai, China	32217649		https://pubmed.ncbi.nlm.nih.gov/32217649	44				20-Jan-2020	30-Jan-2020	11	No		Retrospective	Shanghai, China	30-Apr-2020	
#00013	CT_32217556	Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.	32217556		https://pubmed.ncbi.nlm.nih.gov/32217556	799				13-Jan-2020	28-Feb-2020	47	No	Case series	Retrospective	Wuhan, China	26-Mar-2020	
#00014	CT_32219428	Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.	32219428		https://pubmed.ncbi.nlm.nih.gov/32219428	5	Plasma	Methylprednisolone | Empirical Antivirals	Improvement in viral load and increase in antibodies	20-Jan-2020	25-Mar-2020	66	No	Preliminary uncontrolled case series		Shenzhen, China	27-Mar-2020	
#00015	CT_32213556	Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms.	32213556		https://pubmed.ncbi.nlm.nih.gov/32213556	651	Drug(s)	Lopinavir | Interferon | Ritonavir | Arbidol | Glucocorticoids | Empirical antibiotics		17-Jan-2020	08-Feb-2020	23	No		Retrospective	Zhejiang, China	24-Mar-2020	
#00016	CT_32211963	Coronavirus disease 2019: initial chest CT findings	32211963		https://pubmed.ncbi.nlm.nih.gov/32211963	62	Other			21-Jan-2020	04-Feb-2020	15	No		Retrospective	Chongqing, China	24-Mar-2020	
#00017	CT_32211844	Analysis of Epidemiological and Clinical features in older patients with Corona Virus Disease 2019 (COVID-19) out of Wuhan.	32211844		https://pubmed.ncbi.nlm.nih.gov/32211844	788	CT | Drugs	Interferon-α | Arbidol | Lopinavir/Ritonavir	- (Age <60): 291 discharged,and 361 stayed in hospital. -(Age≥60): 31 discharged, and 105 stayed in hospital.	17-Jan-2020	12-Feb-2020	27	No		Retrospective	Zhejiang, China	25-Mar-2020	
#00018	CT_32211755	Epidemiological and Clinical Predictors of COVID-19.	32211755		https://pubmed.ncbi.nlm.nih.gov/32211755	788	Other			26-Jan-2020	16-Feb-2020	22	No	Case-control study	Retrospective	Singapore	25-Mar-2020	
#00019	CT_32209890	Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study.	32209890		https://pubmed.ncbi.nlm.nih.gov/32209890	225		Empirical Antivirals | Empirical antibiotics | Gammaglobulin (IVIG)		01-Jan-2020	21-Feb-2020	52	No		Retrospective	Wuhan, China	20-Mar-2020	
#00020	CT_32207032	Clinical Characteristics of Children with Coronavirus Disease 2019 in Hubei, China.	32207032		https://pubmed.ncbi.nlm.nih.gov/32207032	25	RT-PCR | CT | Drugs	Glucocorticoids | Arbidol | Interferon-α | Immunoglobulin | Empirical antibiotics | Lopinavir/Ritonavir | Oseltamivir		01-Feb-2020	10-Feb-2020	10	No		Retrospective	Hubei, China	4-Apr-2020	
#00021	CT_32205284	Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings.	32205284		https://pubmed.ncbi.nlm.nih.gov/32205284	573	Other			17-Jan-2020	08-Feb-2020	23	No		Retrospective	Zhejiang, China	20-Mar-2020	
#00022	CT_32205204	Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.	32205204		https://pubmed.ncbi.nlm.nih.gov/32205204	36		Hydroxychloroquine | Azithromycin	Virological clearance at day-6 post-inclusion and during the study period.				No	Open-label non-randomized clinical trial		Marseille, France	20-Mar-2020	
#00023	CT_32204756	Clinical features and chest CT findings of COVID-19 in infants and young children	32204756		https://pubmed.ncbi.nlm.nih.gov/32204756	9	Other			20-Jan-2020	10-Feb-2020	22	No		Retrospective	Guangdong, China	22-Mar-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00024	CT_32200994	High-flow nasal-oxygenation-assisted fiberoptic tracheal intubation in critically ill patients with COVID-19 pneumonia	32200994		https://pubmed.ncbi.nlm.nih.gov/32200994	60	Other						No	Randomized controlled trial	Prospective	China	19-Mar-2020	
#00025	CT_32198776	Clinical features and treatment of COVID-19 patients in northeast Chongqing.	32198776		https://pubmed.ncbi.nlm.nih.gov/32198776	135	Drug(s) | Oxygen support	Empirical antibiotics | Traditional Chinese medicine | Empirical Antivirals	- 120 Hospitalization. - 15 Discharge. - 1 Death.				No			Chongqing, China	21-Mar-2020	
#00026	CT_32193831	Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study.	32193831		https://pubmed.ncbi.nlm.nih.gov/32193831	8	Drug(s) | Oxygen support	Immunoglobulin | Empirical Antivirals | Traditional Chinese medicine | Glucocorticoids | Empirical antibiotics	- 3 patients remained in ICU. - 5 Discharged.	24-Jan-2020	24-Feb-2020	32	No	Single center's observational study		Wuhan, China	19-Mar-2020	
#00027	CT_32191587	Temporal Changes of CT Findings in 90 Patients with COVID-19 Pneumonia	32191587		https://pubmed.ncbi.nlm.nih.gov/32191587	90	Other			16-Jan-2020	17-Feb-2020	33	No	Longitudinal Study	Prospective	Wuhan, China	19-Mar-2020	
#00028	CT_32191259	Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State.	32191259		https://pubmed.ncbi.nlm.nih.gov/32191259	21							No	Case series		Washington, USA	19-Mar-2020	
#00029	CT_32203188	Functional exhaustion of antiviral lymphocytes in COVID-19 patients.	32203188		https://pubmed.ncbi.nlm.nih.gov/32203188	68	Drug(s)	Empirical antibiotics | Empirical Antivirals | Chloroquine | Interferon-α					No	Case study		Anhui, China	19-Mar-2020	
#00030	CT_32203186	Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients.	32203186		https://pubmed.ncbi.nlm.nih.gov/32203186	16							No	Case study		Kunming, China	17-Mar-2020	
#00031	CT_32200654	Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection.	32200654		https://pubmed.ncbi.nlm.nih.gov/32200654	16				28-Jan-2020	09-Feb-2020	13	No	Case study	Retrospective	Beijing, China	23-Mar-2020	
#00032	CT_32199880	Effect of gastrointestinal symptoms on patients infected with COVID-19.	32199880		https://pubmed.ncbi.nlm.nih.gov/32199880	254	Drug(s) | ECMO	Empirical Antivirals | Empirical antibiotics | Immunoglobulin | Hormones	- 46 Discharge from hospital. - 192 Staying in hospital. - 16 Death.	20-Dec-2019	09-Feb-2020	52	No			Wuhan, China	18-Mar-2020	
#00033	CT_32199493	Viral dynamics in mild and severe cases of COVID-19	32199493		https://pubmed.ncbi.nlm.nih.gov/32199493	76	Drug(s) | Oxygen support	Lopinavir/Ritonavir | Moxifloxacin		21-Jan-2020	04-Feb-2020	15	No	Observational study		Nanchang, China	19-Mar-2020	
#00034	CT_32204990	Imaging Features of Coronavirus disease 2019 (COVID-19): Evaluation on Thin-Section CT.	32204990		https://pubmed.ncbi.nlm.nih.gov/32204990	53	Other						No	Case study	Retrospective	Beijing, China	20-Mar-2020	
#00035	CT_32215618	Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study.	32215618		https://pubmed.ncbi.nlm.nih.gov/32215618	59							No	Cross-sectional study	Retrospective	Milan, Italy	26-Mar-2020	
#00036	CT_32213337	Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2	32213337		https://pubmed.ncbi.nlm.nih.gov/32213337	23	Other			22-Jan-2020	12-Feb-2020	22	No	Observational cohort study	Prospective	Hong Kong, China	23-Mar-2020	
#00037	CT_32211820	SARS-CoV-2 Transmission in Patients with Cancer at a Tertiary Care Hospital in Wuhan, China.	32211820		https://pubmed.ncbi.nlm.nih.gov/32211820	1,524				30-Dec-2019	17-Feb-2020	50	No	Cross-sectional study	Retrospective	Wuhan, China	25-Mar-2020	
#00038	CT_32211816	Association of Cardiac Injury with Mortality in Hospitalized Patients With COVID-19 in Wuhan, China.	32211816		https://pubmed.ncbi.nlm.nih.gov/32211816	416	Drug(s) | Oxygen support	Empirical antibiotics | Glucocorticoids | Empirical Antivirals | Immunoglobulin	- 319 Remained in hospital. - 40 Discharged. - 57 Died.	20-Jan-2020	10-Feb-2020	22	No	Cohort study	Retrospective	Wuhan, China	25-Mar-2020	
#00039	CT_32216893	Initial Experience of an Emergency Department in Shenzhen in Responding to the Emerging Wuhan Coronavirus Pneumonia	32216893		https://pubmed.ncbi.nlm.nih.gov/32216893	419				10-Jan-2020	03-Feb-2020	25	No	Descriptive study		Shenzhen, China	1-Apr-2020	
#00040	CT_32216863	Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China	32216863		https://pubmed.ncbi.nlm.nih.gov/32216863	714							No			China	27-Mar-2020	
#00041	CT_32222988	Review article: gastrointestinal features in COVID-19 and the possibility of fecal transmission.	32222988		https://pubmed.ncbi.nlm.nih.gov/32222988	2,023							No	Single Centre	Retrospective	Beijing, China	31-Mar-2020	
#00042	CT_32235187	A Comparative Study of Chest Computed Tomography Features in Young and Older Adults with Corona Virus Disease (COVID-19).	32235187		https://pubmed.ncbi.nlm.nih.gov/32235187	72				18-Jan-2020	03-Feb-2020	17	No	Comparative Study	Retrospective	China	31-Mar-2020	
#00043	CT_32231171	Hypertension and its severity or mortality in Coronavirus Disease 2019 (COVID-19): a pooled analysis.	32231171		https://pubmed.ncbi.nlm.nih.gov/32231171	2,893							Yes	Pooled analysis			31-Mar-2020	
#00044	CT_32229732	Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients from Wuhan, China.	32229732		https://pubmed.ncbi.nlm.nih.gov/32229732	116				14-Jan-2020	13-Feb-2020	31	No	Observational study		Wuhan, China	31-Mar-2020	
#00045	CT_32229605	Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2.	32229605		https://pubmed.ncbi.nlm.nih.gov/32229605	214	Other			18-Jan-2020	26-Feb-2020	40	No			Wuhan, China	30-Mar-2020	
#00046	CT_32244498	Impact of the COVID-19 Pandemic on Mental Health and Quality of Life among Local Residents in Liaoning Province, China: A Cross-Sectional Study	32244498		https://pubmed.ncbi.nlm.nih.gov/32244498	263							No	Cross-Sectional Study		Liaoning Province, China	31-Mar-2020	
#00047	CT_32269089	ACE-2 Expression in the Small Airway Epithelia of Smokers and COPD Patients: Implications for COVID-19	32269089		https://pubmed.ncbi.nlm.nih.gov/32269089	491							No	Cross-sectional cohort studies	Retrospective	British Columbia, Canada	8-Apr-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00048	CT_32264963	A new clinical trial to test high-dose vitamin C in patients with COVID-19	32264963		https://pubmed.ncbi.nlm.nih.gov/32264963	140	Drug(s)	IV vitamin C					No	Single-blind	Prospective		7-Apr-2020	
#00049	CT_32259403	Novel coronavirus infection in children outside of Wuhan, China.	32259403		https://pubmed.ncbi.nlm.nih.gov/32259403	9							No	Single-center study	Retrospective	Wuhan, China	7-Apr-2020	
#00050	CT_32259322	Clinical Characteristics of COVID-19 After Gynecologic Oncology Surgery in Three Women: A Retrospective Review of Medical Records.	32259322		https://pubmed.ncbi.nlm.nih.gov/32259322	3							No		Retrospective	Wuhan, China	7-Apr-2020	
#00051	CT_32259279	Maternal and Perinatal Outcomes with COVID-19: a systematic review of 108 pregnancies.	32259279		https://pubmed.ncbi.nlm.nih.gov/32259279	108							No			Malmö/Lund, Sweden	7-Apr-2020	
#00052	CT_32259132	Laboratory Parameters in Detection of COVID-19 Patients with Positive RT-PCR; a Diagnostic Accuracy Study	32259132		https://pubmed.ncbi.nlm.nih.gov/32259132	200							No	Diagnostic accuracy study	Retrospective cohort study, two groups	Tehran, Iran	4-Apr-2020	
#00053	CT_32266184	Infants Born to Mothers with a New Coronavirus (COVID-19).	32266184		https://pubmed.ncbi.nlm.nih.gov/32266184	4	Other						No	Case report		Wuhan, China	16-Mar-2020	
#00054	CT_32258207	High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019.	32258207		https://pubmed.ncbi.nlm.nih.gov/32258207	3	IVIG	Immunoglobulin	A high dose of IVIg administered at the appropriate point could successfully block the progression of the disease cascade and improve the outcome of COVID-19				No	Case report		Wuhan, China	21-Mar-2020	
#00055	CT_32257537	Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia.	32257537		https://pubmed.ncbi.nlm.nih.gov/32257537	7	Other (Intravenous MSC transplantation)		- All the symptoms disappeared in all the patients, - Oxygen saturations rose to ≥ 95% at rest, without or with oxygen uptake. - No acute infusion-related or allergic reactions were observed within two hours after transplantation. - No secondary infections were detected after treatment.				No	Pilot trial		Beijing, China	28-Feb-2020	
#00056	CT_32256547	Clinical trials on drug repositioning for COVID-19 treatment.	32256547		https://pubmed.ncbi.nlm.nih.gov/32256547		Drug(s)	Hydroxychloroquine | Chloroquine | Immunoglobulin | Remdesivir | Arbidol | Darunavir/cobicistat | Lopinavir/ritonavir | Traditional Chinese medicine + Lopinavir-ritonavir/Interferon-α | Interferon α2β | Carrimycin | Danoprevir/ritonavir + Interferon | Xiyanping | Xiyanping + Lopinavir/ritonavir | Oseltamivir/favipiravir/chloroquine | Thalidomide | Vitamin C | Methylprednisolone | Pirfenidone | Bromhexine HCl | Bevacizumab | Fingolimod					Yes				20-Mar-2020	
#00057	CT_32228222	Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension.	32228222		https://pubmed.ncbi.nlm.nih.gov/32228222	42							No	Observational study	Retrospective	Shenzhen, China	17-Mar-2020	
#00058	CT_32208917	The different clinical characteristics of corona virus disease cases between children and their families in China - the character of children with COVID-19.	32208917		https://pubmed.ncbi.nlm.nih.gov/32208917	23	Drug(s) | Others	Interferon-β (Inhaled interferon)					No	Case report	Retrospective	Jinan, China	12-Mar-2020	
#00059	CT_32134381	Lack of Vertical Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, China.	32134381		https://pubmed.ncbi.nlm.nih.gov/32134381	9							No	Descriptive study		China	17-Jun-2020	
#00060	CT_32156607	Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020.	32156607		https://pubmed.ncbi.nlm.nih.gov/32156607	4,880	Other			22-Jan-2020	14-Feb-2020	24	No		Retrospective	Renmin Hospital of Wuhan University, China	6-Mar-2020	
#00061	CT_32238024	A case of imported COVID-19 diagnosed by PCR-positive lower respiratory specimen but with PCR-negative throat swabs.	32238024		https://pubmed.ncbi.nlm.nih.gov/32238024	1	Other						No	Case report		Chiba, Japan	14-Mar-2020	
#00062	CT_32233816	Novel coronavirus in a 15-day-old neonate with clinical signs of sepsis, a case report.	32233816		https://pubmed.ncbi.nlm.nih.gov/32233816	1	Drug(s) | Oxygen therapy	Empirical antibiotics | Empirical Antivirals	The clinical course of COVID-19 in children is milder than in adults.				No	Case report		Tehran, Iran	23-Mar-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00063	CT_32125873	Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study.	32125873		https://pubmed.ncbi.nlm.nih.gov/32125873	101							No	Multicenter Study	Retrospective	Hunan, China	3-Mar-2020	
#00064	CT_32216961	Imaging manifestations and diagnostic value of chest CT of coronavirus disease 2019 (COVID-19) in the Xiaogan area.	32216961		https://pubmed.ncbi.nlm.nih.gov/32216961	114	Other						No			Hubei, China	23-Mar-2020	
#00065	CT_32107577	Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2.	32107577		https://pubmed.ncbi.nlm.nih.gov/32107577	90	Other						No		Retrospective	Guangzhou, China	28-Feb-2020	
#00066	CT_32088847	18F-FDG PET/CT findings of COVID-19: a series of four highly suspected cases.	32088847		https://pubmed.ncbi.nlm.nih.gov/32088847	4	Other						No		Retrospective	Wuhan, China	22-Feb-2020	
#00067	CT_32346491	Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study	32346491		https://pubmed.ncbi.nlm.nih.gov/32346491	56	Drug(s)	Favipiravir	The median time of viral clearance for the patients treated with FPV				No	Open-label, nonrandomized, before-after controlled study	Prospective	Shenzhen, China	18-Mar-2020	
#00068	CT_32240913	High-resolution computed tomography manifestations of COVID-19 infections in patients of different ages.	32240913		https://pubmed.ncbi.nlm.nih.gov/32240913	98	Other						No		Retrospective	Zhejiang, China	24-Mar-2020	
#00069	CT_32229322	Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT?	32229322		https://pubmed.ncbi.nlm.nih.gov/32229322	36	Other						No		Retrospective	Nanchang, China.	25-Mar-2020	
#00070	CT_32199142	Asymptomatic SARS-CoV-2 infected patients with persistent negative CT findings.	32199142		https://pubmed.ncbi.nlm.nih.gov/32199142	295				23-Jan-2020	18-Feb-2020	27	No		Retrospective	Guangzhou, China	12-Mar-2020	
#00071	CT_32193037	CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity.	32193037		https://pubmed.ncbi.nlm.nih.gov/32193037	73	Other			21-Jan-2020	03-Feb-2020	14	No		Retrospective	Anhui, China	12-Mar-2020	
#00072	CT_32091414	Chest CT Findings in Patients With Coronavirus Disease 2019 and Its Relationship With Clinical Features.	32091414		https://pubmed.ncbi.nlm.nih.gov/32091414	80	Other			01-Jan-2020	01-Feb-2020	32	No		Retrospective	Chongqing, China	21-Feb-2020	
#00073	CT_32171869	Clinical progression of patients with COVID-19 in Shanghai, China.	32171869		https://pubmed.ncbi.nlm.nih.gov/32171869	249	Drug(s)	Lopinavir/ritonavir | Arbidol	- 215 Discharged. - 13 Hospitalization. - 16 Still in ICU. - 19 In a stable condition. - 2 Died.	20-Jan-2020	06-Feb-2020	18	No	Single-center	Retrospective	Shanghai, China	19-Mar-2020	
#00074	CT_32171867	Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation.	32171867		https://pubmed.ncbi.nlm.nih.gov/32171867	55	Others | Drug(s)	Glucocorticoids | Empirical antibiotics | Empirical Antivirals		08-Jan-2020	10-Feb-2020	34	No		Retrospective	Wuhan, China	20-Mar-2020	
#00075	CT_32171865	Clinical and CT imaging features of the COVID-19 pneumonia: Focus on pregnant women and children.	32171865		https://pubmed.ncbi.nlm.nih.gov/32171865	59	Other			27-Jan-2020	14-Feb-2020	19	No		Retrospective	Hubei, China	21-Mar-2020	
#00076	CT_32174054	Evolution of Computed Tomography Manifestations in Five Patients Who Recovered from Coronavirus Disease 2019 (COVID-19) Pneumonia.	32174054		https://pubmed.ncbi.nlm.nih.gov/32174054	5	Drug(s) | Oxygen therapy | others	Glucocorticoids | Immunoglobulin | Empirical antibiotics | Interferon α2β | Traditional Chinese medicine | Arbidol | Lopinavir/ritonavir		17-Jan-2020	29-Jan-2020	13	No			Taizhou, China	13-Mar-2020	
#00077	CT_32146694	Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China.	32146694		https://pubmed.ncbi.nlm.nih.gov/32146694	24	Drug(s) | others	Antifungal drugs | Empirical antibiotics | Immunoglobulin | Empirical Antivirals		28-Jan-2020	09-Feb-2020	13	No		Retrospective	Nanjing, China	4-Mar-2020	
#00078	CT_32306597	Analysis of selective endoscopy results during the epidemic of coronavirus disease 2019 (COVID-19)	32306597		https://pubmed.ncbi.nlm.nih.gov/32306597	911	Other			20-Feb-2020	06-Mar-2020	16	No		Retrospective	Shanghai, China	1-Apr-2020	
#00079	CT_32336042	Evaluation of ocular symptoms and tropism of SARS-CoV-2 in patients confirmed with COVID-19.	32336042		https://pubmed.ncbi.nlm.nih.gov/32336042	56	Other						No		Retrospective	Hangzhou, Zhejiang, China	26-Apr-2020	
#00080	CT_32335900	The impact of respiratory protective equipment on difficult airway management: a randomised, crossover, simulation study.	32335900		https://pubmed.ncbi.nlm.nih.gov/32335900	25	Airtraq intubation | VL intubation | FO intubation | Direct laryngoscopy			01-Dec-2019	01-Feb-2020	63	No	Randomised, crossover, simulation study.	Prospective	London, UK	26-Apr-2020	
#00081	CT_32167524	Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China.	32167524		https://pubmed.ncbi.nlm.nih.gov/32167524	201	Drug(s)	Methylprednisolone | Empirical Antivirals | Thymosin | Immunoglobulin | Recombinant human granulocyte colony stimulating factor | Empirical antibiotics	- 84 had ARDS. - 53 ICU admission. - 44 Death.				No		Retrospective	Wuhan, China	13-Mar-2020	
#00082	CT_32335513	Incidence and clinical course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis.	32335513		https://pubmed.ncbi.nlm.nih.gov/32335513	123	Drug(s)	Hydroxychloroquine | Mycophenolate | Methotrexate | Azathioprine | Cyclosporine | Belimumab | Rituximab | Tocilizumab | Corticosteroids					No	Descriptive observational analysis			25-Apr-2020	
#00083	CT_32333544	Point-of-Care Lung Ultrasound Findings in Patients with Novel Coronavirus Disease (COVID-19) Pneumonia.	32333544		https://pubmed.ncbi.nlm.nih.gov/32333544	10				25-Mar-2020	07-Apr-2020	14	No	Observational study	Retrospective	Rhode Island, USA	24-Apr-2020	
#00084	CT_32331519	Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin.	32331519		https://pubmed.ncbi.nlm.nih.gov/32331519	1	Drug(s)	Chloroquine | Clarithromycin	The patient improved significantly and discharged and isolated at home per 14 days.				No	Case report		Colombia, Latin America	24-Apr-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00085	CT_32332072	Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine	32332072		https://pubmed.ncbi.nlm.nih.gov/32332072	17	Drug(s)	Hydroxychloroquine	- 5 Discharged. - 7 Remained in hospital. - 2 Died.	29-Mar-2020	06-Apr-2020	9	No	Observational study		France	24-Apr-2020	
#00086	CT_32330112	Asymptomatic SARS-CoV-2 Infection in Household Contacts of a Healthcare Provider, Wuhan, China.	32330112		https://pubmed.ncbi.nlm.nih.gov/32330112	5				11-Feb-2020	01-Mar-2020	20	No	Single-household observational study		Wuhan, China	24-Apr-2020	
#00087	CT_32330303	Characteristics of Patients with Coronavirus Disease (COVID-19) Confirmed using an IgM-IgG Antibody Test.	32330303		https://pubmed.ncbi.nlm.nih.gov/32330303	56	Other			15-Feb-2020	25-Feb-2020	11	No	Descriptive observational study	Retrospective	Wuhan, China	24-Apr-2020	
#00088	CT_32330291	Diagnostic accuracy of an automated chemiluminescent immunoassay for anti-SARS-CoV-2 IgM and IgG antibodies: an Italian experience.	32330291		https://pubmed.ncbi.nlm.nih.gov/32330291	61	Other						No			Florence, Italy	24-Apr-2020	
#00089	CT_32330277	Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.	32330277		https://pubmed.ncbi.nlm.nih.gov/32330277	81	Drug(s)	Chloroquine	Reduction in lethality by at least 50% in the high-dosage group compared with the low-dosage group.	23-Mar-2020	05-Apr-2020	14	No	Parallel, double-masked, randomized, phase IIb clinical trial	Retrospective	Manaus, Brazil	24-Apr-2020	
#00090	CT_32332320	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vertical Transmission in Neonates Born to Mothers With Coronavirus Disease 2019 (COVID-19) Pneumonia.	32332320		https://pubmed.ncbi.nlm.nih.gov/32332320	7	Other			20-Jan-2020	20-Feb-2020	32	No			Wuhan, China	24-Apr-2020	
#00091	CT_32329978	Retrospective study of risk factors for severe SARS-Cov-2 infections in hospitalized adult patients.	32329978		https://pubmed.ncbi.nlm.nih.gov/32329978	108	Drug(s) | Others	Empirical antibiotics | Empirical Antivirals | Immunoglobulin | Corticosteroid		31-Jan-2020	10-Mar-2020	40	No		Retrospective	Huanggang, China.	24-Apr-2020	
#00092	CT_32335053	Coronavirus disease 2019 (COVID-19) in pregnant women: A report based on 116 cases.	32335053		https://pubmed.ncbi.nlm.nih.gov/32335053	116	Drug(s) | Others	Empirical Antivirals | Empirical antibiotics | Corticosteroid	- 40 Remained in hospital. - 72 Discharged.	20-Jan-2020	24-Mar-2020	65	No		Retrospective	China	23-Apr-2020	
#00093	CT_32330304	Conjunctivitis and COVID-19: a meta-analysis.	32330304		https://pubmed.ncbi.nlm.nih.gov/32330304	1,167							Yes		1st one 30 pt. Prospective 2nd one 1099 pt. Retrospective 3rd one 38 pt. Retrospective	Roma, Italy	24-Apr-2020	
#00094	CT_32335338	Clinical analysis of ten pregnant women with COVID-19 in Wuhan, China: A retrospective study.	32335338		https://pubmed.ncbi.nlm.nih.gov/32335338	10	Other			23-Jan-2020	23-Feb-2020	32	No	Observational study	Retrospective	Wuhan, China	23-Apr-2020	
#00095	CT_32335176	Positive rectal swabs in young patients recovered from coronavirus disease 2019 (COVID-19).	32335176		https://pubmed.ncbi.nlm.nih.gov/32335176	7	Drug(s)	Arbidol | Lopinavir/ritonavir | Interferon α1β | Oseltamivir		30-Jan-2020	05-Feb-2020	7	No	Observational case study		Guangdong, China	23-Apr-2020	
#00096	CT_32335171	Clinical and epidemiological features of COVID-19 family clusters in Beijing, China.	32335171		https://pubmed.ncbi.nlm.nih.gov/32335171	24	Other						No	Observational study		Beijing, China	23-Apr-2020	
#00097	CT_32335169	Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis.	32335169		https://pubmed.ncbi.nlm.nih.gov/32335169	3,027							Yes		Retrospective studies	China	23-Apr-2020	
#00098	CT_32335168	Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients.	32335168		https://pubmed.ncbi.nlm.nih.gov/32335168	42	Other						No	Positive-negative (control) study	Retrospective	Taiwan	23-Apr-2020	
#00099	CT_32327757	Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States.	32327757		https://pubmed.ncbi.nlm.nih.gov/32327757	12	Drug(s) | Other	Remdesivir | Corticosteroids	Improvement in each patient's respiratory symptoms	01-Jan-2020	01-Feb-2020	32	No	Observational study	Retrospective	USA	23-Apr-2020	
#00100	CT_32320384	Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19.	32320384		https://pubmed.ncbi.nlm.nih.gov/32320384	8	Plasma | Drug(s)	Immunoglobulin (IVIG) | Methylprednisolone | Lopinavir/ritonavir | Interferon-α					No		Prospective	Jiangsu, China	22-Apr-2020	
#00101	CT_32323011	Characteristic CT findings distinguishing 2019 novel coronavirus disease (COVID-19) from influenza pneumonia.	32323011		https://pubmed.ncbi.nlm.nih.gov/32323011	13	Other			16-Jan-2020	25-Feb-2020	41	No		Retrospective	Shanghai, China	22-Apr-2020	
#00102	CT_32334118	Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019.	32334118		https://pubmed.ncbi.nlm.nih.gov/32334118	127				23-Jan-2020	20-Feb-2020	29	No	Observational study	Retrospective	Ningbo, China	22-Apr-2020	
#00103	CT_32320003	Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.	32320003		https://pubmed.ncbi.nlm.nih.gov/32320003	5,700				01-Mar-2020	04-Apr-2020	35	No	Descriptive study	Retrospective	New York, USA	22-Apr-2020	
#00104	CT_32335406	Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19.	32335406		https://pubmed.ncbi.nlm.nih.gov/32335406	59	Other						No		Retrospective	Qingdao, Shandong Province, China	22-Apr-2020	
#00105	CT_32317267	Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study.	32317267		https://pubmed.ncbi.nlm.nih.gov/32317267	96	Drug(s) | Other	Favipiravir | Empirical antibiotics | Lopinavir/ritonavir | Darunavir/cobicistat | Interferon-α | Arbidol | Glucocorticoids		01-Jan-2020	01-Mar-2020	61	No		Retrospective	Zhejiang, China	21 Apirl 2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00106	CT_32330593	A multinational, multicentre study on the psychological outcomes and associated physical symptoms amongst healthcare workers during COVID-19 outbreak.	32330593		https://pubmed.ncbi.nlm.nih.gov/32330593	906				19-Feb-2020	17-Apr-2020	59	No			Singapore and India	21 Apirl 2020	
#00107	CT_32315487	Clinical and Autoimmune Characteristics of Severe and Critical Cases with COVID-19.	32315487		https://pubmed.ncbi.nlm.nih.gov/32315487	21	Drug(s) | Oxygen therapy	Empirical antibiotics | Ribavirin | Hormones | Immunoglobulin (IVIG) | Arbidol					No		Retrospective	Hubei, China	21 Apirl 2020	
#00108	CT_32314805	CT imaging features of 4,121 patients with COVID-19: a meta-analysis.	32314805		https://pubmed.ncbi.nlm.nih.gov/32314805	4,121	Other						Yes		Retrospective		21 Apirl 2020	
#00109	CT_32318916	Imaging characteristics of initial chest computed tomography and clinical manifestations of patients with COVID-19 pneumonia.	32318916		https://pubmed.ncbi.nlm.nih.gov/32318916	150	Other			10-Jan-2020	12-Feb-2020	34	No		Retrospective	Wuhan, Hubei Province, China	21 Apirl 2020	
#00110	CT_32322478	Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases.	32322478		https://pubmed.ncbi.nlm.nih.gov/32322478	2	Drug(s)	Glutathione	Oral and IV glutathione as well as glutathione precursors may represent a novel treatment approach for blocking NFKappaB and addressing "cytokine storm syndrome" and respiratory distress in patients suffering with COVID 19 pneumonia.				No	Case report		New York, USA	21 Apirl 2020	
#00111	CT_32318325	The clinical data from 19 critically ill patients with coronavirus disease 2019: a single-centered, retrospective, observational study.	32318325		https://pubmed.ncbi.nlm.nih.gov/32318325	19				16-Jan-2020	20-Feb-2020	36	No	Single-centered, observational study.	Retrospective	Wuhan, China	21 Apirl 2020	
#00112	CT_32306755	Clinical and Dynamic Computed Tomography Features of 24 Patients With Coronavirus Disease 2019.	32306755		https://pubmed.ncbi.nlm.nih.gov/32306755	24	Drug(s) | Other	Empirical antibiotics | Empirical Antivirals | Treatment for interstitial fibrosis: Pirfenidone)		22-Jan-2020	05-Feb-2020	15	No		Retrospective	Dezhou, China	20-Apr-2020	
#00113	CT_32307550	Down-regulated gene expression spectrum and immune responses changed during the disease progression in COVID-19 patients.	32307550		https://pubmed.ncbi.nlm.nih.gov/32307550	11	Drug(s)	Empirical Antivirals | Glucocorticoids | Traditional Chinese medicine		31-Jan-2020	07-Feb-2020	8	No		Retrospective	Beijing, China	20-Apr-2020	
#00114	CT_32314129	A Case Series of Recurrent Viral RNA Positivity in Recovered COVID-19 Chinese Patients.	32314129		https://pubmed.ncbi.nlm.nih.gov/32314129	20	Other						No	Observational study	Prospective	Wenzhou, China	20-Apr-2020	
#00115	CT_32325129	The profile of peripheral blood lymphocyte subsets and serum cytokines in children with 2019 novel coronavirus pneumonia.	32325129		https://pubmed.ncbi.nlm.nih.gov/32325129	56	Drug(s) | Other	Immunoglobulin (IVIG) | Oseltamivir | Glucocorticoids | Interferon-α | Azithromycin					No		Retrospective	Hubei, China	20-Apr-2020	
#00116	CT_32311151	Description of COVID-19 cases along with the measures taken on prevention and control in Zhejiang, China	32311151		https://pubmed.ncbi.nlm.nih.gov/32311151	889				27-Jan-2020	03-Mar-2020	37	No		Retrospective	Zhejiang, China	20-Apr-2020	
#00117	CT_32311109	Positive result of Sars-Cov-2 in faeces and sputum from discharged patient with COVID-19 in Yiwu, China.	32311109		https://pubmed.ncbi.nlm.nih.gov/32311109	13	Other						No			Yiwu, China	20-Apr-2020	
#00118	CT_32325167	Characteristics, symptom management and outcomes of 101 patients with COVID-19 referred for hospital palliative care.	32325167		https://pubmed.ncbi.nlm.nih.gov/32325167	101				04-Mar-2020	26-Mar-2020	23	No	Case series		London, England	20-Apr-2020	
#00119	CT_32314274	Clinical Manifestation and Laboratory Characteristics of SARS-CoV-2 Infection in Pregnant Women.	32314274		https://pubmed.ncbi.nlm.nih.gov/32314274	8	Other						No		Retrospective	Wuhan, China	20-Apr-2020	
#00120	CT_32331955	Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: A meta-analysis.	32331955		https://pubmed.ncbi.nlm.nih.gov/32331955	2,389							Yes	Observational studies	Retrospective	Jakarta, Indonesia	19-Apr-2020	
#00121	CT_32327245	Early chest computed tomography to diagnose COVID-19 from suspected patients: A multicenter retrospective study.	32327245		https://pubmed.ncbi.nlm.nih.gov/32327245	130	Other						No	Multicenter study	Retrospective	Shanghai, China	19-Apr-2020	
#00122	CT_32306036	Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients.	32306036		https://pubmed.ncbi.nlm.nih.gov/32306036	56	Other			21-Jan-2020	12-Feb-2020	23	No	Preliminary study	Retrospective	Wuhan, China	19-Apr-2020	
#00123	CT_32315614	Laboratory data analysis of novel coronavirus (COVID-19) screening in 2510 patients.	32315614		https://pubmed.ncbi.nlm.nih.gov/32315614	2,510	Other						No		Retrospective	Hunan, China	18-Apr-2020	
#00124	CT_32304092	New-onset acute symptomatic seizure and risk factors in Corona Virus Disease 2019: A Retrospective Multicenter Study.	32304092		https://pubmed.ncbi.nlm.nih.gov/32304092	304				18-Jan-2020	18-Feb-2020	32	No	Multicenter study	Retrospective	Hubei, China	18-Apr-2020	
#00125	CT_32317180	Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China.	32317180		https://pubmed.ncbi.nlm.nih.gov/32317180	10	Other						No		Retrospective	Wuhan, China	18-Apr-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00126	CT_32315725	Suppressed T cell-mediated immunity in patients with COVID-19: A clinical retrospective study in Wuhan, China.	32315725		https://pubmed.ncbi.nlm.nih.gov/32315725	187	Drug(s) | Other | Oxygen therapy	Lopinavir/ritonavir | Arbidol | Immunoglobulin (IVIG) | Hormones | Interferon-α | Oseltamivir | Ribavirin	-Lower T lymphocyte subsets levels, [(<500/uL), CD3+T-cell (<200/uL), CD4+ T-cell (<100/uL), CD8+ T-cell (<100/uL) and B-cell (<50/uL)], were associated with higher risk of in-hospital death.	26-Dec-2019	01-Mar-2020	67	No	Single-center observational study	Retrospective	Wuhan, China	18-Apr-2020	
#00127	CT_32311350	COVID19 during pregnancy: a systematic review of reported cases.	32311350		https://pubmed.ncbi.nlm.nih.gov/32311350	51							No		Retrospective	Bologna, Italy	17-Apr-2020	
#00128	CT_32302265	Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19.	32302265		https://pubmed.ncbi.nlm.nih.gov/32302265	1,128	Drug(s)	ACEI/ARB	- All-cause mortality was significantly lower in ACEI/ARB group versus non-ACEI/ARB group - The incidence of septic shock and disseminated intravascular coagulation were lower in the ACEI/ARB group than the non-ACEI/ARB group	31-Dec-2019	20-Feb-2020	52	No	Multi-center study	Retrospective	Hubei, China	17-Apr-2020	
#00129	CT_32303885	Summary of 20 tracheal intubation by anesthesiologists for patients with severe COVID-19 pneumonia: retrospective case series.	32303885		https://pubmed.ncbi.nlm.nih.gov/32303885	20	Oxygen support			17-Feb-2020	19-Mar-2020	32	No	Single-center, observational case series	Retrospective	Wuhan, China	17-Apr-2020	
#00130	CT_32305487	Risk factors for severe COVID-19: Evidence from 167 hospitalized patients in Anhui, China.	32305487		https://pubmed.ncbi.nlm.nih.gov/32305487	167							No			Anhui, China	17-Apr-2020	
#00131	CT_32353762	Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study.	32353762		https://pubmed.ncbi.nlm.nih.gov/32353762	2,968	Other			19-Feb-2020	15-Apr-2020	57	No	Single center study	Retrospective	Tehran, Iran	21-Apr-2020	
#00132	CT_32318327	Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19.	32318327		https://pubmed.ncbi.nlm.nih.gov/32318327	155	Drug(s) | Oxygen therapy	Dipyridamole | Ribavirin | Glucocorticoids	All the 8 DIP-treated severely ill patients showed remarkable improvement after DIP treatment, with 87.5% discharged from the hospitals and a further 12.5% showing clinical remission.	03-Feb-2020	08-Mar-2020	35	No	Multicenter parallel randomized controlled clinical trial	Retrospective	China	20-Apr-2020	
#00133	CT_32312290	Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis.	32312290		https://pubmed.ncbi.nlm.nih.gov/32312290	100,000	Drug(s)	Tissue Plasminogen Activator (tPA)					No	Short-term randomized clinical trial		Denver, USA	20-Apr-2020	
#00134	CT_32315809	Comparison of nasopharyngeal and oropharyngeal swabs for SARS-CoV-2 detection in 353 patients received tests with both specimens simultaneously.	32315809		https://pubmed.ncbi.nlm.nih.gov/32315809	353	Other			16-Feb-2020	02-Mar-2020	16	No		Retrospective	Wuhan, China	18-Apr-2020	
#00135	CT_32301631	Lung Base Findings of Coronavirus Disease (COVID-19) on Abdominal CT in Patients With Predominant Gastrointestinal Symptoms.	32301631		https://pubmed.ncbi.nlm.nih.gov/32301631	3	Other						No		Retrospective	Chicago	17-Apr-2020	
#00136	CT_32317557	Extracorporeal Membrane Oxygenation in the Treatment of Severe Pulmonary and Cardiac Compromise in COVID-19: Experience with 32 patients.	32317557		https://pubmed.ncbi.nlm.nih.gov/32317557	32	Oxygen support			17-Mar-2020	09-Apr-2020	24	No	A real time cohort study	Prospective	USA	17-Apr-2020	
#00137	CT_32325282	Chest CT findings of COVID-19 pneumonia by duration of symptoms.	32325282		https://pubmed.ncbi.nlm.nih.gov/32325282	112	Other						No		Retrospective	Wuhan, China	18-Apr-2020	
#00138	CT_32303970	Gastrointestinal symptoms associated with severity of coronavirus disease 2019 (COVID-19): a pooled analysis.	32303970		https://pubmed.ncbi.nlm.nih.gov/32303970	1,989							Yes				17-Apr-2020	
#00139	CT_32320677	Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure	32320677		https://pubmed.ncbi.nlm.nih.gov/32320677	54							No				21-Apr-2020	
#00140	CT_32301997	Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients.	32301997		https://pubmed.ncbi.nlm.nih.gov/32301997	48	Drug(s)	Tocilizumab					No		Retrospective	Wuhan, China	17-Apr-2020	
#00141	CT_32302081	ST-Segment Elevation in Patients with Covid-19 — A Case Series	32302081		https://pubmed.ncbi.nlm.nih.gov/32302081	18	Other						No	Case series		New York, USA	17-Apr-2020	
#00142	CT_32302077	Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China.	32302077		https://pubmed.ncbi.nlm.nih.gov/32302077	118	Other			08-Dec-2019	20-Mar-2020	104	No			Wuhan, China	17-Apr-2020	
#00143	CT_32302078	Clinical Characteristics of Covid-19 in New York City.	32302078		https://pubmed.ncbi.nlm.nih.gov/32302078	393	Other			03-Mar-2020	27-Mar-2020	25	No	Case series	Retrospective	New York, USA	17-Apr-2020	
#00144	CT_32311437	Detection and analysis of nucleic acid in various biological samples of COVID-19 patients.	32311437		https://pubmed.ncbi.nlm.nih.gov/32311437	132	Other			31-Jan-2020	29-Feb-2020	30	No	Observation study		Wuhan, China	17-Apr-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
	Count >>>	1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00145	CT_32303575	Case series of coronavirus (SARS-CoV-2) in a military recruit school: clinical, sanitary and logistical implications.	32303575		https://pubmed.ncbi.nlm.nih.gov/32303575	55	Other						No	Case series	Retrospective review	Switzerland	16-Apr-2020	
#00146	CT_32301750	Assessment of immune response to SARS-CoV-2 with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays.	32301750		https://pubmed.ncbi.nlm.nih.gov/32301750	131	Other						No			Verona, Italy	16-Apr-2020	
#00147	CT_32301745	Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2)-infected pneumonia (COVID-19).	32301745		https://pubmed.ncbi.nlm.nih.gov/32301745	52	Other			07-Feb-2020	16-Feb-2020	10	No	Single-center study	Retrospective	Wuhan, China	16-Apr-2020	
#00148	CT_32301099	Clinical characteristics of COVID-19 in children compared with adults in Shandong Province, China.	32301099		https://pubmed.ncbi.nlm.nih.gov/32301099	67	Other						No		Retrospective	Shandong, China	16-Apr-2020	
#00149	CT_32297540	Association between platelet parameters and mortality in coronavirus disease 2019: Retrospective cohort study.	32297540		https://pubmed.ncbi.nlm.nih.gov/32297540	383	Other			02-Jan-2020	01-Mar-2020	60	No	Hospital-based cohort study	Retrospective	Wuhan, China	16-Apr-2020	
#00150	CT_32298251	Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020.	32298251		https://pubmed.ncbi.nlm.nih.gov/32298251	1,482				01-Mar-2020	30-Mar-2020	30	No		Retrospective case identification of patients admitted during March 1–22, 2020. And Prospective case identification during March 23–30, 2020.	USA	17-Apr-2020	
#00151	CT_32296824	A Tool to Early Predict Severe Corona Virus Disease 2019 (COVID-19) : A Multicenter Study using the Risk Nomogram in Wuhan and Guangdong, China.	32296824		https://pubmed.ncbi.nlm.nih.gov/32296824	372	Other						No	Cohort three-centers study	Retrospective	Wuhan and Guangdong, China	16-Apr-2020	
#00152	CT_32300971	A diagnostic model for coronavirus disease 2019 (COVID-19) based on radiological semantic and clinical features: a multi-center study.	32300971		https://pubmed.ncbi.nlm.nih.gov/32300971	136	Other			01-Jan-2020	08-Feb-2020	39	No	A consecutive cohort multi-center study.	Retrospective	Guangdong, China	16-Apr-2020	
#00153	CT_32297851	Positive RT-PCR tests among discharged COVID-19 patients in Shenzhen, China.	32297851		https://pubmed.ncbi.nlm.nih.gov/32297851	209	Other			23-Jan-2020	21-Feb-2020	30	No			Shenzhen, China	16-Apr-2020	
#00154	CT_32305439	Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients.	32305439		https://pubmed.ncbi.nlm.nih.gov/32305439	22							No	Multicenter case series	Retrospective	Italy	16-Apr-2020	
#00155	CT_32345579	Clinical characteristics and outcomes of patients with severe covid-19 with diabetes.	32345579		https://pubmed.ncbi.nlm.nih.gov/32345579	193	Other | Oxygen therapy			10-Jan-2020	24-Feb-2020	46	No	Single-center observational study	Retrospective	Wuhan, China	8-Apr-2020	
#00156	CT_32352401	Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States.	32352401		https://pubmed.ncbi.nlm.nih.gov/32352401	43	Other | Drug(s)	Azithromycin | Vitamin C | Hydroxychloroquine | Corticosteroid		01-Mar-2020	04-Apr-2020	35	No	Cohort study	Retrospective	USA	29-Apr-2020	
#00157	CT_32374815	Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study.	32374815		https://pubmed.ncbi.nlm.nih.gov/32374815	12	Other						No	Cohort study	Prospective	Hamburg, Germany	6-May-2020	
#00158	CT_32118639	Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients.	32118639		https://pubmed.ncbi.nlm.nih.gov/32118639	66	Other | Drug(s)	Glucocorticoids		20-Jan-2020	10-Feb-2020	22	No	Observational study	Retrospective	Shanghai, China	5-May-2020	
#00159	CT_32366299	Early recovery following new onset anosmia during the COVID-19 pandemic - an observational cohort study.	32366299		https://pubmed.ncbi.nlm.nih.gov/32366299	382							No	Observational cohort study.		Ormskirk, UK	4-May-2020	
#00160	CT_32178954	Anesthetic Management of Patients with COVID 19 Infections during Emergency Procedures.	32178954		https://pubmed.ncbi.nlm.nih.gov/32178954	37	Other			23-Jan-2020	31-Jan-2020	9	No	Multicenter clinical study.	Retrospective	Wuhan, China	28-Feb-2020	
#00161	CT_32232648	Diagnostic performance of chest CT to differentiate COVID-19 pneumonia in non-high-epidemic area in Japan.	32232648		https://pubmed.ncbi.nlm.nih.gov/32232648	21	Other			14-Feb-2020	01-Mar-2020	17	No	Cohort study	Retrospective	Wakayama, Japan	30-Mar-2020	
#00162	CT_32134205	Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults.	32134205		https://pubmed.ncbi.nlm.nih.gov/32134205	20	Other			23-Jan-2020	08-Feb-2020	17	No		Retrospective	Wuhan, China	5-Mar-2020	
#00163	CT_32354360	Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China.	32354360		https://pubmed.ncbi.nlm.nih.gov/32354360	107				01-Jan-2020	10-Feb-2020	41	No	Cohort study	Retrospective	Wuhan, China	30-Apr-2020	
#00164	CT_32360583	Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis.	32360583		https://pubmed.ncbi.nlm.nih.gov/32360583	4,941							Yes			Shanghai, China	30-Apr-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00165	CT_32345226	Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study.	32345226		https://pubmed.ncbi.nlm.nih.gov/32345226	91	Other | Drug(s)	Lopinavir/ritonavir | Empirical antibiotics | Glucocorticoids | Empirical Antivirals | Oseltamivir | Immunoglobulin (IVIG) | Umifenovir	- 45 Remained in hospitall. - 14 Discharged. - 2 Died.	16-Jan-2020	10-Feb-2020	26	No		Retrospective	Jingzhou, China	29-Apr-2020	
#00166	CT_32341331	A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia.	32341331		https://pubmed.ncbi.nlm.nih.gov/32341331	46	Drug(s)	Methylprednisolone | Empirical antibiotics | Thymosin | Interferon-α | Lopinavir/ritonavir	Early, low-dose and short-term application of methylprednisolone was associated with better clinical outcomes in severe patients with COVID-19 pneumonia, and should be considered before the occurrence of ARDS.	20-Jan-2020	25-Feb-2020	37	No	Cohort study	Retrospective	Wuhan, China	28-Apr-2020	
#00167	CT_32351196	Initial experiences from patients with COVID-19 on ventilatory support in Denmark.	32351196		https://pubmed.ncbi.nlm.nih.gov/32351196	16				11-Mar-2020	01-Apr-2020	22	No	Single-centre descriptive study	Retrospective	Zealand, Denmark	27-Apr-2020	
#00168	CT_32293518	Prognosis when using extracorporeal membrane oxygenation (ECMO) for critically ill COVID-19 patients in China: a retrospective case series.	32293518		https://pubmed.ncbi.nlm.nih.gov/32293518	12	Oxygen support | Drug(s)	Empirical Antivirals | Empirical antibiotics | Glucocorticoids					No	Case series	Retrospective	Wuhan, China	15-Apr-2020	
#00169	CT_32252023	Interpreting COVID-19 and Virtual Care Trends: Cohort Study.	32252023		https://pubmed.ncbi.nlm.nih.gov/32252023	257				01-Feb-2020	15-Mar-2020	44	No	Cohort Study		North Carolina, USA	15-Apr-2020	
#00170	CT_32293449	Prognostic value of NT-proBNP in patients with severe COVID-19.	32293449		https://pubmed.ncbi.nlm.nih.gov/32293449	54	Other						No	Observational study	Retrospective	Chongqing, China	15-Apr-2020	
#00171	CT_32283162	Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19.	32283162		https://pubmed.ncbi.nlm.nih.gov/32283162	245	Other			01-Jan-2020	29-Feb-2020	60	No	Cohort Study	Retrospective	Wuhan, China	10-Apr-2020	
#00172	CT_32269086	Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): A Nationwide Analysis of China.	32269086		https://pubmed.ncbi.nlm.nih.gov/32269086	1,590				21-Nov-2019	31-Jan-2020	72	Yes	Cohort Study	Retrospective	China	4-Jun-2020	
#00173	CT_32294858	CT imaging analysis of 33 cases with the 2019 novel coronavirus infection	32294858		https://pubmed.ncbi.nlm.nih.gov/32294858	33	Other			13-Jan-2020	31-Jan-2020	19	No		Retrospective	Suzhou, China	7-Apr-2020	
#00174	CT_32242348	Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19.	32242348		https://pubmed.ncbi.nlm.nih.gov/32242348	28	Other			19-Jan-2020	17-Feb-2020	30	No	Multicenter study, cohort study	Retrospective	Seoul, Korea	6-Apr-2020	
#00175	CT_32251668	Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples from the Hong Kong Cohort and Systematic Review and Meta-analysis.	32251668		https://pubmed.ncbi.nlm.nih.gov/32251668	59	Other			02-Feb-2020	29-Feb-2020	28	Yes	Analysis of a cohort study		Hong Kong, China	3-Apr-2020	
#00176	CT_32234131	Analysis of CT features of 15 children with 2019 novel coronavirus infection	32234131		https://pubmed.ncbi.nlm.nih.gov/32234131	15	Other			16-Jan-2020	06-Feb-2020	22	No	Analytical study	Retrospective	Shenzhen, China	2-Apr-2020	
#00177	CT_32232652	Clinical and Transmission Characteristics of Covid-19 - A Retrospective Study of 25 Cases from a Single Thoracic Surgery Department.	32232652		https://pubmed.ncbi.nlm.nih.gov/32232652	25	Other			01-Jan-2020	20-Feb-2020	51	No	Analytical study	Retrospective	Wuhan, China	30-Mar-2020	
#00178	CT_32371463	Clinicopathological characteristics of 8697 patients with COVID-19 in China: a meta-analysis.	32371463		https://pubmed.ncbi.nlm.nih.gov/32371463	8,697							Yes		Retrospective studies (Meta-analysis)	Guangxi, China	8-Apr-2020	
#00179	CT_32243304	Characteristics and Early Prognosis of COVID-19 Infection in Fracture Patients.	32243304		https://pubmed.ncbi.nlm.nih.gov/32243304	10	Other | Drug(s)	Glucocorticoids | Immunoglobulin (IVIG) | Moxifloxacin | Oseltamivir	- 6 Remained in hospital. - 4 Died.	01-Jan-2020	27-Feb-2020	58	No	Anaytical cohort study		Hubei, China	1-Apr-2020	
#00180	CT_32112886	Characteristics of COVID-19 infection in Beijing.	32112886		https://pubmed.ncbi.nlm.nih.gov/32112886	262				20-Jan-2020	10-Feb-2020	22	No		Retrospective	Beijing, China	27-Feb-2020	
#00181	CT_32112884	Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China.	32112884		https://pubmed.ncbi.nlm.nih.gov/32112884	85	Drug(s) | Other	Glucocorticoids | Antifungal drugs | Empirical antibiotics | Empirical Antivirals | Interferon-α | Immunoglobulin (IVIG)	- 76 Remained in hospital. - 73 Discharged.	17-Jan-2020	10-Feb-2020	25	No	Cohort study	Retrospective	Zhejiang, China	26-Feb-2020	
#00182	CT_32109443	Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2.	32109443		https://pubmed.ncbi.nlm.nih.gov/32109443	50	Other			01-Jan-2020	01-Feb-2020	32	No	Analytical study	Retrospective	Beijing, China	25-Feb-2020	
#00183	CT_32073213	Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.	32073213		https://pubmed.ncbi.nlm.nih.gov/32073213	183	Other			01-Jan-2020	03-Feb-2020	34	No	Analytical study	Retrospective	Wuhan, China	13-Mar-2020	
#00184	CT_32027573	Emerging 2019 Novel Coronavirus (2019-nCoV) Pneumonia.	32027573		https://pubmed.ncbi.nlm.nih.gov/32027573	51	Other			20-Jan-2020	27-Jan-2020	8	No		Retrospective	Shanghai, China	6-Feb-2020	
#00185	CT_32017661	CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV).	32017661		https://pubmed.ncbi.nlm.nih.gov/32017661	21	Other			18-Jan-2020	27-Jan-2020	10	No	Observational study	Retrospective	China	4-Feb-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
	Count >>>	1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00186	CT_32171076	**Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.**	32171076		https://pubmed.ncbi.nlm.nih.gov/32171076	191	Other | Drug(s)	Empirical antibiotics | Corticosteroid | Immunoglobulin (IVIG) | Lopinavir/ritonavir	- 137 Discharged. - 54 Died.	29-Dec-2019	31-Jan-2020	34	No	Multicentre cohort study (Two cohorts of adult inpatients 135 from Jinyintan Hospital and 56 from Wuhan Pulmonary Hospital)	Retrospective	Wuhan, China	9-Mar-2020	
#00187	CT_32191764	**Association of radiologic findings with mortality of patients infected with 2019 novel coronavirus in Wuhan, China.**	32191764		https://pubmed.ncbi.nlm.nih.gov/32191764	27	Drug(s) | Other	Ribavirin | Immunoglobulin (IVIG) | Glucocorticoids | Empirical antibiotics | Oseltamivir	- 17 Discharged with twice negative test for 2019-nCoV viral RNA in throat-swab specimens. - 10 Died.	01-Jan-2020	25-Jan-2020	25	No		Retrospective	Wuhan, China	19-Mar-2020	
#00188	CT_32037389	**Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment.**	32037389		https://pubmed.ncbi.nlm.nih.gov/32037389	4	Drug(s) | Other	Lopinavir/ritonavir | Arbidol | Traditional Chinese medicine | Immunoglobulin (IVIG) | Empirical antibiotics	- 2 Discharged. - 2 Remained in hospital.	21-Jan-2020	24-Jan-2020	4	No	Case report	Retrospective	Shanghai, China	16-Mar-2020	
#00189	CT_32226287	**Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau.**	32226287		https://pubmed.ncbi.nlm.nih.gov/32226287	10	Drug(s) | Other	Methylprednisolone | Lopinavir/ritonavir | Interferon-β1b | Empirical antibiotics	- 5 Discharged. - 5 Remained in hospital.	21-Jan-2020	16-Feb-2020	27	No	Case report	Retrospective	Macau, China	15-Mar-2020	
#00190	CT_32164091	**Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing**	32164091		https://pubmed.ncbi.nlm.nih.gov/32164091	9				18-Jan-2020	03-Feb-2020	17	No	Case report	Retrospective	Beijing, China	12-Mar-2020	
#00191	CT_32164090	**Clinical characteristics of 30 medical workers infected with new coronavirus pneumonia**	32164090		https://pubmed.ncbi.nlm.nih.gov/32164090	30				10-Jan-2020	31-Jan-2020	22	No	Observational study	Retrospective	Jianghan, China	12-Mar-2020	
#00192	CT_32151335	**Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records.**	32151335		https://pubmed.ncbi.nlm.nih.gov/32151335	9	Drug(s) | Oxygen support | Other	Methylprednisolone | Empirical antibiotics | Empirical Antivirals	No evidence for intrauterine infection caused by vertical transmission in women who develop COVID-19 pneumonia in late pregnancy.	20-Jan-2020	31-Jan-2020	12	No	Observational study	Retrospective	Wuhan, China	12-Feb-2020	
#00193	CT_32233642	**Risk factors associated with disease progression in a cohort of patients infected with the 2019 novel coronavirus.**	32233642		https://pubmed.ncbi.nlm.nih.gov/32233642	17	Drug(s) | Oxygen support	Corticosteroid | Lopinavir/ritonavir	A higher cell count of total lymphocytes may indicate a better outcome of the disease.	28-Jan-2020	06-Feb-2020	10	No	Cohort study	Retrospective	Nanchang, China	17-Mar-2020	
#00194	CT_32102625	**Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity**	32102625		https://pubmed.ncbi.nlm.nih.gov/32102625	85	Other			23-Jan-2020	04-Feb-2020	13	No	Analytical cohort study	Retrospective	Guangzhou, China	15-Feb-2020	
#00195	CT_32075786	**Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series.**	32075786		https://pubmed.ncbi.nlm.nih.gov/32075786	62	Drug(s) | Other	Corticosteroid | Lopinavir/ritonavir | Immunoglobulin (IVIG) | Interferon-α | Arbidol	- 61 Hospital admission. - 1 Discharge.	10-Jan-2020	26-Jan-2020	17	No	Case series.	Retrospective	Zhejiang, China	19-Feb-2020	
#00196	CT_32354634	**A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia.**	32354634		https://pubmed.ncbi.nlm.nih.gov/32354634	20				27-Feb-2020	24-Mar-2020	27	No	A single center observational study		Brescia, Italy	9-Apr-2020	
#00197	CT_32328724	**15-day mortality and associated risk factors for hospitalized patients with COVID-19 in Wuhan, China: an ambispective observational cohort study.**	32328724		https://pubmed.ncbi.nlm.nih.gov/32328724	548							No	Single-center observational cohort study	Ambispective	Wuhan, China	23-Apr-2020	
#00198	CT_32333918	**Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact.**	32333918		https://pubmed.ncbi.nlm.nih.gov/32333918	24	Drug(s)	Baricitinib	- Clinical characteristics and respiratory function parameters significantly improved both at week 1 and week 2 compared to baseline.	16-Mar-2020	30-Mar-2020	15	No	Non-randomized open-label study		Rome, Italy	23-Apr-2020	
#00199	CT_32320508	**Acute-onset smell and taste disorders in the context of Covid-19: a pilot multicenter PCR-based case-control study.**	32320508		https://pubmed.ncbi.nlm.nih.gov/32320508	119				23-Mar-2020	25-Mar-2020	3	No	Multicenter PCR-based case-control study	Retrospective	Madrid, Spain	22-Apr-2020	
#00200	CT_32333911	**Prevalence and Characteristics of Gastrointestinal Symptoms in Patients with SARS-CoV-2 Infection in the United States: A Multicenter Cohort Study.**	32333911		https://pubmed.ncbi.nlm.nih.gov/32333911	318							No	Multicenter cohort study	Retrospective	Boston, USA	22-Apr-2020	
#00201	CT_32361250	**Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.**	32361250		https://pubmed.ncbi.nlm.nih.gov/32361250	40	Drug(s)	Methylprednisolone | Arbidol | Ribavirin | Oseltamivir | Antifungal drugs | Interferon α2β | Empirical antibiotics		05-Jan-2020	24-Jan-2020	20	No	Single-center study	Retrospective	Wuhan, China	18-Apr-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00202	CT_32304402	The performance of chest CT in evaluating the clinical severity of COVID-19 pneumonia: identifying critical cases based on CT characteristics.	32304402		https://pubmed.ncbi.nlm.nih.gov/32304402	51	Other			15-Jan-2020	24-Feb-2020	41	No	Cohort study	Retrospective	Zhengzhou, China	17-Apr-2020	
#00203	CT_32301155	COVID-19 in solid organ transplant recipients: A single-center case series from Spain.	32301155		https://pubmed.ncbi.nlm.nih.gov/32301155	18	Other			05-Mar-2020	23-Mar-2020	19	No	A single-center case series	Retrospective	Madrid, Spain	16-Apr-2020	
#00204	CT_32301761	Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes.	32301761		https://pubmed.ncbi.nlm.nih.gov/32301761	206	Other			13-Feb-2020	29-Feb-2020	17	No		Retrospective	Wuhan, China	15-Apr-2020	
#00205	CT_32293905	SARS-CoV-2 Viral Load in Clinical Samples of Critically Ill Patients.	32293905		https://pubmed.ncbi.nlm.nih.gov/32293905	16	Other			26-Jan-2020	25-Feb-2020	31	No	Descriptive study	Retrospective	Guangzhou, China	15-Apr-2020	
#00206	CT_32355546	Clinical evaluation of a rapid colloidal gold immunochromatography assay for SARS-Cov-2 IgM/IgG.	32355546		https://pubmed.ncbi.nlm.nih.gov/32355546	150	Other			20-Jan-2020	02-Feb-2020	14	No	Cohort study	Prospective	Zhejiang, China	15-Apr-2020	
#00207	CT_32308732	Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan, Hubei Province, China.	32308732		https://pubmed.ncbi.nlm.nih.gov/32308732	54	Drug(s)	Traditional Chinese medicine					No	Observational study		Wuhan, China	15-Apr-2020	
#00208	CT_32294796	A Clinical Study of Noninvasive Assessment of Lung Lesions in Patients with Coronavirus Disease-19 (COVID-19) by Bedside Ultrasound.	32294796		https://pubmed.ncbi.nlm.nih.gov/32294796	30	Other			18-Jan-2020	05-Feb-2020	19	No		Retrospective	Zhuhai, China	15-Apr-2020	
#00209	CT_32295322	Clinical analysis of 150 cases of 2019 novel coronavirus infection in Nanyang City, Henan Province	32295322		https://pubmed.ncbi.nlm.nih.gov/32295322	150				24-Jan-2020	16-Feb-2020	24	No		Retrospective	Henan, China	15-Apr-2020	
#00210	CT_32304745	Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China.	32304745		https://pubmed.ncbi.nlm.nih.gov/32304745	663	Other			11-Jan-2020	06-Feb-2020	27	No	Cohort study	Retrospective	Wuhan, China	15-Apr-2020	
#00211	CT_32293741	Analysis of 92 deceased patients with COVID-19.	32293741		https://pubmed.ncbi.nlm.nih.gov/32293741	92	Other			06-Jan-2020	25-Feb-2020	51	No		Retrospective	Wuhan, China	15-Apr-2020	
#00212	CT_32293716	Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis.	32293716		https://pubmed.ncbi.nlm.nih.gov/32293716	3,062				01-Jan-2020	28-Feb-2020	59	Yes		Retrospective	Nanning, China	15-Apr-2020	
#00213	CT_32304638	Enteric involvement in hospitalised patients with COVID-19 outside Wuhan.	32304638		https://pubmed.ncbi.nlm.nih.gov/32304638	230				19-Jan-2020	06-Mar-2020	48	No		Retrospective	Guangzhou, China	15-Apr-2020	
#00214	CT_32298677	Clinical characteristics and prognosis in cancer patients with COVID-19: A single center's retrospective study	32298677		https://pubmed.ncbi.nlm.nih.gov/32298677	37	Other			01-Jan-2020	30-Mar-2020	90	No	A single center study	Retrospective	Wuhan, China	14-Apr-2020	
#00215	CT_32298802	A longitudinal study on the mental health of general population during the COVID-19 epidemic in China.	32298802		https://pubmed.ncbi.nlm.nih.gov/32298802	861							No	Longitudinal study	Prospective	China	13-Apr-2020	
#00216	CT_32301807	Emergency Surgery in Suspected COVID-19 Patients with Acute Abdomen: Case Series and Perspectives.	32301807		https://pubmed.ncbi.nlm.nih.gov/32301807	4	Other			23-Jan-2020	23-Mar-2020	61	No	Case Series		Beijing, China	13-Apr-2020	
#00217	CT_32325421	Increased expression of CD8 marker on T-cells in COVID-19 patients.	32325421		https://pubmed.ncbi.nlm.nih.gov/32325421	25	Other						No	Open label study		Arak, Iran	13-Apr-2020	
#00218	CT_32294477	Gastrointestinal Symptoms and COVID-19: Case-Control Study from the United States.	32294477		https://pubmed.ncbi.nlm.nih.gov/32294477	516				10-Mar-2020	21-Mar-2020	12	No	Case-control study	Retrospective	New York, USA	12-Apr-2020	
#00219	CT_32279676	Nosocomial infection among patients with COVID-19: A retrospective data analysis of 918 cases from a single center in Wuhan, China.	32279676		https://pubmed.ncbi.nlm.nih.gov/32279676	918	Other			30-Dec-2019	29-Feb-2020	62	No		Retrospective	Wuhan, China	13-Apr-2020	
#00220	CT_32305269	Coronavirus-19 disease (COVID-19): A case series of early suspected cases reported and the implications towards the response to the pandemic in Zimbabwe.	32305269		https://pubmed.ncbi.nlm.nih.gov/32305269	8				19-Feb-2020	13-Mar-2020	24	No			Harare, Zimbabwe	13-Apr-2020	
#00221	CT_32294504	CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China.	32294504		https://pubmed.ncbi.nlm.nih.gov/32294504	58	Other			01-Jan-2020	23-Feb-2020	54	No	Observational study	Retrospective	Wuhan, China	12-Apr-2020	
#00222	CT_32304994	The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients.	32304994		https://pubmed.ncbi.nlm.nih.gov/32304994	93	Other						No		Retrospective	Jiangxi, China	13-Apr-2020	
#00223	CT_32279441	Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms.	32279441		https://pubmed.ncbi.nlm.nih.gov/32279441	1,480				03-Mar-2020	29-Mar-2020	27	No	A single-institution, cross-sectional study		California, USA	12-Apr-2020	
#00224	CT_32294485	Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan.	32294485		https://pubmed.ncbi.nlm.nih.gov/32294485	548	Drug(s) | Other	Corticosteroid | Interferon-α | Lopinavir/ritonavir | Oseltamivir | Ribavirin | Umifenovir	- 287 Discharged. - 168 In-hospitalization. - 90 Death.	26-Jan-2020	05-Feb-2020	11	No		Retrospective	Wuhan, China	12-Apr-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00225	CT_32305025	Epidemiological and initial clinical characteristics of patients with family aggregation of COVID-19.	32305025		https://pubmed.ncbi.nlm.nih.gov/32305025	10	Other			23-Jan-2020	18-Feb-2020	27	No			Chongqing, China	12-Apr-2020	
#00226	CT_32344321	Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19.	32344321		https://pubmed.ncbi.nlm.nih.gov/32344321	140	Other			18-Jan-2020	12-Mar-2020	55	No	Cohort study	Retrospective	Wuhan, China	14-Apr-2020	
#00227	CT_32330817	Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy.	32330817		https://pubmed.ncbi.nlm.nih.gov/32330817	44	Drug(s)	Lopinavir/ritonavir | Hydroxychloroquine | Chloroquine | Empirical antibiotics | Corticosteroid | Tocilizumab | Parenteral nutrition | Vasopressors | Renal Replacement Therapy | Neuromuscular Blockade Agents	- 9 Discharged from ICU - 23 Stayed in ICU. - 1 Died in ICU.	02-Mar-2020	13-Mar-2020	12	No	A single-center observational cohort study		Brescia, Italy	14-Apr-2020	
#00228	CT_32363222	The clinical and immunological features of pediatric COVID-19 patients in China.	32363222		https://pubmed.ncbi.nlm.nih.gov/32363222	32	Drug(s) | Other	Lopinavir/ritonavir | Ribavirin | Interferon α1β	All patients relieved the symptom 3–4 days after admitted to hospital. No case progressed to severe state.	28-Jan-2020	11-Feb-2020	15	No	Descriptive study	Retrospective	Chongqing, China	14-Apr-2020	
#00229	CT_32281110	Distinct characteristics of COVID-19 patients with initial rRT-PCR-positive and rRT-PCR-negative results for SARS-CoV-2.	32281110		https://pubmed.ncbi.nlm.nih.gov/32281110	290	Other			29-Dec-2019	16-Feb-2020	50	No		Retrospective	Wuhan, China	13-Apr-2020	
#00230	CT_32361324	Dynamic profile of RT-PCR findings from 301 COVID-19 patients in Wuhan, China: A descriptive study.	32361324		https://pubmed.ncbi.nlm.nih.gov/32361324	301	Other			21-Jan-2020	11-Feb-2020	22	No	Observational study	Retrospective	Wuhan, China	11-Apr-2020	
#00231	CT_32279081	Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study.	32279081		https://pubmed.ncbi.nlm.nih.gov/32279081	203	Drug(s) | Other	Corticosteroid | Immunoglobulin (IVIG) | Lopinavir/ritonavir | Arbidol | Interferon-α		01-Jan-2020	10-Feb-2020	41	No	A single-centered study	Retrospective	Wuhan, China	11-Apr-2020	
#00232	CT_32279115	CT features of SARS-CoV-2 pneumonia according to clinical presentation: a retrospective analysis of 120 consecutive patients from Wuhan city.	32279115		https://pubmed.ncbi.nlm.nih.gov/32279115	120	Other			10-Jan-2020	10-Feb-2020	32	No	A single-center, observational cohort study	Retrospective	Wuhan, China	11-Apr-2020	
#00233	CT_32289565	Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China.	32289565		https://pubmed.ncbi.nlm.nih.gov/32289565	125	Other | Oxygen therapy | Drug(s)	Empirical Antivirals | Empirical antibiotics | Glucocorticoids | Immunoglobulin (IVIG)	- 78 Remained in hospital. - 47 Discharged.	20-Jan-2020	09-Feb-2020	21	No	A single-center, descriptive study	Retrospective	Anhui, China	11-Apr-2020	
#00234	CT_32283159	Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19.	32283159		https://pubmed.ncbi.nlm.nih.gov/32283159	39				18-Jan-2020	10-Feb-2020	24	No	A single-center study	Retrospective	Wuhan, China	11-Apr-2020	
#00235	CT_32275452	COVID-19 with Different Severity: A Multi-center Study of Clinical Features.	32275452		https://pubmed.ncbi.nlm.nih.gov/32275452	476	Drug(s) | Oxygen therapy	lopinavir and tonavir | Arbidol | Darunavir | Corbicostat | Chloroquine | Empirical antibiotics | Antifulgal therapy | Corticosteroids	- 403 Discharged. - 38 Died.	01-Jan-2020	15-Feb-2020	46	No	Multi-center study	Retrospective	China	10-Apr-2020	
#00236	CT_32339960	Clinical characteristics of older patients infected with COVID-19: A descriptive study.	32339960		https://pubmed.ncbi.nlm.nih.gov/32339960	141				20-Jan-2020	29-Feb-2020	41	No	A descriptive study.	Retrospective	Beijing, China	10-Apr-2020	
#00237	CT_32283156	Rapid asymptomatic transmission of COVID-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside Wuhan and characteristics of young patients with COVID-19: A prospective contact-tracing study.	32283156		https://pubmed.ncbi.nlm.nih.gov/32283156	22	Other						No	Contact-tracing study.	Prospective	Anhui, China	10-Apr-2020	
#00238	CT_32307189	Audiological profile of asymptomatic Covid-19 PCR-positive cases.	32307189		https://pubmed.ncbi.nlm.nih.gov/32307189	20	Other						No			Qena, Egypt	10-Apr-2020	
#00239	CT_32302954	Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu.	32302954		https://pubmed.ncbi.nlm.nih.gov/32302954	99	Other			16-Jan-2020	20-Feb-2020	36	No	Single-center case series	Retrospective	Chengdu, China	10-Apr-2020	
#00240	CT_32302953	Epidemiologic and clinical characteristics of 10 children with coronavirus disease 2019 in Changsha, China.	32302953		https://pubmed.ncbi.nlm.nih.gov/32302953	10	Other			27-Jan-2020	10-Mar-2020	44	No	Single center study	Retrospective	Chengdu, China	10-Apr-2020	
#00241	CT_32298988	Clinical characteristics of 225 patients with COVID-19 in a tertiary Hospital near Wuhan, China.	32298988		https://pubmed.ncbi.nlm.nih.gov/32298988	225	Other			20-Jan-2020	14-Feb-2020	26	No			Wuhan, China	10-Apr-2020	
#00242	CT_32376101	Association Between Hypoxemia and Mortality in Patients With COVID-19.	32376101		https://pubmed.ncbi.nlm.nih.gov/32376101	140	Oxygen support | Drug(s)	Empirical antibiotics		28-Jan-2020	28-Feb-2020	32	No	Cohort study	Retrospective	Wuhan, China	11-Apr-2020	
#00243	CT_32312571	Emergency tracheal intubation in 202 patients with COVID-19 in Wuhan, China: lessons learnt and international expert recommendations.	32312571		https://pubmed.ncbi.nlm.nih.gov/32312571	202	Other			04-Feb-2020	12-Mar-2020	38	No	Two-centre observational case series	Retrospective	Wuhan, China	10-Apr-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00244	CT_32275643	Predictors for imaging progression on chest CT from coronavirus disease 2019 (COVID-19) patients.	32275643		https://pubmed.ncbi.nlm.nih.gov/32275643	273	Other						No	Single-center cohort study	Prospective	Shanghai, China	10-Apr-2020	
#00245	CT_32308494	Epidemiologic and Clinical Characteristics of 26 Cases of COVID-19 Arising from Patient-to-Patient Transmission in Liaocheng, China.	32308494		https://pubmed.ncbi.nlm.nih.gov/32308494	26	Drug(s) | Oxygen therapy	Glucocorticoids | Empirical antibiotics | Empirical Antivirals | Traditional Chinese medicine | Gastric mucosal protection | Immunotherapy		31-Jan-2020	12-Feb-2020	13	No			Liaocheng, China	9-Apr-2020	
#00246	CT_32278005	Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study.	32278005		https://pubmed.ncbi.nlm.nih.gov/32278005	202	Other			20-Jan-2020	17-Feb-2020	29	No		Retrospective	Beijing, China	8-Apr-2020	
#00247	CT_32311650	Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China.	32311650		https://pubmed.ncbi.nlm.nih.gov/32311650	221	Drug(s) | Other	Empirical Antivirals | Glucocorticoids		02-Jan-2020	10-Feb-2020	40	No	Case series	Retrospective	Wuhan, China	9-Apr-2020	
#00248	CT_32278758	A cross-sectional comparison of epidemiological and clinical features of patients with coronavirus disease (COVID-19) in Wuhan and outside Wuhan, China.	32278758		https://pubmed.ncbi.nlm.nih.gov/32278758	20	Drug(s) | Oxygen therapy | Other	Immunoglobulin (IVIG) | Traditional Chinese medicine | Methylprednisolone | Arbidol | Interferon-α | Ribavirin | Thymosin-α1 | Empirical antibiotics | Lopinavir/ritonavir	- 6 Remained in hospital. - 14 Discharged.	22-Jan-2020	12-Feb-2020	22	No	Comparitive study		Guangzhou, China	9-Apr-2020	
#00249	CT_32267160	Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19.	32267160		https://pubmed.ncbi.nlm.nih.gov/32267160	344	Drug(s)	Empirical antiviral | Empirical antibiotics | Immunoglobulin (IVIG) | Glucocorticoids | Muscle relaxant	- 133 Died. - Of the 211 survivors, 185 were discharged	25-Jan-2020	25-Feb-2020	32	No	Cohort study		Nanjing, China	8-Apr-2020	
#00250	CT_32291207	Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China.	32291207		https://pubmed.ncbi.nlm.nih.gov/32291207	112	Other			06-Jan-2020	20-Feb-2020	46	No	Observational study	Retrospective	Wuhan, China	8-Apr-2020	
#00251	CT_32275925	Clinical and Imaging features of COVID-19 Patients: Analysis of Data from High-Altitude Areas.	32275925		https://pubmed.ncbi.nlm.nih.gov/32275925	68	Other			08-Feb-2020	01-Mar-2020	23	No			Sichuan, China	8-Apr-2020	
#00252	CT_32253535	Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study.	32253535		https://pubmed.ncbi.nlm.nih.gov/32253535	417	Drug(s) | Other	Paracetamol | NSAIDs | Nasal saline irrigations | Chloroquine | Mucolytics | Corticosteroids | Empirical antibiotics					No	Multicenter European study.	Prospective	Europe	6-Apr-2020	
#00253	CT_32253448	Clinicolaboratory study of 25 fatal cases of COVID-19 in Wuhan	32253448		https://pubmed.ncbi.nlm.nih.gov/32253448	174	Drug(s) | Other | Oxygen therapy	Lopinavir | Oseltamivir | Umifenovir | Methylprednisolone		03-Jan-2020	24-Feb-2020	53	No	Single-center study	Retrospective	Wuhan, China	6-Apr-2020	
#00254	CT_32252784	CT imaging changes of corona virus disease 2019(COVID-19): a multi-center study in Southwest China.	32252784		https://pubmed.ncbi.nlm.nih.gov/32252784	131	Other			28-Dec-2019	10-Feb-2020	45	No	Descriptive study	Retrospective	Chongqing, China	6-Apr-2020	
#00255	CT_32268195	Epidemiology of 2019 novel coronavirus in Jiangsu Province, China after wartime control measures: A population-level retrospective study.	32268195		https://pubmed.ncbi.nlm.nih.gov/32268195	613				22-Jan-2020	20-Feb-2020	30	No	A population-level study.	Retrospective	Jiangsu, China	5-Apr-2020	
#00256	CT_32272262	High-resolution Chest CT Features and Clinical Characteristics of Patients Infected with COVID-19 in Jiangsu, China.	32272262		https://pubmed.ncbi.nlm.nih.gov/32272262	234	Other			10-Jan-2020	07-Feb-2020	29	No	A multi-center study	Retrospective	Jiangsu, China	6-Apr-2020	
#00257	CT_32242738	Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study.	32242738		https://pubmed.ncbi.nlm.nih.gov/32242738	85	Drug(s)	Empirical Antivirals | Glucocorticoid | Immunoglobulin (IVIG) | Interferon α2β		09-Jan-2020	15-Feb-2020	38	No	Observational study	Retrospective	Wuhan, China	3-Apr-2020	
#00258	CT_32251805	Clinical characteristics of 25 death cases with COVID-19: A retrospective review of medical records in a single medical center, Wuhan, China.	32251805		https://pubmed.ncbi.nlm.nih.gov/32251805	25	Other			14-Jan-2020	13-Feb-2020	31	No	A single medical center,	Retrospective	Wuhan, China	3-Apr-2020	
#00259	CT_32251842	Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital.	32251842		https://pubmed.ncbi.nlm.nih.gov/32251842	1,012	Other			07-Feb-2020	12-Feb-2020	6	No	Descriptive study	Retrospective	Wuhan, China	3-Apr-2020	
#00260	CT_32243608	Detection of antibodies against SARS-CoV-2 in patients with COVID-19	32243608		https://pubmed.ncbi.nlm.nih.gov/32243608	60	Other						No			Wuhan, China	3-Apr-2020	
#00261	CT_32243607	The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients.	32243607		https://pubmed.ncbi.nlm.nih.gov/32243607	42	Other			20-Jan-2020	09-Feb-2020	21	No	Single-center study	Retrospective	Wuhan, China	3-Apr-2020	
#00262	CT_32247326	Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study.	32247326		https://pubmed.ncbi.nlm.nih.gov/32247326	8,579				19-Jan-2020	17-Feb-2020	30	Yes	A descriptive and modelling study.		China	2-Apr-2020	
#00263	CT_32239591	Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study.	32239591		https://pubmed.ncbi.nlm.nih.gov/32239591	79	Other			02-Feb-2020	23-Feb-2020	22	No		Retrospective	Wuhan, China	2-Apr-2020	
#00264	CT_32239796	Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China.	32239796		https://pubmed.ncbi.nlm.nih.gov/32239796	115	Other			18-Jan-2020	22-Feb-2020	36	No	Single-center study	Retrospective	Wuhan, China	2-Apr-2020	
#00265	CT_32239127	Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease 2019 in Wuhan, China.	32239127		https://pubmed.ncbi.nlm.nih.gov/32239127	102	Drug(s) | Other	Empirical Antivirals | Empirical antibiotics | Immunoglobulin (IVIG) | Glucocorticoids | Traditional Chinese medicine	- 85 Discharged. - 17 Died.	03-Jan-2020	01-Feb-2020	30	No	Cohort study		Wuhan, China	2-Apr-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00266	CT_32347198	Epidemiological characteristics of the first 53 laboratory-confirmed cases of COVID-19 epidemic in Hong Kong, 13 February 2020.	32347198		https://pubmed.ncbi.nlm.nih.gov/32347198	53							No	Descriptive study		Hong Kong, Shenzhen, China	23-Apr-2020	
#00267	CT_32234107	Epidemiologic Features of 135 Patients With Coronavirus Disease (COVID-19) in Tianjin, China.	32234107		https://pubmed.ncbi.nlm.nih.gov/32234107	135				21-Jan-2020	24-Feb-2020	35	No	Descriptive study		Tianjin, China	1-Apr-2020	
#00268	CT_32237148	Differences between COVID-19 and suspected then confirmed SARS-CoV-2-negative pneumonia: a retrospective study from a single center.	32237148		https://pubmed.ncbi.nlm.nih.gov/32237148	104	Other | Drug(s)	Emprical Antivirals | Empirical antibiotics | Nebulization inhalation	- COVID-19 patients: 34 Discharge. 9 Admission to ICU 10 ARDS 10 Acute respiratory injury - Control cases: 16 Discharge 1 ARDS 2 Acute respiratory injury	26-Jan-2020	31-Jan-2020	6	No	A single center study	Retrospective	Chongqing, China	1-Apr-2020	
#00269	CT_32339248	Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.	32339248		https://pubmed.ncbi.nlm.nih.gov/32339248	81	Drug(s)	Chloroquine Diphosphate	Reduction in lethality by at least 50% in the high-dosage group compared with the low-dosage group.	23-Mar-2020	05-Apr-2020	14	No	A parallel, double-masked, randomized, phase IIb clinical trial	Prospective	Manaus, Brazil	1-Apr-2020	
#00270	CT_32329881	Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience.	32329881		https://pubmed.ncbi.nlm.nih.gov/32329881	4	Drug(s)	Eculizumab	Eculizumab could ameliorate COVID-19-induced lung injury, improving outcomes in patients with severe pneumonia or ARDS associated with COVID- 19 infection.				No	Case series		Pozzuoli, Italy	1-Apr-2020	
#00271	CT_32309796	Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowdsourced data: a population-level observational study.	32309796		https://pubmed.ncbi.nlm.nih.gov/32309796	507				13-Jan-2020	31-Jan-2020	19	No	A population-level observational study		USA	20-Feb-2020	
#00272	CT_32105637	Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study.	32105637		https://pubmed.ncbi.nlm.nih.gov/32105637	81	Other			20-Dec-2019	23-Jan-2020	35	No	A descriptive study.	Retrospective	Wuhan, China	24-Feb-2020	
#00273	CT_32100485	Chest Radiographic and CT Findings of the 2019 Novel Coronavirus Disease (COVID-19): Analysis of Nine Patients Treated in Korea.	32100485		https://pubmed.ncbi.nlm.nih.gov/32100485	9	Other						No	Analytical study	Retrospective	Korea	26-Feb-2020	
#00274	CT_32312363	Clinical features of children with SARS-CoV-2 infection: an analysis of 115 cases	32312363		https://pubmed.ncbi.nlm.nih.gov/32312363	115	Other						No	Observational study,	Retrospective	Wuhan, China	1-Apr-2020	
#00275	CT_32227091	Novel Coronavirus Pneumonia (COVID-19) Progression Course in 17 Discharged Patients: Comparison of Clinical and Thin-Section CT Features During Recovery.	32227091		https://pubmed.ncbi.nlm.nih.gov/32227091	17	Drug(s) | Other	Ganciclovir | Abidol | Oseltamivir | interferon | Empirical antibiotic | Methylprednisolone					No	Analytical observational study	Retrospective	Wuhan, China	30-Mar-2020	
#00276	CT_32234250	Spinal anaesthesia for patients with coronavirus disease 2019 and possible transmission rates in anaesthetists: retrospective, single-centre, observational cohort study.	32234250		https://pubmed.ncbi.nlm.nih.gov/32234250	49	Other			01-Jan-2020	14-Feb-2020	45	No	A single-centre, observational cohort study.	Retrospective	Wuhan, China	28-Mar-2020	
#00277	CT_32224151	Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China.	32224151		https://pubmed.ncbi.nlm.nih.gov/32224151	28	Drug(s) | Oxygen therapy	Arbidol | Empirical antibiotics | Lopinavir/ritonavir | Ribavirin | Ganciclovir | Corticosteroid	- 10 Staying in hospital. - 10 Discharged. - 8 Death.	13-Jan-2020	26-Feb-2020	45	No	Cohort study	Retrospective	Wuhan, China	26-Mar-2020	
#00278	CT_32324236	Epidemiological Assessment of Imported Coronavirus Disease 2019 (COVID-19) Cases in the Most Affected City Outside of Hubei Province, Wenzhou, China.	32324236		https://pubmed.ncbi.nlm.nih.gov/32324236	482				21-Jan-2020	15-Feb-2020	26	No	Observational study,		Wenzhou, China	23-Apr-2020	
#00279	CT_32174053	False-Negative Results of Real-Time Reverse-Transcriptase Polymerase Chain Reaction for Severe Acute Respiratory Syndrome Coronavirus 2: Role of Deep-Learning-Based CT Diagnosis and Insights from Two Cases.	32174053		https://pubmed.ncbi.nlm.nih.gov/32174053	2				21-Jan-2020	31-Jan-2020	11	No	Observational study,		Beijing, China	5-Mar-2020	
#00280	CT_32235945	Virological assessment of hospitalized patients with COVID-2019.	32235945		https://pubmed.ncbi.nlm.nih.gov/32235945	9	Other						No	Non-randomized, unblinded study		Munichm, Germany	1-Apr-2020	
#00281	CT_32232685	The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China.	32232685		https://pubmed.ncbi.nlm.nih.gov/32232685	318	Oxygen support			01-Jan-2020	04-Mar-2020	64	No	Observational study	Retrospective	Chongqing, China	30-Mar-2020	
#00282	CT_32232421	Community Prevalence of SARS-CoV-2 Among Patients With Influenzalike Illnesses Presenting to a Los Angeles Medical Center in March 2020	32232421		https://pubmed.ncbi.nlm.nih.gov/32232421	131	Other			12-Mar-2020	16-Mar-2020	5	No	A a rapid sentinel surveillance study		California, USA	31-Mar-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00283	CT_32240670	Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up.	32240670		https://pubmed.ncbi.nlm.nih.gov/32240670	339	Other			01-Jan-2020	06-Feb-2020	37	No	Single-center study	Retrospective	Wuhan, China	30-Mar-2020	
#00284	CT_32276848	Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019.	32276848		https://pubmed.ncbi.nlm.nih.gov/32276848	3	Other			17-Jan-2020	23-Feb-2020	38	No			Qingdao, Shandong, China	28-Mar-2020	
#00285	CT_32229257	Risk-adapted Treatment Strategy For COVID-19 Patients.	32229257		https://pubmed.ncbi.nlm.nih.gov/32229257	55	Drug(s) | Oxygen therapy	Arbidol | Ribavirin | Interferon-α2b | Traditional Chinese medicine | Methylprednisolone | Empirical antibiotic					No		Retrospective	Hefei, China	27-Mar-2020	
#00286	CT_32224074	Comparison of Hospitalized Patients With ARDS Caused by COVID-19 and H1N1.	32224074		https://pubmed.ncbi.nlm.nih.gov/32224074	148	Drug(s) | Other	Oseltamivir | Lopinavir/ritonavir | Traditional Chinese medicine | Ganciclovir | Interferon α2β | Glucocorticoids	- 75 Discharge. - 47 Death. - 26 In hospital.	24-Dec-2019	07-Feb-2020	46	No	Case-control study	Retrospective	Wuhan, China	26-Mar-2020	
#00287	CT_32171866	Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients.	32171866		https://pubmed.ncbi.nlm.nih.gov/32171866	56	Drug(s) | Oxygen therapy	Immunoglobulin (IVIG) | Traditional Chinese medicine | Interferon-α | Empirical antibiotics | Lopinavir/ritonavir | Thymopentin	- 53 Healed and discharged. - 3 Death.	15-Jan-2020	18-Feb-2020	35	No		Retrospective	Hainan, China	27-Mar-2020	
#00288	CT_32291098	Assessing Viral Shedding and Infectivity of Tears in Coronavirus Disease 2019 (COVID-19) Patients	32291098		https://pubmed.ncbi.nlm.nih.gov/32291098	17	Other						No		Prospective	Singapore	27-Mar-2020	
#00289	CT_32209381	Comparisons of viral shedding time of SARS-CoV-2 of different samples in ICU and non-ICU patients.	32209381		https://pubmed.ncbi.nlm.nih.gov/32209381	32	Other						No			Hunan, China	21-Mar-2020	
#00290	CT_32174128	Clinical Features and Chest CT Manifestations of Coronavirus Disease 2019 (COVID-19) in a Single-Center Study in Shanghai, China.	32174128		https://pubmed.ncbi.nlm.nih.gov/32174128	33	Other			19-Jan-2020	06-Feb-2020	19	No	Single-Center Study	Cohort study	Shanghai, China	14-Mar-2020	
#00291	CT_31986264	Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.	31986264	https://doi.org/10.1016/S0140-6736(20)30183-5	https://pubmed.ncbi.nlm.nih.gov/31986264	41	Drug(s) | Other | Oxygen therapy	Oseltamivir | Corticosteroid | Empirical antibiotics	- 28 Discharge. - 7 Hospitalisation. - 6 Death.	16-Dec-2019	02-Jan-2020	18	No	Cohort study	Prospective	Wuhan, China	15-Feb-2020	
#00292	CT_32161968	A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias.	32161968		https://pubmed.ncbi.nlm.nih.gov/32161968	34	Other			23-Jan-2020	05-Feb-2020	14	No	Comparative study		Anhui, China	12-Mar-2020	
#00293	CT_32171872	Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.	32171872		https://pubmed.ncbi.nlm.nih.gov/32171872	33	Drug(s)	Arbidol | Lopinavir/ritonavir	The chest CT scans were improving for 11 of 16 patients in the combination group after seven days, compared with 5 of 17 in the monotherapy group.	17-Jan-2020	13-Feb-2020	28	No	Single-center, cohort study	Retrospective	Guangdong, China	11-Mar-2020	
#00294	CT_32176772	Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China.	32176772		https://pubmed.ncbi.nlm.nih.gov/32176772	69	Drug(s) | Other | Oxygen therapy	Arbidol | Empirical antibiotics| Empirical Antivirals | Antifungal drugs | Corticosteroid	- 18 Discharge. - 44 Hospitalization. - 5 Death.	16-Jan-2020	04-Feb-2020	20	No	Case series	Retrospective	Wuhan, China	16-Mar-2020	
#00295	CT_32180140	Clinical features of pediatric patients with COVID-19: a report of two family cluster cases.	32180140		https://pubmed.ncbi.nlm.nih.gov/32180140	2	Other						No	Case report	Retrospective	Beijing, China	16-Mar-2020	
#00296	CT_32162699	A report of clinical diagnosis and treatment of nine cases of coronavirus disease 2019.	32162699		https://pubmed.ncbi.nlm.nih.gov/32162699	9	Drug(s) | Other | Oxygen therapy	Interferon α2β | Immunoglobulin (IVIG) | Methylprednisolone | Lopinavir/ritonavir | Thymalfasin | Moxifloxacin					No	Case report	Retrospective	Anhui, China	12-Mar-2020	
#00297	CT_32292517	CT Scans of Patients with 2019 Novel Coronavirus (COVID-19) Pneumonia.	32292517		https://pubmed.ncbi.nlm.nih.gov/32292517	118	Other | Drug(s) | Oxygen therapy	Interferon α2β | Lopinavir/ritonavir | Corticosteroid | Empirical antibiotics	- 76 Remained in hospital. - 42 Discharged.	16-Jan-2020	04-Feb-2020	20	No	Single-center study	Retrospective	Hunan, China	15-Mar-2020	
#00298	CT_32171190	Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients	32171190		https://pubmed.ncbi.nlm.nih.gov/32171190	54				03-Feb-2020	24-Feb-2020	22	No	Analytical study	Retrospective	Wuhan, China	15-Mar-2020	
#00299	CT_32179140	Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19.	32179140		https://pubmed.ncbi.nlm.nih.gov/32179140	51	Other			23-Jan-2020	27-Feb-2020	36	No	Cohort study	Retrospective	Changzhou, China	14-Mar-2020	
#00300	CT_32161940	Dysregulation of immune response in patients with COVID-19 in Wuhan, China.	32161940		https://pubmed.ncbi.nlm.nih.gov/32161940	452	Other			10-Jan-2020	12-Feb-2020	34	No	Single-center study	Retrospective	Wuhan, China	12-Mar-2020	
#00301	CT_32173576	Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression.	32173576		https://pubmed.ncbi.nlm.nih.gov/32173576	10	Drug(s)	Glucocorticoids | Lopinavir | Interferon α2β | Immunoglobulin (IVIG)	- 7 Discharged. - 3 Transferred.	22-Jan-2020	11-Feb-2020	21	No	Observational single-center study	Retrospective	Hangzhou, China	12-Mar-2020	
#00302	CT_32159775	Detection of SARS-CoV-2 in Different Types of Clinical Specimens.	32159775		https://pubmed.ncbi.nlm.nih.gov/32159775	205	Other			01-Jan-2020	17-Feb-2020	48	No		Prospective	Hubei, China Shandong, China Beijing, China	11-Mar-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00303	CT_32077660	Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study	32077660		https://pubmed.ncbi.nlm.nih.gov/32077660	32				03-Jan-2020	08-Feb-2020	37	No	A multicenter study	Retrospective	China	20-Feb-2020	
#00304	CT_31986261	A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster.	31986261		https://pubmed.ncbi.nlm.nih.gov/31986261	6	Other			10-Jan-2020	20-Jan-2020	11	No		Retrospective	Shenzhen, China	15-Feb-2020	
#00305	CT_32112072	A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features.	32112072		https://pubmed.ncbi.nlm.nih.gov/32112072	10	Other			19-Jan-2020	03-Feb-2020	16	No	Case Series		Shanghai, China	28-Feb-2020	
#00306	CT_32107200	Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series.	32107200		https://pubmed.ncbi.nlm.nih.gov/32107200	62				10-Jan-2020	26-Jan-2020	17	No	Case Series	Retrospective	Zhejiang, China	27-Feb-2020	
#00307	CT_32114074	Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: A retrospective single center analysis.	32114074		https://pubmed.ncbi.nlm.nih.gov/32114074	34	Drug(s) | Oxygen therapy	Corticosteroid | Empirical Antivirals | Empirical antibiotics	- 33 Hospitalization. - 1 Home isolation.	21-Dec-2019	29-Jan-2020	40	No	A single center analysis study.	Retrospective	Wuhan, China	27-Feb-2020	
#00308	CT_32101510	Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases.	32101510		https://pubmed.ncbi.nlm.nih.gov/32101510	1,014	Other			06-Jan-2020	06-Feb-2020	48	No	Case report	Retrospective	Wuhan, China	26-Feb-2020	
#00309	CT_32271459	Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha.	32271459		https://pubmed.ncbi.nlm.nih.gov/32271459	161	Other			17-Jan-2020	07-Feb-2020	22	No	Case analysis	Retrospective	Changsha, China	24-Mar-2020	
#00310	CT_32159317	Comparison of epidemic characteristics between SARS in 2003 and COVID-19 in 2020 in Guangzhou	32159317		https://pubmed.ncbi.nlm.nih.gov/32159317	1,418						164	No		Retrospective	Guangzhou, China	11-Mar-2020	
#00311	CT_32169498	Vicarious traumatization in the general public, members, and non-members of medical teams aiding in COVID-19 control.	32169498		https://pubmed.ncbi.nlm.nih.gov/32169498	740	Other			17-Feb-2020	21-Feb-2020	5	No	Descriptive study	Retrospective	China	10-Mar-2020	
#00312	CT_32155105	Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT.	32155105		https://pubmed.ncbi.nlm.nih.gov/32155105	219	Other			6-Jan-2020	20-Feb-2020	46	No		Retrospective	China	10-Mar-2020	
#00313	CT_32340507	Survival rate in acute kidney injury superimposed COVID-19 patients: a systematic review and meta-analysis.	32340507		https://pubmed.ncbi.nlm.nih.gov/32340507	701							Yes			USA & Egypt	27-Apr-2020.	
#00314	CT_32408753	Rhinologic Procedures in the Era of COVID-19: Health-care Provider Protection Protocol.	32408753		https://pubmed.ncbi.nlm.nih.gov/32408753	152	Other			11-Mar-2020	14-Apr-2020	35	No	Cohort study	Prospective	Louisiana, USA & Cairo, Egypt	14-May-2020	
#00315	CT_32271458	A classifier prediction model to predict the status of Coronavirus COVID-19 patients in South Korea.	32271458		https://pubmed.ncbi.nlm.nih.gov/32271458	1,308				20-Feb-2020	09-Mar-2020	19	No			Istanbul, Turkey	24-Mar-2020	
#00316	CT_32269939	CT imaging of one extended family cluster of corona virus disease 2019 (COVID-19) including adolescent patients and "silent infection".	32269939		https://pubmed.ncbi.nlm.nih.gov/32269939	6	Other | Drug(s)	Lopinavir/ritonavir | Interferon inhalation					No	Cohort study		Guizhou, China	1-Mar-2020	
#00317	CT_32048163	Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury.	32048163		https://pubmed.ncbi.nlm.nih.gov/32048163	12	Drug(s) | Other	Ribavirin | Interferon-α | Oseltamivir		11-Jan-2020	20-Jan-2020	10	No	Descriptive study		Shenzhen, China	9-Feb-2020	
#00318	CT_32114745	Characteristics of peripheral blood leukocyte differential counts in patients with COVID-19	32114745		https://pubmed.ncbi.nlm.nih.gov/32114745	40				22-Jan-2020	07-Feb-2020	17	No			Shanghai, China	1-Mar-2020	
#00319	CT_32271456	Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019.	32271456		https://pubmed.ncbi.nlm.nih.gov/32271456	47	Drug(s)	Lopinavir/ritonavir	Compared with the treatment of pneumonia-associated adjuvant drugs alone, the combination treatment with LPV/r and adjuvant drugs has a more evident therapeutic effect in lowering the body temperature and restoring normal physiological mechanisms with no evident toxic and side effects.	22-Jan-2020	29-Jan-2020	8	No		Prospective	Rui'an, China	1-Mar-2020	
#00320	CT_32114744	Pregnant women with new coronavirus infection: a clinical characteristics and placental pathological analysis of three cases	32114744		https://pubmed.ncbi.nlm.nih.gov/32114744	3				04-Feb-2020	25-Feb-2020	22	No	Analysis study	Retrospective	Wuhan, China	1-Mar-2020	
#00321	CT_32109279	Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study.	32109279		https://pubmed.ncbi.nlm.nih.gov/32109279	80	Drug(s) | Other	Methylprednisolone | Ribavirin | Moxifloxacin	- 61 Remained in hospital. - 21 Discharged.	22-Jan-2020	14 Feb 2020	24	No	A Multicenter Descriptive Study.	Retrospective	Jiangsu, China	29-Feb-2020	
#00322	CT_32108351	Clinical characteristics of hospitalized patients with SARS-CoV-2 infection: A single arm meta-analysis.	32108351		https://pubmed.ncbi.nlm.nih.gov/32108351	50,466							Yes	A single arm meta-analysis.		Beijing, China	28-Feb-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00323	CT_32087623	Comparison of the clinical characteristics between RNA positive and negative patients clinically diagnosed with 2019 novel coronavirus pneumonia	32087623		https://pubmed.ncbi.nlm.nih.gov/32087623	54							No	Single-center study	Retrospective	Wuhan, China	23-Feb-2020	
#00324	CT_32077115	Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.	32077115		https://pubmed.ncbi.nlm.nih.gov/32077115	140	Other			16-Jan-2020	03-Feb-2020	19	No	Case series		Wuhan, China	19-Feb-2020	
#00325	CT_32105304	Positive RT-PCR Test Results in Patients Recovered From COVID-19.	32105304		https://pubmed.ncbi.nlm.nih.gov/32105304	4	Other | Drug(s)	Oseltamivir		01-Jan-2020	15-Feb-2020	46	No	Case series		Wuhan, China	27-Feb-2020	
#00326	CT_32100876	Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection.	32100876		https://pubmed.ncbi.nlm.nih.gov/32100876	30	Other			26-Jan-2020	09-Feb-2020	15	No	Case series study	Prospective	Zhejiang, China	26-Feb-2020	
#00327	CT_32061066	Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing	32061066		https://pubmed.ncbi.nlm.nih.gov/32061066	9	Other			18-Jan-2020	03-Feb-2020	17	No	Case analysis	Retrospective	Beijing, China	15-Feb-2020	
#00328	CT_32055945	Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China.	32055945		https://pubmed.ncbi.nlm.nih.gov/32055945	63	Other			30-Dec-2019	31-Jan-2020	33	No	Cross sectional study	Retrospective	Wuhan, China	13-Feb-2020	
#00329	CT_32091533	Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.	32091533		https://pubmed.ncbi.nlm.nih.gov/32091533	72,314				08-Dec-2019	11-Feb-2020	66	No	Case record	Retrospective	Beijing, China	24-Feb-2020	
#00330	CT_32031570	Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.	32031570		https://pubmed.ncbi.nlm.nih.gov/32031570	138	Drug(s)	Oseltamivir | Glucocorticoids | Empirical antibiotics	- 47 Discharged. - 85 Remained in hospital. - 6 Died.	01-Jan-2020	28-Jan-2020	28	No	Single-center case series	Retrospective	Wuhan, China	7-Feb-2020	
#00331	CT_32031568	Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China.	32031568		https://pubmed.ncbi.nlm.nih.gov/32031568	13	Other			16-Jan-2020	29-Jan-2020	14	No	Case series		Beijing, China	7-Feb-2020	
#00332	CT_32026671	Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia	32026671		https://pubmed.ncbi.nlm.nih.gov/32026671	29				14-Jan-2020	29-Jan-2020	16	No	Case analysis	Retrospective	Wuhan, China	6-Feb-2020	
#00333	CT_32289051	COVID-19 pneumonia manifestations at the admission on chest ultrasound, radiographs, and CT: single-center study and comprehensive radiologic literature review.	32289051		https://pubmed.ncbi.nlm.nih.gov/32289051	58	Other			15-Feb-2020	15-Mar-2020	30	No	Single-center study	Retrospective	Como, Italy	4-Apr-2020	
#00334	CT_32149037	Early Epidemiological and Clinical Characteristics of 28 Cases of Coronavirus Disease in South Korea.	32149037		https://pubmed.ncbi.nlm.nih.gov/32149037	28	Other						No	Case series		South Korea	21-Feb-2020	
#00335	CT_32154135	Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia.	32154135		https://pubmed.ncbi.nlm.nih.gov/32154135	10	Plasma | Other	Gammaglobulin | Platelets | Symptomatic and supportive therapy	- 5 Cured. - 4 In hospital. - 1 Died.	20-Jan-2020	05-Feb-2020	17	No	Case analysis	Retrospective	Hubei, China	10-Feb-2020	
#00336	CT_32179124	Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis.	32179124		https://pubmed.ncbi.nlm.nih.gov/32179124	2,874				01-Jan-2020	21-Feb-2020	52	Yes			Risaralda, Colombia	13-Mar-2020	
#00337	CT_32167181	Initial clinical features of suspected coronavirus disease 2019 in two emergency departments outside of Hubei, China.	32167181		https://pubmed.ncbi.nlm.nih.gov/32167181	116	Other			24-Jan-2020	20-Feb-2020	28	No	Observational study	Retrospective	Hefei, China	13-Mar-2020	
#00338	CT_32179890	Risk Factors of Healthcare Workers with Corona Virus Disease 2019: A Retrospective Cohort Study in a Designated Hospital of Wuhan in China.	32179890		https://pubmed.ncbi.nlm.nih.gov/32179890	72	Other						No	Cohort Study	Retrospective	Wuhan, China	17-Mar-2020	
#00339	CT_32292624	Quantitative computed tomography analysis for stratifying the severity of Coronavirus Disease 2019.	32292624		https://pubmed.ncbi.nlm.nih.gov/32292624	44	Other			22-Jan-2020	07-Feb-2020	17	No		Retrospective	Shaanxi, China	6-Mar-2020	
#00340	CT_32134681	CT Features of Coronavirus Disease 2019 (COVID-19) Pneumonia in 62 Patients in Wuhan, China.	32134681		https://pubmed.ncbi.nlm.nih.gov/32134681	62	Other			16-Jan-2020	30-Jan-2020	15	No		Retrospective	Wuhan, China	5-Mar-2020	
#00341	CT_32181807	Epidemiologic and Clinical Characteristics of 91 Hospitalized Patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series.	32181807		https://pubmed.ncbi.nlm.nih.gov/32181807	91	Other			20-Jan-2020	11-Feb-2020	23	No	Case series.	Retrospective	Zhejiang, China	17-Mar-2020	
#00342	CT_32130038	Coronavirus Disease 2019 (COVID-19): Role of Chest CT in Diagnosis and Management.	32130038		https://pubmed.ncbi.nlm.nih.gov/32130038	53	Other			23-Jan-2020	29-Jan-2020	7	No	Cohort study	Retrospective	Wuhan, China	4-Mar-2020	
#00343	CT_32153170	Clinical characteristics and influencing factors of new coronavirus pneumonia patients with liver injury in Shaanxi	32153170		https://pubmed.ncbi.nlm.nih.gov/32153170	40				21-Jan-2020	21-Feb-2020	32	No	Case analysis	Retrospective	Shaanxi, China	20-Mar-2020	
#00344	CT_32129843	Genomic diversity of SARS-CoV-2 in Coronavirus Disease 2019 patients	32129843		https://pubmed.ncbi.nlm.nih.gov/32129843	53	Other						No			Wuhan, China	4-Mar-2020	
#00345	CT_32181911	Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19.	32181911		https://pubmed.ncbi.nlm.nih.gov/32181911	43	Other			23-Jan-2020	02-Feb-2020	11	No		Retrospective	Anhui, China	17-Mar-2020	
#00346	CT_32124995	Fecal specimen diagnosis 2019 novel coronavirus-infected pneumonia.	32124995		https://pubmed.ncbi.nlm.nih.gov/32124995	14	Other						No			Jinhua, China	3-Mar-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00347	CT_32125362	Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.	32125362		https://pubmed.ncbi.nlm.nih.gov/32125362	18	Drug(s) | Oxygen therapy | Other	Lopinavir/ritonavir		23-Jan-2020	25-Feb-2020	34	No	Descriptive study		Singapore	3-Mar-2020	
#00348	CT_32196707	The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China.	32196707		https://pubmed.ncbi.nlm.nih.gov/32196707	115	Drug(s) | Oxygen therapy | Other	Empirical Antivirals | Empirical antibiotics | Glucocorticoids	All patients did not receive ICU and were discharged from the hospital without death.				No	Case series, descriptive study		Wuhan, China	20-Mar-2020	
#00349	CT_32450107	Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis	32450107	https://doi.org/10.1016/S0140-6736(20)31180-6	https://pubmed.ncbi.nlm.nih.gov/32450107	96,032	Drug(s)	Azithromycin | Chloroquine | Hydroxychloroquine		20-Dec-2019	14-Apr-2020	117	No	Multinational, observational, real world cohort study	Prospective	USA	22-May-2020	
#00350	CT_32232429	Computed Tomographic Imaging of 3 Patients With Coronavirus Disease 2019 Pneumonia With Negative Virus Real-time Reverse-Transcription Polymerase Chain Reaction Test.	32232429		https://pubmed.ncbi.nlm.nih.gov/32232429	3	Other			29-Jan-2020	02-Feb-2020	5	No	Case report		Shenzhen, China	31-Mar-2020	
#00351	CT_32199864	Clinical characteristics of novel coronavirus disease 2019 (COVID-19) in newborns, infants and children.	32199864		https://pubmed.ncbi.nlm.nih.gov/32199864	9	Other			08-Dec-2019	06-Feb-2020	61	No	Case report		China	10-Mar-2020	
#00352	CT_32249918	Maternal and neonatal outcomes of pregnant women with COVID-19 pneumonia: a case-control study.	32249918		https://pubmed.ncbi.nlm.nih.gov/32249918	34	Other | Drug(s) | Oxygen therapy	Empirical antibiotics | Corticosteroid | Empirical Antivirals		24-Jan-2020	29-Feb-2020	37	No	Case-control study		Hubei, China	30-Mar-2020	
#00353	CT_32232979	Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China.	32232979		https://pubmed.ncbi.nlm.nih.gov/32232979	273	Other			01-Jan-2020	18-Feb-2020	49	No	Single-center study	Retrospective	Wuhan, China	31-Mar-2020	
#00354	CT_32232433	Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China.	32232433		https://pubmed.ncbi.nlm.nih.gov/32232433	38	Other			09-Feb-2020	15-Feb-2020	7	No	Case series	Retrospective	Hubei, China	31-Mar-2020	
#00355	CT_32223012	Sixty-eight consecutive patients assessed for COVID-19 infection: Experience from a UK Regional infectious diseases Unit.	32223012		https://pubmed.ncbi.nlm.nih.gov/32223012	68	Other			29-Jan-2020	24-Feb-2020	27	No	Case series		Hull, UK	29-Mar-2020	
#00356	CT_32222992	Detectable SARS-CoV-2 viral RNA in feces of three children during recovery period of COVID-19 pneumonia.	32222992		https://pubmed.ncbi.nlm.nih.gov/32222992	3	Other | Drug(s)	Ribavirin | Traditional Chinese medicine | Vitamin C | Interferon atomization		03-Feb-2020	17-Feb-2020	15	No	Case report		Tianjin, China	15-Apr-2020	
#00357	CT_32224310	Clinical and virological data of the first cases of COVID-19 in Europe: a case series.	32224310		https://pubmed.ncbi.nlm.nih.gov/32224310	5	Other | Drug(s)	Remdesivir	All other patients had recovered and been discharged by Feb 19, 2020.	24-Jan-2020	29-Jan-2020	6	No	Case series		France	27-Mar-2020	
#00358	CT_32221523	Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients.	32221523		https://pubmed.ncbi.nlm.nih.gov/32221523	76	Other			05-Feb-2020	19-Feb-2020	15	No		Prospective	Beijing, China	28-Mar-2020	
#00359	CT_32221519	Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019.	32221519		https://pubmed.ncbi.nlm.nih.gov/32221519	173	Other			11-Jan-2020	09-Feb-2020	30	No			Shenzhen, China	28-Mar-2020	
#00360	CT_32216803	Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis.	32216803		https://pubmed.ncbi.nlm.nih.gov/32216803	95	Other			16-Jan-2020	25-Feb-2020	41	No		Retrospective	Wuhan, China	26-Mar-2020	
#00361	CT_32232218	Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis.	32232218		https://pubmed.ncbi.nlm.nih.gov/32232218	76,993							Yes			Shiraz, Iran	24-Mar-2020	
#00362	CT_32215691	CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19).	32215691		https://pubmed.ncbi.nlm.nih.gov/32215691	78	Other			18-Jan-2020	07-Feb-2020	21	No	Single-center study	Retrospective	Zhuhai, China	25-Mar-2020	
#00363	CT_32172226	Prominent changes in blood coagulation of patients with SARS-CoV-2 infection.	32172226		https://pubmed.ncbi.nlm.nih.gov/32172226	94	Other			31-Jan-2020	10-Feb-2020	11	No	Cohort study	Prospective	Wuhan. China	16-Mar-2020	
#00364	CT_32164089	Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia	32164089		https://pubmed.ncbi.nlm.nih.gov/32164089	29				14-Jan-2020	29-Jan-2020	16	No	Case analysis	Retrospective	Wuhan. China	12-Mar-2020	
#00365	CT_32141280	Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19	32141280		https://pubmed.ncbi.nlm.nih.gov/32141280	150							No	Cross-sectional study	Retrospective	Wuhan. China	6-Mar-2020	
#00366	CT_32120458	Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV	32120458		https://pubmed.ncbi.nlm.nih.gov/32120458	112				20-Jan-2020	15-Feb-2020	27	No	Case analysis	Retrospective	Wuhan. China	2-Mar-2020	
#00367	CT_32156327	First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020.	32156327		https://pubmed.ncbi.nlm.nih.gov/32156327	38	Other			24-Jan-2020	21-Feb-2020	29	No	Case analysis		Europe (Nine European countries)	5-Mar-2020	
#00368	CT_32007143	Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.	32007143		https://pubmed.ncbi.nlm.nih.gov/32007143	99	Drug(s) | Oxygen therapy | Other	Glucocorticoids | Empirical antibiotics | Immunoglobulin (IVIG) | Empirical Antivirals	- 57 Remained in hospital. - 31 Discharged. - 11 Died.	01-Jan-2020	20-Jan-2020	20	No	Single-centre, descriptive study	Retrospective	Wuhan. China	15-Feb-2020	
#00369	CT_32289548	Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study.	32289548		https://pubmed.ncbi.nlm.nih.gov/32289548	80	Drug(s) | Other	Hydroxychloroquine | Azithromycin	All patients improved clinically except one 86 year-old patient who died, and one 74 year-old patient remained in ICU.	03-Mar-2020	20-Mar-2020	18	No	Uncontrolled, non-comparative, observational, cohort study	Retrospective	Marseille, France	11-Apr-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00370	CT_32183930	Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020	32183930		https://pubmed.ncbi.nlm.nih.gov/32183930	634	Other			05-Feb-2020	20-Feb-2020	16	No	Case report		Diamond Princess cruise ship, Yokohama, Japan	12-Mar-2020	
#00371	CT_32145216	Clinical manifestations and outcome of SARS-CoV-2 infection during pregnancy.	32145216		https://pubmed.ncbi.nlm.nih.gov/32145216	13	Other			08-Dec-2019	25-Feb-2020	80	No	Case report		Wuhan, China	4-Mar-2020	
#00372	CT_32129583	Comparison of heart failure and 2019 novel coronavirus pneumonia in chest CT features and clinical characteristics	32129583		https://pubmed.ncbi.nlm.nih.gov/32129583	19				01-Dec-2019	15-Feb-2020	77	No		Retrospective	Changsha, China	4-Mar-2020	
#00373	CT_32216717	Frequency and Distribution of Chest Radiographic Findings in COVID-19 Positive Patients.	32216717		https://pubmed.ncbi.nlm.nih.gov/32216717	64	Other			01-Jan-2020	05-Mar-2020	65	No	Cohort study	Retrospective	Hong Kong, China	27-Mar-2020	
#00374	CT_32044814	Clinical Characteristics of Novel Coronavirus Cases in Tertiary Hospitals in Hubei Province	32044814		https://pubmed.ncbi.nlm.nih.gov/32044814	137	Other | Drug(s) | Oxygen therapy	Immunoglobulin (IVIG) | Empirical antibiotics | Methylprednisolone | Corticosteroid		30-Dec-2019	24-Jan-2020	26	No	Cohort study	Retrospective	Wuhan, China	5-May-2020	
#00375	CT_32187464	A Trial of Lopinavir-Ritonavir in Adults Hospitalized With Severe Covid-19	32187464	https://doi.org/10.1056/NEJMoa2001282	https://pubmed.ncbi.nlm.nih.gov/32187464	199	Drug(s)	Lopinavir | ritonavir	No benefit was observed with lopinavir–ritonavir treatment beyond standard care	18-Jan-2020	03-Feb-2020	17	No	Randomized, controlled, open-label trial	Prospective	Wuhan, China	18-Mar-2020	
#00376	CT_32192581	Clinical Course and Risk Factors for Mortality of Adult Inpatients With COVID-19 in Wuhan, China: A Retrospective Cohort Study	32192581		https://pubmed.ncbi.nlm.nih.gov/32192581	191				29-Dec-2019	31-Jan-2020	34	No	Multicentre cohort study	Retrospective	Wuhan, China	28-Mar-2020	
#00377	CT_32441574	A Case Series Describing the Epidemiology and Clinical Characteristics of COVID-19 Infection in Jilin Province	32441574		https://pubmed.ncbi.nlm.nih.gov/32441574	12	Other | Oxygen therapy			23-Jan-2020	11-Feb-2020	20	No	Case series	Retrospective	Jilin, China	22-May-2020	
#00378	CT_32470486	Ruxolitinib in Treatment of Severe Coronavirus Disease 2019 (COVID-19): A Multicenter, Single-Blind, Randomized Controlled Trial	32470486	https://doi.org/10.1016/j.jaci.2020.05.019	https://pubmed.ncbi.nlm.nih.gov/32470486	43	Drug(s)	Ruxolitinib	Ruxolitinib recipients had a numerically faster clinical improvement on on a seven-category ordinal scale or live discharge from the hospital.	09-Feb-2020	28-Feb-2020	20	No	A Multicenter, Single-Blind, Randomized Controlled Trial	Prospective	Wuhan, China	26-May-2020	
#00379	CT_32255437	Radiographic and Clinical Features of Children With Coronavirus Disease (COVID-19) Pneumonia	32255437		https://pubmed.ncbi.nlm.nih.gov/32255437	22	Other			16-Jan-2020	14-Mar-2020	59	No		Retrospective	Yichang, China	21-May-2020	
#00380	CT_32510106	Clinical Presentation of COVID19 in Dementia Patients.	32510106		https://pubmed.ncbi.nlm.nih.gov/32510106	627	Other						No		Retrospective	Brescia, Italy	15-May-2020	
#00381	CT_32380903	Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2.	32380903		https://pubmed.ncbi.nlm.nih.gov/32380903	7	Anti SARS-COV-1 plasma			24-Jan-2020	07-Feb-2020	15	No			Singapore, Singapore	8-May-2020	
#00382	CT_32243945	Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection	32243945		https://pubmed.ncbi.nlm.nih.gov/32243945	4	Drug(s) | Plasma | IVIG	Lopinavir/Ritonavir | Oseltamivir | Ribavirin | Interferon α2β | Empirical antibiotics | Immunoglobulin (IVIG) | Antifungal drugs	Clinical recovery and discharge from hospital				No	Case series		Dongguan, China	31-Mar-2020	
#00383	CT_32525844	Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients	32525844	https://doi.org/10.1172/JCI140200	https://pubmed.ncbi.nlm.nih.gov/32525844	5,000	Plasma		Transfusion of convalescent plasma is safe in hospitalized patients with COVID-19.	03-Apr-2020	11-May-2020	39	No			USA	11-Jun-2020	
#00384	CT_32492105	A Randomized Trial of Convalescent Plasma for COVID-19—Potentially Hopeful Signals	32492105	https://doi.org/10.1001/jama.2020.10218	https://pubmed.ncbi.nlm.nih.gov/32492105	103			No statistically significant benefit in clinical improvement at 28 days or mortality among all randomized patients, but does provide an important signal of possible benefit in the subgroup of severely ill patients and suggests that high titer antibody against SARS-CoV-2 may have antiviral efficacy.				No	Randomized clinical trial	Prospective	USA	3-Jun-2020	
#00385	CT_32492084	Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial	32492084	https://doi.org/10.1001/jama.2020.10044	https://pubmed.ncbi.nlm.nih.gov/32492084	103	Plasma			14-Feb-2020	01-Apr-2020	48	No	Open-label, multicenter, randomized clinical trial		Wuhan, China	3-Jun-2020	
#00386	CT_32473109	Treatment of COVID-19 Patients With Convalescent Plasma	32473109		https://pubmed.ncbi.nlm.nih.gov/32473109	25	Plasma | Drug(s)	Tocilizumab | Methylprednisolone	Administration of convalescent plasma is a safe treatment option for those with severe COVID-19 disease.	28-Mar-2020	28-Apr-2020	32	No			Texas, USA	27-May-2020	
#00387	CT_32519944	The Characteristics of 50 Hospitalized COVID-19 Patients With and Without ARDS.	32519944		https://pubmed.ncbi.nlm.nih.gov/32519944	50	Oxygen support						No			Aachen, Germany	6-Mar-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00388	CT_32305291	Multicenter analysis of clinical characteristics and outcomes in patients with COVID-19 who develop liver injury	32305291		https://pubmed.ncbi.nlm.nih.gov/32305291	70	Drug(s)	Interferon inhalation | Lopinavir | Ritonavir | Probiotics	The hospital stay of 68 discharged patients with liver injury was not statistically different to that in patients without liver injury.	23-Jan-2020	18-Feb-2020	27	No	Multicenter cohort analysis		China	17-Apr-2020	
#00389	CT_32511384	Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals	32511384		https://pubmed.ncbi.nlm.nih.gov/32511384	157	Other			01-Apr-2020	08-May-2020	38	No	Cohort study		New Yor, USA	22-May-2020	
#00390	CT_32437017	Epidemiological and Clinical Characteristics of Discharged Patients Infected With SARS-CoV-2 on the Qinghai Plateau	32437017		https://pubmed.ncbi.nlm.nih.gov/32437017	18	Other | Dtug(s)	Interferon-α | Oseltamivir | Ribavirin | Empirical antibiotics | Lopinavir | Ritonavir | Interferon α2β | Traditional Chinese medicine		25-Jan-2020	05-Feb-2020	12	No		Retrospective	Qinghai, China	21-May-2020	
#00391	CT_32253318	Effectiveness of Convalescent Plasma Therapy in Severe COVID-19 Patients	32253318		https://pubmed.ncbi.nlm.nih.gov/32253318	10	Plasma | IVIG (Neutralizing antibodies) | Drug(s) | Oxygen support	Interferon-α | Empirical antibiotics | Remdesivir | Methylprednisolone | Arbidol | Ribavirin | Oseltamivir | Peramivir	-The clinical status of all patients improved. -No severe adverse effects reported. -The viraemia was also disappeared on day 7.	23-Jan-2020	19-Feb-2020	28	No	Pilot experiment	Prospective	Wuhan, China	6-Apr-2020	
#00392	CT_32383183	A Comparison Study of SARS-CoV-2 IgG Antibody Between Male and Female COVID-19 Patients: A Possible Reason Underlying Different Outcome Between Sex	32383183		https://pubmed.ncbi.nlm.nih.gov/32383183	331	Plasma		-More female patients generated a relatively high level of IgG antibody after SARS-CoV-2 infection in severe status. - The production of IgG in female patients was stronger than male patients in the early phase of COVID-19.				No	Comparative study	Prospective	Wuhan, China	22-May-2020	
#00393	CT_32293713	Treatment With Convalescent Plasma for COVID-19 Patients in Wuhan, China	32293713		https://pubmed.ncbi.nlm.nih.gov/32293713	6	Plasma | Drug(s)	Arbidol	Reduction of viral load and increase of SARS-CoV-2 IgG and IgM antibodies.	11-Feb-2020	12-Mar-2020	31	No	Case series, descriptive study		Wuhan, China	15-Apr-2020	
#00394	CT_32281317	Use of Convalescent Plasma Therapy in Two COVID-19 Patients With Acute Respiratory Distress Syndrome in Korea	32281317		https://pubmed.ncbi.nlm.nih.gov/32281317	2	Plasma | Drug(s)	Lopinavir | Ritonavir | Hydroxychloroquine | Empirical antibiotics	Reduction of viral load and increase of SARS-CoV-2 IgG and IgM antibodies.				No	Case report		Korea.	13-Apr-2020	
#00395	CT_32376398	Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.	32376398		https://pubmed.ncbi.nlm.nih.gov/32376398	100	Drug(s)	Tocilizumab | Ritonavir | Hydroxychloroquine | Empirical antibiotics | Lopinavir | Dexamethasone	Improvement in acute respiratory failure at 24–72 h and 10 days after Tocilizumab administration.	09-Mar-2020	20-Mar-2020	12	No	A single center study	Prospective	Brescia, Italy	3-May-2020	
#00396	CT_32370577	Risk factors for disease progression in hospitalized patients with COVID-19: a retrospective cohort study.	32370577		https://pubmed.ncbi.nlm.nih.gov/32370577	101	Other | Drug(s) | Oxygen support	Empirical Antivirals | Corticosteroid | Immunoglobulin (IVIG)	A total of 17 patients (16.8%) were included in the progression (to critically ill) group and 84 patients (83.2%) in the improvement group.	21-Jan-2020	09-Mar-2020	49	No	Cohort study.	Retrospective	Beijing, China	6-May-2020	
#00397	CT_32391667	A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19	32391667	https://doi.org/10.3785/j.issn.1008-9292.2020.03.03	https://pubmed.ncbi.nlm.nih.gov/32391667	30	Drug(s)	Hydroxychloroquine		06-Feb-2020	25-Feb-2020	20	No	Randomized controlled clinical trial	Prospective	Shanghai, China	25-May-2020	
#00398	CT_32240719	No Evidence of Rapid Antiviral Clearance or Clinical Benefit With the Combination of Hydroxychloroquine and Azithromycin in Patients With Severe COVID-19 Infection	32240719	https://doi.org/10.1016/j.medmal.2020.03.006	https://pubmed.ncbi.nlm.nih.gov/32240719	11	Drug(s)	Hydroxychloroquine | Azithromycin	No evidence of a strong antiviral activity or clinical benefit of the combination of Hydroxychloroquine and Azithromycin for the treatment of the hospitalised patients with severe COVID-19.				No	Cohort study.	Prospective	France	30-Mar-2020	
#00399	CT_32534945	Clinical characteristics of COVID-19 in Saudi Arabia: A national retrospective study.	32534945	https://doi.org/10.1016/j.jiph.2020.05.026	https://pubmed.ncbi.nlm.nih.gov/32534945	1,519	Other			01-Mar-2020	31-Mar-2020	31	No	A multi-center, cross-sectional study	Retrospective	Saudi Arabia	8-Jun-2020	
#00400	CT_32342566	Objective evaluation of anosmia and ageusia in COVID-19 patients: Single-center experience on 72 cases.	32342566	https://doi.org/10.1002/hed.26204	https://pubmed.ncbi.nlm.nih.gov/32342566	72	Other			31-Mar-2020	06-Apr-2020	7	No	Single-center case series		Sassari, Italy	29-Apr-2020	
#00401	CT_32374248	Characteristics of disease progress in patients with coronavirus disease 2019 in Wuhan, China.	32374248	https://doi.org/10.1017/S0950268820000977	https://pubmed.ncbi.nlm.nih.gov/32374248	101	Other | Drug(s)	Empirical antibiotics | Empirical Antivirals | Thymosin | Interferon-α		02-Jan-2020	28-Jan-2020	27	No	Single-centre study	Retrospective	Wuhan, China	6-May-2020	
#00402	CT_32462545	Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review.	32462545	https://doi.org/10.1007/s40121-020-00303-8	https://pubmed.ncbi.nlm.nih.gov/32462545	9,152	Drug(s)	Lopinavir | Thymosin | Hydroxychloroquine | Ganciclovir | Interferon-α | Methylprednisolone | Favipiravir | Oseltamivir | Ribavirin | Empirical antibiotics | Chloroquine | Interferon-β | Immunoglobulin (IVIG) | Ritonavir					Yes			Philadelphia, PA, USA	27-May-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00403	CT_32423435	Chest CT imaging characteristics of COVID-19 pneumonia in preschool children: a retrospective study.	32423435	https://doi.org/10.1186/s12887-020-02140-7.	https://pubmed.ncbi.nlm.nih.gov/32423435	8	Other | Drug(s)	Empirical Antivirals | Supportive treatment		26-Jan-2020	20-Feb-2020	26	No	Case report	Retrospective	Hubei, China	18-May-2020	
#00404	CT_32397011	Epidemiological, clinical, and virological characteristics of 465 hospitalized cases of coronavirus disease 2019 (COVID-19) from Zhejiang province in China.	32397011	https://doi.org/10.1111/irv.12758	https://pubmed.ncbi.nlm.nih.gov/32397011	465	Drug(s) | Other | Oxygen support	Antifungal drugs | Arbidol | Ritonavir | Interferon-α | Empirical antibiotics | Lopinavir		17-Jan-2020	31-Jan-2020	15	No		Retrospective	Zhejiang, China	12-May-2020	
#00405	CT_32405603	Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis.	32405603	https://doi.org/10.1016/S2468-1253(20)30126-6	https://pubmed.ncbi.nlm.nih.gov/32405603	6,686				01-Jan-2020	04-Apr-2020	95	Yes			Guangzhou, China	12-May-2020	
#00406	CT_32420929	Screening of COVID-19 in children admitted to the hospital for acute problems: preliminary data.	32420929	https://doi.org/10.23750/abm.v91i2.9607	https://pubmed.ncbi.nlm.nih.gov/32420929	42	Other			01-Mar-2020	13-Apr-2020	44	No			Catanzaro, Italy	11-May-2020	
#00407	CT_32370747	A single-center, retrospective study of COVID-19 features in children: a descriptive investigation.	32370747	https://doi.org/10.1186/s12916-020-01596-9.	https://pubmed.ncbi.nlm.nih.gov/32370747	76	Other			21-Jan-2020	14-Feb-2020	25	No	Single-center study descriptive study	Retrospective	Wuhan, China	6-May-2020	
#00408	CT_32287140	Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study.	32287140	https://doi.org/10.14309/ajg.0000000000000620	https://pubmed.ncbi.nlm.nih.gov/32287140	204	Other | Drug(s)	Empirical antibiotics | Ritonavir | Immunoglobulin (IVIG) | Interferon-α | Glucocorticoids | Antifungal drugs | Lopinavir		18-Jan-2020	28-Feb-2020	42	No	A Descriptive, Cross-Sectional, Multicenter Study.	Retrospective	Hubei, China	14-Apr-2020	
#00409	CT_32412891	Hyperbaric oxygen therapy in preventing mechanical ventilation in COVID-19 patients: a retrospective case series	32412891	https://doi.org/10.12968/jowc.2020.29.Sup5a.S4	https://pubmed.ncbi.nlm.nih.gov/32412891	5	Hyperbaric oxygen therapy		Patients exhibited dramatic improvement with HBOT	13-Apr-2020	20-Apr-2020	8	No	Case series	Retrospective	Louisiana, USA	15-May-2020	
#00410	CT_32438333	COVID-19 and diabetes mellitus: A need for prudence in elderly patients from a pooled analysis.	32438333	https://doi.org/10.1016/j.dsx.2020.05.021	https://pubmed.ncbi.nlm.nih.gov/32438333	2,084							Yes	Pooled analysis		Georgia, USA	12-May-2020	
#00411	CT_32357072	CLINICAL CHARACTERISTICS OF 28 PATIENTS WITH DIABETES AND COVID-19 IN WUHAN, CHINA.	32357072	https://doi.org/10.4158/EP-2020-0108	https://pubmed.ncbi.nlm.nih.gov/32357072	28	Drugs(s) | Oxygen support | Other	Oseltamivir | Arbidol | Glucocorticoids | Empirical antibiotics | Metformin | Sulfonylurea | α-glucosidase inhibitor | Dipeptidyl peptidase	-ICU cases showed higher rates of organ failure and mortality than non-ICU cases. -Patients with diabetes and COVID-19 showed poor outcome.	29-Jan-2020	10-Feb-2020	13	No		Retrospective	Wuhan. China	1-May-2020	
#00412	CT_32390367	Clinical Features and Outcomes of 98 Patients Hospitalized with SARS-CoV-2 Infection in Daegu, South Korea: A Brief Descriptive Study.	32390367	https://doi.org/10.3349/ymj.2020.61.5.431	https://pubmed.ncbi.nlm.nih.gov/32390367	98	Drug(s) | Oxygen support	Glucocorticoids | Lopinavir | Empirical antibiotics | Ritonavir | Hydroxychloroquine	57 patients, remained in hospital. 30 patients, discharged. 5 patients, died. 6 patients, transferred.				No	Single-center descriptive study	Retrospective	Daegu, South Korea	1-May-2020	
#00413	CT_32354990	Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study.	32354990	https://doi.org/10.1136/gutjnl-2020-321411	https://pubmed.ncbi.nlm.nih.gov/32354990	79	Oxygen support		Active IBD, old age and comorbidities were associated with a negative COVID-19 outcome,	11-Mar-2020	29 Mar	19	No	Observational cohort study	Prospective	Italy	30-Apr-2020	
#00414	CT_32348166	Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.	32348166	https://doi.org/10.1161/HYPERTENSIONAHA.120.15143	https://pubmed.ncbi.nlm.nih.gov/32348166	251	Drug(s)	Glucocorticoids | Immunoglobulin (IVIG) | Empirical Antivirals | Empirical antibiotics	- Hypertension results in the poor clinical outcome of COVID-19. -Compared with non-HTN controls, patients with COVID-19 and HTN have markedly increased levels of inflammatory high-sensitivity CRP, procalcitonin, and IL-6 suggesting that dysregulated inflammatory response might contribute.	05-Jan-2020	22-Feb-2020	49	No	Single-Center case control study	Retrospective	Wuhan, China	29-Apr-2020	
#00415	CT_32283153	Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19.	32283153	https://doi.org/10.1016/j.jinf.2020.03.039	https://pubmed.ncbi.nlm.nih.gov/32283153	78	Drug(s) | Oxygen support | Other	Empirical antibiotics | Empirical Antivirals | Corticosteroid	No difference between patients in the low-dose group and controls, while high doses of corticosteroids (>150 mg/d methylprednisolone) are associated with increased risks of mortality and delayed viral clearance.	22-Jan-2020	01-Mar-2020	40	No	Cohort study	Retrospective	Anhui, China	11-Apr-2020	
#00416	CT_32283144	The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis.	32283144	https://doi.org/10.1016/j.jinf.2020.03.062	https://pubmed.ncbi.nlm.nih.gov/32283144	5,270				01-Jan-2020	15-Mar-2020	75	Yes			Wuhan, China	10-Apr-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00417	CT_32524516	Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis.	32524516	https://doi.org/10.1007/s11239-020-02171-y	https://pubmed.ncbi.nlm.nih.gov/32524516	57	Other			09-Feb-2020	15-Feb-2020	7	No	Case report	Retrospective	China	10-Jun-2020	
#00418	CT_32524786	CT Quantitative Analysis and Its Relationship with Clinical Features for Assessing the Severity of Patients with COVID-19.	32524786	https://doi.org/10.3348/kjr.2020.0293	https://pubmed.ncbi.nlm.nih.gov/32524786	84	Other		80% of the critical patients had lymphopenia, and lymphocytopenia was a prominent feature of critical patients with SARS-CoV infection.	23-Jan-2020	19-Feb-2020	28	No	Case analysis	Retrospective	Chongqing, China	6-May-2020	
#00419	CT_32414594	Clinical course of coronavirus disease 2019 in 11 patients after thoracic surgery and challenges in diagnosis.	32414594	https://doi.org/10.1016/j.jtcvs.2020.04.005	https://pubmed.ncbi.nlm.nih.gov/32414594	11	Other		8 Recoveries and 3 deaths	01-Jan-2020	24-Jan-2020	24	No	Case report	Retrospective	Wuhan, China	10-Apr-2020	
#00420	CT_32275753	Plasminogen improves lung lesions and hypoxemia in patients with COVID-19.	32275753	https://doi.org/10.1093/qjmed/hcaa121	https://pubmed.ncbi.nlm.nih.gov/32275753	13	Drug(s)	Tissue Plasminogen Activator (tPA) (Atomization inhalation of freeze-dried plasminogen.)	-Decreased range and density of 'ground glass' opacity - Improvements of oxygen saturation	10-Feb-2020	20-Feb-2020	11	No		Prospective	China	10-Apr-2020	
#00421	CT_32378844	COVID-19: Symptoms, course of illness and use of clinical scoring systems for the first 42 patients admitted to a Norwegian local hospital.	32378844	https://doi.org/10.4045/tidsskr.20.0301	https://pubmed.ncbi.nlm.nih.gov/32378844	42				09-Mar-2020	31-Mar-2020	23	No	Observational qualitative study		Baerum, Norway	23-Apr-2020	
#00422	CT_32290644	Clinical and epidemiologic profile of the initial COVID-19 patients at a tertiary care centre in India.	32290644	https://doi.org/10.4081/monaldi.2020.1294	https://pubmed.ncbi.nlm.nih.gov/32290644	21	Other			01-Feb-2020	19-Mar-2020	48	No	Case series	Retrospective	New Delhi, India	10-Apr-2020	
#00423	CT_32133829	Analysis of bronchoscope-guided tracheal intubation in 12 cases with coronavirus disease 2019 under the personal protective equipment with positive pressure protective hood	32133829	https://doi.org/10.3760/cma.j.cn112147-20200222-00153	https://pubmed.ncbi.nlm.nih.gov/32133829	12	Other			20-Jan-2020	10-Feb-2020	22	No	Case report	Retrospective	Guangzhou, China	12-Apr-2020	
#00424	CT_32271376	Factors associated with prolonged viral RNA shedding in patients with COVID-19.	32271376	https://doi.org/10.1093/cid/ciaa351	https://pubmed.ncbi.nlm.nih.gov/32271376	113	Drug(s) | Other	Lopinavir | Interferon-α | Ritonavir	-69 paptients cured and released. -13 patients hospitalized without viral RNA shedding. -29 patients hospitalized with viral RNA shedding. -2 patients died without viral RNA shedding.	19-Feb-2020	20-Mar-2020	31	No	Cohort study	Retrospective	Shenzhen, China	9-Apr-2020	
#00425	CT_32266381	PCR Assays Turned Positive in 25 Discharged COVID-19 Patients.	32266381	https://doi.org/10.1093/cid/ciaa398	https://pubmed.ncbi.nlm.nih.gov/32266381	25	Other | Drug(s)	Ritonavir | Lopinavir | Interferon-α		23-Jan-2020	21-Feb-2020	30	No	Observational study		Shenzhen, China	8-Apr-2020	
#00426	CT_32267826	Clinical Characteristics of Patients Hospitalized with Coronavirus Disease, Thailand	32267826	https://doi.org/10.3201/eid2607.200598	https://pubmed.ncbi.nlm.nih.gov/32267826	11	Other						No	Case series		Bangkok, Thailand	8-Apr-2020	
#00427	CT_32255489	Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients.	32255489	https://doi.org/10.1093/cid/ciaa394	https://pubmed.ncbi.nlm.nih.gov/32255489	13	Drug(s) | Oxygen supporrt	Hydroxychloroquine		13-Mar-2020	23-Mar-2020	11	No	Cohort study	Prospective	Saint-Etienne, France	7-Apr-2020	
#00428	CT_32258207	High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019.	32258207	https://doi.org/10.1093/ofid/ofaa102	https://pubmed.ncbi.nlm.nih.gov/32258207	3	IVIG	Immunoglobulin (IVIG)	All patients were clinically improved shortly after the administration.				No	Case report.		Wuhan, China	21-Mar-2020	
#00429	CT_32272197	New clinical experiences and evaluation of clinical and paraclinical features of deceased patients with COVID-19 infection referred to Shahid Mostafa Khomeini Hospital of Ilam.	32272197	https://doi.org/10.1016/j.tmaid.2020.101657	https://pubmed.ncbi.nlm.nih.gov/32272197	56	Other			03-Feb-2020	09-Mar-2020	36	No	Cross-sectional descriptive-analytic study,		Ilam, Iran	7-Apr-2020	
#00430	CT_32250385	Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.	32250385	https://doi.org/10.1001/jama.2020.5394	https://pubmed.ncbi.nlm.nih.gov/32250385	1,591	Other			20-Feb-2020	18-Mar-2020	28	No	Case series, observational study	Retrospective	Lombardy, Italy	6-Apr-2020	
#00431	CT_32292899	Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection.	32292899	https://doi.org/10.1016/j.eclinm.2020.100331	https://pubmed.ncbi.nlm.nih.gov/32292899	34	Drug(s) | Oxygen support | IVIG	Empirical antibiotics | Immunoglobulin (IVIG) | Glucocorticoids | Empirical Antivirals		01-Jan-2020	05-Feb-2020	36	No	Cohort study	Retrospective	Wuhan, China	5-Apr-2020	
#00432	CT_32242947	Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: A systematic review and meta-analysis.	32242947	https://doi.org/10.1002/jmv.25822	https://pubmed.ncbi.nlm.nih.gov/32242947	46,959							Yes			Wuhan, China	3-Apr-2020	
#00433	CT_32118389	Clinical analysis of 31 cases of 2019 novel coronavirus infection in children from six provinces (autonomous region) of northern China.	32118389	https://doi.org/10.3760/cma.j.cn112140-20200225-00138.	https://pubmed.ncbi.nlm.nih.gov/32118389	31	Other			25-Jan-2020	21-Feb-2020	28	No	Case analysis	Retrospective	China	2-Apr-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00434	CT_32411770	Clinical characteristics of 60 discharged cases of 2019 novel coronavirus-infected pneumonia in Taizhou, China.	32411770	https://doi.org/10.21037/atm.2020.04.20	https://pubmed.ncbi.nlm.nih.gov/32411770	60	Drug(s)	Glucocorticoids | Lopinavir | Ritonavir | Immunoglobulin (IVIG) | Interferon-β | Empirical antibiotics | Oseltamivir | Arbidol		31-Jan-2020	16-Feb-2020	17	No	Single-center, observational study	Retrospective	Taizhou, China	8-Apr-2020	
#00435	CT_32173725	Clinical characteristics of 60 discharged cases of 2019 novel coronavirus-infected pneumonia in Taizhou, China.	32173725	https://doi.org/10.1093/cid/ciaa270	https://pubmed.ncbi.nlm.nih.gov/32173725	155	Drug(s) | Oxygen support | IVIG	Lopinavir | Interferon | Arbidol | Ritonavir | Immunoglobulin (IVIG) | Corticosteroid | Thymalfasin		1 Jan	05-Feb-2020	36	No	Single-center study	Retrospective	Wuhan, China	16-Mar-2020	
#00436	CT_32445881	Arbidol/IFN-α2b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study.	32445881	https://doi.org/10.1016/j.micinf.2020.05.012	https://pubmed.ncbi.nlm.nih.gov/32445881	141	Drug(s)	Arbidol | Interferon α2β					No	Multicenter cohort study.	Retrospective	China	20-May-2020	
#00437	CT_32425649	Clinical characteristics and co-infections of 354 hospitalized patients with COVID-19 in Wuhan, China: a retrospective cohort study.	32425649	https://doi.org/10.1016/j.micinf.2020.05.007	https://pubmed.ncbi.nlm.nih.gov/32425649	354	Other			04-Feb-2020	28-Feb-2020	25	No	Cohort study	Retrospective	Wuhan, China	18-May-2020	
#00438	CT_32425648	A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients.	32425648	https://doi.org/10.1016/j.micinf.2020.05.008	https://pubmed.ncbi.nlm.nih.gov/32425648	238	Other			06-Feb-2020	14-Feb-2020	9	No	Case report		Hubei, China	18-May-2020	
#00439	CT_32387682	Characteristics of asymptomatic patients with SARS-CoV-2 infection in Jinan, China.	32387682	https://doi.org/10.1016/j.micinf.2020.04.011	https://pubmed.ncbi.nlm.nih.gov/32387682	47	Drug(s)	Arbidol | Ritonavir | Lopinavir | Interferon-α	- 45 Discharge. - 2 Hospitalization.	23-Jan-2020	10-Mar-2020	48	No	Case report	Retrospective	Jinan, China	7-May-2020	
#00440	CT_32434211	Viral and host factors related to the clinical outcome of COVID-19	32434211	https://doi.org/10.1038/s41586-020-2355-0	https://pubmed.ncbi.nlm.nih.gov/32434211	326	Other			20-Jan-2020	25-Feb-2020	37	No	Case analysis		Shanghai, China	20-May-2020	
#00441	CT_32291260	Covid-19: Nine in 10 pregnant women with infection when admitted for delivery are asymptomatic, small study finds.	32291260	https://doi.org/10.1136/bmj.m1485	https://pubmed.ncbi.nlm.nih.gov/32291260	215	Other			22-Mar-2020	04-Apr-2020	14	No	Case report		New York, USA	14-Apr-2020	
#00442	CT_32243501	First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab.	32243501	https://doi.org/10.1182/bloodadvances.2020001907	https://pubmed.ncbi.nlm.nih.gov/32243501	1	Drug(s)	Tocilizumab	The patient's clinical conditions gradually recovered after Tocilizumab treatment.	01-Feb-2020	13-Mar-2020	42	No	Case study		Wuhan, China	14-Apr-2020	
#00443	CT_32302722	Clinical characteristics of 80 hospitalized frontline medical workers infected with COVID-19 in Wuhan, China.	32302722	https://doi.org/10.1016/j.jhin.2020.04.019	https://pubmed.ncbi.nlm.nih.gov/32302722	80	Drug(s) | Oxygen support	Corticosteroid | Empirical antibiotics | Empirical Antivirals	- 78 Discharged. - 1 Died. - 1 Remained in ICU.	10-Jan-2020	24-Feb-2020	46	No	Case report		Wuhan, China	14-Apr-2020	
#00444	CT_32275288	Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China.	32275288	https://doi.org/10.1001/jamaneurol.2020.1127	https://pubmed.ncbi.nlm.nih.gov/32275288	214				16-Jan-2020	19-Feb-2020	35	No	Observational case series	Retrospective	Wuhan, China	10-Apr-2020	
#00445	CT_32283154	Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19	32283154	https://doi.org/10.1016/j.jinf.2020.03.044	https://pubmed.ncbi.nlm.nih.gov/32283154	58	IVIG | Drug(s)	Immunoglobulin (IVIG) | Arbidol | Moxifloxacin	- 23 patients died within 28 days of admission. Treatment with IVIG within 48 h of admission not only reduced ventilator use, but also reduced hospital and ICU length of stay, ultimately improving 28-day mortality.				No		Retrospective	Wuhan, China	10-Apr-2020	
#00446	CT_32278670	SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day survival in Vitoria.	32278670	https://doi.org/10.1016/j.accpm.2020.04.001	https://pubmed.ncbi.nlm.nih.gov/32278670	48	Drug(s) | IVIG | Oxygen support	Ganciclovir | Empirical antibiotics | Corticosteroid | Lopinavir | Interferon-α | Oseltamivir | Chloroquine | Immunoglobulin (IVIG) | Ritonavir	- Seven-day mortality in SARS-CoV-2 requiring intubation was lower than 15%. - 80% of patients still requiring prolonged mechanical ventilation. - After 15 days of ICU admission, half of patients remained intubated, whereas one third were non-survivors	04-Mar-2020	31-Mar-2020	28	No	Cohort study	Prospective	Vitoria, Spain	9-Apr-2020	
#00447	CT_32267998	Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series	32267998	https://doi.org/10.1111/jth.14828	https://pubmed.ncbi.nlm.nih.gov/32267998	3	Drug(s)	Tissue Plasminogen Activator (tPA) | Hydroxychloroquine | Azithromycin	The patients demonstrated an initial improvement in their P/F ratio, with improvements ranging from a 38% improvement (case 3) to a ~100% improvement (case 1)				No	Case report		Colorado, USA	8-Apr-2020	
#00448	CT_32249943	A comparative-descriptive analysis of clinical characteristics in 2019-coronavirus-infected children and adults	32249943	https://doi.org/10.1002/jmv.25835	https://pubmed.ncbi.nlm.nih.gov/32249943	32	Drug(s) | Oxygen support	Glucocorticoids | Empirical Antivirals | Empirical antibiotics	All patients were discharge from hospital.	31-Jan-2020	16-Feb-2020	17	No	Descriptive analysis study	Retrospective	Xi'an, China	6-Apr-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00449	CT_32395474	The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension.	32395474	https://doi.org/10.21037/atm.2020.03.229	https://pubmed.ncbi.nlm.nih.gov/32395474	50			There is no obvious difference between the RAS blockers and non-RAS blockers in clinical features and course of hypertension patients suffering from the COVID-19.	07-Feb-2020	03-Mar-2020	26	No	Observational study		Wuhan, China	30-Mar-2020	
#00450	CT_32347201	Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020.	32347201	https://doi.org/10.2807/1560-7917.ES.2020.25.16.2000460	https://pubmed.ncbi.nlm.nih.gov/32347201	44	Drug(s)	Hydroxychloroquine | Lopinavir | Ritonavir | Empirical antibiotics	- 14 patients were discharged. - 17 pts. had severe disease. - 2 fatalities.	21-Feb-2020	28-Feb-2020	8	No		Retrospective	Pavia, Italy	23-Apr-2020	
#00451	CT_32285380	Clinical characteristics of 19 neonates born to mothers with COVID-19.	32285380	https://doi.org/10.1007/s11684-020-0772-y	https://pubmed.ncbi.nlm.nih.gov/32285380	19	Other			31-Jan-2020	29-Feb-2020	30	No			Wuhan, China	13-Apr-2020	
#00452	CT_32544155	Clinical and epidemiological characteristics of pediatric SARS-CoV-2 infections in China: A multicenter case series.	32544155	https://doi.org/10.1371/journal.pmed.1003130	https://pubmed.ncbi.nlm.nih.gov/32544155	34	Drug(s) | Oxygen support | Other	Interferon-α | Traditional Chinese medicine | Corticosteroid | Ribavirin | Empirical antibiotics	- All patients were discharged once the main symptoms disappeared and the SARS-CoV-2 tests became negative. - Lesions in lobules recovered in only 8 patients. - lesions still existed in 24 patients (75%).	27-Jan-2020	23-Feb-2020	28	No	Multicenter observational case series.	Retrospective	West China	16-Jun-2020	
#00453	CT_32584326	CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS OF PATIENTS DIAGNOSED WITH COVID-19 IN A TERTIARY CARE CENTER IN MEXICO CITY: A PROSPECTIVE COHORT STUDY.	32584326	https://doi.org/10.24875/RIC.20000211	https://pubmed.ncbi.nlm.nih.gov/32584326	309	Drug(s) | Other	Hydroxychloroquine | Oseltamivir | Tocilizumab | Chloroquine | Empirical antibiotics | Remdesivir		26-Feb-2020	11-Apr-2020	46	No	Cohort study	Prospective	Mexico City, Mexico	14-May-2020	
#00454	CT_32275812	Compassionate Use of Remdesivir for Patients With Severe Covid-19	32275812	https://doi.org/10.1056/NEJMoa2007016	https://pubmed.ncbi.nlm.nih.gov/32275812	53	Drug(s)	Remdesivir	Clinical improvement was observed in 36 of 53 patients (68%).	25-Jan-2020	07-Mar-2020	43	No	Cohort study			10-Apr-2020	
#00455	CT_32007145	Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.	32007145	https://doi.org/10.1016/S0140-6736(20)30251-8	https://pubmed.ncbi.nlm.nih.gov/32007145	9	Other						No			China	30-Jan-2020	
#00456	CT_32522037	A Case Series of Patients Coinfected With Influenza and COVID-19.	32522037	https://doi.org/10.1177/2324709620934674	https://pubmed.ncbi.nlm.nih.gov/32522037	3	Drug(s) | Oxygen support	Empirical Antivirals | Glucocorticoids | Empirical antibiotics	Two patients were treated successfully and discharged home.				No	Case series		USA	10-Jun-2020	
#00457	CT_32474479	Analysis of thin-section CT in patients with coronavirus disease (COVID-19) after hospital discharge.	32474479	https://doi.org/10.3233/XST-200685	https://pubmed.ncbi.nlm.nih.gov/32474479	59	Other			18-Jan-2020	01-Mar-2020	44	No	Multi-center, retrospective study		China	9-Jun-2020	
#00458	CT_32634855	Clinical Observations in the Very Elderly Patients With COVID-19 in Wuhan	32634855	https://doi.org/10.1111/ggi.13974	https://pubmed.ncbi.nlm.nih.gov/32634855	7	Drug(s) | Oxygen support | Other		- Probably due to low immune response, the ratio of fatal cases in the very elderly COVID-19 infected patients is not higher to that reported in the non-elderly patients. - The elderly patients manifested minor clinical symptoms and atypical changes in chest CT images.				No	Single center clinical study	Retrospective	Wuhan, China	7-Jul-2020	
#00459	CT_32049601	Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing.	32049601	https://doi.org/10.1148/radiol.2020200343	https://pubmed.ncbi.nlm.nih.gov/32049601	5	Other						No	Case report		Hunan, China	12-Feb-2020	
#00460	CT_32640484	Blood Component Use in Critical Care in Patients with COVID-19 Infection: A Single Centre Experience.	32640484	https://doi.org/10.1111/bjh.17007	https://pubmed.ncbi.nlm.nih.gov/32640484	50	Plasma			03-Mar-2020	14-Apr-2020	43	No	Cohort study	Prospective	London, United Kingdom	8-Jul-2020	
#00461	CT_32634129	Kinetics of viral load and antibody response in relation to COVID-19 severity.	32634129	https://doi.org/10.1172/JCI138759	https://pubmed.ncbi.nlm.nih.gov/32634129	23	Plasma | Other		- 8 Discharged. - 10 Remained in ICU. - 3 Isolation ward. - 2 Transferred out of ICU.	28-Jan-2020	24-Feb-2020	28	No			Guangzhou, China	7-Jul-2020	
#00462	CT_32627216	Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation.	32627216	https://doi.org/10.1111/trf.15918	https://pubmed.ncbi.nlm.nih.gov/32627216	49	Plasma		The S-RBD-specific IgG antibody reaches higher levels after 4 weeks from the onset of COVID-19 symptoms.	12-Feb-2020	02-Mar-2020	20	No		Prospective	Wuhan, China	6-Jul-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00463	CT_32491199	Feasibility of a Pilot Program for COVID-19 Convalescent Plasma Collection in Wuhan, China.	32491199	https://doi.org/10.1111/trf.15921	https://pubmed.ncbi.nlm.nih.gov/32491199	64	Plasma			13-Feb-2020	03-Mar-2020	20	No	Case report		Wuhan, China	3-Jun-2020	
#00464	CT_32609874	ABO Phenotype and Death in Critically Ill Patients with COVID-19.	32609874	https://doi.org/10.1111/bjh.16984	https://pubmed.ncbi.nlm.nih.gov/32609874	2,033			- 799 died. - The data suggest that type A blood may be a risk factor for COVID-19-related critical illness among White patients, and that type O blood may be protective.	04-Mar-2020	11-Apr-2020	39	No	A multicenter cohort study		USA	1-Jul-2020	
#00465	CT_32588051	Epidemiological and clinical characteristics of 671 COVID-19 patients in Henan Province, China.	32588051	https://doi.org/10.1093/ije/dyaa081	https://pubmed.ncbi.nlm.nih.gov/32588051	671	Other		- 615 Remained in hospital. - 54 Discharged. - 2 Died.	23-Jan-2020	05-Feb-2020	14	No	Cohort study		Henan, China	26-Jun-2020	
#00466	CT_32234127	Epidemiological characteristics of COVID-19 in Gansu province.	32234127	https://doi.org/10.3760/cma.j.cn112338-20200229-00216	https://pubmed.ncbi.nlm.nih.gov/32234127	91	Other			08-Jan-2020	18-Feb-2020	42	No	Case report		Gansu, China	1-Apr-2020	
#00467	CT_32228732	Epidemiological Characteristics on the Clustering Nature of COVID-19 in Qingdao City, 2020: A Descriptive Analysis.	32228732	https://doi.org/10.1017/dmp.2020.59	https://pubmed.ncbi.nlm.nih.gov/32228732	44	Other		- 42 Discharged. - 1 Remained in hospital. - 1 Died.	29-Jan-2020	23-Feb-2020	26	No	A Descriptive Analysis	Retrospective	Qingdao, China	31-Mar-2020	
#00468	CT_32300051	Characteristics of COVID-19 infection in Beijing.	32300051	https://doi.org/10.1016/j.jinf.2020.02.018	https://pubmed.ncbi.nlm.nih.gov/32300051	262			- 45 Discharged. - 214 Hospitalization. - 3 Death.	20-Jan-2020	10-Feb-2020	22	No	Observational study	Retrospective	Beijing, China	27-Feb-2020	
#00469	CT_32275319	Clinical Characteristics of Patients Who Died of Coronavirus Disease 2019 in China.	32275319	https://doi.org/10.1001/jamanetworkopen.2020.5619	https://pubmed.ncbi.nlm.nih.gov/32275319	168	Other			21-Jan-2020	30-Jan-2020	10	No	Case series		Wuhan, China	10-Apr-2020	
#00470	CT_32284613	Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding.	32284613	https://doi.org/10.1038/s41591-020-0817-4	https://pubmed.ncbi.nlm.nih.gov/32284613	10	Other | Drug(s) | IVIG	Immunoglobulin (IVIG) | Interferon-β | Azithromycin	- 4 Discharged. - 6 continued to be under hospital isolation and observation.	22-Jan-2020	20 Feb	30	No	Single-center, observational study	Prospective	Guangzhou, China	13-Mar-2020	
#00471	CT_32273604	Lopinavir-ritonavir in severe COVID-19.	32273604	https://doi.org/10.1038/s41591-020-0849-9	https://pubmed.ncbi.nlm.nih.gov/32273604	199	Drug(s)	lopinavir | ritonavir	No benefit was observed with lopinavir–ritonavir treatment beyond standard care.	18-Jan-2020	03-Feb-2020	17	No	Randomized, controlled, open-label trial		Wuhan, China	7-May-2020	
#00472	CT_32450106	Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial	32450106	https://doi.org/10.1016/S0140-6736(20)31208-3	https://pubmed.ncbi.nlm.nih.gov/32450106	108	Vaccine	Recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine	A positive antibody response (seroconversion) was defined as at least a four-fold increase in post-vaccination titre from baseline.	16-Mar-2020	27-Mar-2020	12	No	A single-centre, open-label, non-randomised, dose-escalation phase one trial		Wuhan, China	22-May-2020	
#00473	CT_32350134	Effective treatment of severe COVID-19 patients with tocilizumab	32350134	https://doi.org/10.1073/pnas.2005615117	https://pubmed.ncbi.nlm.nih.gov/32350134	21	Drug(s)	Tocilizumab | Ribavirin | Ritonavir | Interferon-α | Glucocorticoids | Lopinavir	Tocilizumab effectively improve clinical symptoms and represses the deterioration of severe COVID-19 patients.	05-Feb-2020	14-Feb-2020	10	No		Prospective	Shanghai, China	29-Apr-2020	
#00474	CT_32408793	Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression.	32408793	https://doi.org/10.1177/1470320320926899	https://pubmed.ncbi.nlm.nih.gov/32408793	6,560			Hypertension was associated with increased composite poor outcome.				Yes			Indonesia	14-May-2020	
#00475	CT_32361738	Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Hospitalized Patients in Wuhan, China	32361738	https://doi.org/10.1093/cid/ciaa539	https://pubmed.ncbi.nlm.nih.gov/32361738	323	Other | Drug(s) | Oxygen support	Corticosteroid | Interferon-α | Ganciclovir | Oseltamivir | Ritonavir | Arbidol | Lopinavir	- 252 Discharged. - 36 Still hospitalized. - 35 Died.	08-Jan-2020	20-Feb-2020	44	No		Retrospective	Wuhan, China	3-May-2020	
#00476	CT_32527342	Clinical characteristics and risk factors of acute kidney injury in coronavirus disease 2019	32527342	https://doi.org/10.3760/cma.j.cn121430-20200302-00198	https://pubmed.ncbi.nlm.nih.gov/32527342	394	Other			01-Jan-2020	01-Feb-2020	32	No	A multi-center cohort study	Retrospective	Wuhan, China	4-Apr-2020	
#00477	CT_32215598	Neonatal Early-Onset Infection With SARS-CoV-2 in 33 Neonates Born to Mothers With COVID-19 in Wuhan, China.	32215598	https://doi.org/10.1001/jamapediatrics.2020.0878	https://pubmed.ncbi.nlm.nih.gov/32215598	33	Other		- 3 Infected neonates. - 30 Noninfected neonates.				No	Cohort study		Wuhan, China	26-Mar-2020	
#00478	CT_32213270	Epidemiological analysis on 1052 cases of COVID-19 in epidemic clusters.	32213270	https://doi.org/10.3760/cma.j.cn112338-20200301-00223	https://pubmed.ncbi.nlm.nih.gov/32213270	1,052	Other			19-Jan-2020	25-Feb-2020	38	No	Case study		China	26-Mar-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00479	CT_32376589	**Chest CT findings and their dynamic changes in patients with COVID-19**	32376589	https://doi.org/10.12122/j.issn.1673-4254.2020.03.05	https://pubmed.ncbi.nlm.nih.gov/32376589	6	Other			27-Jan-2020	26-Feb-2020	31	No		Retrospective	Xi'an, China	20-Mar-2020	
#00480	CT_32395487	**Clinical characteristics of Coronavirus Disease 2019 and development of a prediction model for prolonged hospital length of stay.**	32395487	https://doi.org/10.21037/atm.2020.03.147	https://pubmed.ncbi.nlm.nih.gov/32395487	75	Drug(s)	Corticosteroid | Empirical Antivirals | Empirical antibiotics		Jan 2020	20-Feb-2020	51	No	Cohort study	Retrospective	Zhejiang, China	8-Apr-2020	
#00481	CT_32702731	**Hospitalized COVID-19 Patients treated with Convalescent Plasma in a Mid-size City in the Midwest.**	32702731	https://doi.org/10.21203/rs.3.rs-39447/v1	https://pubmed.ncbi.nlm.nih.gov/32702731	31	Plasma		A high rate clinical improvement was observed among mechanically ventilated patients who received COVID-19 convalescent plasma. Although 4 (29%) of the patients with life-threatening disease died.	12-Apr-2020	02-Jun-2020	52	No		Retrospective	Wisconsin, USA	27-Mar-2020	
#00482	CT_32702298	**Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.**	32702298	https://doi.org/10.1016/S0140-6736(20)31604-4	https://pubmed.ncbi.nlm.nih.gov/32702298	1,077	Vaccine		ChAdOx1 nCoV-19 showed an acceptable safety profile, and homologous boosting increased antibody responses.	23-Apr-2020	21-May-2020	29	No	Single-blind, randomised controlled trial		Oxford, UK	20-Jul-2020	
#00483	CT_32706425	**The dynamic changes of serum IgM and IgG against SARS-CoV-2 in patients with COVID-19.**	32706425	https://doi.org/10.1002/jmv.26353	https://pubmed.ncbi.nlm.nih.gov/32706425	97	Other		All patients were discharged from hospital before April 8, 2020, except one critical patient who died from acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome 33 days after symptom onset.	26-Jan-2020	05-Mar-2020	40	No		Retrospective	Wuhan, China	24-Jul-2020	
#00484	CT_32301646	**Diagnostic Performance of CT and Reverse Transcriptase-Polymerase Chain Reaction for Coronavirus Disease 2019: A Meta-Analysis.**	32301646	https://doi.org/10.1148/radiol.2020201343	https://pubmed.ncbi.nlm.nih.gov/32301646	6,218	Other			01-Jan-2020	03-Apr-2020	94	Yes			Seoul, South Korea	17-Apr-2020	
#00485	CT_32297987	**Off-label use of tocilizumab in patients with SARS-CoV-2 infection.**	32297987	https://doi.org/10.1002/jmv.25897	https://pubmed.ncbi.nlm.nih.gov/32297987	3	Drug(s)	Tocilizumab					No			Roma, Italy	16-Apr-2020	
#00486	CT_32293753	**The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis.**	32293753	https://doi.org/10.1002/jmv.25889	https://pubmed.ncbi.nlm.nih.gov/32293753	2,002	Other			Dec 2019	22-Mar-2020	113	Yes			China	17-May-2020	
#00487	CT_32275072	**Vaginal delivery report of a healthy neonate born to a convalescent mother with COVID--19.**	32275072	https://doi.org/10.1002/jmv.25857	https://pubmed.ncbi.nlm.nih.gov/32275072	1	Drug(s) | Other	Empirical antibiotics | Corticosteroid | Empirical Antivirals	Intrauterine vertical transmission was not observed in this case.				No	Case report		Beijing, China	10-Apr-2020	
#00488	CT_32292903	**COVID-19 infection among asymptomatic and symptomatic pregnant women: Two weeks of confirmed presentations to an affiliated pair of New York City hospitals.**	32292903	https://doi.org/10.1016/j.ajogmf.2020.100118	https://pubmed.ncbi.nlm.nih.gov/32292903	43	Other			13-Mar-2020	27-Mar-2020	15	No	Cohort study	Retrospective	New York, USA	9-Apr-2020	
#00489	CT_32241316	**Case Report on Early Diagnosis of COVID-19**	32241316	https://doi.org/10.1017/dmp.2020.66	https://pubmed.ncbi.nlm.nih.gov/32241316	4	Other						No	Case report		China	3-Apr-2020	
#00490	CT_32271602	**Improved Early Recognition of Coronavirus Disease-2019 (COVID-19): Single-Center Data from a Shanghai Screening Hospital.**	32271602	https://doi.org/10.34172/aim.2020.10	https://pubmed.ncbi.nlm.nih.gov/32271602	86	Other			23-Jan-2020	16-Feb-2020	25	No	Cross-sectional, single-center case reports		Shanghai, China	1-Apr-2020	
#00491	CT_32198088	**Transmission potential and severity of COVID-19 in South Korea.**	32198088	https://doi.org/10.1016/j.ijid.2020.03.031	https://pubmed.ncbi.nlm.nih.gov/32198088	6,284			- 108 Discharged. - 6134 Isolated. - 42 Death.	20-Jan-2020	06-Mar-2020	47	No	Case report		South Korea	18-Mar-2020	
#00492	CT_32527344	**Clinical study of artesunate in the treatment of new coronavirus pneumonia**	32527344	https://doi.org/10.3760/cma.j.cn121430-20200312-00412	https://pubmed.ncbi.nlm.nih.gov/32527344	43	Drug(s)	Artesunate | Lopinavir | Ritonavir | Interferon-α	Artesunate can significantly improve the clinical symptoms of patients with new coronary pneumonia, shorten the time for 2019-nCoV nucleic acid to become negative, and promote the absorption of lung lesions	22-Jan-2020	15-Feb-2020	25	No		Prospective	Nanning, China	1-Apr-2020	
#00493	CT_32292866	**Management Of Patients On Dialysis And With Kidney Transplant During SARS-COV-2 (COVID-19) Pandemic In Brescia, Italy.**	32292866	https://doi.org/10.1016/j.ekir.2020.04.001	https://pubmed.ncbi.nlm.nih.gov/32292866	46	Drug(s) | Other	Hydroxychloroquine | Dexamethasone | Tocilizumab		28-Feb-2020	22-Mar-2020	24	No	Cohort study		Brescia, Italy	4-Apr-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00494	CT_32246819	Pulmonary High-Resolution Computed Tomography (HRCT) Findings of Patients with Early-Stage Coronavirus Disease 2019 (COVID-19) in Hangzhou, China	32246819	https://doi.org/10.12659/MSM.923885	https://pubmed.ncbi.nlm.nih.gov/32246819	6	Other			20-Jan-2020	02-Feb-2020	14	No		Retrospective	Hangzhou, Zhejiang, China	4-Apr-2020	
#00495	CT_32246317	Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2.	32246317	https://doi.org/10.1007/s11239-020-02105-8	https://pubmed.ncbi.nlm.nih.gov/32246317	553	Other		COVID group 28-day mortality: 134 (29.8%). Non-COVID group 28-day mortality: 16 (15.4%).	01-Jan-2020	13-Feb-2020	44	No		Retrospective	Wuhan, China	3-Apr-2020	
#00496	CT_32163697	Detection of Covid-19 in Children in Early January 2020 in Wuhan, China.	32163697	https://doi.org/10.1056/NEJMc2003717	https://pubmed.ncbi.nlm.nih.gov/32163697	6	Drug(s) | Other | IVIG | Oxygen support	Immunoglobulin (IVIG) | Ribavirin | Oseltamivir		07-Jan-2020	15-Jan-2020	9	No		Retrospective	Wuhan, China	2-Apr-2020	
#00497	CT_32347200	Strong associations and moderate predictive value of early symptoms for SARS-CoV-2 test positivity among healthcare workers, the Netherlands, March 2020.	32347200	https://doi.org/10.2807/1560-7917.ES.2020.25.16.2000508	https://pubmed.ncbi.nlm.nih.gov/32347200	803				10-Mar-2020	29-Mar-2020	20	No	Cohort study		Nijmegen, Netherlands	23-Apr-2020	
#00498	CT_32170559	Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19.	32170559	https://doi.org/10.1007/s11684-020-0757-x	https://pubmed.ncbi.nlm.nih.gov/32170559	3	Drug(s) | IVIG | Other	Traditional Chinese medicine | Empirical antibiotics | Immunoglobulin (IVIG) | Empirical Antivirals | Dexamethasone		17-Jan-2020	06-Feb-2020	21	No	Case report		Wuhan, China	13-Mar-2020	
#00499	CT_32733980	Prevalence of Comorbidities in COVID-19 Patients: A Systematic Review and Meta-Analysis.	32733980	https://doi.org/10.22038/abjs.2020.47754.2346	https://pubmed.ncbi.nlm.nih.gov/32733980	9,249							Yes			Mashhad, Iran	10-Apr-2020	
#00500	CT_32347027	Acute Hyperglycemic Crises with Coronavirus Disease-19: Case Reports	32347027	https://doi.org/10.4093/dmj.2020.0091	https://pubmed.ncbi.nlm.nih.gov/32347027	2	Drug(s) | Other	Empirical Antivirals | Empirical antibiotics | Intravenous fluid | Regular insulin					No	Case report	Retrospective	Daegu, Korea	23-Apr-2020	
#00501	CT_32073353	Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR	32073353	https://doi.org/10.1148/radiol.2020200432	https://pubmed.ncbi.nlm.nih.gov/32073353	51	Other			19-Jan-2020	04-Feb-2020	17	No	Case series	Retrospective	Wenzhou, China	19-Feb-2020	
#00502	CT_32297925	Sequential analysis of viral load in a neonate and her mother infected with SARS-CoV-2.	32297925	https://doi.org/10.1093/cid/ciaa447	https://pubmed.ncbi.nlm.nih.gov/32297925	2	Other			11-Feb-2020	26-Mar-2020	45	No	Case report		Seoul, Korea	16-Apr-2020	
#00503	CT_32305557	The impact of 2019 novel coronavirus on heart injury: A Systematic review and Meta-analysis.	32305557	https://doi.org/10.1016/j.pcad.2020.04.008	https://pubmed.ncbi.nlm.nih.gov/32305557	4,189				01-Dec-2019	27-Mar-2020	118	Yes			China	16-Apr-2020	
#00504	CT_32291502	Evolution of CT findings in patients with mild COVID-19 pneumonia	32291502	https://doi.org/10.1007/s00330-020-06823-8	https://pubmed.ncbi.nlm.nih.gov/32291502	88	Other			22-Jan-2020	08-Feb-2020	18	No	Cohort study	Retrospective	Shaanxi, China	15-Apr-2020	
#00505	CT_32511595	Covid-19 Testing, Hospital Admission, and Intensive Care Among 2,026,227 United States Veterans Aged 54–75 Years	32511595	https://doi.org/10.1101/2020.04.09.20059964	https://pubmed.ncbi.nlm.nih.gov/32511595	2,026,227				08-Feb-2020	30-Mar-2020	52	No	Cohort study	Retrospective	USA	14-Apr-2020	
#00506	CT_32302000	The duration of viral shedding of discharged patients with severe COVID-19.	32302000	https://doi.org/10.1093/cid/ciaa451	https://pubmed.ncbi.nlm.nih.gov/32302000	41	Other			05-Feb-2020	16-Mar-2020	41	No	Cohort study		Wuhan, China	17-Apr-2020	
#00507	CT_32420523	Clinical characteristics of hospitalised patients with schizophrenia who were suspected to have coronavirus disease (COVID-19) in Hubei Province, China.	32420523	https://doi.org/10.1136/gpsych-2020-100222	https://pubmed.ncbi.nlm.nih.gov/32420523	51	Other		Patients with schizophrenia suspected to have COVID-19 showed increased stress and mood and sleep disturbances.	30-Jan-2020	15-Feb-2020	17	No	Double-centre study	Retrospective	Hubei, China	19-Apr-2020	
#00508	CT_32301967	SARS-CoV-2 infection (COVID-19) in febrile infants without respiratory distress.	32301967	https://doi.org/10.1093/cid/ciaa452	https://pubmed.ncbi.nlm.nih.gov/32301967	2	Other | Drug(s)	Empirical antibiotics (Ceftriaxone)	Discharged				No	Case report		New York, USA	17-Apr-2020	
#00509	CT_32301964	The characteristics of household transmission of COVID-19.	32301964	https://doi.org/10.1093/cid/ciaa450	https://pubmed.ncbi.nlm.nih.gov/32301964	497	Other			01-Jan-2020	20 Feb	51	No	Cohort study	Retrospective	Hubei, China	17-Apr-2020	
#00510	CT_32297985	Evaluation of antiviral therapies for coronavirus disease 2019 pneumonia in Shanghai, China.	32297985	https://doi.org/10.1002/jmv.25893	https://pubmed.ncbi.nlm.nih.gov/32297985	184	Drug(s)	Arbidol | Lopinavir/Ritonavir | Interferon | Darunavir | Interferon-α2β		20-Jan-2020	07-Feb-2020	19	No	Single-center cohort study	Retrospective	Shanghai, China	16-Apr-2020	
#00511	CT_32373237	Multicenter cohort study demonstrates more consolidation in upper lungs on initial CT increases the risk of adverse clinical outcome in COVID-19 patients.	32373237	https://doi.org/10.7150/thno.46465	https://pubmed.ncbi.nlm.nih.gov/32373237	421	Other		350 were discharged and no deaths, as of March 6, 2020.	10-Jan-2020	18-Feb-2020	40	No	Cohort study	Retrospective	Jiangsu, China	27-Apr-2020	
#00512	CT_32373235	CT quantification of pneumonia lesions in early days predicts progression to severe illness in a cohort of COVID-19 patients	32373235	https://doi.org/10.7150/thno.45985	https://pubmed.ncbi.nlm.nih.gov/32373235	134	Other			20-Jan-2020	03-Feb-2020	15	No	Cohort study	Retrospective	Shanghai, China	27-Apr-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00513	CT_32340095	Clinical outcomes of COVID-19 cases and influencing factors in Guangdong province	32340095	https://doi.org/10.3760/cma.j.cn112338-20200318-00378	https://pubmed.ncbi.nlm.nih.gov/32340095	1,350	Other						No	Case analysis		Guangdong, China	27-Apr-2020	
#00514	CT_32340096	A preliminary clinical study on the direct renin inhibitor Aliskiren in the treatment of patients with severe new coronavirus pneumonia and hypertension	32340096	https://doi.org/10.3760/cma.j.cn112138-20200326-00310	https://pubmed.ncbi.nlm.nih.gov/32340096	4	Drug(s) | Oxygen support |Other	Empirical Antivirals | Empirical Antibiotic | Glucocorticoid | Aliskiren					No	Case analysis	Retrospective	Wuhan, China	27-Apr-2020	
#00515	CT_32307322	Clinical characteristics and diagnostic challenges of pediatric COVID-19: A systematic review and meta-analysis	32307322	https://doi.org/10.1016/j.jfma.2020.04.007	https://pubmed.ncbi.nlm.nih.gov/32307322	93							Yes	Case series		Tainan, Taiwan	16-Apr-2020	
#00516	CT_32350161	Analysis of coagulation parameters in patients with COVID-19 in Shanghai, China	32350161	https://doi.org/10.5582/bst.2020.03086	https://pubmed.ncbi.nlm.nih.gov/32350161	303	Other		240 patient were discharged	20-Jan-2020	24-Feb-2020	36	No	Case aalysis	Retrospective	Shanghai, China	30-Apr-2020	
#00517	CT_32109013	Clinical Characteristics of Coronavirus Disease 2019 in China	32109013	https://doi.org/10.1056/NEJMoa2002032	https://pubmed.ncbi.nlm.nih.gov/32109013	1,099	Drug(s) | Oxygen support	Oseltamivir | Glucocorticoids | Antifungal drugs | Empirical Antivirals	1029 Hospitalization. 55 Discharge from hospital. 15 Death. 9 Recovery.	11-Dec-2019	29-Jan-2020	50	No	Cohort study		China	28-Feb-2020	
#00518	CT_32457924	Analysis of Mortality in Patients With COVID-19: Clinical and Laboratory Parameters.	32457924	https://doi.org/10.1093/ofid/ofaa152.	https://pubmed.ncbi.nlm.nih.gov/32457924	14	Other | Drug(s)	Glucocorticoids					No	Cohort study	Retrospective	Wuhan, China	29-Apr-2020	
#00519	CT_32345311	Clinical determinants for fatality of 44,672 patients with COVID-19.	32345311	https://doi.org/10.1186/s13054-020-02902-w	https://pubmed.ncbi.nlm.nih.gov/32345311	44,672	Other		43,649 Survivors. 1023 Non-survivors.				Yes	case series		Hunan, China	28-Apr-2020	
#00520	CT_32353991	Early Transmission Dynamics of Novel Coronavirus (COVID-19) in Nigeria.	32353991	https://doi.org/10.3390/ijerph17093054	https://pubmed.ncbi.nlm.nih.gov/32353991	318				17-Feb-2020	11-Apr-2020	55	No	Case report		Nigeria	28-Apr-2020	
#00521	CT_32343745	Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: A retrospective study of 168 severe patients.	32343745	https://doi.org/10.1371/journal.ppat.1008520	https://pubmed.ncbi.nlm.nih.gov/32343745	168	Other		136 patients discharge. 17 patients died.	16-Jan-2020	04-Feb-2020	20	No	Case series	Retrospective	Wuhan, China	28-Apr-2020	
#00522	CT_32346493	Clinical presentations and outcomes of SARS-CoV-2 infected pneumonia in pregnant women and health status of their neonates	32346493	https://doi.org/10.1016/j.scib.2020.04.040	https://pubmed.ncbi.nlm.nih.gov/32346493	10	Other			21-Jan-2020	09-Feb-2020	20	No		Retrospective	Wuhan, China	28-Apr-2020	
#00523	CT_32423584	Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.	32423584	https://doi.org/10.1016/S0140-6736(20)31022-9	https://pubmed.ncbi.nlm.nih.gov/32423584	237	Drug(s)	Remdesivir	Patients receiving Remdesivir had a numerically faster time to clinical improvement than those receiving placebo	06-Feb-2020	12-Mar-2020	36	No	Randomised, double-blind, placebo-controlled, multicentre trial		Hubei, China	29-Apr-2020	
#00524	CT_32409825	Analysis of the infection status of the health care workers in Wuhan during the COVID-19 outbreak: A cross-sectional study	32409825	https://doi.org/10.1093/cid/ciaa588	https://pubmed.ncbi.nlm.nih.gov/32409825	2,457				20-Jan-2020	05-Feb-2020	17	No	Cross-sectional study		Wuhan, China	15-May-2020	
#00525	CT_32422408	Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study.	32422408	https://doi.org/10.1016/j.cmi.2020.05.001	https://pubmed.ncbi.nlm.nih.gov/32422408	200	Other		Saliva might be a non-invasive alternative specimen for the diagnosis of COVID-19.	27-Mar-2020	04-Apr-2020	9	No	Cross-sectional study	Prospective	Bangkok, Thailand	15-May-2020	
#00526	CT_32415585	Chest CT for detecting COVID-19: a systematic review and meta-analysis of diagnostic accuracy.	32415585	https://doi.org/10.1007/s00330-020-06934-2	https://pubmed.ncbi.nlm.nih.gov/32415585	3,186							Yes			China	15-May-2020	
#00527	CT_32574328	Clinical Features, Diagnosis, and Treatment of COVID-19 in Hospitalized Patients: A Systematic Review of Case Reports and Case Series.	32574328	https://doi.org/10.3389/fmed.2020.00231	https://pubmed.ncbi.nlm.nih.gov/32574328	417	Drug(s)	Oseltamivir | Methylprednisolone | Empirical Antivirals | Lopinavir | Ganciclovir | Arbidol | Remdesivir | Ritonavir | Ribavirin | Veletonavir					Yes	A systematic review of case reports and case series		Tehran, Iran	15-May-2020	
#00528	CT_32410285	A retrospective study on the epidemiological characteristics and establishment of an early warning system of severe COVID-19 patients.	32410285	https://doi.org/10.1002/jmv.26022	https://pubmed.ncbi.nlm.nih.gov/32410285	133				01-Jan-2020	Mar 2020	61	No	Cohort study	Retrospective	Chongqing, China	2-Jun-2020	
#00529	CT_32483458	Risk factors for adverse clinical outcomes with COVID-19 in China: a multicenter, retrospective, observational study.	32483458	https://doi.org/10.7150/thno.46833	https://pubmed.ncbi.nlm.nih.gov/32483458	703	Other		- 648 discharged without any adverse outcome. - 55 developed adverse outcomes (including 33 deceased)	10-Jan-2020	13-Mar-2020	64	No	A multicenter, observational study	Retrospective	China	15-May-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00530	CT_32483442	Association of clinical and radiographic findings with the outcomes of 93 patients with COVID-19 in Wuhan, China.	32483442	https://doi.org/10.7150/thno.46569	https://pubmed.ncbi.nlm.nih.gov/32483442	93	Other | Drug(s) | IVIG | Oxygen support	Immunoglobulin (IVIG) | Empirical antibiotics | Empirical Antivirals | Corticosteroid	- 68 survivors - 25 nonsurvivors	10-Jan-2020	22-Feb-2020	44	No	Cohort study	Retrospective	Wuhan, China	15-May-2020	
#00531	CT_32422076	Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center, Clinicopathologic Case Series	32422076	https://doi.org/10.7326/M20-2566	https://pubmed.ncbi.nlm.nih.gov/32422076	11	Other			28-Feb-2020	14-Apr-2020	47	No	Single-Center, Clinicopathologic Case Series	Prospective	Styria, Austria	14-May-2020	
#00532	CT_32613199	Correlation between Chest Computed Tomography Scan Findings and Mortality of COVID-19 Cases; a Cross sectional Study.	32613199		https://pubmed.ncbi.nlm.nih.gov/32613199	380	Other			22-Feb-2020	22-Mar-2020	30	No	Single-center, cross sectional study	Retrospective	Tehran, Iran	14-May-2020	
#00533	CT_32409561	Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.	32409561	https://doi.org/10.1136/bmj.m1849	https://pubmed.ncbi.nlm.nih.gov/32409561	150	Drug(s)	Hydroxychloroquine		11-Feb-2020	29 Feb	19	No	Multicentre, open label, randomised controlled trial		China	14-May-2020	
#00534	CT_32339715	Statistical and network analysis of 1212 COVID-19 patients in Henan, China	32339715	https://doi.org/10.1016/j.ijid.2020.04.051	https://pubmed.ncbi.nlm.nih.gov/32339715	1,212				21-Jan-2020	14-Feb-2020	25	Yes			Henan, China	24-Apr-2020	
#00535	CT_32330305	SARS-CoV-2 can be detected in urine, blood, anal swabs, and oropharyngeal swabs specimens	32330305	https://doi.org/10.1002/jmv.25936	https://pubmed.ncbi.nlm.nih.gov/32330305	9	Other | Drug(s)	Lopinavir/ritonavir | Arbidol | Interferon-α		22-Jan-2020	29-Feb-2020	39	No			Guangzhou, China	30-Apr-2020	
#00536	CT_32329797	Characteristics of Hospitalized Adults With COVID-19 in an Integrated Health Care System in California	32329797	https://doi.org/10.1001/jama.2020.7202	https://pubmed.ncbi.nlm.nih.gov/32329797	1,299	Other			01-Mar-2020	31-Mar-2020	31	No	Case series	Retrospective	California, USA	24-Apr-2020	
#00537	CT_32360500	Clinical and transmission dynamics characteristics of 406 children with coronavirus disease 2019 in China: A review	32360500	https://doi.org/10.1016/j.jinf.2020.04.030	https://pubmed.ncbi.nlm.nih.gov/32360500	406				01-Feb-2020	03-Apr-2020	63	Yes	Review		Beijing, China	28-Apr-2020	
#00538	CT_32346790	Coronavirus disease 2019 (COVID-19) imaging reporting and data system (COVID-RADS) and common lexicon: a proposal based on the imaging data of 37 studies	32346790	https://doi.org/10.1007/s00330-020-06863-0	https://pubmed.ncbi.nlm.nih.gov/32346790	3,647							Yes	Systematic review		Los Angeles, California, USA	28-Apr-2020	
#00539	CT_32345594	Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak	32345594	https://doi.org/10.1158/2159-8290.CD-20-0422	https://pubmed.ncbi.nlm.nih.gov/32345594	105	Other			01-Jan-2020	24-Feb-2020	55	No	Cohort study		Hubei, China	28-Apr-2020	
#00540	CT_32344439	COVID-19-Response - Strategies of the Task-Force Coronavirus and experiences upon implementation in the management of 115 cases at the University Medical Center Freiburg	32344439	https://doi.org/10.1055/a-1147-6244	https://pubmed.ncbi.nlm.nih.gov/32344439	115	Other			25-Feb-2020	31-Mar-2020	36	No	Observational, descriptive analysis cohort study	Retrospective	Freiburg, Germany	28-Apr-2020	
#00541	CT_32342479	Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang, China	32342479	https://doi.org/10.1007/s15010-020-01432-5	https://pubmed.ncbi.nlm.nih.gov/32342479	145	Other			01-Jan-2020	11-Mar-2020	71	No	Case series	Retrospective	Zhejiang, China	28-Apr-2020	
#00542	CT_32392129	Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission.	32392129	https://doi.org/10.7554/eLife.58728	https://pubmed.ncbi.nlm.nih.gov/32392129	1,270	Other			06-Apr-2020	24-Apr-2020	19	No		Retrospective	Cambridge, United Kingdom	11-May-2020	
#00543	CT_32394344	COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients.	32394344	https://doi.org/10.1007/s15010-020-01438-z	https://pubmed.ncbi.nlm.nih.gov/32394344	33	Other			11-Mar-2020	17-Apr-2020	38	No	Case series	Retrospective	Germany	11-May-2020	
#00544	CT_32392288	Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units.	32392288	https://doi.org/10.1001/jamapediatrics.2020.1948	https://pubmed.ncbi.nlm.nih.gov/32392288	48	Drug(s) | Oxygen support	Azithromycin | Hydroxychloroquine | Tocilizumab	- 31 Discharged. - 2 Died. - 9 Severe or critical condition. - 6 Mild or moderate condition.	14-Mar-2020	03-Apr-2020	21	No	Cross-sectional study	Retrospective	USA	11-May-2020	
#00545	CT_32489708	Immune Characteristics of Patients with Coronavirus Disease 2019 (COVID-19).	32489708	https://doi.org/10.14336/AD.2020.0317	https://pubmed.ncbi.nlm.nih.gov/32489708	18	Other			30-Jan-2020	21-Feb-2020	23	No		Retrospective	Zhejiang, China	17-Mar-2020	
#00546	CT_32395069	Knowledge, attitude and preventive practices related to COVID-19: a cross-sectional study in two Pakistani university populations.	32395069	https://doi.org/10.1007/s40267-020-00737-7	https://pubmed.ncbi.nlm.nih.gov/32395069	417				22-Feb-2020	12-Mar-2020	20	No	Cross-sectional study		Lahore, Pakistan	9-May-2020	
#00547	CT_32397399	Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE).	32397399	https://doi.org/10.3390/microorganisms8050695	https://pubmed.ncbi.nlm.nih.gov/32397399	112	Drug(s) | Other	Tocilizumab | Hydroxychloroquine | prophylactic dose of low weight Heparin)		14-Mar-2020	27-Mar-2020	14	No	Cohort study	Retrospective	Pavia, Italy	9-May-2020	
#00548	CT_32384180	Clinical and histological characterization of vesicular COVID-19 rashes: a prospective study in a tertiary care hospital.	32384180	https://doi.org/10.1111/ced.14277	https://pubmed.ncbi.nlm.nih.gov/32384180	24	Other	Lopinavir/ritonavir | Hydroxychloroquine | Azithromycin		01-Mar-2020	20-Apr-2020	51	No	Observational study	Prospective	Madrid, Spain	8-May-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00549	CT_32385648	Clinical and radiological changes of hospitalised patients with COVID-19 pneumonia from disease onset to acute exacerbation: a multicentre paired cohort study.	32385648	https://doi.org/10.1007/s00330-020-06916-4	https://pubmed.ncbi.nlm.nih.gov/32385648	24	Other		- 23 Hospitalisation. - 1 Death.				No	Multicentre paired cohort study.	Retrospective	Hunan, China	8-May-2020	
#00550	CT_32574321	Clinical Time Features and Chest Imaging of 85 Patients With COVID-19 in Zhuhai, China.	32574321	https://doi.org/10.3389/fmed.2020.00209	https://pubmed.ncbi.nlm.nih.gov/32574321	85	Other			17-Jan-2020	24-Feb-2020	39	No	Cohort study	Retrospective	Zhuhai, China	8-May-2020	
#00551	CT_32389667	Gastrointestinal and Hepatic Manifestations of 2019 Novel Coronavirus Disease in a Large Cohort of Infected Patients From New York: Clinical Implications.	32389667	https://doi.org/10.1053/j.gastro.2020.05.010	https://pubmed.ncbi.nlm.nih.gov/32389667	1,059	Other			04-Mar-2020	09-Apr-2020	37	No	Cohort study	Retrospective	Manhattan, NY, USA	8-May-2020	
#00552	CT_32379726	Epidemiological Analysis of the First 1389 Cases of COVID-19 in Poland: A Preliminary Report.	32379726	https://doi.org/10.12659/MSM.924702	https://pubmed.ncbi.nlm.nih.gov/32379726	1,389	Other			03-Mar-2020	27-Mar-2020	25	No	Cross-sectional study		Poland	7-May-2020	
#00553	CT_32105632	Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study	32105632	https://doi.org/10.1016/S2213-2600(20)30079-5	https://pubmed.ncbi.nlm.nih.gov/32105632	52	Other | Oxygen support | Drug(s) | IVIG	Empirical Antivirals | Glucocorticoids | Immunoglobulin (IVIG) | Empirical antibiotics	- 20 Survivors. - 32 -Non-Survivors.	24-Dec-2019	26-Jan-2020	34	No	Single-centered, observational study	Retrospective	Wuhan, China	24-Feb-2020	
#00554	CT_32507692	Clinical characteristics of coronavirus disease (COVID-19) patients with gastrointestinal symptoms: A report of 164 cases.	32507692	https://doi.org/10.1016/j.dld.2020.04.034	https://pubmed.ncbi.nlm.nih.gov/32507692	505	Other		The proportion of COVID-19 patients who experience gastrointestinal symptoms is relatively high. Patients who experience gastrointestinal symptoms are more likely to suffer from severe pneumonia.				No	Cohort study	Retrospective	Wuhan, China	8-May-2020	
#00555	CT_32384078	Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: A retrospective, multi-center study.	32384078	https://doi.org/10.1371/journal.pntd.0008280	https://pubmed.ncbi.nlm.nih.gov/32384078	202	Drug(s) | Other	Lopinavir/ritonavir | Arbidol | Interferon α2β | Immunoglobulin (IVIG) | Empirical Antivirals | Oseltamivir | Empirical antibiotics | Corticosteroid	- 165 Remained in hospital. - 37 Hospital discharge.	22-Jan-2020	10-Feb-2020	20	No	Multi-center study	Retrospective	Jiangsu, China	8-May-2020	
#00556	CT_32269088	Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study.	32269088	https://doi.org/10.1183/13993003.00524-2020	https://pubmed.ncbi.nlm.nih.gov/32269088	179	Other			25-Dec-2019	07-Feb-2020	45	No	Single-centre case cohort	Prospective	Wuhan, China	7-May-2020	
#00557	CT_32392741	Clotting Factors in COVID-19: Epidemiological Association and Prognostic Values in Different Clinical Presentations in an Italian Cohort.	32392741	https://doi.org/10.3390/jcm9051371	https://pubmed.ncbi.nlm.nih.gov/32392741	134	Other						No	Cohort study		Italy	7-May-2020	
#00558	CT_32149773	Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial.	32149773	https://doi.org/10.1097/CM9.0000000000000791	https://pubmed.ncbi.nlm.nih.gov/32149773	48	Drug(s)	Methylprednisolone					No	Open-labeled, randomized, controlled trial		Chongqing, China	5-May-2020	
#00559	CT_32367793	Epidemiological characteristics of confirmed COVID-19 in Guizhou province, China.	32367793	https://doi.org/10.1017/dmp.2020.134	https://pubmed.ncbi.nlm.nih.gov/32367793	135			- 20 Rehabilitation. - 100 Stable condition. - 14 Severe. - 1 Death.	20-Jan-2020	12-Feb-2020	24	No	Study analysis	Retrospective	Guizhou, China	5-May-2020	
#00560	CT_32422209	Are Gastrointestinal Symptoms Specific for Coronavirus 2019 Infection? A Prospective Case-Control Study From the United States.	32422209	https://doi.org/10.1053/j.gastro.2020.05.036	https://pubmed.ncbi.nlm.nih.gov/32422209	340				09-Mar-2020	15-Apr-2020	38	No	Telephone survey–based case-control study	Prospective	Maryland, USA	16-May-2020	
#00561	CT_32518804	Correlation Between Chest CT Findings and Clinical Features of 211 COVID-19 Suspected Patients in Wuhan, China	32518804	https://doi.org/10.1093/ofid/ofaa171	https://pubmed.ncbi.nlm.nih.gov/32518804	211	Other			29-Jan-2020	04-Feb-2020	7	No	Cohort study	Retrospective	Wuhan, China	16-May-2020	
#00562	CT_32425361	Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial.	32425361	https://doi.org/10.1016/j.phymed.2020.153242	https://pubmed.ncbi.nlm.nih.gov/32425361	284	Drug(s)	Traditional Chinese medicine		02-Feb-2020	15-Feb-2020	14	No	A multicenter, open-label, randomized controlled trial	Prospective	China	16-May-2020	
#00563	CT_32418114	Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19.	32418114	https://doi.org/10.1007/s11427-020-1732-2	https://pubmed.ncbi.nlm.nih.gov/32418114	550	Drug(s)	Hydroxychloroquine	- 247 patients died. - Nine out of 48 HCQ-treated patients died.	01-Feb-2020	04-Apr-2020	64	No	Cohort study	Retrospective	Wuhan, China	15-May-2020	
#00564	CT_32435272	Clinical characteristics of 9 cancer patients with SARS-CoV-2 infection.	32435272	https://doi.org/10.1186/s13020-020-00328-8	https://pubmed.ncbi.nlm.nih.gov/32435272	9	Drug(s)	Arbidol | Traditional Chinese medicine		23-Jan-2020	29-Feb-2020	38	No	Single-institutional review	Retrospective	Jingzhou, China	14-May-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00565	CT_32407467	**Clinical features and outcomes of HIV patients with coronavirus disease 2019.**	32407467	https://doi.org/10.1093/cid/ciaa579	https://pubmed.ncbi.nlm.nih.gov/32407467	47	Drug(s)	Empirical antibiotics | Tocilizumab | Azithromycin | Remdesivir | Lopinavir/ritonavir | Hydroxychloroquine | TAF/FTC/bictegravir | ABC/3TC/dolutegravir | TAF/FTC + INI | Dolutegravir/3TC | Dolutegravir + boosted PI	- 45 Fully recovered. - 2 Died.	21-Feb-2020	16-Apr-2020	56	No	Observational study	Retrospective	Italy	14-May-2020	
#00566	CT_32410714	**Patients with COVID-19 in 19 ICUs in Wuhan, China: a cross-sectional study.**	32410714	https://doi.org/10.1186/s13054-020-02939-x	https://pubmed.ncbi.nlm.nih.gov/32410714	226	Other		- 204 Remained in ICU. - 13 Discharged. - 9 Died.	26-Feb-2020	27-Feb-2020	2	No	A multicenter, observational, cross-sectional study	Prospective	Wuhan, China	14-May-2020	
#00567	CT_32419876	**Early decrease in blood platelet count is associated with poor prognosis in COVID-19 patients-indications for predictive, preventive, and personalized medical approach.**	32419876	https://doi.org/10.1007/s13167-020-00208-z	https://pubmed.ncbi.nlm.nih.gov/32419876	532	Other		Early decrease in platelet count was associated with mortality in patients with COVID-19. - 503 Survivors. - 29 Non-survivors.	07-Jan-2020	28-Feb-2020	53	No	Cohort study	Retrospective	Wuhan, China	14-May-2020	
#00568	CT_32383763	**Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy**	32383763	https://doi.org/10.1093/eurheartj/ehaa388	https://pubmed.ncbi.nlm.nih.gov/32383763	99	Oxygen support | Other			04-Mar-2020	25-Mar-2020	22	No	Case report		Lombardy, Italy	14-May-2020	
#00569	CT_32402056	**Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease 2019.**	32402056	https://doi.org/10.1001/jamacardio.2020.2159	https://pubmed.ncbi.nlm.nih.gov/32402056	28	Drug(s)	Hydroxychloroquine | Tocilizumab | Glucocorticoids |	- Overall mortality 7 patients. - Overall survival 21 patients.	01-Mar-2020	24-Apr-2020	55	No	Case series	Retrospective	New York, USA	13-May-2020	
#00570	CT_32404896	**Clinical features of coronavirus disease 2019 (COVID-19) in a cohort of patients with disability due to spinal cord injury.**	32404896	https://doi.org/10.1038/s41394-020-0288-3	https://pubmed.ncbi.nlm.nih.gov/32404896	7	Other			20-Mar-2020	04-Apr-2020	16	No	Observational analysis, case series	Prospective	Toledo, Spain	13-May-2020	
#00571	CT_32397699	**Study on transmission dynamic of 15 clusters of coronavirus disease 2019 cases in Ningbo**	32397699	https://doi.org/10.3760/cma.j.cn112338-20200330-00466.	https://pubmed.ncbi.nlm.nih.gov/32397699	52				23-Jan-2020	04-Feb-2020	13	No	Descriptive study		Ningbo, China	13-May-2020	
#00572	CT_32883744	**A Direct Comparison of Enhanced Saliva to Nasopharyngeal Swab for the Detection of SARS-CoV-2 in Symptomatic Patients**	32883744	https://doi.org/10.1128/JCM.01946-20	https://pubmed.ncbi.nlm.nih.gov/32883744	216	Other						No	Case study analysis		Cleveland, Ohio, USA	3-Sep-2020	
#00573	CT_32409486	**Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data.**	32409486	https://doi.org/10.1136/bmj.m1844	https://pubmed.ncbi.nlm.nih.gov/32409486	181	Drug(s)	Hydroxychloroquine		12-Mar-2020	31-Mar-2020	20	No	Observational comparative study		France	14-May-2020	
#00574	CT_32401361	**Clinical characteristics of rehospitalized patients with COVID-19 in China.**	32401361	https://doi.org/10.1002/jmv.26002	https://pubmed.ncbi.nlm.nih.gov/32401361	11	Other			01-Mar-2020	07-Mar-2020	7	No	Single-center, small-sample study	Retrospective	Hubei, China	13-May-2020	
#00575	CT_32574322	**Clinical Characteristics and Reasons for Differences in Duration From Symptom Onset to Release From Quarantine Among Patients With COVID-19 in Liaocheng, China.**	32574322	https://doi.org/10.3389/fmed.2020.00210	https://pubmed.ncbi.nlm.nih.gov/32574322	37	Other						No	Case report	Retrospective	Liaocheng, China	12-May-2020	
#00576	CT_32574284	**Clinical Characteristics of 5 COVID-19 Cases With Non-respiratory Symptoms as the First Manifestation in Children.**	32574284	https://doi.org/10.3389/fped.2020.00258	https://pubmed.ncbi.nlm.nih.gov/32574284	5	Other			23-Jan-2020	20-Feb-2020	29	No	Case report		Wuhan, China	12-May-2020	
#00577	CT_32396239	**The impact of laryngopharyngeal reflux disease on 95 hospitalized patients with COVID-19 in Wuhan, China: A retrospective study.**	32396239	https://doi.org/10.1002/jmv.25998	https://pubmed.ncbi.nlm.nih.gov/32396239	95	Other			26-Jan-2020	21-Feb-2020	27	No	Single-center study	Retrospective	Wuhan, China	12-May-2020	
#00578	CT_32179910	**Clinical Outcomes in 55 Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Who Were Asymptomatic at Hospital Admission in Shenzhen, China.**	32179910	https://doi.org/10.1093/infdis/jiaa119	https://pubmed.ncbi.nlm.nih.gov/32179910	55	Drug(s)	Lopinavir/ritonavir		11-Jan-2020	29-Feb-2020	50	No	Case study analysis	Retrospective	Shenzhen, China	17-Mar-2020	
#00579	CT_32393381	**Perceived infection transmission routes, infection control practices, psychosocial changes, and management of COVID-19 infected healthcare workers in a tertiary acute care hospital in Wuhan: a cross-sectional survey.**	32393381	https://doi.org/10.1186/s40779-020-00254-8	https://pubmed.ncbi.nlm.nih.gov/32393381	103				15-Feb-2020	29-Feb-2020	15	No	Cross-sectional, single hospital-based study		Wuhan, China	11-May-2020	
#00580	CT_32392262	**Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis.**	32392262	https://doi.org/10.1371/journal.pone.0233147	https://pubmed.ncbi.nlm.nih.gov/32392262	2,473							Yes		Retrospective	London, United Kingdom	11-May-2020	
#00581	CT_32387967	**A single centre study of viral community-acquired pneumonia in children: No evidence of SARS-CoV-2 from October 2019 to March 2020**	32387967	https://doi.org/10.1016/j.jcv.2020.104385	https://pubmed.ncbi.nlm.nih.gov/32387967	42	Other			01-Oct-2019	31-Mar-2020	183	No	Longitudinal study	Prospective	Rome, Italy	29-Apr-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00582	CT_32386675	Epidemiological and clinical characteristics of 136 cases of COVID-19 in main district of Chongqing	32386675	https://doi.org/10.1016/j.jfma.2020.04.019	https://pubmed.ncbi.nlm.nih.gov/32386675	136	Other			25-Jan-2020	20-Feb-2020	27	No	Case series	Retrospective	Chongqing, China	29-Apr-2020	
#00583	CT_32402515	Association of Cardiovascular Disease With Coronavirus Disease 2019 (COVID-19) Severity: A Meta-Analysis	32402515	https://doi.org/10.1016/j.cpcardiol.2020.100617	https://pubmed.ncbi.nlm.nih.gov/32402515	4,858				01-Nov-2019	20-Apr-2020	172	Yes			Hubei, China	28-Apr-2020	
#00584	CT_32360498	Clinical features of critically ill patients with confirmed COVID-19	32360498	https://doi.org/10.1016/j.jinf.2020.03.023	https://pubmed.ncbi.nlm.nih.gov/32360498	33	Other			23-Jan-2020	23-Feb-2020	32	No	Multi-center cohort study	Retrospective	Zhejiang, China	28-Apr-2020	
#00585	CT_32353384	Clinical features of 95 sequential hospitalised patients with novel coronavirus 2019 disease (COVID-19), the first UK cohort	32353384	https://doi.org/10.1016/j.jinf.2020.04.020	https://pubmed.ncbi.nlm.nih.gov/32353384	95	Other		- 75 Alive. - 20 Dead.	10-Mar-2020	30-Mar-2020	21	No	Single-centre, cohort study	Retrospective	Bristol, United Kingdom	27-Apr-2020	
#00586	CT_32369656	Coronavirus disease 2019 among pregnant Chinese women: case series data on the safety of vaginal birth and breastfeeding.	32369656	https://doi.org/10.1111/1471-0528.16276	https://pubmed.ncbi.nlm.nih.gov/32369656	13	Other			31-Jan-2020	09-Mar-2020	39	No	Single centre cohort study	Retrospective	Wuhan, China	26-May-2020	
#00587	CT_32118640	Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease.	32118640	https://doi.org/10.1097/CM9.0000000000000775	https://pubmed.ncbi.nlm.nih.gov/32118640	78	Other			30-Dec-2019	15-Jan-2020	17	No			Wuhan, China	5-May-2020	
#00588	CT_32361723	Clinical and laboratory predictors of in-hospital mortality in patients with COVID-19: a cohort study in Wuhan, China.	32361723	https://doi.org/10.1093/cid/ciaa538	https://pubmed.ncbi.nlm.nih.gov/32361723	296	Other		- 277 Discharged. - 19 Died.	07-Jan-2020	11-Feb-2020	36	No	Cohort study		Wuhan, China	3-May-2020	
#00589	CT_32368728	Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: A retrospective case-control study.	32368728	https://doi.org/10.1016/j.eclinm.2020.100375	https://pubmed.ncbi.nlm.nih.gov/32368728	989	Other			31-Jan-2020	21-Feb-2020	22	No	Case-control study	Retrospective	Wuhan, China	3-May-2020	
#00590	CT_32566603	Clinical features of severe patients infected with 2019 novel coronavirus: a systematic review and meta-analysis.	32566603	https://doi.org/10.21037/atm-20-2124	https://pubmed.ncbi.nlm.nih.gov/32566603	5,328				01-Dec-2019	12-Feb-2020	74	Yes			Guangzhou, China	7-Apr-2020	
#00591	CT_32566557	Clinical characteristics of children with COVID-19: a rapid review and meta-analysis.	32566557	https://doi.org/10.21037/atm-20-3302	https://pubmed.ncbi.nlm.nih.gov/32566557	1,667							Yes	Case reports and case series		China	26-Apr-2020	
#00592	CT_32381057	CT differential diagnosis of COVID-19 and non-COVID-19 in symptomatic suspects: a practical scoring method.	32381057	https://doi.org/10.1186/s12890-020-1170-6	https://pubmed.ncbi.nlm.nih.gov/32381057	73	Other			10-Jan-2020	28-Feb-2020	50	No	Cohort study	Retrospective	Shenzhen, China	7-May-2020	
#00593	CT_32389584	Coronavirus disease 2019 (COVID-19) and cardiovascular risk: A meta-analysis.	32389584	https://doi.org/10.1016/j.pcad.2020.05.001	https://pubmed.ncbi.nlm.nih.gov/32389584	49,076				01-Dec-2019	10-Apr-2020	132	Yes			USA	7-May-2020	
#00594	CT_32379114	Characteristics and Early Prognosis of COVID-19 Infection in Fracture Patients.	32379114	https://doi.org/10.2106/JBJS.20.00390	https://pubmed.ncbi.nlm.nih.gov/32379114	10	Other			01-Jan-2020	27-Feb-2020	58	No	Cohort study	Retrospective	Wuhan, China	6-May-2020	
#00595	CT_32367683	Impact of coronavirus disease 2019 (COVID-19) outbreak on outcome of myocardial infarction in Hong Kong, China.	32367683	https://doi.org/10.1002/ccd.28943	https://pubmed.ncbi.nlm.nih.gov/32367683	149	Other			01-Nov-2019	31-Mar-2020	152	No	Single center cross-sectional observational study		Hong Kong, China	5-May-2020	
#00596	CT_32004165	Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study.	32004165	https://doi.org/10.1097/CM9.0000000000000722	https://pubmed.ncbi.nlm.nih.gov/32004165	5	Other | Oxygen support			18-Dec-2019	29-Dec-2019	12	No	Descriptive study		Hubei, China	5-May-2020	
#00597	CT_32371949	Immune dysfunction leads to mortality and organ injury in patients with COVID-19 in China: insights from ERS-COVID-19 study.	32371949	https://doi.org/10.1038/s41392-020-0163-5	https://pubmed.ncbi.nlm.nih.gov/32371949	163	Other			31-Jan-2020	18-Feb-2020	19	No	Multicenter cohort study	Retrospective	China	5-May-2020	
#00598	CT_32539272	Factor VIII and Functional Protein C Activity in Critically Ill Patients With Coronavirus Disease 2019: A Case Series.	32539272	https://doi.org/10.1213/XAA.0000000000001236	https://pubmed.ncbi.nlm.nih.gov/32539272	10	Other		- 4 Discharged. - 2 remained on ECMO. - 7 Extubated. - 1 Died.	01-Apr-2020	05-Apr-2020	5	No	Case series		Maryland, USA	11-May-2020	
#00599	CT_32369191	Tocilizumab for the treatment of severe coronavirus disease 2019.	32369191	https://doi.org/10.1002/jmv.25964	https://pubmed.ncbi.nlm.nih.gov/32369191	25	Drug(s)	Tocilizumab	- 9 Discharged. - 13 were still in ICU. - 3 Died.				No	Cohort study	Retrospective	Doha, Qatar	5-May-2020	
#00600	CT_32566621	Quantitative analysis of chest CT imaging findings with the risk of ARDS in COVID-19 patients: a preliminary study.	32566621	https://doi.org/10.21037/atm-20-3554	https://pubmed.ncbi.nlm.nih.gov/32566621	27	Other						No	Preliminary study	Retrospective	Chengdu, China	7-May-2020	
#00601	CT_32566579	Clinical characteristics of 16 patients with COVID-19 infection outside of Wuhan, China: a retrospective, single-center study.	32566579	https://doi.org/10.21037/atm-20-3422	https://pubmed.ncbi.nlm.nih.gov/32566579	16	Drug(s) | IVIG | Oxygen support | Other	Glucocorticoids | Empirical Antivirals | Empirical antibiotics | Immunoglobulin (IVIG)		25-Jan-2020	24-Feb-2020	31	No	Single-center, cohort study	Retrospective	Shaoxing, China	11-May-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00602	CT_32566574	The epidemiologic and clinical features of suspected and confirmed cases of imported 2019 novel coronavirus pneumonia in north Shanghai, China.	32566574	https://doi.org/10.21037/atm-20-2119	https://pubmed.ncbi.nlm.nih.gov/32566574	105	Drug(s) | Other	Empirical antibiotics | Traditional Chinese medicine | Lopinavir/ritonavir		01-Jan-2020	15-Feb-2020	46	No	Two-center study	Retrospective	Shanghai, China	30-Mar-2020	
#00603	CT_32566572	Combined use of the neutrophil-to-lymphocyte ratio and CRP to predict 7-day disease severity in 84 hospitalized patients with COVID-19 pneumonia: a retrospective cohort study.	32566572	https://doi.org/10.21037/atm-20-2372	https://pubmed.ncbi.nlm.nih.gov/32566572	84	Other		- 8 Discharged. - 73 Still in hospital. - 3 Died.	08-Jan-2020	14-Feb-2020	38	No	Single-center, cohort study	Retrospective	China	17-Apr-2020	
#00604	CT_32566564	Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and meta-analysis	32566564	https://doi.org/10.21037/atm-20-3307	https://pubmed.ncbi.nlm.nih.gov/32566564	13,815							Yes			China	30-Apr-2020	
#00605	CT_32566559	Chest computed tomography for the diagnosis of patients with coronavirus disease 2019 (COVID-19): a rapid review and meta-analysis	32566559	https://doi.org/10.21037/atm-20-3311	https://pubmed.ncbi.nlm.nih.gov/32566559	5,673				01-Jan-2020	31-Mar-2020	91	Yes			China	30-Apr-2020	
#00606	CT_32467353	Reduction of secondary transmission of SARS-CoV-2 in households by face mask use, disinfection and social distancing: a cohort study in Beijing, China	32467353	https://doi.org/10.1136/bmjgh-2020-002794	https://pubmed.ncbi.nlm.nih.gov/32467353	335	Other			28-Feb-2020	27-Mar-2020	29	No	Cohort study	Retrospective	Beijing,China	28-May-2020	
#00607	CT_32356577	Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration.	32356577	https://doi.org/10.1111/dth.13475	https://pubmed.ncbi.nlm.nih.gov/32356577	1,193	Other			21-Feb-2020	09-Apr-2020	49	No	Case-control cohort study		Milan, Italy	1-May-2020	
#00608	CT_32400362	Multicentre Italian study of SARS-CoV-2 infection in children and adolescents, preliminary data as at 10 April 2020.	32400362	https://doi.org/10.2807/1560-7917.ES.2020.25.18.2000600	https://pubmed.ncbi.nlm.nih.gov/32400362	168	Drug(s)	Lopinavir/ritonavir | Azithromycin | Clarithromycin | Hydroxychloroquine		25-Mar-2020	10-Apr-2020	17	No	Multicentre cohort study	Retrospective	Italy	7-May-2020	
#00609	CT_32364962	Association between chest CT features and clinical course of Coronavirus Disease 2019	32364962	https://doi.org/10.1016/j.rmed.2020.105989	https://pubmed.ncbi.nlm.nih.gov/32364962	195	Other			31-Dec-2019	20-Feb-2020	52	No	Case study	Retrospective	Hunan, China	22-Apr-2020	
#00610	CT_32361413	Initial CT imaging characters of an imported family cluster of COVID-19	32361413	https://doi.org/10.1016/j.clinimag.2020.04.010	https://pubmed.ncbi.nlm.nih.gov/32361413	7	Other			31-Jan-2020	11-Feb-2020	12	No	Case analysis	Retrospective	Gansu, China	22-Apr-2020	
#00611	CT_32320004	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review	32320004	https://doi.org/10.1001/jamapediatrics.2020.1467	https://pubmed.ncbi.nlm.nih.gov/32320004	1,065				01-Dec-2019	03-Mar-2020	94	Yes			Pavia, Italy	22-Apr-2020	
#00612	CT_32421546	Correlation analysis of the severity and clinical prognosis of 32 cases of patients with COVID-19	32421546	https://doi.org/10.1016/j.rmed.2020.105981	https://pubmed.ncbi.nlm.nih.gov/32421546	32	Other			01-Jan-2020	20-Mar-2020	80	No	Study analysis	Retrospective	Huangshi, China	20-Apr-2020	
#00613	CT_32611914	Laboratory surveillance for SARS-CoV-2 in India: Performance of testing & descriptive epidemiology of detected COVID-19, January 22 - April 30, 2020.	32611914	https://doi.org/10.4103/ijmr.IJMR_1896_20	https://pubmed.ncbi.nlm.nih.gov/32611914	1,021,518				22-Jan-2020	30-Apr-2020	100	Yes	Surveillance study		India	20-Jun-2020	
#00614	CT_32056087	A multi-vendor, multi-center study on reproducibility and comparability of fast strain-encoded cardiovascular magnetic resonance imaging.	32056087	https://doi.org/10.1007/s10554-020-01775-y	https://pubmed.ncbi.nlm.nih.gov/32056087	15							No	Multi-center study	Prospective	Berlin, Germany	13-Feb-2020	
#00615	CT_32311449	SARS-CoV-2 RNA detection of hospital isolation wards hygiene monitoring during the Coronavirus Disease 2019 outbreak in a Chinese hospital.	32311449	https://doi.org/10.1016/j.ijid.2020.04.024	https://pubmed.ncbi.nlm.nih.gov/32311449	33	Other			19-Feb-2020	24-Feb-2020	6	No	Cohort study		Zhejiang, China	18-Apr-2020	
#00616	CT_32173574	Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis.	32173574	https://doi.org/10.1016/j.ijid.2020.03.017	https://pubmed.ncbi.nlm.nih.gov/32173574	1,576							Yes			China	12-Mar-2020	
#00617	CT_32217900	High-Resolution Computed Tomography Manifestations of 5 Pediatric Patients With 2019 Novel Coronavirus.	32217900	https://doi.org/10.1097/RCT.0000000000001023	https://pubmed.ncbi.nlm.nih.gov/32217900	5	Other						No	Case report		Chongqing, China	25-Mar-2020	
#00618	CT_32376098	A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis.	32376098	https://doi.org/10.1016/j.jcf.2020.04.012	https://pubmed.ncbi.nlm.nih.gov/32376098	40	Other			01-Feb-2020	13-Feb-2020	13	No	Multinational case report		Australia, Canada, France, Ireland, Netherlands, New Zealand, UK and US	25-Apr-2020	
#00619	CT_32307320	CT imaging of the COVID-19.	32307320	https://doi.org/10.1016/j.jfma.2020.04.006	https://pubmed.ncbi.nlm.nih.gov/32307320	5	Other						No	Case report		China	16-Apr-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00620	CT_32362392	Epidemiologic and clinical characteristics of heart transplant recipients during the 2019 coronavirus outbreak in Wuhan, China: A descriptive survey report.	32362392	https://doi.org/10.1016/j.healun.2020.03.008	https://pubmed.ncbi.nlm.nih.gov/32362392	87	Other						No	Single-center descriptive study	Retrospective	Wuhan, China	25-Mar-2020	
#00621	CT_32642164	Clinical features of 2019 novel coronavirus infection in Beijing.	32642164	https://doi.org/10.21037/jtd.2020.03.33	https://pubmed.ncbi.nlm.nih.gov/32642164	16	Other			19-Jan-2020	12-Feb-2020	25	No	Case study analysis		Beijing, China	25-Feb-2020	
#00622	CT_32642086	Clinical characteristics of COVID-19 infection in chronic obstructive pulmonary disease: a multicenter, retrospective, observational study.	32642086	https://doi.org/10.21037/jtd-20-1914	https://pubmed.ncbi.nlm.nih.gov/32642086	1,048	Other			11-Dec-2019	20-Feb-2020	72	No	Multicenter, observational study	Retrospective	China	19-May-2020	
#00623	CT_32425002	Comparison of epidemiological and clinical characteristics of COVID-19 patients with and without Wuhan exposure history in Zhejiang Province, China.	32425002	https://doi.org/10.1631/jzus.B2000112	https://pubmed.ncbi.nlm.nih.gov/32425002	788	Other			17-Jan-2020	07-Feb-2020	22	No	Cohort study	Retrospective	Zhejiang, China	9-May-2020	
#00624	CT_32437575	Coronavirus Disease 2019 (COVID-2019) Infection Among Health Care Workers and Implications for Prevention Measures in a Tertiary Hospital in Wuhan, China.	32437575	https://doi.org/10.1001/jamanetworkopen.2020.9666	https://pubmed.ncbi.nlm.nih.gov/32437575	110	Other			01-Jan-2020	09-Feb-2020	40	No	Cohort study	Retrospective	Wuhan, China	21-May-2020	
#00625	CT_32582309	Chest X-rays findings in COVID 19 patients at a University Teaching Hospital - A descriptive study.	32582309	https://doi.org/10.12669/pjms.36.COVID19-S4.2778	https://pubmed.ncbi.nlm.nih.gov/32582309	30	Other			20-Mar-2020	10-Apr-2020	22	No	Descriptive study	Retrospective	Rawalpindi, Pakistan	18-May-2020	
#00626	CT_32434634	Clinical features of coronavirus disease 2019 in children aged <18 years in Jiangxi, China: an analysis of 23 cases	32434634	https://doi.org/10.7499/j.issn.1008-8830.2003202	https://pubmed.ncbi.nlm.nih.gov/32434634	23	Other			27-Jan-2020	04-Mar-2020	38	No	Case analysis	Retrospective	Nanchang, Jiangxi, China	15-May-2020	
#00627	CT_32139463	High-resolution computed tomography features of 17 cases of coronavirus disease 2019 in Sichuan province, China.	32139463	https://doi.org/10.1183/13993003.00334-2020	https://pubmed.ncbi.nlm.nih.gov/32139463	17	Other						No	Study analysis	Retrospective	Sichuan, China	30-Apr-2020	
#00628	CT_32339382	Vaginal delivery in SARS-CoV-2-infected pregnant women in Northern Italy: a retrospective analysis.	32339382	https://doi.org/10.1111/1471-0528.16278	https://pubmed.ncbi.nlm.nih.gov/32339382	42	Other			01-Mar-2020	20-Mar-2020	20	No	Multicentre study	Retrospective	Italy	27-Apr-2020	
#00629	CT_32337590	Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).	32337590	https://doi.org/10.1093/cid/ciaa489	https://pubmed.ncbi.nlm.nih.gov/32337590	41	Other			11-Jan-2020	10-Feb-2020	31	No	Comparative study		Shenzhen, China	27-Apr-2020	
#00630	CT_32340093	Investigation on a cluster epidemic of COVID-19 in a supermarket in Liaocheng, Shandong province	32340093	https://doi.org/10.3760/cma.j.cn112338-20200228-00206	https://pubmed.ncbi.nlm.nih.gov/32340093	8,437	Other			30-Jan-2020	09-Feb-2020	11	No			Liaocheng, Shandong, China	27-Apr-2020	
#00631	CT_32343419	The application of Temporary Ark Hospitals in controlling COVID-19 spread: The experiences of one Temporary Ark Hospital, Wuhan, China.	32343419	https://doi.org/10.1002/jmv.25947	https://pubmed.ncbi.nlm.nih.gov/32343419	1,124	Other		- 833 Cured and discharged. - 291 Transferred to other hospitals.				No			Wuhan, China	28-Apr-2020	
#00632	CT_32440661	Clinical Characteristics of COVID-19 Infection in Newborns and Pediatrics: A Systematic Review	32440661		https://pubmed.ncbi.nlm.nih.gov/32440661	2,228				01-Jan-2020	30-Mar-2020	90	Yes	Systematic Review		Rasht, Iran	18-Apr-2020	
#00633	CT_32180175	Safety and efficacy of different anesthetic regimens for parturients with COVID-19 undergoing Cesarean delivery: a case series of 17 patients	32180175	https://doi.org/10.1007/s12630-020-01630-7	https://pubmed.ncbi.nlm.nih.gov/32180175	17	Other			30-Jan-2020	23-Feb-2020	25	No	Case series	Retrospective	Wuhan, China	16-Mar-2020	
#00634	CT_32290847	Anti-IL6R role in treatment of COVID-19-related ARDS.	32290847	https://doi.org/10.1186/s12967-020-02333-9	https://pubmed.ncbi.nlm.nih.gov/32290847	21	Drug(s)	Tocilizumab | Lopinavir | Methylprednisolone					No	Single arm study		Naples, Italy	14-Apr-2020	
#00635	CT_32669297	Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications	32669297	https://doi.org/10.1126/science.abc8511	https://pubmed.ncbi.nlm.nih.gov/32669297	125	Other						No	Cohort study		Philadelphia, Pennsylvania, USA	15-Jul-2020	
#00636	CT_32377638	Comorbid Chronic Diseases and Acute Organ Injuries Are Strongly Correlated with Disease Severity and Mortality among COVID-19 Patients: A Systemic Review and Meta-Analysis.	32377638	https://doi.org/10.34133/2020/2402961	https://pubmed.ncbi.nlm.nih.gov/32377638	6,263							Yes	Systemic review and meta-analysis		Hangzhou, Zhejiang, China	19-Apr-2020	
#00637	CT_32440666	Lobar Distribution of COVID-19 Pneumonia Based on Chest Computed Tomography Findings; A Retrospective Study.	32440666		https://pubmed.ncbi.nlm.nih.gov/32440666	63	Other						No	Case report	Retrospective	Tehran, Iran	18-Apr-2020	
#00638	CT_32379955	Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19	32379955	https://doi.org/10.1056/NEJMoa2012410	https://pubmed.ncbi.nlm.nih.gov/32379955	1,376	Drug(s)	Hydroxychloroquine		07-Mar-2020	08-Apr-2020	33	No	Observational study		New York, USA	7-May-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00639	CT_32447934	Clinical and coagulation characteristics in 7 patients with critical COVID-2019 pneumonia and acro-ischemia	32447934	https://doi.org/10.3760/cma.j.issn.0253-2727.2020.0006	https://pubmed.ncbi.nlm.nih.gov/32447934	7	Other			05-Feb-2020	15-Feb-2020	11	No	Study analysis	Retrospective	Wuhan, China	14-Apr-2020	
#00640	CT_32244260	Epidemiological characteristics of COVID-19 in Shaanxi province	32244260	https://doi.org/10.3760/cma.j.cn112338-20200225-00172	https://pubmed.ncbi.nlm.nih.gov/32244260	245	Other			23-Jan-2020	22-Feb-2020	31	No	Case report		Shaanxi, China	3-Apr-2020	
#00641	CT_32347204	Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020.	32347204	https://doi.org/10.2807/1560-7917.ES.2020.25.16.2000421	https://pubmed.ncbi.nlm.nih.gov/32347204	24	Other						No	Cohort study		Hong Kong, China	23-Apr-2020	
#00642	CT_33022834	Anticoagulation outcomes in hospitalized Covid-19 patients: A systematic review and meta-analysis of case-control and cohort studies	33022834	https://doi.org/10.1002/rmv.2180	https://pubmed.ncbi.nlm.nih.gov/33022834	4,992	Other						Yes			Cairo, Egypt	6-Oct-2020	
#00643	CT_32105638	Viral load of SARS-CoV-2 in clinical samples.	32105638	https://doi.org/10.1016/S1473-3099(20)30113-4	https://pubmed.ncbi.nlm.nih.gov/32105638	82	Other						No	Case report		Beijing, China	24-Feb-2020	
#00644	CT_32645053	CT in relation to RT-PCR in diagnosing COVID-19 in The Netherlands: A prospective study	32645053	https://doi.org/10.1371/journal.pone.0235844	https://pubmed.ncbi.nlm.nih.gov/32645053	193	Other			13-Mar-2020	24-Mar-2020	12	No	Cohort study	Prospective	Maastricht, The Netherlands	9-Jul-2020	
#00645	CT_32726151	Body Mass Index and Risk for Intubation or Death in SARS-CoV-2 Infection: A Retrospective Cohort Study	32726151	https://doi.org/10.7326/M20-3214	https://pubmed.ncbi.nlm.nih.gov/32726151	2,466	Other			10-Mar-2020	24-Apr-2020	46	No	Cohort study	Retrospective	USA	29-Jul-2020	
#00646	CT_32257773	Coronavirus Disease-19: Summary of 2,370 Contact Investigations of the First 30 Cases in the Republic of Korea.	32257773	https://doi.org/10.24171/j.phrp.2020.11.2.04	https://pubmed.ncbi.nlm.nih.gov/32257773	2,370	Other			24-Jan-2020	10-Mar-2020	47	No	Case report		South Korea	20-Mar-2020	
#00647	CT_32794386	The Clinical Characteristics and Outcomes of Patients with Moderate-to-Severe Coronavirus Disease 2019 Infection and Diabetes in Daegu, South Korea	32794386	https://doi.org/10.4093/dmj.2020.0146	https://pubmed.ncbi.nlm.nih.gov/32794386	1,082	Other			18-Feb-2020	31-Mar-2020	43	No	Multi-center observational study	Retrospective	Daegu, South Korea	12-Aug-2020	
#00648	CT_32876207	Evaluation of a rapid serological test for detection of IgM and igG antibodies against SARS-CoV-2 under field conditions.	32876207	https://doi.org/10.17843/rpmesp.2020.372.5534.	https://pubmed.ncbi.nlm.nih.gov/32876207	144	Other			30-Mar-2020	31-Mar-2020	2	No	Cross-sectional operative study		Lima, Peru	28-Apr-2020	
#00649	CT_32312364	Clinical features of children with SARS-CoV-2 infection: an analysis of 13 cases from Changsha, China	32312364	https://doi.org/10.7499/j.issn.1008-8830.2003199	https://pubmed.ncbi.nlm.nih.gov/32312364	13	Drug(s) | Other	Lopinavir/ritonavir | Arbidol | Interferon α2β		17-Jan-2020	29-Feb-2020	44	No	Case analysis	Retrospective	Changsha, China	25-Apr-2020	
#00650	CT_32477912	Analysis and suggestions for the preview and triage screening of children with suspected COVID-19 outside the epidemic area of Hubei Province.	32477912	https://doi.org/10.21037/tp.2020.03.08.	https://pubmed.ncbi.nlm.nih.gov/32477912	36	Other			21-Jan-2020	10-Feb-2020	21	No	Study analysis		Chongqing, China	29-May-2020	
#00651	CT_32527341	Analysis of the clinical characteristics and early warning model construction of severe/critical coronavirus disease 2019 patients	32527341	https://doi.org/10.3760/cma.j.cn121430-20200325-00410	https://pubmed.ncbi.nlm.nih.gov/32527341	155	Other			20-Jan-2020	18-Feb-2020	30	No	Study analysis	Retrospective	Anhui, China	4-Apr-2020	
#00652	CT_32376573	Correlation between clinical classification of COVID-19 and imaging characteristics of MSCT volume scanning of the lungs	32376573	https://doi.org/10.12122/j.issn.1673-4254.2020.03.04	https://pubmed.ncbi.nlm.nih.gov/32376573	102	Other			18-Jan-2020	26-Feb-2020	40	No	Study analysis	Retrospective	Bengbu, China	30-Mar-2020	
#00653	CT_32683744	Characteristics and outcomes of COVID-19 in hospitalized patients with and without diabetes	32683744	https://doi.org/10.1002/dmrr.3388	https://pubmed.ncbi.nlm.nih.gov/32683744	433	Other			24-Jan-2020	21-Apr-2020	89	No	Observational cohort study	Retrospective	Amiens, France	19-Jul-2020	
#00654	CT_32270660	Analysis of baseline liver biochemical parameters in 324 cases with novel coronavirus pneumonia in Shanghai area	32270660	https://doi.org/10.3760/cma.j.cn501113-20200229-00076	https://pubmed.ncbi.nlm.nih.gov/32270660	324	Other			20-Jan-2020	24-Feb-2020	36	No	Study analysis	Retrospective	Shanghai, China	20-Mar-2020	
#00655	CT_32603803	Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting	32603803	https://doi.org/10.1016/j.cmi.2020.06.025	https://pubmed.ncbi.nlm.nih.gov/32603803	836	Other		- 514 Discharged. - 262 Died. - 60 Inpatients.	20-Feb-2020	30-Apr-2020	71	No	Observational analysis, case series	Retrospective	London, UK	27-Jun-2020	
#00656	CT_32062957	Clinical characteristics of 30 medical workers infected with new coronavirus pneumonia	32062957	https://doi.org/10.3760/cma.j.issn.1001-0939.2020.0016	https://pubmed.ncbi.nlm.nih.gov/32062957	30	Other			10-Jan-2020	31-Jan-2020	22	No	Case analysis	Retrospective	Wuhan, China	17-Feb-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00657	CT_32983936	Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial.	32983936	https://doi.org/10.34172/bi.2020.27	https://pubmed.ncbi.nlm.nih.gov/32983936	78	Drug(s)	Bromhexine		18-Apr-2020	28-May-2020	41	No	Open-label randomized clinical trial		Tabriz, Iran	19-Jul-2020	
#00658	CT_32721387	A predictive score for COVID-19 diagnosis using clinical, laboratory and chest image data.	32721387	https://doi.org/10.1016/j.bjid.2020.06.009	https://pubmed.ncbi.nlm.nih.gov/32721387	100	Other			17-Mar-2020	10-Apr-2020	25	No	Cross-sectional study		Rio Grande do Sul, Brazil	25-Jul-2020	
#00659	CT_32839725	Knowledge, perception, and practices towards COVID-19 pandemic among general public of India: A cross-sectional online survey	32839725	https://doi.org/10.1016/j.cmrp.2020.07.013	https://pubmed.ncbi.nlm.nih.gov/32839725	2,459				01-May-2020	15-May-2020	15	No	Cross-sectional online survey		Andhra Pradesh, India	21-Jul-2020	
#00660	CT_32554965	Clinical Characteristics and Outcomes of Community- and Hospital-Acquired Acute Kidney Injury with COVID-19 in a US Inner City Hospital System	32554965	https://doi.org/10.1159/000509182	https://pubmed.ncbi.nlm.nih.gov/32554965	223	Other | Drug(s)	Hydroxychloroquine | Tocilizumab | Glucocorticoids					No	Single-center study	Retrospective	Pennsylvania, USA	18-Jun-2020	
#00661	CT_33000640	Management of suspected COVID-19 patients in a low prevalence region.	33000640	https://doi.org/10.1177/1479973120961843	https://pubmed.ncbi.nlm.nih.gov/33000640	100	Other			16-Mar-2020	20-Apr-2020	36	No			Palermo, Italy	1-Oct-2020	
#00662	CT_33030047	A Retrospective Analysis of the Coagulation Dysfunction in COVID-19 Patients	33030047	https://doi.org/10.1177/1076029620964868	https://pubmed.ncbi.nlm.nih.gov/33030047	88	Other			01-Feb-2020	06-Mar-2020	35	No	Study analysis	Retrospective	Hubei, China	8-Oct-2020	
#00663	CT_32854513	Incidence and Risk Factors of Deep Vein Thrombosis in Hospitalized COVID-19 Patients.	32854513	https://doi.org/10.1177/1076029620953217	https://pubmed.ncbi.nlm.nih.gov/32854513	142	Other			01-Dec-2019	01-Apr-2020	123	No	Single centered	Retrospective	Wuhan, China	28-Aug-2020	
#00664	CT_32726134	Characteristics of Acute Pulmonary Embolism in Patients With COVID-19 Associated Pneumonia From the City of Wuhan	32726134	https://doi.org/10.1177/1076029620936772	https://pubmed.ncbi.nlm.nih.gov/32726134	25	Other		- 19 Discharged. - 6 Died.	Jan 2020	01-Feb-2020	32	No	Case series	Retrospective	Wuhan, China	29-Jul-2020	
#00665	CT_32876113	Characteristics and outcomes of patients with COVID-19 admitted to the ICU in a university hospital in São Paulo, Brazil - study protocol.	32876113	https://doi.org/10.6061/clinics/2020/e2294	https://pubmed.ncbi.nlm.nih.gov/32876113	300	Other			30-Mar-2020	30-Jun-2020	93	No	Cohort study	Prospective/Retrospective (combined)	São Paulo, Brazil	21-Aug-2020	
#00666	CT_32844958	Severe clinical spectrum with high mortality in pediatric patients with COVID-19 and multisystem inflammatory syndrome.	32844958	https://doi.org/10.6061/clinics/2020/e2209	https://pubmed.ncbi.nlm.nih.gov/32844958	66	Drug(s) | Other | Oxygen support | IVIG	Empirical antibiotics | Oseltamivir | Glucocorticoid | Immunoglobulin | Enoxaparin | Aspirin		16-Apr-2020	21-Jun-2020	67	No	Cross-sectional study		Sao Paulo, Brazil	14-Aug-2020	
#00667	CT_32771919	Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection	32771919	https://doi.org/10.1016/j.dsx.2020.07.054	https://pubmed.ncbi.nlm.nih.gov/32771919	6,922							Yes			Tangerang, Indonesia	1-Aug-2020	
#00668	CT_32408119	COVID-19 outbreak in Iraqi Kurdistan: The first report characterizing epidemiological, clinical, laboratory, and radiological findings of the disease	32408119	https://doi.org/10.1016/j.dsx.2020.04.047	https://pubmed.ncbi.nlm.nih.gov/32408119	15	Other		- 15 Recovered and discharged	18-Mar-2020	07-Apr-2020	21	No	Descriptive study	Prospective	Iraqi Kurdistan, Iraq	5-May-2020	
#00669	CT_32125452	Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China	32125452	https://doi.org/10.1007/s00134-020-05991-x	https://pubmed.ncbi.nlm.nih.gov/32125452	150	Other		- 62 Died (Death group) - 82 Discharged.				No	Multicenter study	Retrospective	Hubei, China	3-Mar-2020	
#00670	CT_32309388	A quickly, effectively screening process of novel corona virus disease 2019 (COVID-19) in children in Shanghai, China	32309388	https://doi.org/10.21037/atm.2020.03.22.	https://pubmed.ncbi.nlm.nih.gov/32309388	56	Other			19-Jan-2020	12-Feb-2020	25	No			Shanghai, China	10-Mar-2020	
#00671	CT_32074444	SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients	32074444	https://doi.org/10.1056/NEJMc2001737	https://pubmed.ncbi.nlm.nih.gov/32074444	14	Other			07-Jan-2020	26-Jan-2020	20	No			Zhuhai, Guangdong, China	19-Mar-2020	
#00672	CT_32995704	Therapeutic Anticoagulation Delays Death in COVID-19 Patients: Cross-Sectional Analysis of a Prospective Cohort	32995704	https://doi.org/10.1055/s-0040-1716721	https://pubmed.ncbi.nlm.nih.gov/32995704	750	Drug(s)	Anticoagulants | Corticosteroid	- 623 Survived. - 127 Died. The impact of AC on delaying death in severe COVID-19 appears to be dose- and duration-dependent, with greater effect seen for therapeutic compared with prophylactic doses.	13-Mar-2020	08-Apr-2020	27	No	Single-center, cross-sectional analysis	Prospective	Michigan, USA	26-Sep-2020	
#00673	CT_32934901	Severe ischemic complications in Covid-19-A case series.	32934901	https://doi.org/10.1016/j.ijscr.2020.09.009	https://pubmed.ncbi.nlm.nih.gov/32934901	5	Other			01-Apr-2020	01-Jun-2020	62	No	Observational study	Retrospective	Kuwait	10-Sep-2020	
#00674	CT_32781034	Pediatric patients with COVID-19 admitted to intensive care units in Brazil: a prospective multicenter study.	32781034	https://doi.org/10.1016/j.jped.2020.07.002	https://pubmed.ncbi.nlm.nih.gov/32781034	79	Other | Oxygen support			01-Mar-2020	31-May-2020	92	No	Multicenter, observational study	Prospective	Brazil	4-Aug-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00675	CT_32924762	Analysis of Glucose Levels in Patients Hospitalized With COVID-19 During the First Phase of This Pandemic in West Texas.	32924762	https://doi.org/10.1177/2150132720958533.	https://pubmed.ncbi.nlm.nih.gov/32924762	63	Other			01-Mar-2020	15-May-2020	o	No			Texas, USA	13-Sep-2020	
#00676	CT_32592843	Clinical characteristics and outcome in patients with combined diabetic ketoacidosis and hyperosmolar hyperglycemic state associated with COVID-19: A retrospective, hospital-based observational case series	32592843	https://doi.org/10.1016/j.diabres.2020.108279	https://pubmed.ncbi.nlm.nih.gov/32592843	6	Other			20-Mar-2020	20-Apr-2020	32	No	Observational case series	Retrospective		25-Jun-2020	
#00677	CT_32804112	A retrospective study of the initial chest CT imaging findings in 50 COVID-19 patients stratified by gender and age.	32804112	https://doi.org/10.3233/XST-200709	https://pubmed.ncbi.nlm.nih.gov/32804112	50	Other						No	Study analysis	Retrospective	China	19-Sep-2020	
#00678	CT_32741802	Dynamic CT assessment of disease change and prognosis of patients with moderate COVID-19 pneumonia.	32741802	https://doi.org/10.3233/XST-200711	https://pubmed.ncbi.nlm.nih.gov/32741802	33	Other			15-Jan-2020	05-Mar-2020	51	No		Retrospective	Jiangxi, China	19-Sep-2020	
#00679	CT_32923361	A case series of coinfection with SARS-CoV-2 and influenza virus in Louisiana.	32923361	https://doi.org/10.1016/j.rmcr.2020.101214	https://pubmed.ncbi.nlm.nih.gov/32923361	4	Other			27-Mar-2020	18-Apr-2020	23	No	Case series	Retrospective	Louisiana, USA	9-Sep-2020	
#00680	CT_32874906	Clinical course and findings of 14 patients with COVID-19 compared with 5 patients with conventional human coronavirus pneumonia.	32874906	https://doi.org/10.1016/j.rmcr.2020.101207.	https://pubmed.ncbi.nlm.nih.gov/32874906	16	Drug(s) | IVIG | Other | Oxygen support	Empirical antibiotics | Empirical Antivirals	- 15 Recovered. - 1 Died.				No		Retrospective	Saitama, Japan	27-Aug-2020	
#00681	CT_32841948	Clinical Characteristics of Patients with Severe Pneumonia Caused by the SARS-CoV-2 in Wuhan, China.	32841948	https://doi.org/10.1159/000507940	https://pubmed.ncbi.nlm.nih.gov/32841948	110	Other			01-Jan-2020	10-Feb-2020	41	No	Cross-sectional study	Retrospective	Wuhan, China	25-Aug-2020	
#00682	CT_32874905	Dexamethasone in severe COVID-19 infection: A case series.	32874905	https://doi.org/10.1016/j.rmcr.2020.101205	https://pubmed.ncbi.nlm.nih.gov/32874905	5	Drug(s) | Oxygen support	Dexamethasone					No	Case series		Manama, Bahrain	28-Aug-2020	
#00683	CT_32570240	Clinical Characteristics of Metastatic Prostate Cancer Patients Infected with COVID-19 in South Italy.	32570240	https://doi.org/10.1159/000509434	https://pubmed.ncbi.nlm.nih.gov/32570240	72	Other			01-Mar-2020	27-Mar-2020	27	No		Retrospective/prospective (combined)	Italy	22-Jun-2020	
#00684	CT_32584330	IMPACT OF COMORBIDITIES IN MEXICAN SARS-COV-2-POSITIVE PATIENTS: A RETROSPECTIVE ANALYSIS IN A NATIONAL COHORT.	32584330	https://doi.org/10.24875/RIC.20000207	https://pubmed.ncbi.nlm.nih.gov/32584330	13,842				01-Jan-2020	25-Apr-2020	116	Yes	National cohort	Retrospective	Mexico City, Mexico	25-May-2020	
#00685	CT_32425250	Pharmacological characteristics of patients infected with SARS-Cov-2 admitted to Intensive Care Unit in South of France.	32425250	https://doi.org/10.1016/j.therap.2020.05.005	https://pubmed.ncbi.nlm.nih.gov/32425250	96	Other			10-Mar-2020	21-Apr-2020	43	No	Case series		France	15-May-2020	
#00686	CT_32593867	Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis.	32593867	https://doi.org/10.1016/j.tmaid.2020.101791	https://pubmed.ncbi.nlm.nih.gov/32593867	3,737	Drug(s) | Other	Hydroxychloroquine | Azithromycin		03-Mar-2020	27-Apr-2020	56	No	Study analysis	Retrospective	Marseille, France	25-Jun-2020	
#00687	CT_32387409	Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France	32387409	https://doi.org/10.1016/j.tmaid.2020.101738	https://pubmed.ncbi.nlm.nih.gov/32387409	1,061	Drug(s) | Other	Hydroxychloroquine | Azithromycin		03-Mar-2020	31-Mar-2020	29	No	Study analysis	Retrospective	Marseille, France	5-May-2020	
#00688	CT_32247926	Clinical features of the first cases and a cluster of Coronavirus Disease 2019 (COVID-19) in Bolivia imported from Italy and Spain.	32247926	https://doi.org/10.1016/j.tmaid.2020.101653	https://pubmed.ncbi.nlm.nih.gov/32247926	152	Other			02-Mar-2020	15-Mar-2020	14	No	Cross-sectional, observational study	Retrospective	Bolivia	2-Apr-2020	
#00689	CT_32205269	Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infectious diseases referral hospital in Marseille, France, - January 31st to March 1st, 2020: A respiratory virus snapshot.	32205269	https://doi.org/10.1016/j.tmaid.2020.101632	https://pubmed.ncbi.nlm.nih.gov/32205269	280	Other			31-Jan-2020	01-Mar-2020	31	No			Marseille, France	20-Mar-2020	
#00690	CT_32779705	Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.	32779705	https://doi.org/10.1093/infdis/jiaa505	https://pubmed.ncbi.nlm.nih.gov/32779705	12	Plasma			11-May-2020	29-May-2020	19	No	Single-arm interventional trial		New Mexico, USA	11-Aug-2020	
#00691	CT_33044747	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.	33044747	https://doi.org/10.1002/14651858.CD013600.pub3	https://pubmed.ncbi.nlm.nih.gov/33044747	38,160							Yes	Systematic review			12-Oct-2020	
#00692	CT_33038227	Convalescent plasma for patients with severe COVID-19: a matched cohort study.	33038227	https://doi.org/10.1093/cid/ciaa1548	https://pubmed.ncbi.nlm.nih.gov/33038227	241	Plasma						No	Cohort study		Rhode Island, USA	10-Oct-2020	
#00693	CT_33024082	The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series.	33024082	https://doi.org/10.1038/s41392-020-00329-x	https://pubmed.ncbi.nlm.nih.gov/33024082	8	Plasma | Drug(s)	Lopinavir/ritonavir | Arbidol | Darunavir | Interferon α1β | Moxifloxacin | Thymosin					No	Multi-center, observational case series	Retrospective	Chongqing, China	6-Oct-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00694	CT_33034095	Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial.	33034095	https://doi.org/10.1111/joim.13185	https://pubmed.ncbi.nlm.nih.gov/33034095	103	Plasma			10-Apr-2020	17-May-2020	38	No	Open label clinical study	Prospective	Illinois, USA	9-Oct-2020	
#00695	CT_32978802	Characterization of 100 sequential SARS-CoV-2 convalescent plasma donations.	32978802	https://doi.org/10.1111/trf.16119	https://pubmed.ncbi.nlm.nih.gov/32978802	100	Other						No	Case report		Vienna, Austria	25-Sep-2020	
#00696	CT_32965715	Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report	32965715	https://doi.org/10.1002/jmv.26537	https://pubmed.ncbi.nlm.nih.gov/32965715	40	Other						No	Preliminary report	Retrospective	Doha, Qatar	23-Sep-2020	
#00697	CT_32951151	Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial.	32951151	https://doi.org/10.1007/s40121-020-00341-2	https://pubmed.ncbi.nlm.nih.gov/32951151	38			- 24 Recovered and were discharged. - 14 Died.	20-Apr-2020	08-Jun-2020	50	No	Phase II Clinical Trial	Prospective	Connecticut, USA	20-Sep-2020	
#00698	CT_32950003	Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study.	32950003	https://doi.org/10.1016/j.ebiom.2020.102999	https://pubmed.ncbi.nlm.nih.gov/32950003	138	Drug(s)	Tocilizumab		10-Mar-2020	17-Apr-2020	39	No	Cohort study	Prospective	Alicante, Spain	16-Sep-2020	
#00699	CT_33042873	Analysis of Risk Factors for 24 Patients With COVID-19 Developing From Moderate to Severe Condition.	33042873	https://doi.org/10.3389/fcimb.2020.548582	https://pubmed.ncbi.nlm.nih.gov/33042873	65	Drug(s) | Other	Empirical Antivirals		01-Jan-2020	20-Feb-2020	51	No	Study analysis		Bengbu, China	15-Sep-2020	
#00700	CT_32930632	Clinical characteristics of family-clustered onset of coronavirus disease 2019 in Jilin Province, China	32930632	https://doi.org/10.1080/21505594.2020.1816075	https://pubmed.ncbi.nlm.nih.gov/32930632	8	Other			28-Jan-2020	05-Feb-2020	9	No	Review article	Retrospective	Changchun, China	15-Sep-2020	
#00701	CT_32921249	Exploration of turn-positive RT-PCR results and factors related to treatment outcome in COVID-19: A retrospective cohort study	32921249	https://doi.org/10.1080/21505594.2020.1816076	https://pubmed.ncbi.nlm.nih.gov/32921249	116	Other			01-Jan-2020	01-Mar-2020	61	No	Cohort study	Retrospective	Wuhan, China	13-Sep-2020	
#00702	CT_32795143	Corticosteroid prevents COVID-19 progression within its therapeutic window: a multicentre, proof-of-concept, observational study	32795143	https://doi.org/10.1080/22221751.2020.1807885	https://pubmed.ncbi.nlm.nih.gov/32795143	311	Drug(s) | Other	Corticosteroid		20-Jan-2020	13-Feb-2020	25	No	Multicenter clinical study	Retrospective	Shanghai, China	21-Aug-2020	
#00703	CT_32722990	Characteristics of asymptomatic COVID-19 infection and progression: A multicenter, retrospective study	32722990	https://doi.org/10.1080/21505594.2020.1802194	https://pubmed.ncbi.nlm.nih.gov/32722990	1,568	Other			17-Jan-2020	30-Mar-2020	74	No	Multicenter study	Retrospective	Wuhan, China	12-Aug-2020	
#00704	CT_32573353	Epidemiology and clinical course of COVID-19 in Shanghai, China	32573353	https://doi.org/10.1080/22221751.2020.1787103	https://pubmed.ncbi.nlm.nih.gov/32573353	325	Drug(s) | Other	Empirical Antivirals | Glucocorticoid | Oxygen support		20-Jan-2020	29-Feb-2020	41	No	Study analysis	Retrospective	Shanghai, China	7-Jul-2020	
#00705	CT_32419639	Viral loads in throat and anal swabs in children infected with SARS-CoV-2	32419639	https://doi.org/10.1080/22221751.2020.1771219	https://pubmed.ncbi.nlm.nih.gov/32419639	2,138	Other			01-Jan-2020	18-Mar-2020	78	No	Case series	Retrospective	Wuhan, China	9-Jun-2020	
#00706	CT_32692230	Clinical characteristics and treatment of critically ill patients with COVID-19 in Hebei	32692230	https://doi.org/10.21037/apm-20-1273	https://pubmed.ncbi.nlm.nih.gov/32692230	51	Drug(s) | Oxygen support | IVIG	Empirical antibiotics | Interferon-α | Methylprednisolone | Traditional Chinese medicine | Lopinavir/ritonavir | Arbidol | Immunoglobulin (IVIG) | Oseltamivir		22-Jan-2020	25-Mar-2020	64	No	Multicenter, observational trial	Retrospective	Hebei, China	9-Jul-2020	
#00707	CT_33078138	Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort)	33078138	https://doi.org/10.1016/j.eclinm.2020.100591	https://pubmed.ncbi.nlm.nih.gov/33078138	607	Drug(s) | Other	Hydroxychloroquine | Tocilizumab | Lopinavir/ritonavir | Cyclosporine A | Glucocorticoids		10-Mar-2020	15-Apr-2020	37	No	Observational, longitudinal, cohort study	Retrospective	Madrid, Spain	15-Oct-2020	
#00708	CT_32969605	A novel risk score to predict cardiovascular complications in patients with coronavirus disease 2019 (COVID-19): A retrospective, multicenter, observational study	32969605	https://doi.org/10.1002/iid3.353	https://pubmed.ncbi.nlm.nih.gov/32969605	845	Other			14-Jan-2020	09-Mar-2020	56	No	Multicenter, observational study	Retrospective	Sichuan, China	24-Sep-2020	
#00709	CT_32910179	Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial	32910179	https://doi.org/10.1001/jamainternmed.2020.5503	https://pubmed.ncbi.nlm.nih.gov/32910179	200	Other			18-Feb-2020	10-Apr-2020	53	No	Open-label, multicenter, randomized clinical trial		China	10-Sep-2020	
#00710	CT_32829390	Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU	32829390	https://doi.org/10.1093/jac/dkaa321	https://pubmed.ncbi.nlm.nih.gov/32829390	51	Drug(s)	Remdesivir		29-Feb-2020	20-Mar-2020	21	No	Cohort study	Retrospective	Pesaro, Italy	23-Aug-2020	
#00711	CT_31995857	Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia	31995857	https://doi.org/10.1056/NEJMoa2001316	https://pubmed.ncbi.nlm.nih.gov/31995857	425	Other			01-Jan-2020	22-Jan-2020	22	No	Preliminary analysis		Hubei, China	26-Mar-2020	
#00712	CT_33076729	Immune system changes during COVID-19 recovery play key role in determining disease severity	33076729	https://doi.org/10.1177/2058738420966497	https://pubmed.ncbi.nlm.nih.gov/33076729	97	Other			01-Mar-2020	01-Apr-2020	32	No	Observational, cohort study		Isfahan, Iran	19-Oct-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
	Count >>>	1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00713	CT_33074717	Prevalence and Risk Factors of Thromboembolism among Patients With Coronavirus Disease-19: A Systematic Review and Meta-Analysis	33074717	https://doi.org/10.1177/10760296209670 83	https://pubmed.ncbi.nlm.nih.gov/33074717	2,520				20-Jun-2020	10-Aug-2020	52	Yes	Systematic Review		Amhara, Ethiopia	19-Oct-2020	
#00714	CT_33064701	CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS OF PATIENTS DIAGNOSED WITH COVID-19 IN A TERTIARY CARE CENTER IN MEXICO CITY: A PROSPECTIVE COHORT STUDY	33064701	https://doi.org/10.24875/RIC.20000334	https://pubmed.ncbi.nlm.nih.gov/33064701	309	Other			26-Feb-2020	11-Apr-2020	46	No	Cohort study	Prospective	Mexico City, Mexico	6-Jul-2020	
#00715	CT_33086028	Assessing the Elevation of Cardiac Biomarkers and the Severity of COVID-19 Infection: A Meta-analysis	33086028	https://doi.org/10.18433/jpps31501	https://pubmed.ncbi.nlm.nih.gov/33086028	5,626				01-Dec-2019	10-Jul-2020	223	Yes	Meta-analysis		USA	24-Oct-2020	
#00716	CT_33072871	Hospitalized COVID-19 patients treated with convalescent plasma in a mid-size city in the Midwest	33072871	https://doi.org/10.1186/s41231-020-00068-9	https://pubmed.ncbi.nlm.nih.gov/33072871	31	Plasma			12-Apr-2020	02-Jun-2020	52	No		Retrospective	Madison, Wisconsin, USA	12-Oct-2020	
#00717	CT_33070706	Oxygen therapy via high flow nasal cannula in severe respiratory failure caused by Sars-Cov-2 infection: a real-life observational study	33070706	https://doi.org/10.1177/1753466620963016	https://pubmed.ncbi.nlm.nih.gov/33070706	59	Oxygen support | Other			27-Mar-2020	25 Jun	91	No	Observational study	Retrospective	Catanzaro, Italy	18-Oct-2020	
#00718	CT_32945149	Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients	32945149	https://doi.org/10.1002/cam4.3457	https://pubmed.ncbi.nlm.nih.gov/32945149	24	Plasma			11-Apr-2020	10-May-2020	30	No	Case series		New York, USA	17-Sep-2020	
#00719	CT_33087047	The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial	33087047	https://doi.org/10.1186/s12879-020-05507-4	https://pubmed.ncbi.nlm.nih.gov/33087047	59	IVIG			09-May-2020	09-Jun-2020	32	No	Randomized placebo-controlled double-blind clinical trial	Retrospective	Iran	21-Oct-2020	
#00720	CT_	Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibodies in Egyptian Convalescent Plasma Donors		https://doi.org/10.3389/fmicb.2020.596851	N/A	227	Other						No		Case study	Egypt	24-Nov-2020	
#00721	CT_33134417	Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients	33134417	https://doi.org/10.1093/ofid/ofaa446	https://pubmed.ncbi.nlm.nih.gov/33134417	128	Drug(s) I other	Hydroxychloroquine		17-Apr-2020	12-May-2020	26	No	Multicenter, double-blind randomized clinical		New York, USA	23-Sep-2020	
#00722	CT_33135795	Characterization of antibody responses to SARS-CoV-2 in convalescent COVID-19 patients	33135795	https://doi.org/10.1002/jmv.26646	https://pubmed.ncbi.nlm.nih.gov/33135795	52	Other						No			China	2-Nov-2020	
#00723	CT_33135909	Clinical progression and changes of chest CT findings among asymptomatic and pre-symptomatic patients with SARS-CoV-2 infection in Wuhan, China	33135909	https://doi.org/10.1080/17476348.2021.1840358	https://pubmed.ncbi.nlm.nih.gov/33135909	109	Other			20-Dec-2019	08-Mar-2020	80	No		Retrospective	Wuhan, China	2-Nov-2020	
#00724	CT_33136163	Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis	33136163	https://doi.org/10.1093/jnci/djaa168	https://pubmed.ncbi.nlm.nih.gov/33136163	3,019							Yes	Systematic Review and Meta-Analysis		New York, USA	2-Nov-2020	
#00725	CT_33136164	Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience	33136164	https://doi.org/10.7556/jaoa.2020.156	https://pubmed.ncbi.nlm.nih.gov/33136164	76	Drug(s)	Remdesivir		01-May-2020	19-Aug-2020	111	No		Retrospective	Arizona, USA	1-Dec-2020	
#00726	CT_33169109	Using Anti-SARS-CoV-2 IgG and IgM Antibodies to Detect Outpatient Cases with Olfactory and Taste Disorders Suspected as Mild Form of COVID-19: a Retrospective Survey	33169109	https://doi.org/10.1007/s42399-020-00623-3	https://pubmed.ncbi.nlm.nih.gov/33169109	108	Other			01-Mar-2020	01-Apr-2020	32	No	Cross-sectional study	Retrospective	Iran	3-Nov-2020	
#00727	CT_33170927	Clinical experience with SARS CoV-2 related illness in children - hospital experience in Cape Town, South Africa	33170927	https://doi.org/10.1093/cid/ciaa1666	https://pubmed.ncbi.nlm.nih.gov/33170927	159	Other			17-Apr-2020	24-Jul-2020	99	No	Observational cohort study		South Africa	10-Nov-2020	
#00728	CT_33169114	Why will it never be known if convalescent plasma is effective for COVID-19	33169114	https://doi.org/10.1016/j.jtauto.2020.100069	https://pubmed.ncbi.nlm.nih.gov/33169114	792							Yes	Systematic review		Bogota, Colombia	4-Nov-2020	
#00729	CT_33271421	Pulmonary embolism in COVID-19 patients: prevalence, predictors and clinical outcome	33271421	https://doi.org/10.1016/j.thromres.2020.11.017	https://pubmed.ncbi.nlm.nih.gov/33271421	224	Other			28-Feb-2020	20-Apr-2020	53	No	Multi-center observational study	Retrospective	Italy	17-Nov-2020	
#00730	CT_33268103	Epidemiological Features of 105 Patients Infected with the COVID-19	33268103	https://doi.org/10.1016/j.jnma.2020.09.151	https://pubmed.ncbi.nlm.nih.gov/33268103	105	Other			17-Jan-2020	20-Feb-2020	35	No		Retrospective	Wenzhou, China	23-Oct-2020	
#00731	CT_33266474	Risk and Severity of COVID-19 and ABO Blood Group in Transcatheter Aortic Valve Patients	33266474	https://doi.org/10.3390/jcm9113769	https://pubmed.ncbi.nlm.nih.gov/33266474	702	Other						No	Observational investigational study	Retrospective	Strasbourg, France	22-Nov-2020	
#00732	CT_33263697	CLINICAL MANIFESTATIONS OF CHILDREN AND ADOLESCENTS WITH COVID-19: REPORT OF THE FIRST 115 CASES FROM SABARÁ HOSPITAL INFANTIL	33263697	https://doi.org/10.1590/1984-0462/2021/39/2020305	https://pubmed.ncbi.nlm.nih.gov/33263697	115	Other			01-Mar-2020	30-Jun-2020	122	No	Cross-sectional, observational study.	Retrospective	São Paulo, Brazil	27-Nov-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
	Count >>>	1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00733	CT_33271558	**Clinical Role of Lung Ultrasound for the Diagnosis and Prognosis of Coronavirus Disease Pneumonia in Elderly Patients: A Pivotal Study**	33271558	https://doi.org/10.1159/000512209	https://pubmed.ncbi.nlm.nih.gov/33271558	37	Other						No		Prospective	Bologna, Italy	3-Dec-2020	
#00734	CT_33271549	**Association between Prolonged Intermittent Renal Replacement Therapy and All-Cause Mortality in COVID-19 Patients Undergoing Invasive Mechanical Ventilation: A Retrospective Cohort Study**	33271549	https://doi.org/10.1159/000512099	https://pubmed.ncbi.nlm.nih.gov/33271549	36	Drug(s) | other	Moxifloxacin hydrochloride | Abidol | Lopinavir/ritonavir | Hydroxychloroquine |Empirical antibiotics | Empirical antiviral | Antifungi | Traditional Chinese medicine | Glucocorticoid | Human albumin | Gamma globulin | Heparin		12-Feb-2020	02-Mar-2020	20	No	Cohort Study	Retrospective	Wuhan, China,	3-Dec-2020	
#00735	CT_33270978	**The characteristic peripheral blood morphological features of hospitalized patients infected with COVID-19**	33270978	https://doi.org/10.1111/ijlh.13417	https://pubmed.ncbi.nlm.nih.gov/33270978	102	Other			03-Aug-2020	21-Aug-2020	19	No	Cohort Study		Johannesburg, South Africa.	3-Dec-2020	
#00736	CT_33270790	**Characteristics associated with COVID-19 or other respiratory viruses' infections at a single-center emergency department**	33270790	https://doi.org/10.1371/journal.pone.0243261	https://pubmed.ncbi.nlm.nih.gov/33270790	1,104	Other			18-Nov-2019	02-Mar-2020	106	No	Cohort Study	Prospective	Paris, France	3-Dec-2020	
#00737	CT_33270769	**U-shaped-aggressiveness of SARS-CoV-2: Period between initial symptoms and clinical progression to COVID-19 suspicion. A population-based cohort study**	33270769	https://doi.org/10.1371/journal.pone.0243268	https://pubmed.ncbi.nlm.nih.gov/33270769	65,500	Other			01-Jan-2020	25-Apr-2020	116	Yes	A population-based cohort study		Mexico City, Mexico	3-Dec-2020	
#00738	CT_33270741	**Epidemiology, outcomes, and the use of intensive care unit resources of critically ill patients diagnosed with COVID-19 in Sao Paulo, Brazil: A cohort study**	33270741	https://doi.org/10.1371/journal.pone.0243269	https://pubmed.ncbi.nlm.nih.gov/33270741	212	Other			01-Mar-2020	01-Jun-2020	93	No	Cohort study	Retrospective	Sao Paulo, Brazil	3-Dec-2020	
#00739	CT_33270136	**Characteristics of Adults aged 18-49 Years without Underlying Conditions Hospitalized with Laboratory-Confirmed COVID-19 in the United States, COVID-NET - March-August 2020**	33270136	https://doi.org/10.1093/cid/ciaa1806	https://pubmed.ncbi.nlm.nih.gov/33270136	513	Other			01-Mar-2020	01-Aug-2020	154	No	Study analysis		USA	3-Dec-2021	
#00740	CT_33270101	**Identification of presymptomatic and asymptomatic cases using cohort-based testing approaches at a large correctional facility - Chicago, Illinois, USA, May 2020**	33270101	https://doi.org/10.1093/cid/ciaa1802	https://pubmed.ncbi.nlm.nih.gov/33270101	169	Other			01-May-2020	19-May-2020	19	No	Cohort study		Chicago, Illinois, USA	3-Dec-2020	
#00741	CT_33272198	**Risk factors for a positive SARS-CoV-2 PCR in patients with common cold symptoms in a primary care setting - a retrospective analysis based on a joint documentation standard**	33272198	https://doi.org/10.1186/s12875-020-01322-7	https://pubmed.ncbi.nlm.nih.gov/33272198	374	Other			24-Mar-2020	17-Apr-2020	25	No	Study analysis	Retrospective	Germany	3-Dec-2020	
#00742	CT_33275765	**Challenges in treatment of patients with acute leukemia and COVID-19: a series of 12 patients**	33275765	https://doi.org/10.1182/bloodadvances.2020002543	https://pubmed.ncbi.nlm.nih.gov/33275765	12	Other | Drug(s) | Plasma | IVIG	Lopinavir/ritonavir | Tocilizumab | Pentaglobin		18-Mar-2020	18-May-2020	62	No	Case series		Hamburg, Germany	4-Dec-2020	
#00743	CT_33275094	**Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis**	33275094		https://pubmed.ncbi.nlm.nih.gov/33275094	1,520	Drug(s)	Tocilizumab		01-Jan-2020	21-Jun-2020	173	Yes	Systematic review		L'Aquila, Italy	3-Dec-2020	
#00744	CT_33274479	**Cyclosporine A plus low-dose steroid treatment in COVID-19 improves clinical outcomes in patients with moderate to severe disease: A pilot study**	33274479	https://doi.org/10.1111/joim.13223	https://pubmed.ncbi.nlm.nih.gov/33274479	209	Drug(s)	Cyclosporine A | Low-dose steroid Methylprednisolone | Clarithromycin | Enoxaparin		01-Apr-2020	01-May-2020	31	No	Open-label, non randomized pilot study		México	3-Dec-2020	
#00745	CT_33274414	**Derivation of a Clinical Risk Score to Predict 14-Day Occurrence of Hypoxia, ICU Admission, and Death Among Patients with Coronavirus Disease 2019**	33274414	https://doi.org/10.1007/s11606-020-06353-5	https://pubmed.ncbi.nlm.nih.gov/33274414	1,014	Other			01-Mar-2020	12-Apr-2020	43	No	Cohort study	Retrospective	Massachusetts, USA	3-Dec-2020	
#00746	CT_33274410	**SARS-CoV-2 antibodies in ICU and clinic staff : From Germany's region with the highest infection rate**	33274410	https://doi.org/10.1007/s00063-020-00761-5	https://pubmed.ncbi.nlm.nih.gov/33274410	2,824	Other			29-Jun-2020	29-Jul-2020	31	No	Single-center, observational study	Prospective	Germany	3-Dec-2020	
#00747	CT_33274223	**Circulating Cytokines and Lymphocyte Subsets in Patients Who Have Recovered from COVID-19**	33274223	https://doi.org/10.1155/2020/7570981	https://pubmed.ncbi.nlm.nih.gov/33274223	68	Other			01-Feb-2020	01-Mar-2020	30	No	Case study	Retrospective	Shanxi, China	26-Nov-2020	
#00748	CT_33273803	**Vertical Transmission of COVID-19 to the Neonate**	33273803	https://doi.org/10.1155/2020/8460672	https://pubmed.ncbi.nlm.nih.gov/33273803	40	Other			20-Mar-2020	30-Apr-2020	42	No	Observational, cohort study	Retrospective	New York, USA	12-Nov-2020	
#00749	CT_33273040	**Post-exertion oxygen saturation as a prognostic factor for adverse outcome in patients attending the emergency department with suspected COVID-19: a substudy of the PRIEST observational cohort study**	33273040	https://doi.org/10.1136/emermed-2020-210528	https://pubmed.ncbi.nlm.nih.gov/33273040	817	Other			26-Mar-2020	28-May-2020	64	No	Observational cohort study	Retrospective	UK	3-Dec-2020	
#00750	CT_33273026	**Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort**	33273026	https://doi.org/10.1136/thoraxjnl-2020-216086	https://pubmed.ncbi.nlm.nih.gov/33273026	163	Other			30-Mar-2020	03-Jun-2020	66	No	Cohort study	Prospective	UK	3-Dec-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00751	CT_33273023	A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations	33273023	https://doi.org/10.1136/thoraxjnl-2020-216308	https://pubmed.ncbi.nlm.nih.gov/33273023	60	Other						No	Cohort study	Prospective	Vancouver, Canada	3-Dec-2020	
#00752	CT_33272357	Association between SARS-CoV-2 infection and Kawasaki-like multisystem inflammatory syndrome: a retrospective matched case–control study, Paris, France, April to May 2020	33272357		https://pubmed.ncbi.nlm.nih.gov/33272357	125	Other			14-Apr-2020	26-May-2020	43	No	Case control	Retrospective	Paris, France	3-Dec-2020	
#00753	CT_33272355	Clinical characteristics and risk factors associated with severe COVID-19: prospective analysis of 1,045 hospitalised cases in North-Eastern France, March 2020	33272355		https://pubmed.ncbi.nlm.nih.gov/33272355	1,045							No	Study analysis	Prospective	Alsace, France	3-Dec-2020	
#00754	CT_33298872	Patient-derived SARS-CoV-2 mutations impact viral replication dynamics and infectivity in vitro and with clinical implications in vivo	33298872	https://doi.org/10.1038/s41421-020-00226-1	https://pubmed.ncbi.nlm.nih.gov/33298872	11				22-Jan-2020	04-Feb-2020	14	No	Observational study		Zhejiang, China	29-Oct-2020	
#00755	CT_33659220	Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitively Get a Role to Fusobacterium periodonticum?	33659220	https://doi.org/10.3389/fcimb.2021.625581	https://pubmed.ncbi.nlm.nih.gov/33659220	38	Other			May 2020	01-Sep-2020	124	No	Study analysis		Napoli, Italy	15-Feb-2021	
#00756	CT_33298370	Corticosteroids for Patients With Coronavirus Disease 2019 (COVID-19) With Different Disease Severity: A Meta-Analysis of Randomized Clinical Trials	33298370	https://doi.org/10.1053/j.jvca.2020.11.057	https://pubmed.ncbi.nlm.nih.gov/33298370	7,692	Drug(s)	Corticosteroid					Yes	Meta-Analysis of Randomized Clinical Trials		Italy	28-Nov-2020	
#00757	CT_33298149	A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study	33298149	https://doi.org/10.1186/s13063-020-04878-y	https://pubmed.ncbi.nlm.nih.gov/33298149	200	Other						No	A randomized, open-label, adaptive, proof-of-concept clinical trial		Leuven, Belgium	9-Dec-2020	
#00758	CT_33297986	Clinical characteristics and laboratory biomarkers changes in COVID-19 patients requiring or not intensive or sub-intensive care: a comparative study	33297986	https://doi.org/10.1186/s12879-020-05647-7	https://pubmed.ncbi.nlm.nih.gov/33297986	303	Other			22-Feb-2020	20-May-2020	89	No	Observational study	Retrospective	Padova, Italy	9-Dec-2020	
#00759	CT_33296777	Predictive value of chest CT scoring in COVID-19 patients in Wuhan, China: A retrospective cohort study	33296777	https://doi.org/10.1016/j.rmed.2020.106271	https://pubmed.ncbi.nlm.nih.gov/33296777	53	Other			08-Feb-2020	07-Mar-2020	29	No	Cohort study	Retrospective	Beijing, China	28-Nov-2020	
#00760	CT_33296536	ABO blood groups in COVID-19 patients; Cross-sectional study	33296536	https://doi.org/10.1111/ijcp.13927	https://pubmed.ncbi.nlm.nih.gov/33296536	1,667	Other			16-Mar-2020	10-Jul-2020	117	No	Study analysis	Retrospective	Diyarbakır, Turkey	19-Dec-2020	
#00761	CT_33296409	COVID-MATCH65-A prospectively derived clinical decision rule for severe acute respiratory syndrome coronavirus 2	33296409	https://doi.org/10.1371/journal.pone.0243414	https://pubmed.ncbi.nlm.nih.gov/33296409	2,935	Other			11-Mar-2020	22-Apr-2020	43	No	Cohort study	Prospective	Melbourne, Australia	9-Dec-2020	
#00762	CT_33296405	COVID-19 mortality risk assessment: An international multi-center study	33296405	https://doi.org/10.1371/journal.pone.0243262	https://pubmed.ncbi.nlm.nih.gov/33296405	3,062	Other						No	A multi-center derivation cohort study			9-Dec-2020	
#00763	CT_33296337	Clinical Characteristics of 33 Asymptomatic COVID-19 Infections in Wuhan, China	33296337	https://doi.org/10.3855/jidc.13222	https://pubmed.ncbi.nlm.nih.gov/33296337	33	Other			21-Jan-2020	05-Mar-2020	45	No	Cohort study	Retrospective	Wuhan, China	30-Nov-2020	
#00764	CT_33296132	Validation of pneumonia prognostic scores in a statewide cohort of hospitalised patients with COVID-19	33296132	https://doi.org/10.1111/ijcp.13926	https://pubmed.ncbi.nlm.nih.gov/33296132	257	Other			01-Mar-2020	18-May-2020	79	No	Cohort study	Retrospective	Rhode Island, USA	31-Dec-2020	
#00765	CT_33301928	Corticosteroids in patients hospitalized for COVID-19 pneumonia who require oxygen: observational comparative study using routine care data	33301928	https://doi.org/10.1016/j.cmi.2020.11.035	https://pubmed.ncbi.nlm.nih.gov/33301928	891	Drug(s)	Corticosteroid		01-Mar-2020	01-May-2020	62	No	Observational study	Retrospective	France	8-Dec-2020	
#00766	CT_33301818	Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients	33301818	https://doi.org/10.1016/j.jinf.2020.12.005	https://pubmed.ncbi.nlm.nih.gov/33301818	552	Drug(s)	Favipiravir					Yes	Meta-analysis		Tainan, Taiwan	7-Dec-2020	
#00767	CT_33301533	Epidemiological profile of SARS-CoV-2 among selected regions in Ghana: A cross-sectional retrospective study	33301533	https://doi.org/10.1371/journal.pone.0243711	https://pubmed.ncbi.nlm.nih.gov/33301533	72,434	Other			02-Feb-2020	08-Jul-2020	158	No	A cross-sectional study	Retrospective	Kumasi, Ghana	10-Dec-2020	
#00768	CT_33301529	Impact of chronic liver disease upon admission on COVID-19 in-hospital mortality: Findings from COVOCA study	33301529	https://doi.org/10.1371/journal.pone.0243700	https://pubmed.ncbi.nlm.nih.gov/33301529	618	Other			13-Mar-2020	06-Jul-2020	116	No	Observational, cohort study	Retrospective	Naples, Italy	10-Dec-2020	
#00769	CT_33301459	False-negative results of initial RT-PCR assays for COVID-19: A systematic review	33301459	https://doi.org/10.1371/journal.pone.0242958	https://pubmed.ncbi.nlm.nih.gov/33301459	12,057	Other			01-Jan-2020	15-Apr-2020	106	Yes	Systematic review			10-Dec-2020	
#00770	CT_33301190	The impact of COVID-19 pandemic on the management of patients with chronic urticaria: An observational two-center study from Turkey	33301190	https://doi.org/10.1111/dth.14652	https://pubmed.ncbi.nlm.nih.gov/33301190	194	Other						No	Observational ,two-center study	Prospective	Turkey	19-Dec-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00771	CT_33300981	Retrospective Analyses Associate Hemostasis Activation Biomarkers With Poor Outcomes in Patients With COVID-19	33300981	https://doi.org/10.1093/ajcp/aqaa266	https://pubmed.ncbi.nlm.nih.gov/33300981	81	Other						No	Chart review	Retrospective	Atlanta, Georgia, USA	10-Dec-2020	
#00772	CT_33304660	Characteristics and outcomes of hemodialysis patients with COVID-19: a retrospective single center study	33304660	https://doi.org/10.7717/peerj.10459	https://pubmed.ncbi.nlm.nih.gov/33304660	16	Other			05-Feb-2020	20-Mar-2020	45	No	Single-center study.	Retrospective	Wuhan, China	26-Nov-2020	
#00773	CT_33304584	Treatment of COVID-19 patients with the anti-CD6 antibody itolizumab	33304584	https://doi.org/10.1002/cti2.1218	https://pubmed.ncbi.nlm.nih.gov/33304584	70	Drug(s)	Itolizumab		04-Apr-2020	13-May-2020	40	No	Open-label, expanded-access trial		Havana, Cuba	25-Nov-2020	
#00774	CT_33303539	Cardiopulmonary recovery after COVID-19 - an observational prospective multi-center trial	33303539	https://doi.org/10.1183/13993003.03481-2020	https://pubmed.ncbi.nlm.nih.gov/33303539	145	Other						No	Multicentre, observational study	Prospective	Innsbruck, Austria	10-Dec-2020	
#00775	CT_33303472	Factors associated with the mental health status of medical students during the COVID-19 pandemic: a cross-sectional study in Japan	33303472	https://doi.org/10.1136/bmjopen-2020-043728	https://pubmed.ncbi.nlm.nih.gov/33303472	571	Other			29-May-2020	06-Jun-2020	9	No	Cross-sectional study		Tokyo, Japan	10-Dec-2020	
#00776	CT_33302944	Hospice care self-efficacy among clinical medical staff working in the coronavirus disease 2019 (COVID-19) isolation wards of designated hospitals: a cross-sectional study	33302944	https://doi.org/10.1186/s12904-020-00692-0	https://pubmed.ncbi.nlm.nih.gov/33302944	281	Other						No	Cross-sectional study		Guiyang, China	10-Dec-2020	
#00777	CT_33306063	Investigating the factors affecting the survival rate in patients with COVID-19: A retrospective cohort study	33306063	https://doi.org/10.34171/mjiri.34.88	https://pubmed.ncbi.nlm.nih.gov/33306063	3,188	Other			22-Feb-2020	25-Mar-2020	33	No	Cohort study	Retrospective	Tehran, Iran	30-Jul-2020	
#00778	CT_33306989	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK	33306989	https://doi.org/10.1016/S0140-6736(20)32661-1	https://pubmed.ncbi.nlm.nih.gov/33306989	23,848	Other			23-Apr-2020	04-Nov-2020	196	Yes	Analysis of four randomised controlled trials			9-Jan-2021	
#00779	CT_33306725	Behavioral preventive measures and the use of medicines and herbal products among the public in response to Covid-19 in Bangladesh: A cross-sectional study	33306725	https://doi.org/10.1371/journal.pone.0243706	https://pubmed.ncbi.nlm.nih.gov/33306725	1,222	Other			27-Jun-2020	20-Jul-2020	24	No	A cross-sectional study		Bangladesh	11-Dec-2020	
#00780	CT_33306283	Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19	33306283	https://doi.org/10.1056/NEJMoa2031994	https://pubmed.ncbi.nlm.nih.gov/33306283	1,033	Drug(s)	Baricitinib | Remdesivir					No	Double-blind, randomized, placebo-controlled trial			11-Dec-2020	
#00781	CT_33305544	COVID-19 Outcomes in Patients with Systemic Autoimmune Rheumatic Diseases (SARDs) Compared to the General Population: A US Multi-Center Comparative Cohort Study	33305544	https://doi.org/10.1002/art.41619	https://pubmed.ncbi.nlm.nih.gov/33305544	2,379	Other			20-Jan-2020	15-Aug-2020	209	No	Multi-center comparative cohort study		Massachusetts, USA	10-Dec-2020	
#00782	CT_33304913	First Report of Tocilizumab Use in a Cohort of Latin American Patients Hospitalized for Severe COVID-19 Pneumonia	33304913	https://doi.org/10.3389/fmed.2020.596916	https://pubmed.ncbi.nlm.nih.gov/33304913	29	Other			13-Apr-2020	16-Jun-2020	65	No	Observational, cohort study	Retrospective	Santiago, Chile	16-Nov-2020	
#00783	CT_33304910	Clinical Characteristics of Patients With Progressive and Non-progressive Coronavirus Disease 2019: Evidence From 365 Hospitalised Patients in Honghu and Nanchang, China	33304910	https://doi.org/10.3389/fmed.2020.556818	https://pubmed.ncbi.nlm.nih.gov/33304910	365	Other			01-Jan-2020	18-Mar-2020	78	No	Cohort study	Retrospective	Guangzhou, China	16-Nov-2020	
#00784	CT_33309934	Prevalence of Comorbid Asthma and Related Outcomes in COVID-19: A Systematic Review and Meta-Analysis	33309934	https://doi.org/10.1016/j.jaip.2020.11.054	https://pubmed.ncbi.nlm.nih.gov/33309934	410,382							Yes	Systematic review and meta-analysis		China	9-Dec-2020	
#00785	CT_33309392	The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis	33309392	https://doi.org/10.1016/j.blre.2020.100785	https://pubmed.ncbi.nlm.nih.gov/33309392	54,218							Yes			Beijing, China	8-Dec-2020	
#00786	CT_32379894	Association between ABO blood groups and risk of SARS-CoV-2 pneumonia	32379894	https://doi.org/10.1111/bjh.16797	https://pubmed.ncbi.nlm.nih.gov/32379894	5,847	Other			01-Feb-2020	25-Mar-2020	54	No	Cohort study	Retrospective	Wuhan, Hubei, China	26-May-2020	
#00787	CT_33309057	Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study	33309057	https://doi.org/10.1016/j.jcf.2020.11.021	https://pubmed.ncbi.nlm.nih.gov/33309057	105	Other			01-Feb-2020	07-Aug-2020	189	No	Observational study		United Kingdom	20-Jan-2021	
#00788	CT_33307916	A case-control study of determinants for COVID-19 infection based on contact tracing in Dungun district, Terengganu state of Malaysia	33307916	https://doi.org/10.1080/23744235.2020.1857829	https://pubmed.ncbi.nlm.nih.gov/33307916	4,610	Other			22-Oct-2020	15-Nov-2020	25	No	Case-control study	Retrospective	Terengganu, Malaysia	13-Dec-2020	
#00789	CT_33307901	Risk factors for mortality in hospitalized patients with COVID-19: a study in Milan, Italy	33307901	https://doi.org/10.1080/23744235.2020.1859131	https://pubmed.ncbi.nlm.nih.gov/33307901	378	Other			07-Mar-2020	07-Apr-2020	32	No	Case report	Retrospective	Milan, Italy	13-Dec-2020	
#00790	CT_33315531	Causes and Circumstances of Death Among Patients Hospitalized with COVID-19: A Retrospective Cohort Study	33315531	https://doi.org/10.1513/AnnalsATS.202011-1381RL	https://pubmed.ncbi.nlm.nih.gov/33315531	82	Other						No	Cohort study	Retrospective	Michigan, USA	14-Dec-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00791	CT_33320904	Clinical characteristics and outcomes of critically ill patients with COVID-19 admitted to an intensive care unit in London: A prospective observational cohort study	33320904	https://doi.org/10.1371/journal.pone.0243710	https://pubmed.ncbi.nlm.nih.gov/33320904	156	Other			02-Mar-2020	06-May-2020	66	No	Observational cohort study	Prospective	London, United Kingdom	15-Dec-2020	
#00792	CT_33320875	Metabolic risk factors and risk of Covid-19: A systematic review and meta-analysis	33320875	https://doi.org/10.1371/journal.pone.0243600	https://pubmed.ncbi.nlm.nih.gov/33320875	15,268	Other						Yes	Systematic review and meta-analysis		Tehran, Iran	15-Dec-2020	
#00793	CT_33320874	Coagulation profile of COVID-19 patients admitted to the ICU: An exploratory study	33320874	https://doi.org/10.1371/journal.pone.0243604	https://pubmed.ncbi.nlm.nih.gov/33320874	30	Other						No	Single center, longitudinal study	Prospective	São Paulo, Brazil	15-Dec-2020	
#00794	CT_33320847	Comparative effectiveness of N95 respirators and surgical/face masks in preventing airborne infections in the era of SARS-CoV2 pandemic: A meta-analysis of randomized trials	33320847	https://doi.org/10.1371/journal.pone.0242901	https://pubmed.ncbi.nlm.nih.gov/33320847	8,406	Other						Yes			Warsaw, Poland	15-Dec-2020	
#00795	CT_33708777	Factors Influencing Participation in COVID-19 Clinical Trials: A Multi-National Study	33708777	https://doi.org/10.3389/fmed.2021.608959	https://pubmed.ncbi.nlm.nih.gov/33708777	1,576	Other			27-Jul-20	4 Aug 20	9	No	Cross-sectional study		Egypt, KSA, and Jordan	23-Feb-2021	
#00796	CT_32359035	Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19	32359035		https://pubmed.ncbi.nlm.nih.gov/32359035	63	Drug(s)	Tocilizumab					No	Pilot, open, single-arm multicentre study	Prospective	Italy	26-May-2020	
#00797	CT_32357084	A Feasibility Study of Urgent Implementation of Cystic Fibrosis Multidisciplinary Telemedicine Clinic in the Face of COVID-19 Pandemic: Single-Center Experience	32357084	https://doi.org/10.1089/tmj.2020.0091	https://pubmed.ncbi.nlm.nih.gov/32357084	63	Other						No	Single-center experience		Virginia, USA	4-Aug-2020	
#00798	CT_33344791	Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: A meta-analysis with 55 studies and 10014 cases	33344791	https://doi.org/10.1016/j.heliyon.2020.e05684	https://pubmed.ncbi.nlm.nih.gov/33344791	10,014				01-Jan-2020	23-May-2020	144	Yes	Meta-analysis		Noakhali, Bangladesh	15-Dec-2020	
#00799	CT_33355697	Chest CT-derived pulmonary artery enlargement at the admission predicts overall survival in COVID-19 patients: insight from 1461 consecutive patients in Italy	33355697	https://doi.org/10.1007/s00330-020-07622-x	https://pubmed.ncbi.nlm.nih.gov/33355697	1,469	Other			01-Mar-2020	20-Apr-2020	51	No	Multicenter, cohort study	Retrospective	Italy	23-Dec-2020	
#00800	CT_33355217	Effectiveness of early treatment of lopinavir-ritonavir in patients with severe COVID-19: a case series	33355217	https://doi.org/10.7861/clinmed.2020-0348	https://pubmed.ncbi.nlm.nih.gov/33355217	19	Drug(s)	Lopinavir/ritonavir					No	Case series	Retrospective	Wuhan, China	21-Jan-2021	
#00801	CT_33359476	Eruptions and related clinical course among 296 hospitalized adults with confirmed COVID-19	33359476	https://doi.org/10.1016/j.jaad.2020.12.046	https://pubmed.ncbi.nlm.nih.gov/33359476	296	Other			11-May-2020	15-Jun-2020	36	No	Cohort study	Prospective	New York, USA	25-Dec-2020	
#00802	CT_33359234	Prospective Latin American cohort evaluating outcomes of patients with COVID-19 and abnormal liver tests on admission	33359234	https://doi.org/10.1016/j.aohep.2020.100298	https://pubmed.ncbi.nlm.nih.gov/33359234	1,611	Other			15-Apr-2020	31-Jul-2020	108	No	Cohort study	Prospective	Latin American	7-Jan-2021	
#00803	CT_33359040	Palliative Care Consultation in Hospitalized Patients With COVID-19: A Retrospective Study of Characteristics, Outcomes, and Unmet Needs	33359040	https://doi.org/10.1016/j.jpainsymman.2020.12.015	https://pubmed.ncbi.nlm.nih.gov/33359040	376	Other			01-Mar-2020	11-May-2020	72	No	Chart review	Retrospective	New York, USA	29-Jan-2021	
#00804	CT_33357219	Application of high-flow nasal cannula in hypoxemic patients with COVID-19: a retrospective cohort study	33357219	https://doi.org/10.1186/s12890-020-01354-w	https://pubmed.ncbi.nlm.nih.gov/33357219	105	Oxygen support			01-Jan-2020	01-Mar-2020	61	No	Cohort study	Retrospective	Wuhan, China	24-Dec-2020	
#00805	CT_33361171	Changes in demand for emergency ambulances during a nationwide lockdown that resulted in elimination of COVID-19: an observational study from New Zealand	33361171	https://doi.org/10.1136/bmjopen-2020-044726	https://pubmed.ncbi.nlm.nih.gov/33361171	624,928							No	Cross-sectional, observational study	Retrospective	New Zealand	23-Dec-2020	
#00806	CT_33361083	Development and external validation of a COVID-19 mortality risk prediction algorithm: a multicentre retrospective cohort study	33361083	https://doi.org/10.1136/bmjopen-2020-044028	https://pubmed.ncbi.nlm.nih.gov/33361083	1,364	Other			08-Jan-2020	19-Mar-2020	72	No	Multicentre, cohort study	Retrospective	China	24-Dec-2020	
#00807	CT_33359593	Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: A retrospective cohort study	33359593	https://doi.org/10.1016/j.jaad.2020.12.043	https://pubmed.ncbi.nlm.nih.gov/33359593	704	Other			17-Apr-2020	29-May-2020	43	No	Cohort study	Retrospective	Tehran, Iran	24-Dec-2020	
#00808	CT_33363191	Increased Red Cell Distribution Width Is Associated With Disease Severity in Hospitalized Adults With SARS-CoV-2 Infection: An Observational Multicentric Study	33363191	https://doi.org/10.3389/fmed.2020.616292	https://pubmed.ncbi.nlm.nih.gov/33363191	193	Other | Drug(s)	Azithromycin | Hydroxychloroquine | LMWH (prophylactic dose) | Lopinavir/Ritonavir | Empirical antibiotics | Colchicine | Tocilizumab | Remdesivir | Anakinra		26-Feb-2020	15-May-2020	80	No	Observational, multicentric study	Prospective	Patras, Greece	11-Dec-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00809	CT_33369066	Independent and combined effects of hypertension and diabetes on clinical outcomes in patients with COVID-19: A retrospective cohort study of Huoshen Mountain Hospital and Guanggu Fangcang Shelter Hospital	33369066	https://doi.org/10.1111/jch.14146	https://pubmed.ncbi.nlm.nih.gov/33369066	3,400	Other		Survivors = 3327 Non-survivors = 73	04-Feb-2020	14-Apr-2020	71	No	Cohort study	Retrospective	Beijing, China	25-Dec-2020	
#00810	CT_33368150	Clinical and Virological Follow-Up of a Cohort of 76 COVID-19 Older Hospitalized Adults	33368150	https://doi.org/10.1111/jgs.17023	https://pubmed.ncbi.nlm.nih.gov/33368150	76	Other			10-Mar-2020	09-Jun-2020	92	No	Observational, cohort study		Strasbourg, France	25-Dec-2020	
#00811	CT_33365277	Clinical Characteristics and Immune Responses of 137 Deceased Patients With COVID-19: A Retrospective Study	33365277	https://doi.org/10.3389/fcimb.2020.595333	https://pubmed.ncbi.nlm.nih.gov/33365277	836	Other		699 were cured. 137 died	14-Jan-2020	09-Mar-2020	56	No	Cohort study	Retrospective	Wuhan, China	7-Dec-2020	
#00812	CT_33372300	Chronic rhinosinusitis is associated with prolonged SARS-CoV-2 RNA shedding in upper respiratory tract samples: A case-control study	33372300	https://doi.org/10.1111/joim.13237	https://pubmed.ncbi.nlm.nih.gov/33372300	54	Other			01-Mar-2020	01-Jul-2020	123	No	Case-control study	Retrospective	Pamplona, Spain	29-Dec-2020	
#00813	CT_33371426	Effects of Prone Ventilation on Oxygenation, Inflammation, and Lung Infiltrates in COVID-19 Related Acute Respiratory Distress Syndrome: A Retrospective Cohort Study	33371426	https://doi.org/10.3390/jcm9124129	https://pubmed.ncbi.nlm.nih.gov/33371426	23	Other						No	Cohort study	Retrospective	Newark, New Jersey, USA	21-Dec-2020	
#00814	CT_33371260	Relevance and Clinical Significance of Magnetic Resonance Imaging of Neurological Manifestations in COVID-19: A Systematic Review of Case Reports and Case Series	33371260	https://doi.org/10.3390/brainsci10121017	https://pubmed.ncbi.nlm.nih.gov/33371260	171							Yes	Systematic review of case reports and case series			21-Dec-2020	
#00815	CT_33371079	Clinical characteristics and viral shedding kinetics of 38 asymptomatic patients with coronavirus disease 2019: A retrospective observational study	33371079	https://doi.org/10.1097/MD.0000000000023547	https://pubmed.ncbi.nlm.nih.gov/33371079	38	Other						No	Observational study	Retrospective	China	18-Dec-2020	
#00816	CT_33758946	Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials	33758946	https://doi.org/10.1093/jac/dkab093	https://pubmed.ncbi.nlm.nih.gov/33758946	13,544							Yes	Meta-analysis of randomized controlled trials		Taiwan	24-Mar-2021	
#00817	CT_33758637	Chest computed tomography signs associated with pejorative evolution in COVID-19 patients	33758637	https://doi.org/10.5114/pjr.2021.104047	https://pubmed.ncbi.nlm.nih.gov/33758637	109	Other			19-Mar-2020	28-Apr-2020	41	No	Cohort study	Retrospective	France	20-Feb-2021	
#00818	CT_33757803	Epidemiological and clinical characteristics of patients with COVID-19 who have cancer: A systematic review and meta-analysis of global data	33757803	https://doi.org/10.1016/j.canlet.2021.02.012	https://pubmed.ncbi.nlm.nih.gov/33757803	4,106							Yes	Systematic review and meta-analysis		China	20-Mar-2021	
#00819	CT_33756192	Coronavirus disease in children: A multicentre study from the Kingdom of Saudi Arabia	33756192	https://doi.org/10.1016/j.ijph.2021.01.011	https://pubmed.ncbi.nlm.nih.gov/33756192	88	Other			01-Mar-2020	30-Jun-2020	122	No	Multicentre, cohort study	Retrospective	Saudi Arabia	18-Jan-2021	
#00820	CT_33755725	Longitudinal Analysis of Human Memory T-Cell Response according to the Severity of Illness up to 8 Months after SARS-CoV-2 Infection	33755725	https://doi.org/10.1093/infdis/jiab159	https://pubmed.ncbi.nlm.nih.gov/33755725	24	Other						No	Cohort study		Seoul, Republic of Korea	23-Mar-2021	
#00821	CT_33755683	Fatality and risk features for prognosis in COVID-19 according to the care approach – a retrospective cohort study	33755683	https://doi.org/10.1371/journal.pone.0248869	https://pubmed.ncbi.nlm.nih.gov/33755683	306	Other			03-Mar-2020	02-May-2020	61	No	Cohort study	Retrospective	Alicante, Spain	23-Mar-2021	
#00822	CT_33755238	Outcomes among 10,314 hospitalized COVID-19 patients at a tertiary care government hospital in Delhi, India	33755238	https://doi.org/10.1002/jmv.26956	https://pubmed.ncbi.nlm.nih.gov/33755238	10,314	Other			01-Apr-2020	15-Nov-2020	229	No	Cohort study	Retrospective	Delhi, India	23-Mar-2021	
#00823	CT_33754981	Characteristics and Risk Factors of Hospitalized and Nonhospitalized COVID-19 Patients, Atlanta, Georgia, USA, March-April 2020	33754981	https://doi.org/10.3201/eid2704.204709	https://pubmed.ncbi.nlm.nih.gov/33754981	531				01-Mar-2020	07-Apr-2020	38	No	Study analysis		Atlanta, Georgia, USA	26-Feb-2021	
#00824	CT_33754512	Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study	33754512	https://doi.org/10.3346/jkms.2021.36.e83	https://pubmed.ncbi.nlm.nih.gov/33754512	86	Drug(s)	Remdesivir		01-Jun-2020	31-Jul-2020	61	No	Multicenter, cohort study	Retrospective	Seoul, Korea	12-Mar-2021	
#00825	CT_33754280	Clinical characteristics and risk factors for mortality in cancer patients with COVID-19	33754280	https://doi.org/10.1007/s11684-021-0845-6	https://pubmed.ncbi.nlm.nih.gov/33754280	109	Other			18-Jan-2020	20-Mar-2020	63	No	Cohort study	Retrospective	Wuhan, China	23-Mar-2021	
#00826	CT_33754144	Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial	33754144	https://doi.org/10.1016/S2665-9913(21)00070-9	https://pubmed.ncbi.nlm.nih.gov/33754144	40	Drug(s)	Mavrilimumab	There was no significant difference in time to clinical improvement up to day 28 for patients treated with mavrilimumab compared with placebo	28-May-2020	15-Sep-2020	111	No	Investigator-initiated, multicentre, double-blind, randomised trial		USA	17-Mar-2021	
#00827	CT_33753799	Moderate vs. mild cases of overseas-imported COVID-19 in Beijing: a retrospective cohort study	33753799	https://doi.org/10.1038/s41598-021-85869-0	https://pubmed.ncbi.nlm.nih.gov/33753799	53	Other			15-Mar-2020	30-Apr-2020	47	No	Cohort study	Retrospective	Beijing, China	22-Mar-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00828	CT_33750394	Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients	33750394	https://doi.org/10.1186/s12985-021-01530-2	https://pubmed.ncbi.nlm.nih.gov/33750394	245	Other						No	Cross-sectional study		Bangkok, Thailand	9-Mar-2021	
#00829	CT_33747892	A Clinical Study of Smell Disorders in COVID-19 Patients in a Tertiary Care Hospital in Pondicherry: A Cross Sectional Study	33747892	https://doi.org/10.1007/s12070-021-02499-8	https://pubmed.ncbi.nlm.nih.gov/33747892	1,000	Other						No	Cross-sectional study		Pondicherry, India	13-Mar-2021	
#00830	CT_33746884	COVID-19-Related Neuropsychiatric Symptoms in Patients With Alcohol Abuse Conditions During the SARS-CoV-2 Pandemic: A Retrospective Cohort Study Using Real World Data From Electronic Health Records of a Tertiary Hospital	33746884	https://doi.org/10.3389/fneur.2021.630566	https://pubmed.ncbi.nlm.nih.gov/33746884	188	Other			25-Feb-2020	04-Sep-2020	193	No	Descriptive, observational, cohort study	Retrospective	Madrid, Spain	3-Mar-2021	
#00831	CT_33301246	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine	33301246	https://doi.org/10.1056/NEJMoa2034577	https://pubmed.ncbi.nlm.nih.gov/33301246	37,706	Vaccine	BNT162b2 mRNA Covid-19 Vaccine		27-Jul-2020	14-Nov-2020	111	No	Multinational, placebo-controlled, observer-blinded, pivotal efficacy trial		Worldwide	10-Dec-2020	
#00832	CT_33794836	Epidemiological investigation and intergenerational clinical characteristics of 24 coronavirus disease patients associated with a supermarket cluster: a retrospective study	33794836	https://doi.org/10.1186/s12889-021-10713-z	https://pubmed.ncbi.nlm.nih.gov/33794836	8,437							No	Study analysis	Retrospective	Shandong, China	1-Apr-2021	
#00833	CT_33794829	The association between SARS-CoV-2 infection and preterm delivery: a prospective study with a multivariable analysis	33794829	https://doi.org/10.1186/s12884-021-03742-4	https://pubmed.ncbi.nlm.nih.gov/33794829	1,009	Other			23-Mar-2020	31-May-2020	70	No	Multicentre, cohort study	Prospective	Spain	1-Apr-2021	
#00834	CT_33792892	Quantitative description of SARS-CoV-2 RT-PCR, a cohort of 76 COVID-19 older hospitalized adults	33792892	https://doi.org/10.1111/jgs.17102	https://pubmed.ncbi.nlm.nih.gov/33792892	76	Other			10-Mar-2020	09-Jun-2020	92	No	Observational, cohort study		Strasbourg, France	1-Apr-2021	
#00835	CT_33790504	Tocilizumab: An Effective Therapy for Severely and Critically Ill COVID-19 Patients	33790504	https://doi.org/10.5005/jp-journals-10071-23747	https://pubmed.ncbi.nlm.nih.gov/33790504	30	Drug(s)	Tocilizumab					No	Observational study	Retrospective	Rajasthan, India	25-Mar-2021	
#00836	CT_33789877	Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study	33789877	https://doi.org/10.1136/bmj.n693	https://pubmed.ncbi.nlm.nih.gov/33789877	47,780	Other			01-Jan-2020	31-Aug-2020	244	No	Observational, matched, cohort study	Retrospective	UK	31-Mar-2021	
#00837	CT_33788873	Seroprevalence of COVID-19 infection in a rural district of South India: A population-based seroepidemiological study	33788873	https://doi.org/10.1371/journal.pone.0249247	https://pubmed.ncbi.nlm.nih.gov/33788873	509	Other						No	Cross-sectional study		Karnataka, India	31-Mar-2021	
#00838	CT_33788846	Clinical characteristics and outcomes for 7,995 patients with SARS-CoV-2 infection	33788846	https://doi.org/10.1371/journal.pone.0243291	https://pubmed.ncbi.nlm.nih.gov/33788846	7,995	Other			01-Mar-2020	30-Apr-2020	61	No	Observational study	Retrospective	Connecticut, USA	31-Mar-2021	
#00839	CT_33788264	Increased B Cell activity with consumption of activated monocytes in severe COVID-19 patients	33788264	https://doi.org/10.1002/eji.202049163	https://pubmed.ncbi.nlm.nih.gov/33788264	87	Other						No	Cohort study	Prospective	Homburg, Germany	31-Mar-2021	
#00840	CT_33787911	Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis	33787911	https://doi.org/10.1001/jamanetworkopen.2021.3594	https://pubmed.ncbi.nlm.nih.gov/33787911	101,949				31-Dec-2019	01-Sep-2020	246	Yes	Systematic review		United Kingdom	31-Mar-2021	
#00841	CT_33786658	Clinical characteristics of COVID-19 in neonates and young infants	33786658	https://doi.org/10.1007/s00431-021-04042-x	https://pubmed.ncbi.nlm.nih.gov/33786658	253	Other						No	Case report		Athens, Greece	31-Mar-2021	
#00842	CT_33786567	Clinical Characteristics and Short-Term Outcomes of Acute Kidney Injury Missed Diagnosis in Older Patients with Severe COVID-19 in Intensive Care Unit	33786567	https://doi.org/10.1007/s12603-020-1550-x	https://pubmed.ncbi.nlm.nih.gov/33786567	107	Other			04-Feb-2020	16-Apr-2020	73	No	Cohort study	Retrospective	Beijing, China	8-Dec-2020	
#00843	CT_33786454	COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study	33786454	https://doi.org/10.1016/S2665-9913(21)00059-X	https://pubmed.ncbi.nlm.nih.gov/33786454	1,090	Other			15-Apr-2020	20-Nov-2020	220	No	Cohort study	Retrospective	France	25-Mar-2021	
#00844	CT_33812260	The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials	33812260	https://doi.org/10.1016/j.intimp.2021.107602	https://pubmed.ncbi.nlm.nih.gov/33812260	6,314							Yes	A systematic review and meta-analysis of randomized controlled trials		Tainan, Taiwan	24-Mar-2021	
#00845	CT_33809772	Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel)	33809772	https://doi.org/10.3390/curroncol28020118	https://pubmed.ncbi.nlm.nih.gov/33809772	150	Other			22-May-2020	11-Jun-2020	21	No	Multicenter study	Prospective	Spain	16-Mar-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00846	CT_33809465	Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort Study	33809465	https://doi.org/10.3390/cancers13061324	https://pubmed.ncbi.nlm.nih.gov/33809465	231	Other						No	Multicenter, observational, ambispective, cohort study	Ambispective	Italy	16-Mar-2021	
#00847	CT_33829722	Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection	33829722	https://doi.org/10.37201/req/037.2021	https://pubmed.ncbi.nlm.nih.gov/33829722	171	Drug(s)	Tocilizumab					No	Cohort study	Retrospective	Barcelona, Spain	7-Apr-2021	
#00848	CT_33827831	3219 hospitalised patients with COVID-19 in Southeast Michigan: a retrospective case cohort study	33827831	https://doi.org/10.1136/bmjopen-2020-042042	https://pubmed.ncbi.nlm.nih.gov/33827831	3,219	Other			13-Mar-2020	29-Apr-2020	48	No	Cohort study	Retrospective	Michigan, USA	7-Apr-2021	
#00849	CT_33826651	Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: Results from a pilot service implemented during the first pandemic wave	33826651	https://doi.org/10.1371/journal.pone.0249791	https://pubmed.ncbi.nlm.nih.gov/33826651	108	Other						No	Pilot study		London, United Kingdom	7-Apr-2021	
#00850	CT_32717210	Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study	32717210	https://doi.org/10.1016/S2213-2600(20)30315-5	https://pubmed.ncbi.nlm.nih.gov/32717210	2,104	Other			08-Apr-2020	12-Jun-2020	66	No	Multicentre, two phases, cohort study	Prospective	London, UK	24-Jul-2020	
#00851	CT_33826648	Association of ABO blood groups with presentation and outcomes of confirmed SARS CoV-2 infection: A prospective study in the largest COVID-19 dedicated hospital in Bangladesh	33826648	https://doi.org/10.1371/journal.pone.0249252	https://pubmed.ncbi.nlm.nih.gov/33826648	381	Other			01-Jun-2020	25-Aug-2020	86	No	Single-center, cohort study	Prospective	Dhaka, Bangladesh	7-Apr-2021	
#00852	CT_33825310	Differentiating impacts of non-pharmaceutical interventions on non-coronavirus disease-2019 respiratory viral infections: Hospital-based retrospective observational study in Taiwan	33825310	https://doi.org/10.1111/irv.12858	https://pubmed.ncbi.nlm.nih.gov/33825310	9,693	Other						No	Cross-sectional, observational study	Retrospective	Taiwan	7-Apr-2021	
#00853	CT_33826106	Pharmacokinetic and Pharmacodynamic Evaluation of Ravulizumab in Adults with Severe Coronavirus Disease 2019	33826106	https://doi.org/10.1007/s40121-021-00425-7	https://pubmed.ncbi.nlm.nih.gov/33826106	22	Drug(s)	Ravulizumab					No	Study analysis		Boston, Massachusetts, USA	7-Apr-2021	
#00854	CT_33826042	Risk factors and outcomes for acute-on-chronic liver failure in COVID-19: a large multi-center observational cohort study	33826042	https://doi.org/10.1007/s12072-021-10181-y	https://pubmed.ncbi.nlm.nih.gov/33826042	192	Other			01-Mar-2020	27-Apr-2020	58	No	Multi-center, observational, cohort study	Retrospective	New York, USA	7-Apr-2021	
#00855	CT_33824342	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses	33824342	https://doi.org/10.1038/s41467-021-21856-3	https://pubmed.ncbi.nlm.nih.gov/33824342	159	Other						No	Cohort study	Prospective	UK	6-Apr-2021	
#00856	CT_33824084	Early awake proning in critical and severe COVID-19 patients undergoing noninvasive respiratory support: A retrospective multicenter cohort study	33824084	https://doi.org/10.1016/j.pulmoe.2021.03.002	https://pubmed.ncbi.nlm.nih.gov/33824084	114	Oxygen support I Other			01-Mar-2020	01-Jun-2020	93	No	Multicenter, cohort study	Retrospective	Italy	22-Mar-2021	
#00857	CT_33823862	Prone position in intubated, mechanically ventilated patients with COVID-19: a multi-centric study of more than 1000 patients	33823862	https://doi.org/10.1186/s13054-021-03552-2	https://pubmed.ncbi.nlm.nih.gov/33823862	1,057	Other			24-Feb-2020	14-Jun-2020	112	No	Multicentric study	Retrospective	Italy	6-Apr-2021	
#00858	CT_33827287	ABO Blood Group, SARS-CoV-2 Infection, and Risk of Venous Thromboembolism: Population-Based Cohort Study	33827287	https://doi.org/10.1177/10760296211008986	https://pubmed.ncbi.nlm.nih.gov/33827287	222,670	Other			15-Jan-2020	30-Jun-2020	168	No	Population-based cohort study		Toronto, Ontario, Canada	8-Apr-2021	
#00859	CT_33826233	Biomarkers of coagulation, endothelial function and fibrinolysis in critically-ill patients with COVID-19: A single-centre prospective longitudinal study	33826233	https://doi.org/10.1111/jth.15327	https://pubmed.ncbi.nlm.nih.gov/33826233	14	Other			16-Mar-2020	24-Apr-2020	40	No	Single-center, longitudinal study	Prospective	Ontario, Canada	7-Apr-2021	
#00860	CT_33824066	How Does SARS-CoV-2 Infection Affect Survival of Emergency Cardiovascular Patients? A Cohort Study From a German Insurance Claims Database	33824066	https://doi.org/10.1016/j.ejvs.2021.03.006	https://pubmed.ncbi.nlm.nih.gov/33824066	316,718	Other			01-Jan-2020	31-Oct-2020	305	No	Cohort study	Retrospective	Hamburg, Germany	12-Mar-2021	
#00861	CT_33823283	The spatiotemporal trend of renal involvement in COVID-19: a pooled analysis of 17,134 patients	33823283	https://doi.org/10.1016/j.ijid.2021.03.082	https://pubmed.ncbi.nlm.nih.gov/33823283	17,134							Yes	Pooled analysi		China	3-Apr-2021	
#00862	CT_33823118	ECMO for COVID-19-Associated Severe ARDS in Chile: A Nationwide Incidence and Cohort Study	33823118	https://doi.org/10.1164/rccm.202011-4166OC	https://pubmed.ncbi.nlm.nih.gov/33823118	94	Oxygen support			03-Mar-2020	31-Aug-2020	182	No	Cohort study	Retrospective	Santiago, Chile	6-Apr-2021	
#00863	CT_33822812	Prevalence and characteristics of fever in adult and paediatric patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis of 17515 patients	33822812	https://doi.org/10.1371/journal.pone.0249788	https://pubmed.ncbi.nlm.nih.gov/33822812	17,515				01-Dec-2019	03-Apr-2020	125	Yes	A systematic review and meta-analysis			6-Apr-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00864	CT_33842908	A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19	33842908	https://doi.org/10.1016/j.lanepe.2021.100084	https://pubmed.ncbi.nlm.nih.gov/33842908	44	Drug(s)	Niclosamide		29-Jun-2020	08-Aug-2020	41	No	A randomized, double-blind, placebo-controlled phase 1		Copenhagen, Denmark	6-Apr-2021	
#00865	CT_33842494	Clinical Characteristics of Severe COVID-19 Patients Admitted to an Intensive Care Unit in Lombardy During the Italian Pandemic	33842494	https://doi.org/10.3389/fmed.2021.582896	https://pubmed.ncbi.nlm.nih.gov/33842494	18	Other						No		Retrospective	Milan, Italy	25-Mar-2021	
#00866	CT_33842302	Clinical Audit on Symptomatology of Covid-19 Healthcare Workers and Impact on Quality-of-Life (QOL) Due to Continuous Facemask Usage: A Prospective Study	33842302	https://doi.org/10.1007/s12070-021-02530-y	https://pubmed.ncbi.nlm.nih.gov/33842302	2,451	Other						No	Cross-sectional study	Prospective	Tamil Nadu, India	3-Apr-2021	
#00867	CT_33846272	Shared B cell memory to coronaviruses and other pathogens varies in human age groups and tissues	33846272	https://doi.org/10.1126/science.abf6648	https://pubmed.ncbi.nlm.nih.gov/33846272	51	Other						No	Study analysis		Stanford, California, USA	12-Apr-2021	
#00868	CT_33853067	COVID-19: Clinical Presentation and Prognostic Factors of Severe Disease and Mortality in the Oldest-Old Population: A Cohort Study	33853067	https://doi.org/10.1159/000515159	https://pubmed.ncbi.nlm.nih.gov/33853067	103	Other			12-Mar-2020	02-May-2020	52	No	Cohort study	Ambispective	Barcelona, Spain	14-Apr-2021	
#00869	CT_33852775	Clinical features and follow-up of pediatric patients hospitalized for COVID-19	33852775	https://doi.org/10.1002/ppul.25407	https://pubmed.ncbi.nlm.nih.gov/33852775	127	Other			20-Jan-2020	15-Mar-2020	56	No	Cohort study	Retrospective	China	14-Apr-2021	
#00870	CT_33852149	Can Thoracic Ultrasound on Admission Predict the Outcome of Critically Ill Patients with SARS-CoV-2? A French Multi-Centric Ancillary Retrospective Study	33852149	https://doi.org/10.1007/s12325-021-01702-0	https://pubmed.ncbi.nlm.nih.gov/33852149	57	Other			15-Mar-2020	03-May-2020	50	No	Multi-centric, observational study	Retrospective	France	14-Apr-2021	
#00871	CT_33852032	Evolving changes in mortality of 13,301 critically ill adult patients with COVID-19 over 8 months	33852032	https://doi.org/10.1007/s00134-021-06388-0	https://pubmed.ncbi.nlm.nih.gov/33852032	13,301	Other			27-Feb-2020	28-Oct-2020	245	No	Multicenter, cohort study	Prospective	Rio de Janeiro, RJ, Brazil	14-Apr-2021	
#00872	CT_33849115	Comparison of the antiviral effect of Arbidol and Chloroquine in treating COVID-19	33849115	https://doi.org/10.21037/apm-21-400	https://pubmed.ncbi.nlm.nih.gov/33849115	62	Drug(s)	Arbidol | Chloroquine					No	Cohort study	Retrospective	China	10-Mar-2021	
#00873	CT_33848324	Emergency Airway Management in Patients with COVID-19: A Prospective International Multicenter Cohort Study	33848324	https://doi.org/10.1097/ALN.0000000000003791	https://pubmed.ncbi.nlm.nih.gov/33848324	4,476	Other			23-Mar-2020	24-Oct-2020	216	No	International, multicenter, cohort study	Prospective	Worlidwide	13-Apr-2021	
#00874	CT_33847084	Clinical Application of the Standard Q COVID-19 Ag Test for the Detection of SARS-CoV-2 Infection	33847084	https://doi.org/10.3346/jkms.2021.36.e101	https://pubmed.ncbi.nlm.nih.gov/33847084	98	Other			05-Jan-2021	11-Jan-2021	7	No	Study analysis		Seoul, Korea	12-Apr-2021	
#00875	CT_33846714	Epidemiologic characteristics associated with SARS-CoV-2 antigen-based test results, rRT-PCR cycle threshold values, subgenomic RNA, and viral culture results from university testing	33846714	https://doi.org/10.1093/cid/ciab303	https://pubmed.ncbi.nlm.nih.gov/33846714	1,051	Other			01-Oct-2020	09-Oct-2020	9	No	Study analysis		Wisconsin, USA	13-Apr-2021	
#00876	CT_33858945	Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination	33858945	https://doi.org/10.1126/sciimmunol.abi6950	https://pubmed.ncbi.nlm.nih.gov/33858945	44	Vaccine						No	Longitudinal cohort study	Retrospective	Philadelphia, Pennsylvania, USA	12-Apr-2021	
#00877	CT_33846699	Quantitative analysis based on chest CT classifies common and severe patients with coronavirus disease 2019 pneumonia in Wuhan, China	33846699	https://doi.org/10.1007/s42058-021-00061-7	https://pubmed.ncbi.nlm.nih.gov/33846699	93	Other			04-Jan-2020	17-Feb-2020	45	No	Observational, cohort study	Retrospective	Wuhan, China	8-Apr-2021	
#00878	CT_33846096	D-dimer at hospital admission for COVID-19 are associated with in-hospital mortality, independent of venous thromboembolism: Insights from a French multicenter cohort study	33846096	https://doi.org/10.1016/j.acvd.2021.02.003	https://pubmed.ncbi.nlm.nih.gov/33846096	2,878	Other			26-Feb-2020	20-Apr-2020	55	No	Multicenter cohort study	Retrospective	Paris, France	9-Mar-2021	
#00879	CT_33846041	A multi-center study of COVID-19 patient prognosis using deep learning-based CT image analysis and electronic health records	33846041	https://doi.org/10.1016/j.ejrad.2021.109583	https://pubmed.ncbi.nlm.nih.gov/33846041	306	Other			01-Jan-2020	30-Mar-2020	90	No	Cohort study	Retrospective		5-Feb-2021	
#00880	CT_33845787	Clinical characteristics and outcome of influenza virus infection among adults hospitalized with severe COVID-19: a retrospective cohort study from Wuhan, China	33845787	https://doi.org/10.1186/s12879-021-05975-2	https://pubmed.ncbi.nlm.nih.gov/33845787	140	Other			08-Feb-2020	15-Mar-2020	37	No	Cohort study	Retrospective	Wuhan, China	12-Apr-2021	
#00881	CT_33844996	Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial	33844996	https://doi.org/10.1016/S2213-2600(21)00160-0	https://pubmed.ncbi.nlm.nih.gov/33844996	146	Drug(s)	Budesonide		16-Jul-2020	09-Dec-2020	147	No	A phase II, open-label, randomised controlled trial	Prospective	UK	9-Apr-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00882	CT_33844963	SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)	33844963	https://doi.org/10.1016/S0140-6736(21)00675-9	https://pubmed.ncbi.nlm.nih.gov/33844963	25,661	Other			18-Jun-2020	31-Dec-2020	197	No	A large, multicentre, cohort study	Prospective	UK	9-Apr-2021	
#00883	CT_33844678	Epidemiological and Clinical Characteristics of 217 Cases of COVID-19 in Jiangsu Province, China	33844678	https://doi.org/10.12659/MSM.930853	https://pubmed.ncbi.nlm.nih.gov/33844678	283	Other						No	Multi-center, observational study	Retrospective	Jiangsu, China	12-Apr-2021	
#00884	CT_33844425	Effectiveness of Theory-Based Health Information Technology Interventions on Coronary Artery Disease Self-Management Behavior: A Clinical Randomized Waitlist-Controlled Trial	33844425	https://doi.org/10.1111/jnu.12661	https://pubmed.ncbi.nlm.nih.gov/33844425	60	Other						No	Clinical randomized waitlist-controlled trial		Taipei, Taiwan	12-Apr-2021	
#00885	CT_33843941	Clinical and epidemiological characteristics of COVID-19 during the early phase of the SARS-CoV-2 pandemic: a cross-sectional study among medical school physicians and residents employed in a regional reference teaching hospital in Northern Italy	33843941	https://doi.org/10.13075/ijomeh.1896.01759	https://pubmed.ncbi.nlm.nih.gov/33843941	162	Other						No	Cross-sectional study		Italy	1-Apr-2021	
#00886	CT_33843159	Factors associated with a SARS-CoV-2 recurrence after hospital discharge among patients with COVID-19: systematic review and meta-analysis	33843159	https://doi.org/10.1631/jzus.B2000304	https://pubmed.ncbi.nlm.nih.gov/33843159	2,071							Yes	Systematic review and meta-analysis		Hangzhou, China	26-Dec-2020	
#00887	CT_33842709	Clinical characteristics and outcomes of COVID-19 patients with diabetes mellitus in Kuwait	33842709	https://doi.org/10.1016/j.heliyon.2021.e06706	https://pubmed.ncbi.nlm.nih.gov/33842709	417	Other			24-Feb-2020	24-May-2020	91	No	Single-center study	Retrospective	Kuwait	5-Apr-2021	
#00888	CT_33842415	Analysis of Epidemiological and Clinical Characteristics of COVID-19 in Northwest Mexico and the Relationship Between the Influenza Vaccine and the Survival of Infected Patients	33842415	https://doi.org/10.3389/fpubh.2021.570098	https://pubmed.ncbi.nlm.nih.gov/33842415	4,040	Other			28-Feb-2020	15-May-2020	78	No	Study analysis		Sinaloa, Mexico	25-Mar-2021	
#00889	CT_33841944	Changes of quantitative CT-based airway wall dimensions in patients with COVID-19 during early recovery	33841944	https://doi.org/10.21037/jtd-20-2790	https://pubmed.ncbi.nlm.nih.gov/33841944	69	Other			05-Feb-2020	17-Mar-2020	42	No		Retrospective	Guangzhou, China	13-Mar-2021	
#00890	CT_33839972	Accuracy of the serological detection of IgG and IgM to SARS-Cov-2: a prospective, cross-sectional study	33839972	https://doi.org/10.1007/s10096-021-04224-3	https://pubmed.ncbi.nlm.nih.gov/33839972	259	Other						No	Cross-sectional study	Prospective	Italy	10-Apr-2021	
#00891	CT_33838684	COVID-19 in adults with dementia: clinical features and risk factors of mortality-a clinical cohort study on 125 patients	33838684	https://doi.org/10.1186/s13195-021-00820-9	https://pubmed.ncbi.nlm.nih.gov/33838684	125				14-Mar-2020	07-May-2020	55	No	Cohort study	Prospective	France	10-Apr-2021	
#00892	CT_33838657	Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial	33838657	https://doi.org/10.1186/s12879-021-06045-3	https://pubmed.ncbi.nlm.nih.gov/33838657	86	Drug(s)	Methylprednisolone | Dexamethasone					No	Triple-blinded randomized controlled trial	Prospective	Shiraz, Iran	10-Apr-2021	
#00893	CT_33838224	Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomized control clinical trial	33838224	https://doi.org/10.1016/j.ijantimicag.2021.106334	https://pubmed.ncbi.nlm.nih.gov/33838224	87	Plasma						No	Open-label, randomized clinical trial		Riyadh, Kingdom of Saudi Arabia	7-Apr-2021	
#00894	CT_33837906	A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm	33837906	https://doi.org/10.1007/s11739-021-02734-8	https://pubmed.ncbi.nlm.nih.gov/33837906	62	Plasma						No	A randomized clinical trial		Ahvaz, Iran	10-Apr-2021	
#00895	CT_33837630	Prevalence, clinical characteristics and outcomes of Guillain-Barré syndrome spectrum associated with COVID-19: a systematic review and meta-analysis	33837630	https://doi.org/10.1111/ene.14860	https://pubmed.ncbi.nlm.nih.gov/33837630	136,746							Yes	A systematic review and meta-analysis		Athens, Greece	9-Apr-2021	
#00896	CT_33833931	Coronavirus Disease Clinical and Laboratory Parameters: Dismembering the Values Reveals Outcomes	33833931	https://doi.org/10.7759/cureus.13720	https://pubmed.ncbi.nlm.nih.gov/33833931	51	Other						No	Observational, cohort study	Retrospective	Islamabad, Pakistan	5-Mar-2021	
#00897	CT_33833912	Clinical Features and Prognostic Factors of 245 Portuguese Patients Hospitalized With COVID-19	33833912	https://doi.org/10.7759/cureus.13687	https://pubmed.ncbi.nlm.nih.gov/33833912	245	Other			20-Mar-2020	01-Jun-2020	74	No	Observational study	Prospective	Vila Nova de Gaia, Portugal	4-Mar-2021	
#00898	CT_33828607	The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study	33828607	https://doi.org/10.7573/dic.2020-11-1	https://pubmed.ncbi.nlm.nih.gov/33828607	32	Drug(s)	Azoximer bromide		31-Mar-2020	12-Jun-2020	74	No	Open-label, multicentre, interventional clinical study		Russia	25-Mar-2021	
#00899	CT_33827848	Prognostic model to identify and quantify risk factors for mortality among hospitalised patients with COVID-19 in the USA	33827848	https://doi.org/10.1136/bmjopen-2020-047121	https://pubmed.ncbi.nlm.nih.gov/33827848	17,086	Other			20-Feb-2020	05-Jun-2020	107	No	Cohort study		California, USA	7-Apr-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00900	CT_33826953	Clinical relevance of serum α-L-fucosidase activity in the SARS-CoV-2 infection	33826953	https://doi.org/10.1016/j.cca.2021.03.031	https://pubmed.ncbi.nlm.nih.gov/33826953	585	Other			26-Dec-2019	09-Mar-2020	75	No	Study analysis	Retrospective	China	4-Apr-2021	
#00901	CT_33823733	Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis	33823733	https://doi.org/10.1080/1744666X.2021.1908128	https://pubmed.ncbi.nlm.nih.gov/33823733	14,959							No	A systematic review and meta-analysis		Tehran, Iran	7-Apr-2021	
#00902	CT_33822738	Prediction models for clinical severity of COVID-19 patients using multi-center clinical data in Korea	33822738	https://doi.org/10.2196/25852	https://pubmed.ncbi.nlm.nih.gov/33822738	5,628	Other						No	Multicenter, cohort study	Retrospective	Korea	18-Mar-2021	
#00903	CT_33819304	Clinical characteristics of COVID-19 patients with clinically diagnosed bacterial co-infection: A multi-center study	33819304	https://doi.org/10.1371/journal.pone.0249668	https://pubmed.ncbi.nlm.nih.gov/33819304	905	Other			10-Jan-2020	28-Feb-2020	50	No	Multi-center study	Retrospective	China	5-Apr-2021	
#00904	CT_33819166	Tele-management of home isolated COVID-19 patients via oxygen therapy with non-invasive positive pressure ventilation and physical therapy techniques: A randomized clinical trial	33819166	https://doi.org/10.2196/23446	https://pubmed.ncbi.nlm.nih.gov/33819166	60	Other						No	Randomized, single-blinded, clinical trial		Cairo, Egypt	1-Apr-2021	
#00905	CT_33818909	Clinical and etiological analysis of co-infections and secondary infections in COVID-19 patients: an observational study	33818909	https://doi.org/10.1111/crj.13369	https://pubmed.ncbi.nlm.nih.gov/33818909	408	Other			11-Jan-2020	01-Mar-2020	51	No	Observational study	Retrospective	Shenzhen, China	5-Apr-2021	
#00906	CT_33818731	Retrospective analysis of vitamin D status on inflammatory markers and course of the disease in patients with COVID-19 infection	33818731	https://doi.org/10.1007/s40618-021-01566-9	https://pubmed.ncbi.nlm.nih.gov/33818731	56	Other						No	Study analysis	Retrospective	Bursa, Turkey	5-Apr-2021	
#00907	CT_33817971	Viral epidemiology and SARS-CoV-2 co-infections with other respiratory viruses during the first COVID-19 wave in Paris, France	33817971	https://doi.org/10.1111/irv.12853	https://pubmed.ncbi.nlm.nih.gov/33817971	3,768				25-Jan-2020	30-Apr-2020	97	No	Cohort study	Retrospective	Paris, France	4-Apr-2021	
#00908	CT_33817359	SARS-CoV-2 molecular identification and clinical data analysis of associated risk factors from a COVID-19 testing laboratory of a coastal region in Bangladesh	33817359	https://doi.org/10.1016/j.heliyon.2021.e06650	https://pubmed.ncbi.nlm.nih.gov/33817359	5,589	Other						No	Cross-sectional study		Bangladesh	29-Mar-2021	
#00909	CT_33815405	The Role of Immunological and Clinical Biomarkers to Predict Clinical COVID-19 Severity and Response to Therapy-A Prospective Longitudinal Study	33815405	https://doi.org/10.3389/fimmu.2021.646095	https://pubmed.ncbi.nlm.nih.gov/33815405	55	Other			15-May-2020	21-Aug-2020	99	No	Longitudinal, cohort study	Prospective	Victoria, Australia	17-Mar-2021	
#00910	CT_33814589	Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study	33814589	https://doi.org/10.4103/ija.IJA_149_21	https://pubmed.ncbi.nlm.nih.gov/33814589	70	Drug(s)	Remdesivir					No	Randomised study	Prospective	Punjab, India	20-Mar-2021	
#00911	CT_33813782	COVID-19 infection in a pediatric kidney transplant population: A single-center experience	33813782	https://doi.org/10.1111/petr.14018	https://pubmed.ncbi.nlm.nih.gov/33813782	22	Other						No	Cohort study	Retrospective	New York, USA	3-Apr-2021	
#00912	CT_33813510	Clinical features and risk factors associated with severe COVID-19 patients in China	33813510	https://doi.org/10.1097/CM9.0000000000001466	https://pubmed.ncbi.nlm.nih.gov/33813510	289	Other			22-Feb-2020	29-Mar-2020	37	No	Multicenter, cross-sectional study	Retrospective	China	1-Apr-2021	
#00913	CT_33811552	Clinical characterization of brief psychotic disorders triggered by the COVID-19 pandemic: a multicenter observational study	33811552	https://doi.org/10.1007/s00406-021-01256-w	https://pubmed.ncbi.nlm.nih.gov/33811552	33	Other			14-Mar-2020	14-May-2020	62	No	Multicenter observational study	Prospective	Seville, Spain	3-Apr-2021	
#00914	CT_33809858	Elevated Monocyte to Lymphocyte Ratio and Increased Mortality among Patients with Chronic Kidney Disease Hospitalized for COVID-19	33809858	https://doi.org/10.3390/jpm11030224	https://pubmed.ncbi.nlm.nih.gov/33809858	107	Other						No	Cohort study	Retrospective	Nicaragua, Central America	22-Mar-2021	
#00915	CT_33802451	Spatial and Temporal Virus Load Dynamics of SARS-CoV-2: A Single-Center Cohort Study	33802451	https://doi.org/10.3390/diagnostics11030427	https://pubmed.ncbi.nlm.nih.gov/33802451	520	Other			26-Feb-2020	02-May-2020	67	No	Single-center, cohort study	Retrospective	Lille, France	3-Mar-2021	
#00916	CT_33800304	COVID-19 Infection among Older People Admitted to Hospital: A Cross-Sectional Analysis	33800304	https://doi.org/	https://pubmed.ncbi.nlm.nih.gov/33800304	26	Other			25-Feb-2020	27-May-2020	93	No	Cross-sectional analysis	Retrospective	Kuala Lumpur, Malaysia	8-Mar-2021	
#00917	CT_33800020	Trends of COVID-19 Admissions in an Italian Hub during the Pandemic Peak: Large Retrospective Study Focused on Older Subjects	33800020	https://doi.org/10.3390/jcm10051115	https://pubmed.ncbi.nlm.nih.gov/33800020	1,264	Other			28-Feb-2020	10-Jun-2020	104	No	Single-center study	Retrospective	Parma, Italy	7-Mar-2021	
#00918	CT_33799224	Association between use of Qingfei Paidu Tang and mortality in hospitalized patients with COVID-19: A national retrospective registry study	33799224	https://doi.org/10.1016/j.phymed.2021.153531	https://pubmed.ncbi.nlm.nih.gov/33799224	8,939	Drug(s) | Other	Traditional Chinese medicine (Qingfei Paidu Tang)					No	Cohort study	Retrospective	China	28-Feb-2021	
#00919	CT_33799139	Recovery rate and factors associated with smell and taste disruption in patients with coronavirus disease 2019	33799139	https://doi.org/10.1016/j.amjoto.2020.102648	https://pubmed.ncbi.nlm.nih.gov/33799139	151	Other			03-Mar-2020	24-Mar-2020	22	No	Observational cohort study		Lugo, Spain	14-Jul-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00920	CT_33795030	Impact of a clinical pharmacist on ultrasound-guided venous thromboembolism screening in hospitalized COVID-19 patients: a pilot prospective study	33795030	https://doi.org/10.1186/s40780-021-00201-2	https://pubmed.ncbi.nlm.nih.gov/33795030	31	Other			28-Apr-2020	20-May-2020	23	No	Pilot study	Prospective	USA	1-Apr-2021	
#00921	CT_33791920	Clinical validation of a computerized algorithm to determine mean systemic filling pressure	33791920	https://doi.org/10.1007/s10877-020-00636-2	https://pubmed.ncbi.nlm.nih.gov/33791920	18	Other						No	Observational study	Prospective	Netherlands	31-Mar-2021	
#00922	CT_33791320	Early Viral Clearance and Antibody Kinetics of COVID-19 Among Asymptomatic Carriers	33791320	https://doi.org/10.3389/fmed.2021.595773	https://pubmed.ncbi.nlm.nih.gov/33791320	56	Other			23-Jan-2020	01-Apr-2020	70	No	Single-center study	Retrospective	Shenzhen, China	15-Mar-2021	
#00923	CT_33790623	Longitudinal Chest CT Features in Severe/Critical COVID-19 Cases and the Predictive Value of the Initial CT for Mortality	33790623	https://doi.org/10.2147/JIR.S303773	https://pubmed.ncbi.nlm.nih.gov/33790623	155	Other			10-Jan-2020	06-Apr-2020	88	No	Single-centre cohort study	Retrospective	Wuhan, China	25-Mar-2021	
#00924	CT_33790514	Changes in Mode of Oxygen Delivery and Physiological Parameters with Physiotherapy in COVID-19 Patients: A Retrospective Study	33790514	https://doi.org/10.5005/jp-journals-10071-23763	https://pubmed.ncbi.nlm.nih.gov/33790514	433	Oxygen support | Other			13-May-2020	31-Jul-2020	80	No	Study analysis	Retrospective	Maharashtra, India	25-Mar-2021	
#00925	CT_33790365	Risk factors on admission associated with hospital length of stay in patients with COVID-19: a retrospective cohort study	33790365	https://doi.org/10.1038/s41598-021-86853-4	https://pubmed.ncbi.nlm.nih.gov/33790365	75	Drug(s) | Other	Lopinavir | ritonavir		20-Jan-2020	16-Mar-2020	57	No	Cohort study	Retrospective	China	31-Mar-2021	
#00926	CT_33789854	Which parameters support disposition decision in suspected COVID-19 cases in the emergency department (ED): a German clinical cohort study	33789854	https://doi.org/10.1136/bmjopen-2020-044853	https://pubmed.ncbi.nlm.nih.gov/33789854	1,255	Other			01-Mar-2020	05-May-2020	66	No	Cohort study	Prospective	Germany	31-Mar-2021	
#00927	CT_33788884	Characterizing COVID-19 clinical phenotypes and associated comorbidities and complication profiles	33788884	https://doi.org/10.1371/journal.pone.0248956	https://pubmed.ncbi.nlm.nih.gov/33788884	1,022	Other			07-Mar-2020	25-Aug-2020	172	No	Study analysis	Retrospective	Minnesota, USA	31-Mar-2021	
#00928	CT_33788001	The association between vitamin D levels and the clinical severity and inflammation markers in pediatric COVID-19 patients: single-center experience from a pandemic hospital	33788001	https://doi.org/10.1007/s00431-021-04030-1	https://pubmed.ncbi.nlm.nih.gov/33788001	103	Other						No	Cohort study	Retrospective		31-Mar-2021	
#00929	CT_33787632	Inspiratory muscle training for recovered COVID-19 patients after weaning from mechanical ventilation: A pilot control clinical study	33787632	https://doi.org/10.1097/MD.0000000000025339	https://pubmed.ncbi.nlm.nih.gov/33787632	42							No	Pilot control clinical study	Prospective	Al-Kharj, Saudi Arabia	2-Apr-2021	
#00930	CT_33787192	The effects of combination of Zingiber officinale and Echinacea on alleviation of clinical symptoms and hospitalization rate of suspected COVID-19 outpatients: a randomized controlled trial	33787192	https://doi.org/10.1515/jcim-2020-0283	https://pubmed.ncbi.nlm.nih.gov/33787192	100	Drug(s)	Zingiber officinale | Echinacea					No	A randomized, controlled clinical trial with two parallel arms	Prospective	Saveh, Iran	31-Mar-2021	
#00931	CT_33785743	Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial	33785743	https://doi.org/10.1038/s41467-021-22177-1	https://pubmed.ncbi.nlm.nih.gov/33785743	120	Drug(s)	Peginterferon Lambda-1a		25-Apr-2020	17-Jul-2020	84	No	A randomized, single-blind, placebocontrolled trial		California, USA	30-Mar-2021	
#00932	CT_33784669	Clinical Outcome of Acute Ischemic Strokes in Patients with COVID-19	33784669	https://doi.org/10.1159/000514562	https://pubmed.ncbi.nlm.nih.gov/33784669	216	Other			17-Mar-2020	02-May-2020	47	No	Multicentric, observational study	Retrospective	France	30-Mar-2021	
#00933	CT_33784001	Time course of endothelial dysfunction markers and mortality in COVID-19 patients: A pilot study	33784001	https://doi.org/10.1002/ctm2.283	https://pubmed.ncbi.nlm.nih.gov/33784001	54	Other						No	Pilot study	Prospective	Italy	1-Mar-2021	
#00934	CT_33782993	COVID-19 encephalopathy: clinical and neurobiological features	33782993	https://doi.org/10.1002/jmv.26973	https://pubmed.ncbi.nlm.nih.gov/33782993	31	Other						No		Retrospective	Switzerland	30-Mar-2021	
#00935	CT_33782216	Multicenter Analysis of Clinical Features and Prognosis of COVID-19 Patients with Hepatic Impairment	33782216	https://doi.org/10.5009/gnl20267	https://pubmed.ncbi.nlm.nih.gov/33782216	874	Other			20-Feb-2020	14-Apr-2020	55	No	Multicenter study	Retrospective	Daegu, Korea	2-Apr-2021	
#00936	CT_33781275	The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial	33781275	https://doi.org/10.1186/s12967-021-02795-5	https://pubmed.ncbi.nlm.nih.gov/33781275	128	Drug(s) | Other	Omega-3					No	A double-blind, randomized clinical trial		Rasht, Iran	29-Mar-2021	
#00937	CT_33780519	Viral genomic, metagenomic and human transcriptomic characterization and prediction of the clinical forms of COVID-19	33780519	https://doi.org/10.1371/journal.ppat.1009416	https://pubmed.ncbi.nlm.nih.gov/33780519	3,254	Other			09-Mar-2020	30-Mar-2020	22	No	Cohort study	Prospective	Créteil, France	29-Mar-2021	
#00938	CT_33778660	Diagnostic Performance of CO-RADS and the RSNA Classification System in Evaluating COVID-19 at Chest CT: A Meta-Analysis	33778660	https://doi.org/10.1148/ryct.2021200510	https://pubmed.ncbi.nlm.nih.gov/33778660	3,283							Yes	Meta-analysis		Groningen, The Netherlands	14-Jan-2021	
#00939	CT_33778567	Differences in Clinical and Imaging Presentation of Pediatric Patients with COVID-19 in Comparison with Adults	33778567	https://doi.org/10.1148/ryct.2020200117	https://pubmed.ncbi.nlm.nih.gov/33778567	61	Other			25-Jan-2020	15-Feb-2020	22	No	Cohort study	Retrospective	Guangzhou, China	6-Apr-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00940	CT_33778108	Differential clinic in children infected by SARS-CoV-2, traceability of contacts and cost-effectiveness of diagnostic tests: Cross-sectional observational study	33778108	https://doi.org/10.1016/j.anpede.2020.12.011	https://pubmed.ncbi.nlm.nih.gov/33778108	126	Other						No	Cross-sectional observational study		Pontevedra, Spain	24-Mar-2021	
#00941	CT_33777977	Identifying Clinical Phenotypes in Moderate to Severe Acute Respiratory Distress Syndrome Related to COVID-19: The COVADIS Study	33777977	https://doi.org/10.3389/fmed.2021.632933	https://pubmed.ncbi.nlm.nih.gov/33777977	416	Other			10-Mar-2020	15-Apr-2020	37	No	Multicenter, observational study	Prospective	France	11-Mar-2021	
#00942	CT_33777293	Clinical and epidemiological characteristics of 646 hospitalised SARS-Cov-2 positive patients in Rivers State Nigeria: a prospective observational study	33777293	https://doi.org/10.11604/pamj.2021.38.25.26755	https://pubmed.ncbi.nlm.nih.gov/33777293	646	Other						No	Multi-center, observational study	Prospective	Rivers State, Nigeria	12-Jan-2021	
#00943	CT_33776469	Evaluation of Adjunctive Photobiomodulation (PBMT) for COVID-19 Pneumonia via Clinical Status and Pulmonary Severity Indices in a Preliminary Trial	33776469	https://doi.org/10.2147/JIR.S301625	https://pubmed.ncbi.nlm.nih.gov/33776469	10	Other						No	Randomized preliminary study		Massachusetts, USA	19-Mar-2021	
#00944	CT_33774622	Risk Factors, and Clinical and Etiological Characteristics of Ischemic Strokes in COVID-19-Infected Patients: A Systematic Review of Literature	33774622	https://doi.org/10.1159/000514267	https://pubmed.ncbi.nlm.nih.gov/33774622	93							No	Systematic review		Italy	26-Mar-2021	
#00945	CT_33773969	Prognostication of patients with COVID-19 using artificial intelligence based on chest x-rays and clinical data: a retrospective study	33773969	https://doi.org/10.1016/S2589-7500(21)00039-X	https://pubmed.ncbi.nlm.nih.gov/33773969	2,309	Other			09-Mar-2020	20-Jul-2020	134	No		Retrospective	USA	24-Mar-2021	
#00946	CT_33772419	Risk Factors for Hospitalization Among Patients with COVID-19 at a Community Ambulatory Clinic in Massachusetts During the Initial Pandemic Surge	33772419	https://doi.org/10.1007/s10903-021-01189-5	https://pubmed.ncbi.nlm.nih.gov/33772419	460	Other			18-Mar-2020	25-Apr-2020	39	No	Cohort study		Massachusetts, USA	26-Mar-2021	
#00947	CT_32726241	Predictors of Mortality in Adults Admitted with COVID-19: Retrospective Cohort Study from New York City	32726241	https://doi.org/	https://pubmed.ncbi.nlm.nih.gov/32726241	375	Other			09-Mar-2020	09-Apr-2020	32	No	Cohort study	Retrospective	New York, USA	8-Jul-2020	
#00948	CT_33771120	Application of quantitative lung ultrasound instead of CT for monitoring COVID-19 pneumonia in pregnant women: a single-center retrospective study	33771120	https://doi.org/10.1186/s12884-021-03728-2	https://pubmed.ncbi.nlm.nih.gov/33771120	39	Other			28-Jan-2020	15-Apr-2020	79	No	A single-center study	Retrospective	Hubei, China	26-Mar-2021	
#00949	CT_33771080	Clinical characteristics and risk factors for SARS-CoV-2 infection in pregnant women attending a third level reference center in Mexico City	33771080	https://doi.org/10.1080/14767058.2021.1902500	https://pubmed.ncbi.nlm.nih.gov/33771080	1,880							No	Cross-sectional study		Mexico city, Mexico	26-Mar-2021	
#00950	CT_33770367	Bronchoalveolar lavage in suspected COVID-19 cases with a negative nasopharyngeal swab: a retrospective cross-sectional study in a high-impact Northern Italy area	33770367	https://doi.org/10.1007/s11739-021-02714-y	https://pubmed.ncbi.nlm.nih.gov/33770367	198	Other			01-Mar-2020	30-Apr-2020	61	No	Cross-sectional study	Retrospective	Italy	26-Mar-2021	
#00951	CT_33768106	Risk of Clinically Relevant Venous Thromboembolism in Critically Ill Patients With COVID-19: A Systematic Review and Meta-Analysis	33768106	https://doi.org/10.3389/fmed.2021.647917	https://pubmed.ncbi.nlm.nih.gov/33768106	5,400				01-Jan-2020	07-Oct-2020	281	Yes	A systematic review and meta-analysis		Vienna, Austria	9-Mar-2021	
#00952	CT_33768104	Clinical, Serological, Whole Genome Sequence Analyses to Confirm SARS-CoV-2 Reinfection in Patients From Mumbai, India	33768104	https://doi.org/10.3389/fmed.2021.631769	https://pubmed.ncbi.nlm.nih.gov/33768104	4	Other						No	Study analysis		Mumbai, India	9-Mar-2021	
#00953	CT_33766109	Effect of timing of intubation on clinical outcomes of critically ill patients with COVID-19: a systematic review and meta-analysis of non-randomized cohort studies	33766109	https://doi.org/10.1186/s13054-021-03540-6	https://pubmed.ncbi.nlm.nih.gov/33766109	8,944							Yes	A systematic review and meta-analysis of non-randomized cohort studies		Athens, Greece	25-Mar-2021	
#00954	CT_33765902	Clinical effectiveness of drugs in hospitalized patients with COVID-19: a systematic review and meta-analysis	33765902	https://doi.org/10.1177/1753466621100721 4	https://pubmed.ncbi.nlm.nih.gov/33765902	8,282				20-Aug-2020	09-Sep-2020	21	Yes	A systematic review and meta-analysis		Oaxaca, Mexico	25-Mar-2021	
#00955	CT_33765595	SARS-CoV-2 infection in children, clinical characteristics, diagnostic findings and therapeutic interventions at a tertiary care center in Riyadh, Saudi Arabia	33765595	https://doi.org/10.1016/j.jiph.2020.12.034	https://pubmed.ncbi.nlm.nih.gov/33765595	742	Other			07-Apr-2020	17-Jul-2020	102	No	Cohort study	Retrospective	Riyadh, Saudi Arabia	14-Apr-2021	
#00956	CT_33765049	ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida	33765049	https://doi.org/10.1371/journal.pone.0249038	https://pubmed.ncbi.nlm.nih.gov/33765049	131	Other						No	Cohort study	Retrospective	Florida, USA	25-Mar-2021	
#00957	CT_33765013	SARS-COV-2 comorbidity network and outcome in hospitalized patients in Crema, Italy	33765013	https://doi.org/10.1371/journal.pone.0248498	https://pubmed.ncbi.nlm.nih.gov/33765013	539	Other			21-Feb-2020	13-Mar-2020	22	No	Cohort study		Crema, Italy	25-Mar-2021	
#00958	CT_33764378	Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure: The HENIVOT Randomized Clinical Trial	33764378	https://doi.org/10.1001/jama.2021.4682	https://pubmed.ncbi.nlm.nih.gov/33764378	109	Oxygen support | Other			13-Oct-2020	13-Dec-2020	62	No	Open-label, multicenter, randomized clinical trial		Italy	25-Mar-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00959	CT_33763697	Epidemiological, clinical and genomic snapshot of the first 100 B.1.1.7 SARS-CoV-2 cases in Madrid	33763697	https://doi.org/10.1093/jtm/taab044	https://pubmed.ncbi.nlm.nih.gov/33763697	106				01-Dec-2020	28-Jan-2021	59	No	Study analysis		Madrid, Spain	24-Mar-2021	
#00960	CT_33763618	Clinical characteristics and risk factors for disease severity and mortality of COVID-19 patients with diabetes mellitus in Kazakhstan: A nationwide study	33763618	https://doi.org/10.1016/j.heliyon.2021.e06561	https://pubmed.ncbi.nlm.nih.gov/33763618	155	Other			14-Mar-2020	18-Apr-2020	36	No	Case control study	Retrospective	Kazakhstan	18-Mar-2021	
#00961	CT_33763201	Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis	33763201	https://doi.org/10.12688/f1000research.45046.1	https://pubmed.ncbi.nlm.nih.gov/33763201	8,272							Yes	A systematic review and meta-analysis		East Java, Indonesia.	4-Feb-2021	
#00962	CT_33763078	The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients	33763078	https://doi.org/10.3389/fimmu.2021.632814	https://pubmed.ncbi.nlm.nih.gov/33763078	63	Other						No	Cohort study		Shenzhen, China	4-Mar-2021	
#00963	CT_33761909	Deep learning diagnostic and risk-stratification pattern detection for COVID-19 in digital lung auscultations: clinical protocol for a case-control and prospective cohort study	33761909	https://doi.org/10.1186/s12890-021-01467-w	https://pubmed.ncbi.nlm.nih.gov/33761909	1,000	Other						No	Case-control, cohort study	Prospective	Switzerland	24-Mar-2021	
#00964	CT_33761892	Current trends and geographical differences in therapeutic profile and outcomes of COVID-19 among pregnant women - a systematic review and meta-analysis	33761892	https://doi.org/10.1186/s12884-021-03685-w	https://pubmed.ncbi.nlm.nih.gov/33761892	1,239							Yes	A systematic review and meta-analysis		Texas, USA	24-Mar-2021	
#00965	CT_33761870	Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial	33761870	https://doi.org/10.1186/s12879-021-05983-2	https://pubmed.ncbi.nlm.nih.gov/33761870	50	Drug(s)	Levamisole		30-Apr-2020	15-Aug-2020	108	No	A double-blind, randomized, controlled trial	Prospective	Iran	24-Mar-2021	
#00966	CT_33761710	Epidemiology of asymptomatic and symptomatic Coronavirus Disease 2019 confirmed cases in the Emirate of Abu Dhabi, United Arab Emirates: Observational study	33761710	https://doi.org/10.1097/MD.0000000000025219	https://pubmed.ncbi.nlm.nih.gov/33761710	3,827	Other			12-Mar-2020	22-Apr-2020	42	No	Observational, descriptive study	Retrospective	United Arab Emirates	26-Mar-2021	
#00967	CT_33761668	Combined clinical and imaging features better predict the critical outcomes of patients with SARS-COV-2	33761668	https://doi.org/10.1097/MD.0000000000025083	https://pubmed.ncbi.nlm.nih.gov/33761668	180	Other			18-Jan-2020	16-Feb-2020	30	No	A single-center, study	Retrospective	China	26-Mar-2021	
#00968	CT_33761654	Comorbidities' potential impacts on severe and non-severe patients with COVID-19: A systematic review and meta-analysis	33761654	https://doi.org/10.1097/MD.0000000000024971	https://pubmed.ncbi.nlm.nih.gov/33761654	3,286				14-Jan-2020	30-Mar-2020	77	Yes	A systematic review and meta-analysis		Wuhan, China	26-Mar-2021	
#00969	CT_33760885	Baseline clinical characteristics and prognostic factors in hospitalized COVID-19 patients aged ≤ 65 years: A retrospective observational study	33760885	https://doi.org/10.1371/journal.pone.0248829	https://pubmed.ncbi.nlm.nih.gov/33760885	171	Other			01-Mar-2020	30-Apr-2020	61	No	Observational study	Retrospective	Italy	24-Mar-2021	
#00970	CT_33759606	Clinical Features and Risk Factors for In-Hospital Mortality From COVID-19 Infection at a Tertiary Care Medical Center, at the Onset of the US COVID-19 Pandemic	33759606	https://doi.org/	https://pubmed.ncbi.nlm.nih.gov/33759606	565	Other			08-Mar-2020	14-Jun-2020	99	No	A single-center, cohort study	Retrospective	USA	24-Mar-2021	
#00971	CT_33752530	Comparison of clinical manifestations, pre-existing comorbidities, complications and treatment modalities in severe and non-severe COVID-19 patients: A systemic review and meta-analysis	33752530	https://doi.org/10.1177/00368504211000906	https://pubmed.ncbi.nlm.nih.gov/33752530	16,495							Yes	A systemic review and meta-analysis		Chongqing, China	22-Mar-2021	
#00972	CT_33749656	Clinical Features and Outcomes of Patients with Dementia Compared to an Aging Cohort Hospitalized During the Initial New York City COVID-19 Wave	33749656	https://doi.org/10.3233/JAD-210050	https://pubmed.ncbi.nlm.nih.gov/33749656	531	Other			06-Mar-2020	07-Apr-2020	33	No	A single-center, cohort study	Retrospective	USA	13-Mar-2021	
#00973	CT_33746189	Clinical Effect of Traditional Chinese Medicine Shenhuang Granule in Critically Ill Patients with COVID-19: A Single-Centered, Retrospective, Observational Study	33746189	https://doi.org/10.4014/jmb.2009.09029	https://pubmed.ncbi.nlm.nih.gov/33746189	118	Drug(s)	Traditional Chinese medicine		28-Jan-2020	28-Mar-2020	61	No	A single-centered, observational study	Retrospective	China	28-Mar-2021	
#00974	CT_33744175	Coronary and total thoracic calcium scores predict mortality and provides pathophysiologic insights in COVID-19 patients	33744175	https://doi.org/10.1016/j.jcct.2021.03.003	https://pubmed.ncbi.nlm.nih.gov/33744175	1,093	Other						No	Multicenter, observational study	Retrospective	Italy	11-Mar-2021	
#00975	CT_33743654	Covid-19 and gender: lower rate but same mortality of severe disease in women-an observational study	33743654	https://doi.org/10.1186/s12890-021-01455-0	https://pubmed.ncbi.nlm.nih.gov/33743654	431	Other			23-Feb-2020	14-Mar-2020	21	No	Observational study	Retrospective	Bergamo, Italy	20-Mar-2021	
#00976	CT_33743364	Epidemiological and clinical features of COVID-19 patients in Saudi Arabia	33743364	https://doi.org/10.1016/j.jiph.2021.01.003	https://pubmed.ncbi.nlm.nih.gov/33743364	240,474	Other						No	Multicenter, observational, cross-sectional study	Retrospective	Saudi Arabia	14-Apr-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
	Count >>>	1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00977	CT_33743295	Neurophysiological findings and their prognostic value in critical COVID-19 patients: An observational study	33743295	https://doi.org/10.1016/j.clinph.2021.02.007	https://pubmed.ncbi.nlm.nih.gov/33743295	33	Other						No	Observational study	Retrospective	Lille, France	25-Feb-2021	
#00978	CT_33743018	Lung ultrasound for the early diagnosis of COVID-19 pneumonia: an international multicenter study	33743018	https://doi.org/10.1007/s00134-021-06373-7	https://pubmed.ncbi.nlm.nih.gov/33743018	1,462	Other			01-Mar-2020	30-May-2020	91	No	International, multicenter, observational study			20-Mar-2021	
#00979	CT_33742107	Clinical characteristics and related risk factors of disease severity in 101 COVID-19 patients hospitalized in Wuhan, China	33742107	https://doi.org/10.1038/s41401-021-00627-2	https://pubmed.ncbi.nlm.nih.gov/33742107	101	Other			23-Feb-2020	04-Apr-2020	42	No	Study analysis	Retrospective	Wuhan, China	19-Mar-2021	
#00980	CT_33742062	Identification of macrophage activation-related biomarkers in obese type 2 diabetes that may be indicative of enhanced respiratory risk in COVID-19	33742062	https://doi.org/10.1038/s41598-021-85760-y	https://pubmed.ncbi.nlm.nih.gov/33742062	46	Other						No	Parallel pilot study	Prospective	Doha, Qatar	19-Mar-2021	
#00981	CT_33742041	Combining initial chest CT with clinical variables in diferentiating coronavirus disease 2019 (COVID-19) pneumonia from infuenza pneumonia	33742041	https://doi.org/10.1038/s41598-021-85779-1	https://pubmed.ncbi.nlm.nih.gov/33742041	24	Other			21-Jan-2020	09-Feb-2020	20	No	Study analysis	Retrospective	China	19-Mar-2021	
#00982	CT_33741750	Monitoring peripheral neutrophil and T-lymphocyte subsets could assist in differentiating the severity and disease progression of coronavirus disease 2019	33741750	https://doi.org/10.18632/aging.202701	https://pubmed.ncbi.nlm.nih.gov/33741750	79	other						No	Study analysis	Retrospective	Chengdu, China	19-Mar-2021	
#00983	CT_33741319	Clinical features, laboratory findings and persistence of virus in 10 children with coronavirus disease 2019 (COVID-19)	33741319	https://doi.org/10.1016/j.bj.2020.10.007	https://pubmed.ncbi.nlm.nih.gov/33741319	10	Other			01-Jan-2020	11-Mar-2020	71	No	Single-center, cohort study	Retrospective	Hubei, China	24-Oct-2020	
#00984	CT_33739987	Understanding the clinical and demographic characteristics of second coronavirus spike in 192 patients in Tehran, Iran: A retrospective study	33739987	https://doi.org/10.1371/journal.pone.0246314	https://pubmed.ncbi.nlm.nih.gov/33739987	192	Other			16-Jun-2020	11-Jul-2020	26	No	Cohort study	Retrospective	Tehran, Iran	19-Mar-2021	
#00985	CT_33745593	Are history of dietary intake and food habits of patients with clinical symptoms of COVID 19 different from healthy controls? A case-control study	33745593	https://doi.org/10.1016/j.clnesp.2021.01.021	https://pubmed.ncbi.nlm.nih.gov/33745593	505	Other						No	A case-control study	Retrospective	Iran	29-Jan-2021	
#00986	CT_33735712	Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia	33735712	https://doi.org/10.1016/j.intimp.2021.107522	https://pubmed.ncbi.nlm.nih.gov/33735712	373	Drug(s)	Favipiravir		02-Apr-2020	03-Aug-2020	124	No	Multicenter, randomized, open-labeled, clinical trial		Tehran, Iran	11-Mar-2021	
#00987	CT_33731999	Risk Factors and Prognosis in Patients with COVID-19 and Liver Injury: A Retrospective Analysis	33731999	https://doi.org/10.2147/JMDH.S293378	https://pubmed.ncbi.nlm.nih.gov/33731999	356	Other			17-Jan-2020	26-Feb-2020	41	No	Study analysis	Retrospective	Hubei, China	10-Mar-2021	
#00988	CT_33735374	Cardiopulmonary Exercise Testing to Assess Persistent Symptoms at 6 Months in People With COVID-19 Who Survived Hospitalization - A Pilot Study	33735374	https://doi.org/10.1093/ptj/pzab099	https://pubmed.ncbi.nlm.nih.gov/33735374	23	Other						No	Cohort study	Retrospective	France	18-Mar-2021	
#00989	CT_33735205	Clinical characteristics and outcomes of 952 hospitalized COVID-19 patients in The Netherlands: A retrospective cohort study	33735205	https://doi.org/10.1371/journal.pone.0248713	https://pubmed.ncbi.nlm.nih.gov/33735205	952	Other			02-Mar-2020	22-May-2020	82	No	Multicentre, cohort study	Retrospective	The Netherlands	18-May-2021	
#00990	CT_33734977	Variation in COVID-19 Mortality Across 117 US Hospitals in High- and Low-Burden Settings	33734977	https://doi.org/10.12788/jhm.3612	https://pubmed.ncbi.nlm.nih.gov/33734977	14,226	Other			01-Apr-2020	30-Apr-2020	30	No			California, USA	17-Mar-2021	
#00991	CT_33859192	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials	33859192	https://doi.org/10.1038/s41467-021-22446-z	https://pubmed.ncbi.nlm.nih.gov/33859192	10,319							Yes	International collaborative meta-analysis of randomized trials		Basel, Switzerland	15-Apr-2021	
#00992	CT_33841649	Correlation of the ratio of IgM/IgG concentration to days after symptom onset (IgM/T or IgG/T) with disease severity and outcome in non-critical COVID-19 patients	33841649	https://doi.org/	https://pubmed.ncbi.nlm.nih.gov/33841649	50	Other						No		Retrospective	Shenzhen, China	15-Mar-2021	
#00993	CT_33835886	A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19	33835886	https://doi.org/10.1080/14712598.2021.1905794	https://pubmed.ncbi.nlm.nih.gov/33835886	36	Drug(s)	Itolizumab					No	A two-arm, randomized, controlled, multi-centric, open-label phase-II study		India	9-Apr-2021	
#00994	CT_33831042	Neurologic manifestations in hospitalized patients with COVID-19 in Mexico City	33831042	https://doi.org/10.1371/journal.pone.0247433	https://pubmed.ncbi.nlm.nih.gov/33831042	71	Other						No	Cross-sectional, observational study	Prospective	Mexico city, Mexico	8-Apr-2021	
#00995	CT_33827856	Symptomatic, biochemical and radiographic recovery in patients with COVID-19	33827856	https://doi.org/10.1136/bmjresp-2021-000908	https://pubmed.ncbi.nlm.nih.gov/33827856	401	Other			01-May-2020	21-Jul-2020	82	No	Study analysis	Retrospective	London, UK	8-Apr-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#00996	CT_33822106	Inflammatory profiles and clinical features of COVID-19 survivors three months after discharge in Wuhan, China	33822106	https://doi.org/10.1093/infdis/jiab181	https://pubmed.ncbi.nlm.nih.gov/33822106	72	Other						No	Cross-sectional study	Prospective	Hubei, China	4-Apr-2021	
#00997	CT_33768438	Testing olfactory dysfunction in acute and recovered COVID-19 patients: a single center study in Italy	33768438	https://doi.org/10.1007/s10072-021-05200-7	https://pubmed.ncbi.nlm.nih.gov/33768438	51	Other						No	Cross-sectional, two-phase study		Italy	26-Mar-2021	
#00998	CT_33766997	Global Impact of COVID-19 on Stroke Care and Intravenous Thrombolysis	33766997	https://doi.org/10.1212/WNL.0000000000011885	https://pubmed.ncbi.nlm.nih.gov/33766997	91,373	Other			01-Mar-2020	30-Jun-2020	122	No	Cross-sectional, observational study	Retrospective		25-Mar-2021	
#00999	CT_33762056	Correlates of in-hospital COVID-19 deaths: a competing risks survival time analysis of retrospective mortality data	33762056	https://doi.org/10.1017/dmp.2021.85	https://pubmed.ncbi.nlm.nih.gov/33762056	1,147	Other			20-Jun-2020	15-Aug-2020	57	No	Study analysis	Retrospective	Delhi, India	25-Mar-2021	
#01000	CT_33760858	Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study	33760858	https://doi.org/10.1371/journal.pone.0248276	https://pubmed.ncbi.nlm.nih.gov/33760858	141	Drug(s)	Colchicine		25-Feb-2020	08-Apr-2020	44	No	Observational, cohort study	Retrospective	Parma, Italy	24-Mar-2021	
#01001	CT_33596348	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine	33596348	https://doi.org/10.1056/NEJMc2036242	https://pubmed.ncbi.nlm.nih.gov/33596348	43,548	Vaccine	BNT162b2 mRNA		27-Jul-2020	14-Nov-2020	111	No	An ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial		Worldwide	22-Apr-2021	
#01002	CT_33933206	Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	33933206	https://doi.org/10.1016/S0140-6736(21)00676-0	https://pubmed.ncbi.nlm.nih.gov/33933206	4,116	Drug(s)	Tocilizumab		23-Apr-2020	24-Jan-2021	277	No	Randomised, controlled, open-label, platform trial		UK	1-May-2021	
#01003	CT_33933189	SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study	33933189	https://doi.org/10.1016/S2352-3018(21)00072-2	https://pubmed.ncbi.nlm.nih.gov/33933189	2,017	Other			01-Aug-2020	31-Oct-2020	92	No	A matched case-control observational study		San Francisco, CA, USA	29-Apr-2021	
#01004	CT_33932726	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study	33932726	https://doi.org/10.1016/j.ejca.2021.03.035	https://pubmed.ncbi.nlm.nih.gov/33932726	1,392	Other			27-Feb-2020	10-Sep-2020	197	No		Retrospective	UK	6-Apr-2021	
#01005	CT_33932603	Dynamic changes and prevalence of SARS-CoV-2 IgG/IgM antibodies: multiple factors-based analysis	33932603	https://doi.org/10.1016/j.ijid.2021.04.078	https://pubmed.ncbi.nlm.nih.gov/33932603	678	Other						No	Study analysis	Retrospective	Yichang, China	28-Apr-2021	
#01006	CT_33951357	Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants	33951357	https://doi.org/10.1056/NEJMc2104974	https://pubmed.ncbi.nlm.nih.gov/33951357	385,853	Vaccine	BNT162b2		01-Feb-2021	31-Mar-2021	59	No	Cohort study		Doha, Qatar	5-May-2021	
#01007	CT_33959167	Clinical Features and Outcomes of ICU Patients with COVID-19 Infection in Tehran, Iran: a Single-Centered Retrospective Cohort Study	33959167	https://doi.org/	https://pubmed.ncbi.nlm.nih.gov/33959167	133	Other			01-Feb-2020	01-Jun-2020	122	No	Single-centered, cohort study	Retrospective	Tehran, Iran	19-Dec-2020	
#01008	CT_33958668	Seroprevalence of SARS-CoV-2 IgG antibodies and risk factors in health care workers at an academic medical center in Boston, Massachusetts	33958668	https://doi.org/10.1038/s41598-021-89107-5	https://pubmed.ncbi.nlm.nih.gov/33958668	1,743	Other			13-Jul-2020	26-Jul-2020	14	No	Cross-sectional study		Boston, Massachusetts, USA	6-May-2021	
#01009	CT_33957992	Predictors of the prolonged recovery period in COVID-19 patients: a cross-sectional study	33957992	https://doi.org/10.1186/s40001-021-00513-x	https://pubmed.ncbi.nlm.nih.gov/33957992	478	Other			01-Apr-2020	01-Aug-2020	123	No	Cross-sectional study		Tehran, Iran	6-May-2021	
#01010	CT_33957720	Covid-19 Clinical Course and Blood Groups: Turkish Population-Based Study	33957720	https://doi.org/10.3906/sag-2101-321	https://pubmed.ncbi.nlm.nih.gov/33957720	39,850	Other			11-Mar-2020	15-Jun-2020	97	No	Randomized, population-based, cohort study	Retrospective	Turkey	7-May-2021	
#01011	CT_33957412	Outcomes for in-hospital cardiac arrest for COVID-19 patients at a rural hospital in Southern California	33957412	https://doi.org/10.1016/j.ajem.2021.04.070	https://pubmed.ncbi.nlm.nih.gov/33957412	21	Other			01-May-2020	31-Jul-2020	92	No	Single-center observational study	Retrospective	California, USA	27-Apr-2021	
#01012	CT_33957219	Low dose radiation therapy for severe COVID-19 pneumonia: a randomized double-blind study	33957219	https://doi.org/10.1016/j.ijrobp.2021.04.029	https://pubmed.ncbi.nlm.nih.gov/33957219	22	Drug(s)						No	A randomized, double-blind study	Retrospective	Basel, Switzerland	3-May-2021	
#01013	CT_33970846	The effect of recombinant human interferon alpha nasal drops to prevent COVID-19 pneumonia for medical staff in an epidemic area	33970846	https://doi.org/10.2174/1568026621666210429083050	https://pubmed.ncbi.nlm.nih.gov/33970846	2,944	Drug(s)	rhIFN-α nasal drops | Thymosin-α1		21-Jan-2020	30-Jul-2020	192	No	Open-label clinical trial	Prospective	Hubei, China	28-Apr-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01014	CT_33875266	The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years: A phase I randomized, double-blinded, controlled trial	33875266	https://doi.org/10.1016/j.vaccine.2021.04.006	https://pubmed.ncbi.nlm.nih.gov/33875266	191	Vaccine						No	Phase I randomized, double-blinded, placebo-controlled trial		China	12-May-2021	
#01015	CT_33867046	Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial	33867046	https://doi.org/10.1016/j.phymed.2020.153242	https://pubmed.ncbi.nlm.nih.gov/33867046	284	Drug(s)	Traditional chinese medicine (Lianhuaqingwen capsules)					No	Multicenter, open-label, randomized controlled trial	Prospective	Hubei, China	16-May-2021	
#01016	CT_33865239	Intermediate vs Standard-dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to ICU: Ninety-day Results from the INSPIRATION Trial	33865239	https://doi.org/10.1055/a-1485-2372	https://pubmed.ncbi.nlm.nih.gov/33865239	562	Drug(s)	Heparin-based anticoagulants		29-Jul-2020	19-Nov-2020	114	No	Open label randomized controlled trial		USA	17-Apr-2021	
#01017	CT_33850184	Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial	33850184	https://doi.org/10.1038/s41598-021-86859-y	https://pubmed.ncbi.nlm.nih.gov/33850184	60	Drug(s)	Interferon Beta-1a | Interferon Beta-1b		09-Apr-2020	30-Apr-2020	22	No	Investigator-initiated, three-armed, parallel-group, individually-randomized, open-labeled, controlled trial		Tehran, Iran	13-Apr-2021	
#01018	CT_33845874	Longitudinal assessment of IFN-I activity and immune profile in critically ill COVID-19 patients with acute respiratory distress syndrome	33845874	https://doi.org/10.1186/s13054-021-03558-w	https://pubmed.ncbi.nlm.nih.gov/33845874	64	Drug(s) | Other	IFN-I		01-Mar-2020	01-May-2020	62	No		Prospective	Lyon, France	12-Apr-2021	
#01019	CT_33845863	A stepped wedge cluster randomized control trial to evaluate the implementation and effectiveness of optimized initiatives in improving quality of care for ST segment elevation myocardial infarction in response to the COVID-19 outbreak	33845863	https://doi.org/10.1186/s13012-021-01107-1	https://pubmed.ncbi.nlm.nih.gov/33845863	1,581	Other			Jan 2020	01-Jun-2020	153	No	A stepped wedge cluster randomized control trial	Retrospective	China	12-Apr-2021	
#01020	CT_33836013	Knowledge, preventive behaviors and risk perception of the COVID-19 pandemic: A cross-sectional study in Turkish health care workers	33836013	https://doi.org/10.1371/journal.pone.0250017	https://pubmed.ncbi.nlm.nih.gov/33836013	251	Other			10-Jun-2020	18-Jun-2020	9	No	A cross-sectional study		Ankara, Turkey	9-Apr-2021	
#01021	CT_33831043	Post-COVID-19 syndrome among symptomatic COVID-19 patients: A prospective cohort study in a tertiary care center of Bangladesh	33831043	https://doi.org/10.1371/journal.pone.0249644	https://pubmed.ncbi.nlm.nih.gov/33831043	355	Other			01-Jun-2020	10-Aug-2020	71	No	Cohort study	Prospective	Dhaka, Bangladesh	8-Apr-2021	
#01022	CT_33831032	Prevalence of SARS-COV-2 positivity in 516 German intensive care and emergency physicians studied by seroprevalence of antibodies National Covid Survey Germany (NAT-COV-SURV)	33831032	https://doi.org/10.1371/journal.pone.0248813	https://pubmed.ncbi.nlm.nih.gov/33831032	516	Other			16-Jun-2020	02-Jul-2020	17	No			Germany	8-Apr-2021	
#01023	CT_33807957	Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection	33807957	https://doi.org/10.3390/v13030422	https://pubmed.ncbi.nlm.nih.gov/33807957	15	Vaccine | Other	BNT162b2 mRNA					No			Italy	5-Mar-2021	
#01024	CT_33798499	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial	33798499	https://doi.org/10.1016/S0140-6736(21)00628-0	https://pubmed.ncbi.nlm.nih.gov/33798499	8,534	Vaccine	ChAdOx1 nCoV-19		31-May-2020	30-Dec-2020	214	No	Single-blind, multicentre, randomised phase 2/3 trial		UK	10-Apr-2021	"Participants in efficacy cohorts were recruited between May 31 and Nov 13, 2020, and received booster doses between Aug 3 and Dec 30, 2020"
#01025	CT_33790308	Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial	33790308	https://doi.org/10.1038/s41598-021-85227-0	https://pubmed.ncbi.nlm.nih.gov/33790308	100	Drug(s)	Favipiravir | Hydroxychloroquine and oseltamivir		18-Apr-2020	18-May-2020	31	No	Computer-based randomized, controlled, and interventional clinical Phase 3 trial		Cairo, Egypt	31-Mar-2021	
#01026	CT_33731163	Efficacy of the combination of modern medicine and traditional Chinese medicine in pulmonary fibrosis arising as a sequelae in convalescent COVID-19 patients: a randomized multicenter trial	33731163	https://doi.org/10.1186/s40249-021-00813-8	https://pubmed.ncbi.nlm.nih.gov/33731163	514	Drug(s)	Pirfenidone | Acetylcysteine | Glucocorticoid | Traditional chinese medicine					No	multicenter, parallel, double-blind, randomized clinical trial	Prospective	China	18-Mar-2021	
#01027	CT_33713817	Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study	33713817	https://doi.org/10.1016/j.ijid.2021.03.015	https://pubmed.ncbi.nlm.nih.gov/33713817	40	Drug(s)	IFN-α2b		08-Jul-2020	04-Sep-2020	59	No	Phase II, randomized, controlled, open-label study		India	1-Apr-2021	
#01028	CT_33707061	A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine	33707061	https://doi.org/10.1016/j.vaccine.2021.02.007	https://pubmed.ncbi.nlm.nih.gov/33707061	600	Vaccine	mRNA-1273		29-May-2020	08-Jul-2020	41	No	Phase 2, randomized, observer-blind, placebo-controlled trial		USA	12-May-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
	Count >>>	1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01029	CT_33704352	Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19	33704352	https://doi.org/10.1001/jama.2021.3645	https://pubmed.ncbi.nlm.nih.gov/33704352	25	Vaccine	Ad26.COV2.S vaccine		29-Jul-2020	07-Aug-2020	10	No	Randomized, double-blind, placebo-controlled phase 1 clinical trial		Boston, Massachusetts, USA	20-Apr-2021	
#01030	CT_33596494	Randomized placebo-controlled pilot clinical trial on the efficacy of ayurvedic treatment regime on COVID-19 positive patients	33596494	https://doi.org/10.1016/j.phymed.2021.153494	https://pubmed.ncbi.nlm.nih.gov/33596494	95	Drug(s)	Traditional Indian Ayurvedic treatment		01-May-2020	01-Jun-2020	32	No	Placebo controlled randomized double-blind pilot clinical trial.		India	4-Feb-2021	
#01031	CT_33679771	High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China	33679771	https://doi.org/10.3389/fimmu.2021.627844	https://pubmed.ncbi.nlm.nih.gov/33679771	26	IVIG			07-Feb-2020	30-Mar-2020	53	No	Multi-center, cohort study	Retrospective	Wuhan, China	19-Feb-2021	
#01032	CT_33679753	Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia	33679753	https://doi.org/	https://pubmed.ncbi.nlm.nih.gov/33679753	46	Other			07-Apr-2020	07-May-2020	31	No	Single-center, cohort study	Prospective	Portugal	18-Feb-2021	
#01033	CT_33676597	Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial	33676597	https://doi.org/10.1016/S0140-6736(21)00461-X	https://pubmed.ncbi.nlm.nih.gov/33676597	1,388	Drug(s)	Azithromycin		22-May-2020	30-Nov-2020	193	No	UK-based, primary care, open-label, multi-arm, adaptive platform randomised trial	Prospective	UK	4-Mar-2021	
#01034	CT_33676590	Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial	33676590	https://doi.org/10.1016/S2213-2600(21)00099-0	https://pubmed.ncbi.nlm.nih.gov/33676590	420	Drug(s)	Sarilumab		28-Mar-2020	03-Jul-2020	98	No	An adaptive, phase 3, multicentre, randomised, double-blind trial		Worldwide	4-Mar-2021	
#01035	CT_33676589	Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial	33676589	https://doi.org/10.1016/S2213-2600(21)00081-3	https://pubmed.ncbi.nlm.nih.gov/33676589	180	Drug(s)	Tocilizumab		30-May-2020	31-Aug-2020	94	No	An open-label, multicentre, randomised, controlled, phase 3 trial		India	4-Mar-2021	
#01036	CT_33662102	Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial	33662102	https://doi.org/10.1001/jama.2021.3071	https://pubmed.ncbi.nlm.nih.gov/33662102	400	Drug(s)	Ivermectin		15-Jul-2020	30-Nov-2020	139	No	Double-blind, randomized clinical trial		Cali, Colombia	13-Apr-2021	
#01037	CT_33657114	Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial	33657114	https://doi.org/10.1371/journal.pmed.1003415	https://pubmed.ncbi.nlm.nih.gov/33657114	57	Plasma			10-May-2020	18-Jul-2020	70	No	An open-label, single-center randomized clinical trial		Santiago, Chile	3-Mar-2021	
#01038	CT_33644235	Seroconversion and Abundance of IgG Antibodies against S1-RBD of SARS-CoV-2 and Neutralizing Activity in the Chilean Population	33644235	https://doi.org/10.1155/2021/6680337	https://pubmed.ncbi.nlm.nih.gov/33644235	690	Other						No	Cohort study		Santiago, Chile	23-Feb-2021	
#01039	CT_33649408	Ferritin is associated with the severity of lung involvement but not with worse prognosis in patients with COVID-19: data from two Italian COVID-19 units	33649408	https://doi.org/10.1038/s41598-021-83831-8	https://pubmed.ncbi.nlm.nih.gov/33649408	61	Other						No	Cohort study	Retrospective	Italy	1-Mar-2021	
#01040	CT_33646265	Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection	33646265	https://doi.org/10.1084/jem.20202617	https://pubmed.ncbi.nlm.nih.gov/33646265	478	Other						No	Cohort study	Prospective	Singapore	3-May-2021	
#01041	CT_33636568	The use of oxygen hoods in patients failing on conventional high-flow oxygen delivery systems, the effects on oxygenation, mechanical ventilation and mortality rates in hypoxic patients with COVID-19. A Prospective Controlled Cohort Study	33636568	https://doi.org/10.1016/j.rmed.2021.106312	https://pubmed.ncbi.nlm.nih.gov/33636568	136	Oxygen support			06-Mar-2020	01-May-2020	57	No	Single center, controlled cohort study	Prospective	New York, USA	11-Feb-2021	
#01042	CT_33631066	Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia	33631066	https://doi.org/10.1056/NEJMoa2028700	https://pubmed.ncbi.nlm.nih.gov/33631066	438	Drug(s)	Tocilizumab		03-Apr-2020	28-May-2020	56	No	Phase 3, international, randomized, doubleblind, placebo-controlled trial		Worldwide (Europe and North America)	25-Feb-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
	Count >>>	1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01043	CT_33631065	**Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19**	33631065	https://doi.org/10.1056/NEJMoa2100433	https://pubmed.ncbi.nlm.nih.gov/33631065	865	Drug(s)	Tocilizumab | Sarilumab					No	International, multifactorial, adaptive platform trial			25-Feb-2021	865 = "All patient includes those who underwent randomization in the Immune Modulation Therapy domain, with assignment to control (including where tocilizumab and sarilumab were not randomization options; i.e., nondirect controls), tocilizumab, sarilumab, anakinra, or interferon beta-1a"
#01044	CT_33629384	**A pilot double-blind safety and feasibility randomized controlled trial of high-dose intravenous zinc in hospitalized COVID-19 patients**	33629384	https://doi.org/10.1002/jmv.26895	https://pubmed.ncbi.nlm.nih.gov/33629384	33	Drug(s)	IV Zinc					No	A pilot double-blind safety and feasibility randomized controlled trial		Victoria, Australia	25-Feb-2021	
#01045	CT_33629254	**CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients**	33629254	https://doi.org/10.1007/s12192-021-01197-2	https://pubmed.ncbi.nlm.nih.gov/33629254	24	Drug(s) | Other	CIGB-258 (A peptide with anti-inflammatory properties)		31-Mar-2020	30-Jun-2020	92	No	Cohort study		Havana, Cuba	24-Feb-2021	
#01046	CT_33620880	**Negative-Pressure Isolation Mask for Endoscopic Examination During the Coronavirus Disease 2019 Pandemic: A Randomized Controlled Trial**	33620880	https://doi.org/10.14309/ctg.0000000000000314	https://pubmed.ncbi.nlm.nih.gov/33620880	316	Other			28-Feb-2020	10-Mar-2020	12	No	Single-center, randomized controlled study	Prospective	Sichuan, China	18-Feb-2021	
#01047	CT_33620016	**Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial**	33620016	https://doi.org/10.1080/07853890.2021.1890329	https://pubmed.ncbi.nlm.nih.gov/33620016	94	Drug(s)	rSIFN-co | interferon-alpha		10-Feb-2020	05-Apr-2020	56	No	Multicenter randomized (1:1) trial		China	23-Feb-2021	
#01048	CT_33607104	**No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial**	33607104	https://doi.org/10.1016/j.ejphar.2021.173947	https://pubmed.ncbi.nlm.nih.gov/33607104	50	Drug(s) | Other	Dexamethasone					No	A randomized, controlled, clinical trial		Tehran, Iran	16-Feb-2021	
#01049	CT_33595634	**Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial**	33595634	https://doi.org/10.1001/jama.2020.26848	https://pubmed.ncbi.nlm.nih.gov/33595634	237	Drug(s)	Vitamin D3		02-Jun-2020	27-Aug-2020	87	No	A multicenter, double-blind, randomized, placebo-controlled trial		Sao Paulo, Brazil	16-Mar-2021	
#01050	CT_33576820	**Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial**	33576820	https://doi.org/10.1001/jamanetworkopen.2021.0369	https://pubmed.ncbi.nlm.nih.gov/33576820	214	Drug(s) | Other	Zinc | Vitamin C		27-Apr-2020	14-Oct-2020	171	No	A multicenter, single health system randomized clinical factorial open-label trial	Prospective	USA	12-Feb-2021	
#01051	CT_33573699	**Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial**	33573699	https://doi.org/10.1186/s40001-021-00490-1	https://pubmed.ncbi.nlm.nih.gov/33573699	60	Drug(s)	Vitamin C					No	An open-label, randomized, and controlled trial		Tehran, Iran	11-Feb-2021	
#01052	CT_33568628	**Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial**	33568628	https://doi.org/10.1038/s41392-021-00488-5	https://pubmed.ncbi.nlm.nih.gov/33568628	101	Other			05-Mar-2020	28-Mar-2020	24	No	A randomized, double-blind, placebo-controlled phase 2 trial		China	10-Feb-2021	
#01053	CT_33547300	**Efficacy and tolerability of bevacizumab in patients with severe Covid-19**	33547300	https://doi.org/10.1038/s41467-021-21085-8	https://pubmed.ncbi.nlm.nih.gov/33547300	137	Drug(s)	Bevacizumab		15-Feb-2020	05-Apr-2020	51	No	A single-arm trial	Retrospective	Wuhan, China	5-Feb-2021	
#01054	CT_33545094	**Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia**	33545094	https://doi.org/10.1016/S0140-6736(21)00234-8	https://pubmed.ncbi.nlm.nih.gov/33545094	21,862	Vaccine	rAd26 | rAd5		07-Sep-2020	24-Nov-2020	79	No	A randomised, double-blind, placebo-controlled, multicentre, phase 3 trial		Moscow, Russia	2-Feb-2021	"The analysis of serious adverse events included 21862 participants who received at least one dose (of whom 19866 received two doses"
#01055	CT_33542047	**Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial**	33542047	https://doi.org/10.1136/rmdopen-2020-001455	https://pubmed.ncbi.nlm.nih.gov/33542047	72	Drug(s)	Colchicine		11-Apr-2020	30-Aug-2020	142	No	A randomised, double-blinded, placebo-controlled clinical trial		Ribeirao Preto, Brazil	7-Feb-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01056	CT_33534047	Methylprednisolone in adults hospitalized with COVID-19 pneumonia : An open-label randomized trial (GLUCOCOVID)	33534047	https://doi.org/10.1007/s00508-020-01805-8	https://pubmed.ncbi.nlm.nih.gov/33534047	64	Drug(s)	Methylprednisolone		01-Apr-2020	01-Jul-2020	92	No	A randomized, open-label, controlled, two-arm, parallel-group, trial		Spain	3-Feb-2021	
#01057	CT_33525212	Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial	33525212	https://doi.org/10.23750/abm.v91i4.10877	https://pubmed.ncbi.nlm.nih.gov/33525212	82	Drug(s)	Sofosbuvir/Ledipasvir					No	An open-label randomized clinical trial		Tehran, Iran	10-Nov-2020	
#01058	CT_33524311	Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial	33524311	https://doi.org/10.1016/S0140-6736(21)00241-5	https://pubmed.ncbi.nlm.nih.gov/33524311	148	Vaccine	S-Trimer (SCB-2019)		19-Jun-2020	23-Sep-2020	97	No	A phase 1, randomised, double-blind, placebo-controlled trial		Western Australia, Australia	29-Jan-2021	
#01059	CT_33492523	Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study	33492523	https://doi.org/10.1007/s00705-021-04956-9	https://pubmed.ncbi.nlm.nih.gov/33492523	92	Drug(s)	Favipiravir		01-Apr-2020	01-Aug-2020	123	No	A multi-center, randomized, interventional phase2/phase 3 study		Cairo, Egypt	25-Jan-2021	
#01060	CT_33486496	Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial	33486496	https://doi.org/10.1159/000512063	https://pubmed.ncbi.nlm.nih.gov/33486496	86	Drug(s) | Other	Corticosteroid		14-Feb-2020	31-Mar-2020	47	No	A multicenter, single-blind, randomized control trial	Prospective	China	22-Jan-2021	
#01061	CT_33482025	Early mortality benefit with COVID-19 convalescent plasma: a matched control study	33482025	https://doi.org/10.1111/bjh.17272	https://pubmed.ncbi.nlm.nih.gov/33482025	526	Plasma			13-Apr-2020	07-Jul-2020	86	No	Health system-based, matched cohort study	Retrospective	USA	22-Jan-2021	
#01062	CT_33476420	Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis	33476420	https://doi.org/10.1002/ajh.26102	https://pubmed.ncbi.nlm.nih.gov/33476420	382	Drug(s)	Anticoagulants		01-Mar-2020	01-Jun-2020	93	No	Cohort study	Retrospective	USA	21-Jan-2021	
#01063	CT_33475701	Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial	33475701	https://doi.org/10.1001/jama.2021.0202	https://pubmed.ncbi.nlm.nih.gov/33475701	577	Drug(s)	Bamlanivimab | Etesevimab		17-Jun-2020	21-Aug-2020	66	No	A multipart, phase 2/3, randomized, double-blind, placebo-controlled, single-infusion study		USA	21-Jan-2021	
#01064	CT_33472855	Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial	33472855	https://doi.org/10.1136/bmj.n84	https://pubmed.ncbi.nlm.nih.gov/33472855	129	Drug(s)	Tocilizumab		08-May-2020	17-Jul-2020	71	No	A multicentre, randomised, open label, parallel group clinical trial		Brazil	20-Jan-2021	
#01065	CT_33464336	Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial	33464336	https://doi.org/10.1001/jama.2020.25864	https://pubmed.ncbi.nlm.nih.gov/33464336	659	Drug(s)	ACEIs | ARBs		09-Apr-2020	26-Jun-2020	79	No	A randomized clinical trial	Prospective	Brazil	19-Jan-2021	
#01066	CT_33429174	Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: A randomized controlled trial	33429174	https://doi.org/10.1016/j.amjoto.2020.102884	https://pubmed.ncbi.nlm.nih.gov/33429174	100	Drug(s) | Other	Corticosteroid nasal spray					No	A randomized, controlled clinical trial	Prospective	Benha, Egypt	4-Jan-2021	
#01067	CT_33422263	Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial	33422263	https://doi.org/10.1016/S2213-2600(20)30558-0	https://pubmed.ncbi.nlm.nih.gov/33422263	152	Drug(s)	ACEIs | ARBs		31-Mar-2020	20-Aug-2020	143	No	A randomised, open-label clinical trial	Prospective	Worldwide	7-Jan-2021	
#01068	CT_33422143	Prone positioning improves oxygenation and lung recruitment in patients with SARS-CoV-2 acute respiratory distress syndrome; a single centre cohort study of 20 consecutive patients	33422143	https://doi.org/10.1186/s13104-020-05426-2	https://pubmed.ncbi.nlm.nih.gov/33422143	20	Other			16-Mar-2020	08-Apr-2020	24	No	Cohort study	Prospective	Ireland	9-Jan-2021	
#01069	CT_33421928	Safety and efficacy of ozone therapy in mild to moderate COVID-19 patients: A phase 1/11 randomized control trial (SEOT study)	33421928	https://doi.org/10.1016/j.intimp.2020.107301	https://pubmed.ncbi.nlm.nih.gov/33421928	60	Ozone therapy						No	A randomized control trial			23-Dec-2020	
#01070	CT_33419674	Effects and safety of herbal medicines among community-dwelling residents during COVID-19 pandemic: A large prospective, randomized controlled trial (RCT)	33419674	https://doi.org/10.1016/j.phymed.2020.153403	https://pubmed.ncbi.nlm.nih.gov/33419674	22,065	Drug(s)	Traditional chinese medicine (Jinhaoartemisia antipyretic granules | Huoxiangzhengqi oral liquids)		30-Jan-2020	29-Feb-2020	31	No	An open-label, parallel-group, cluster-randomized controlled trial	Prospective	Chengdu, China	5-Nov-2020	
#01071	CT_33400390	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial	33400390	https://doi.org/10.1002/sctm.20-0472	https://pubmed.ncbi.nlm.nih.gov/33400390	28	Other			25-Apr-2020	21-Jul-2020	88	No	A double-blind, phase 1/2a, randomized controlled trial		Florida, USA	5-Jan-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
	Count >>>	1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01072	CT_33382773	**Interleukine-6 in critically ill COVID-19 patients: A retrospective analysis**	33382773	https://doi.org/10.1371/journal.pone.0244628	https://pubmed.ncbi.nlm.nih.gov/33382773	41	Other			10-Mar-2020	30-Apr-2020	52	No	Study analysis	Retrospective	Brussels, Belgium	31-Dec-2020	
#01073	CT_33380344	**Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis**	33380344	https://doi.org/10.1186/s13075-020-02395-6	https://pubmed.ncbi.nlm.nih.gov/33380344	2,050	Other			25-Feb-2020	20-Apr-2020	56	No	A cross-sectional survey		Pavia, Italy	30-Dec-2020	
#01074	CT_33378989	**Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size**	33378989	https://doi.org/10.1016/j.biopha.2020.110825	https://pubmed.ncbi.nlm.nih.gov/33378989	26	Drug(s)	Tocilizumab | Favipiravir		02-Feb-2020	15-Mar-2020	43	No	A multicenter trial		China	30-Sep-2020	
#01075	CT_33378609	**Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine**	33378609	https://doi.org/10.1056/NEJMoa2035389	https://pubmed.ncbi.nlm.nih.gov/33378609	30,420	Vaccine	mRNA-1273 vaccine		27-Jul-2020	23-Oct-2020	89	No	Phase 3 randomized, stratified, observer-blinded, placebo-controlled trial		Massachusetts, USA	4-Feb-2021	
#01076	CT_33357491	**Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland**	33357491	https://doi.org/10.1016/S2213-8587(20)30405-8	https://pubmed.ncbi.nlm.nih.gov/33357491	5,463,300	Other			01-Mar-2020	31-Jul-2020	153	No	Cohort study		Scotland	23-Dec-2020	
#01077	CT_33356051	**A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19**	33356051	https://doi.org/10.1056/NEJMoa2033130	https://pubmed.ncbi.nlm.nih.gov/33356051	314	Drug(s)	LY-CoV555 (A neutralizing monoclonal antibody)		05-Aug-2020	13-Oct-2020	70	No	Randomized, cohort study		USA, Denmark, and Singapore	22-Dec-2020	
#01078	CT_33338232	**Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial**	33338232	https://doi.org/10.1093/jac/dkaa501	https://pubmed.ncbi.nlm.nih.gov/33338232	55	Drug(s)	Sofosbuvir | Daclatasvir		08-Apr-2020	19-May-2020	42	No	A double-blind, randomized controlled trial		Iran	18-Dec-2020	
#01079	CT_33332779	**Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia**	33332779	https://doi.org/10.1056/NEJMoa2030340	https://pubmed.ncbi.nlm.nih.gov/33332779	377	Drug(s)	Tocilizumab					No	Randomized, double-blind, placebo-controlled, phase 3 trial		USA, Mexico, Kenya, South Africa, Peru, and Brazil	17-Dec-2020	
#01080	CT_33332778	**REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19**	33332778	https://doi.org/10.1056/NEJMoa2035002	https://pubmed.ncbi.nlm.nih.gov/33332778	275	Drug(s)	REGN-COV2 (A neutralizing antibody cocktail)		16-Jun-2020	13-Aug-2020	59	No	An ongoing operationally seamless (continual enrollment), multicenter, randomized, double-blind, placebo-controlled, phase 1–3 clinical trial			17-Dec-2020	
#01081	CT_33332386	**Prevalence and risk factors of disability and anxiety in a retrospective cohort of 432 survivors of Coronavirus Disease-2019 (Covid-19) from China**	33332386	https://doi.org/10.1371/journal.pone.0243883	https://pubmed.ncbi.nlm.nih.gov/33332386	432	Other			21-Feb-2020	07-Apr-2020	47	No	A multi-center, cohort study.	Retrospective	China	17-Dec-2020	
#01082	CT_33322317	**High-Dose Cholecalciferol Booster Therapy is Associated with a Reduced Risk of Mortality in Patients with COVID-19: A Cross-Sectional Multi-Centre Observational Study**	33322317	https://doi.org/10.3390/nu12123799	https://pubmed.ncbi.nlm.nih.gov/33322317	444	Drug(s)	Cholecalciferol		26-Jun-2020	05-Aug-2020	41	No	A cross-sectional, multi-centre, observational study	Retrospective	Ashton-under-Lyne, UK	11-Dec-2020	
#01083	CT_33320842	**Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates**	33320842	https://doi.org/10.1172/JCI144930	https://pubmed.ncbi.nlm.nih.gov/33320842	250	Other						No	Cross-sectional, cohort study		Washington, USA	1-Feb-2021	
#01084	CT_33317461	**Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial**	33317461	https://doi.org/10.1186/s12879-020-05698-w	https://pubmed.ncbi.nlm.nih.gov/33317461	100	Drug(s)	Umifenovir		20-Apr-2020	18-Jun-2020	60	No	An open-label, randomized, controlled trial		Tehran, Iran	14-Dec-2020	
#01085	CT_33315181	**Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore**	33315181	https://doi.org/10.1007/s15010-020-01563-9	https://pubmed.ncbi.nlm.nih.gov/33315181	16	Other			01-Jun-2020	01-Aug-2020	62	No	A randomized control trial	Retrospective	Singapore	14-Dec-2020	
#01086	CT_33307107	**Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients**	33307107	https://doi.org/10.1016/j.mad.2020.111413	https://pubmed.ncbi.nlm.nih.gov/33307107	46	Other						No	Phase 2, open-label, single-arm clinical trial		Italy	8-Dec-2020	
#01087	CT_33232588	**A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia**	33232588	https://doi.org/10.1056/NEJMoa2031304	https://pubmed.ncbi.nlm.nih.gov/33232588	333	Plasma			28-May-2020	27-Aug-2020	92	No	A double-blind, placebo-controlled, multicenter trial		Argentina	24-Nov-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01088	CT_33220855	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial	33220855	https://doi.org/10.1016/S0140-6736(20)32466-1	https://pubmed.ncbi.nlm.nih.gov/33220855	560	Vaccine	ChAdOx1 nCoV-19		30-May-2020	08-Aug-2020	71	No	A single-blind, multicentre, randomised, controlled, phase 2/3 trial		UK	18-Nov-2020	
#01089	CT_33217362	Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial	33217362	https://doi.org/10.1016/S1473-3099(20)30843-4	https://pubmed.ncbi.nlm.nih.gov/33217362	743	Vaccine | Other						No	Single-centre, double-blind, randomised, placebo-controlled, phase 1/2 clinical trial		China	17-Nov-2020	
#01090	CT_33214093	Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial	33214093	https://doi.org/10.1016/j.intimp.2020.107205	https://pubmed.ncbi.nlm.nih.gov/33214093	84	IVIG						No	A randomized controlled trial		Tehran, Iran	13-Nov-2020	
#01091	CT_33212256	Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial	33212256	https://doi.org/10.1016/j.ijid.2020.11.142	https://pubmed.ncbi.nlm.nih.gov/33212256	148	Drug(s)	Favipiravir		14-May-2020	03-Jul-2020	51	No	A randomized, comparative, open-label, multicenter, phase 3 clinical trial		India	16-Nov-2020	
#01092	CT_33210302	COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia	33210302	https://doi.org/10.1002/cpt.2117	https://pubmed.ncbi.nlm.nih.gov/33210302	32	Drug(s)	Tocilizumab		01-Apr-2020	13-May-2020	43	No	Phase II clinical trial	Prospective	Chicago, Illinois, USA	18-Nov-2020	
#01093	CT_33189161	Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial	33189161	https://doi.org/10.1016/S2213-2600(20)30511-7	https://pubmed.ncbi.nlm.nih.gov/33189161	101	Drug(s)	Interferon beta-1a		30-Mar-2020	30-May-2020	62	No	A randomised, double-blind, placebo-controlled, phase 2 pilot trial		UK	12-Nov-2020	
#01094	CT_33181328	Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia	33181328	https://doi.org/10.1016/j.ijid.2020.11.008	https://pubmed.ncbi.nlm.nih.gov/33181328	89	Drug(s)	Favipiravir | Interferon beta-1b		22-Jun-2020	13-Aug-2020	53	No	A randomized, open-label controlled trial		Muscat, Oman	9-Nov-2020	
#01095	CT_33152450	Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial	33152450	https://doi.org/10.1016/j.ijantimicag.2020.106216	https://pubmed.ncbi.nlm.nih.gov/33152450	41	Drug(s)	Artemisinin-piperaquine					No	An open-label, randomised, parallel-group, controlled trial		China	2-Nov-2020	
#01096	CT_33115675	Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial	33115675	https://doi.org/10.1016/j.ejps.2020.105631	https://pubmed.ncbi.nlm.nih.gov/33115675	30	Drug(s) | Other	Baloxavir marboxil | favipiravir					No	Single center, open-label, randomized, controlled trial		Hangzhou, China	25-Oct-2020	
#01097	CT_33113295	SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19	33113295	https://doi.org/10.1056/NEJMoa2029849	https://pubmed.ncbi.nlm.nih.gov/33113295	452	Drug(s)	LY-CoV555 (A neutralizing monoclonal antibody)		17-Jun-2020	21-Aug-2020	66	No	Randomized, double-blind, placebo-controlled, single-dose trial		USA	28-Oct-2020	
#01098	CT_33105142	Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19	33105142	https://doi.org/10.1159/000512210	https://pubmed.ncbi.nlm.nih.gov/33105142	72	Drug(s)	Itolizumab					No	Cohort study		Cuba	26-Oct-2020	
#01099	CT_33085857	Efficacy of Tocilizumab in Patients Hospitalized with Covid-19	33085857	https://doi.org/10.1056/NEJMoa2028836	https://pubmed.ncbi.nlm.nih.gov/33085857	243	Drug(s)	Tocilizumab		20-Apr-2020	15-Jun-2020	57	No	A randomized, double-blind, placebo-controlled trial		Boston, Massachusetts, USA	21-Oct-2020	
#01100	CT_33069281	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial	33069281	https://doi.org/10.1016/S1473-3099(20)30831-8	https://pubmed.ncbi.nlm.nih.gov/33069281	640	Vaccine	BBIBP-CorV		29-Apr-2020	30-Jul-2020	93	No	A dose-escalation, randomised, double-blind, placebo-controlled, phase 1/2 trial		Henan, China	15-Oct-2020	192 phase I + 448 phase II
#01101	CT_33053279	Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates	33053279	https://doi.org/10.1056/NEJMoa2027906	https://pubmed.ncbi.nlm.nih.gov/33053279	195	Vaccine	BNT162b1 | BNT162b2		04-May-2020	22-Jun-2020	50	No	An ongoing, placebo-controlled, observer-blinded, dose-escalation, phase 1 trial		USA	14-Oct-2020	
#01102	CT_33010257	IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study	33010257	https://doi.org/10.1016/j.jaci.2020.09.018	https://pubmed.ncbi.nlm.nih.gov/33010257	146	Drug(s)	Tocilizumab		24-Feb-2020	23-Mar-2020	29	No	Observational study	Retrospective	Madrid, Spain	29-Sep-2020	
#01103	CT_32998157	COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses	32998157	https://doi.org/10.1038/s41586-020-2814-7	https://pubmed.ncbi.nlm.nih.gov/32998157	12	Vaccine	BNT162b1		23-Apr-2020	22-May-2020	30	No	Cohort study		Germany	30-Sep-2020	
#01104	CT_32979419	Clinical characteristics and outcome of hospita	32979419	https://doi.org/10.1016/j.diabres.2020.108467	https://pubmed.ncbi.nlm.nih.gov/32979419	595	Other			26-Feb-2020	26-Mar-2020	30	No	A single-center study	Retrospective	Iran	23-Sep-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01105	CT_32958718	A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19	32958718	https://doi.org/10.1128/AAC.01897-20	https://pubmed.ncbi.nlm.nih.gov/32958718	88	Drug(s)	Favipiravir					No	A randomized, open-label, multicenter trial	Prospective		17-Nov-2020	
#01106	CT_32943404	Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial	32943404	https://doi.org/10.1183/13993003.02808-2020	https://pubmed.ncbi.nlm.nih.gov/32943404	62	Drug(s)	Methylprednisolone		20-Apr-2020	20-Jun-2020	62	No	A single-blind, two-arm parallel, randomised controlled trial		Tehran, Iran	24-Dec-2020	
#01107	CT_32896291	Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia	32896291	https://doi.org/10.1016/S0140-6736(20)31866-3	https://pubmed.ncbi.nlm.nih.gov/32896291	76	Vaccine	rAd26 | rAd5		18-Jun-2020	03-Aug-2020	47	No	Two open, non-randomised phase 1/2 trial		Moscow, Russia	4-Sep-2020	
#01108	CT_32877576	Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine	32877576	https://doi.org/10.1056/NEJMoa2026920	https://pubmed.ncbi.nlm.nih.gov/32877576	131	Vaccine	NVX-CoV2373		27-May-2020	06-Jun-2020	11	No	A randomized, placebo-controlled, phase 1-2 trial		Australia	2-Sep-2020	
#01109	CT_32876697	Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial	32876697	https://doi.org/	https://pubmed.ncbi.nlm.nih.gov/32876697	384	Drug(s)	Hydrocortisone		09-Mar-2020	17-Jun-2020	101	No	An ongoing, international, multicenter, openlabel trial		Pennsylvania, USA	2-Sep-2020	
#01110	CT_32814839	Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study	32814839	https://doi.org/10.1038/s41375-020-01018-y	https://pubmed.ncbi.nlm.nih.gov/32814839	40	Drug(s)	Ruxolitinib		07-Apr-2020	08-May-2020	32	No	Observational study		Florence, Italy	19-Aug-2020	
#01111	CT_32812051	The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19	32812051	https://doi.org/10.1093/jac/dkaa331	https://pubmed.ncbi.nlm.nih.gov/32812051	62	Drug(s)	Sofosbuvir/daclatasvir | Ribavirin		18-Mar-2020	16-Apr-2020	30	No	Open-label parallel trial		Abadan, Iran	19-Aug-2020	
#01112	CT_32812039	Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial	32812039	https://doi.org/10.1093/jac/dkaa334	https://pubmed.ncbi.nlm.nih.gov/32812039	66	Drug(s)	Sofosbuvir | Daclatasvir		26-Mar-2020	26-Apr-2020	32	No	A Phase III, multicentred, randomized, controlled trial.		Iran	19-Aug-2020	
#01113	CT_32812025	Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial	32812025	https://doi.org/10.1093/jac/dkaa332	https://pubmed.ncbi.nlm.nih.gov/32812025	48	Drug(s)	Sofosbuvir/daclatasvir | Ribavirin		20-Mar-2020	08-Apr-2020	20	No	A single-centre, randomized controlled trial		Mazandaran, Iran	19-Aug-2020	
#01114	CT_32795330	Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial	32795330	https://doi.org/10.1186/s13054-020-03220-x	https://pubmed.ncbi.nlm.nih.gov/32795330	30	Drug(s)	Auxora		08-Apr-2020	13-May-2020	36	No	Preliminary, phase 2, randomized, controlled, open-label study		USA	14-Aug-2020	
#01115	CT_32789505	Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials	32789505	https://doi.org/10.1001/jama.2020.15543	https://pubmed.ncbi.nlm.nih.gov/32789505	96	Vaccine			12-Apr-2020	02-May-2020	21	No	Double-blind, randomized, placebo-controlled phase 1 and 2 trials		Wuhan, China	13-Aug-2020	
#01116	CT_32661006	A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19	32661006	https://doi.org/10.1128/AAC.01061-20	https://pubmed.ncbi.nlm.nih.gov/32661006	81	Drug(s)	IFN beta-1a		29-Feb-2020	03-Apr-2020	35	No	Randomized, open-label, controlled trial		Tehran, Iran	20-Aug-2020	
#01117	CT_32619411	Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study	32619411	https://doi.org/10.1016/S2352-3026(20)30216-7	https://pubmed.ncbi.nlm.nih.gov/32619411	68	Other			13-Apr-2020	24-Apr-2020	12	No	Single-centre cross-sectional study		Connecticut, USA	30-Jun-2020	
#01118	CT_32579195	Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial	32579195	https://doi.org/10.1001/jamanetworkopen.2020.13136	https://pubmed.ncbi.nlm.nih.gov/32579195	105	Drug(s)	Colchicine		03-Apr-2020	27-Apr-2020	25	No	Open-label, randomized clinical trial	Prospective	Athens, Greece	24-Jun-2020	
#01119	CT_32544867	Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial	32544867	https://doi.org/10.1016/j.intimp.2020.106688	https://pubmed.ncbi.nlm.nih.gov/32544867	20	Drug(s)	IFN-β-1a					No	Non-controlled clinical trial	Prospective	Tehran, Iran	7-Jun-2020	
#01120	CT_32527675	SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients	32527675	https://doi.org/10.1016/j.jaut.2020.102502	https://pubmed.ncbi.nlm.nih.gov/32527675	916	Other			09-Apr-2020	25-Apr-2020	17	No	Cohort study		Padua, Italy	8-Jun-2020	
#01121	CT_32401715	Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial	32401715	https://doi.org/10.1016/S0140-6736(20)31042-4	https://pubmed.ncbi.nlm.nih.gov/32401715	127	Drug(s)	Interferon beta-1b | Lopinavir/ritonavir | Ribavirin		10-Feb-2020	20-Mar-2020	40	No	A phase 2, multicentre, open-label, randomised trial	Prospective	China	8-May-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01122	CT_34068142	Human Milk from Previously COVID-19-Infected Mothers: The Effect of Pasteurization on Specific Antibodies and Neutralization Capacity	34068142	https://doi.org/10.3390/nu13051645g	https://pubmed.ncbi.nlm.nih.gov/34068142	51	Other						No	Case control study	Prospective	The Netherlands	13-May-2021	
#01123	CT_34072977	Relation of Serum Copper Status to Survival in COVID-19	34072977	https://doi.org/10.3390/nu13061898	https://pubmed.ncbi.nlm.nih.gov/34072977	35	Other						No	Cross-sectional study		Germany	31-May-2021	
#01124	CT_34033648	Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia	34033648	https://doi.org/10.1371/journal.pone.0252057	https://pubmed.ncbi.nlm.nih.gov/34033648	216	Drug(s)	Dexamethasone | Methylprednisolone		15-Sep-2020	31-Oct-2020	47	No	Cohort study	Ambispective	Antioquia, Colombia	25-May-2021	
#01125	CT_34142670	Effectiveness of BNT162b2 vaccine against SARS-CoV-2 among healthcare workers	34142670	https://doi.org/10.23749/mdl.v112i3.11747	https://pubmed.ncbi.nlm.nih.gov/34142670	92	Vaccine	BNT162b2		25-Jan-2021	13-Feb-2021	20	No	Observational study		Brescia, Italy	15-Jun-2021	
#01126	CT_34142203	Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey	34142203	https://doi.org/10.1007/s00296-021-04917-0	https://pubmed.ncbi.nlm.nih.gov/34142203	724	Vaccine	ChAdOx1 nCoV-19					No	Cohort study		Kerala, India	17-Jun-2021	
#01127	CT_34141818	Effect of Inadequate Empiric Antibacterial Therapy on Hospital Outcomes in SARS-CoV-2-Positive and -Negative US Patients With a Positive Bacterial Culture: A Multicenter Evaluation From March to November 2020	34141818	https://doi.org/10.1093/ofid/ofab232	https://pubmed.ncbi.nlm.nih.gov/34141818	39,203	Drug(s)	Empiric antibacterial therapy		01-Mar-2020	28-Nov-2020	273	No	A multicenter, cohort analysis	Retrospective	New Jersey, USA	26-May-2021	
#01128	CT_34155754	Identifying patterns in unplanned hospital admissions during the COVID-19 pandemic: a single-centre retrospective study	34155754	https://doi.org/10.1111/imj.15075	https://pubmed.ncbi.nlm.nih.gov/34155754	12,278	Other			01-Mar-2020	30-Apr-2020	61	No	Single-centre, observational study	Retrospective	Victoria, Australia	21-Jun-2021	
#01129	CT_34155573	Antibody responses after documented COVID-19 disease in patients with autoimmune rheumatic disease	34155573	https://doi.org/10.1007/s10067-021-05801-9	https://pubmed.ncbi.nlm.nih.gov/34155573	50	Other						No	Cohort study		Kochi, India	22-Jun-2021	
#01130	CT_34155441	COVID-19 infection across workplace settings in Qatar: a comparison of COVID-19 positivity rates of screened workers from March 1st until July 31st, 2020	34155441	https://doi.org/10.1186/s12995-021-00311-5	https://pubmed.ncbi.nlm.nih.gov/34155441	201,006	Other			01-Mar-2020	31-Jul-2020	153	No	A cross-sectional study		Qatar	17-Jun-2021	
#01131	CT_34155307	SARS-CoV-2 viral load in nasopharyngeal swabs is not an independent predictor of unfavorable outcome	34155307	https://doi.org/10.1038/s41598-021-92400-y	https://pubmed.ncbi.nlm.nih.gov/34155307	321	Other			29-Feb-2020	01-May-2020	63	No	Observational, cohort study	Prospective	Seville, Spain	21-Jun-2021	
#01132	CT_34155259	Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study	34155259	https://doi.org/10.1038/s41598-021-92206-y	https://pubmed.ncbi.nlm.nih.gov/34155259	1,038	Other			21-May-2020	25-Jun-2020	36	No	A population-based study.		Saint Petersburg, Russia	21-Jun-2021	
#01133	CT_34154358	An observational case series of targeted virtual geriatric medicine and palliative care consults for hospitalized older adults with COVID-19	34154358	https://doi.org/10.21037/apm-21-117	https://pubmed.ncbi.nlm.nih.gov/34154358	78	Other			09-Apr-2020	09-May-2020	31	No	Observational case series		New Haven, Connecticut, USA	18-Jun-2021	
#01134	CT_34153731	Clinical characteristics and predictors of mortality among COVID-19 patients in Saudi Arabia	34153731	https://doi.org/10.1016/j.jiph.2021.06.005	https://pubmed.ncbi.nlm.nih.gov/34153731	119	Other			25-Mar-2020	30-Jul-2020	128	No	Observational study	Retrospective	Madina, Saudi Arabia	11-Jun-2021	
#01135	CT_34150012	Study on clinical characteristics of 173 cases of COVID-19 and effect of glucocorticoid on nucleic acid negative conversion	34150012	https://doi.org/	https://pubmed.ncbi.nlm.nih.gov/34150012	173	Drug(s)	Glucocorticoid		10-Feb-2020	17-Mar-2020	37	No	Case study analysis	Retrospective	Wuhan, China	15-May-2021	
#01136	CT_34150575	Clinical Features and Prognosis of Invasive Ventilation in Hospitalized Patients with COVID-19: A Retrospective Study	34150575	https://doi.org/10.5812/aapm.108773	https://pubmed.ncbi.nlm.nih.gov/34150575	45	Oxygen support			08-Apr-2020	09-May-2020	32	No	Observational, descriptive study	Retrospective	Tehran, Iran	19-Dec-2020	
#01137	CT_34152403	Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients	34152403	https://doi.org/10.1182/bloodadvances.2021004629	https://pubmed.ncbi.nlm.nih.gov/34152403	905							Yes	Systematic review and meta-analysis		Toronto, Ontario, Canada	21-Jun-2021	
#01138	CT_34153264	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial	34153264	https://doi.org/10.1016/S2352-3018(21)00103-X	https://pubmed.ncbi.nlm.nih.gov/34153264	54	Vaccine	ChAdOx1 nCoV-19		05-Nov-2020	24-Nov-2020	20	No	A single-arm substudy of a phase 2/3 clinical trial		Oxford, UK	18-Jun-2021	
#01139	CT_34112899	SARS-CoV-2 serology in 4000 health care and administrative staff across seven sites in Lombardy, Italy	34112899	https://doi.org/10.1038/s41598-021-91773-4	https://pubmed.ncbi.nlm.nih.gov/34112899	3,985	Other			28-Apr-2020	16-May-2020	19	No	Cohort study	Retrospective	Lombardy, Italy	10-Jun-2021	
#01140	CT_34097856	Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial	34097856	https://doi.org/10.1016/S0140-6736(21)01203-4	https://pubmed.ncbi.nlm.nih.gov/34097856	615	Drug(s)	Anticoagulants		24-Jun-2020	26-Feb-2021	248	No	A pragmatic, open-label (with blinded adjudication), multicentre, randomised, controlled trial		São Paulo, Brazil	4-Jun-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01141	CT_34086717	Characterization of dysphagia and laryngeal findings in COVID-19 patients treated in the ICU-An observational clinical study	34086717	https://doi.org/10.1371/journal.pone.0252347	https://pubmed.ncbi.nlm.nih.gov/34086717	25	Other						No	Case series	Prospective	Gothenburg, Sweden	4-Jun-2021	
#01142	CT_34073401	Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon	34073401	https://doi.org/10.3390/v13060989	https://pubmed.ncbi.nlm.nih.gov/34073401	100	Drug(s)	Ivermectin					No	A randomized controlled trial		Lebanon	26-May-2021	
#01143	CT_34069412	COVID-19 Disease Severity and Death in Relation to Vitamin D Status among SARS-CoV-2-Positive UAE Residents	34069412	https://doi.org/10.3390/nu13051714	https://pubmed.ncbi.nlm.nih.gov/34069412	464	Other						No	A multicenter observational study		Dubai	19-May-2021	
#01144	CT_34064175	Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study	34064175	https://doi.org/10.3390/nu13061760	https://pubmed.ncbi.nlm.nih.gov/34064175	537	Drug(s)	Calcifediol		05-Feb-2020	05-May-2020	91	No	Multicenter, open, non-randomized cohort study.	Retrospective	Spain	21-May-2021	
#01145	CT_34045486	Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection	34045486	https://doi.org/10.1038/s41467-021-23469-2	https://pubmed.ncbi.nlm.nih.gov/34045486	86	Plasma			08-Apr-2020	14-Jun-2020	68	No	A randomized trial		The Netherlands	27-May-2021	
#01146	CT_34021229	Corticosteroids for hospitalized patients with mild to critically-ill COVID-19: a multicenter, retrospective, propensity score-matched study	34021229	https://doi.org/10.1038/s41598-021-90246-y	https://pubmed.ncbi.nlm.nih.gov/34021229	236	Drug(s)	Corticosteroids		01-May-2020	30-Jun-2020	61	No	A multicenter, propensity score-matched study	Retrospective	Japan	21-May-2021	
#01147	CT_34006847	Dynamics of neutralizing antibody responses to SARS-CoV-2 in patients with COVID-19: an observational study	34006847	https://doi.org/10.1038/s41392-021-00611-6	https://pubmed.ncbi.nlm.nih.gov/34006847	545	Other						No	Observational, cohort study		Guangzhou, China	18-May-2021	
#01148	CT_34001849	Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial	34001849	https://doi.org/10.1038/s41392-021-00603-6	https://pubmed.ncbi.nlm.nih.gov/34001849	59	Drug(s)	Meplazumab		22-Apr-2020	29-May-2020	38	No	A single-centered, randomized, doubleblinded, placebo-controlled trial		Xi'an, China	17-May-2021	
#01149	CT_33995419	Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation	33995419	https://doi.org/10.3389/fimmu.2021.675678	https://pubmed.ncbi.nlm.nih.gov/33995419	210	Drug(s)	Standard of care + Anakinra | Tocilizumab | Sarilumab		25-Feb-2020	20-May-2020	86	No	Cohort study	Retrospective	Milan, Italy	29-Apr-2021	
#01150	CT_33976287	Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease	33976287	https://doi.org/10.1038/s41598-021-89444-5	https://pubmed.ncbi.nlm.nih.gov/33976287	40	Plasma						No	A randomized, controlled open label pilot study	Prospective	Bahrain	11-May-2021	
#01151	CT_33962573	Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh	33962573	https://doi.org/10.1186/s12879-021-06119-2	https://pubmed.ncbi.nlm.nih.gov/33962573	238	Drug(s)	Baricitinib		01-Jul-2020	01-Oct-2020	93	No	Cohort study	Prospective		7-May-2021	
#01152	CT_33956667	One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19	33956667	https://doi.org/10.1172/JCI149154	https://pubmed.ncbi.nlm.nih.gov/33956667	124	Other						No	Observational study		Milan, Italy	6-May-2021	
#01153	CT_33951374	Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant	33951374	https://doi.org/10.1056/NEJMoa2103055	https://pubmed.ncbi.nlm.nih.gov/33951374	4,387	Vaccine	NVX-CoV2373		17-Aug-2020	25-Nov-2020	101	No	Phase 2a–b randomized trial		South Africa	5-May-2021	
#01154	CT_33928916	Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials	33928916	https://doi.org/10.1097/CM9.0000000000001573	https://pubmed.ncbi.nlm.nih.gov/33928916	560	Vaccine	KCONVAC					No	Phase 1 and phase 2 randomized, double-blind, and placebo-controlled trials	A randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials	China	5-Jun-2021	
#01155	CT_33894725	Efficacy and safety of Reduning injection in the treatment of COVID-19: a randomized, multicenter clinical study	33894725	https://doi.org/10.21037/apm-20-2121	https://pubmed.ncbi.nlm.nih.gov/33894725	157	Drug(s)	Traditional Chinese Medicine (Reduning injection)		06-Feb-2020	23-Mar-2020	47	No	A randomized, open-labeled, multicenter, controlled trial		China	9-Apr-2021	
#01156	CT_33888900	Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study	33888900	https://doi.org/10.1038/s41591-021-01330-9	https://pubmed.ncbi.nlm.nih.gov/33888900	144	Vaccine	BNT162b1 mRNA vaccine		18-Jul-2020	14-Aug-2020	28	No	A randomized, placebo-controlled, double-blind phase 1 study		China	22-Apr-2021	
#01157	CT_33882374	Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients	33882374	https://doi.org/10.1016/j.ejca.2021.03.033	https://pubmed.ncbi.nlm.nih.gov/33882374	39	Other			10-Mar-2020	20-May-2020	72	No	Monocentric trial	Prospective	France	26-Mar-2021	
#01158	CT_33882225	Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19	33882225	https://doi.org/10.1056/NEJMoa2101544	https://pubmed.ncbi.nlm.nih.gov/33882225	39,321	Vaccine	Ad26.COV2.S vaccine		21-Sep-2020	22-Jan-2021	124	No	An international, randomized, double-blind, placebo-controlled, phase 3 trial			21-Apr-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01159	CT_33870923	Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial	33870923	https://doi.org/10.1097/CCM.0000000000005066	https://pubmed.ncbi.nlm.nih.gov/33870923	74	Plasma | Drug(s)						No	A double-blind randomized trial		New York, USA	1-Jul-2021	
#01160	CT_33866000	Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers	33866000	https://doi.org/10.1016/j.ijid.2021.04.047	https://pubmed.ncbi.nlm.nih.gov/33866000	1,245	Other			24-Jan-2021	10-Mar-2021	46	No	A randomized, cross-sectional study		USA	15-Apr-2021	
#01161	CT_34226219	Randomised, controlled, open label, multicentre clinical trial to explore safety and efficacy of hyperbaric oxygen for preventing ICU admission, morbidity and mortality in adult patients with COVID-19	34226219	https://doi.org/10.1136/bmjopen-2020-046738	https://pubmed.ncbi.nlm.nih.gov/34226219	200	Oxygen support						No	A randomised, controlled, phase II, open label, multicentre trial		Sweden	5-Jul-2021	
#01162	CT_34215210	Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled tria	34215210	https://doi.org/10.1186/s12879-021-06348-5	https://pubmed.ncbi.nlm.nih.gov/34215210	501	Drug(s)	Ivermectin		19-Aug-2020	22-Feb-2021	188	No	A randomized, double-blind, placebo-controlled trial		Corrientes, Argentina	2-Jul-2021	
#01163	CT_34202578	Effects of a 2-Week 5000 IU versus 1000 IU Vitamin D3 Supplementation on Recovery of Symptoms in Patients with Mild to Moderate Covid-19: A Randomized Clinical Trial	34202578	https://doi.org/10.3390/nu13072170	https://pubmed.ncbi.nlm.nih.gov/34202578	36	Drug(s)	Vitamin D3		29-Jul-2020	22-Sep-2020	56	No	A multi-center, randomized clinical trial		Riyadh, Saudi Arabia	24-Jun-2021	
#01164	CT_34180719	The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial	34180719	https://doi.org/10.1177/0963689711024942	https://pubmed.ncbi.nlm.nih.gov/34180719	30	Other						No	Double controlled trial	Prospective	Istanbul, Turkey	28-Jun-2021	
#01165	CT_34166410	Diagnostic accuracy of Panbio rapid antigen tests on oropharyngeal swabs for detection of SARS-CoV-2	34166410	https://doi.org/10.1371/journal.pone.0253321	https://pubmed.ncbi.nlm.nih.gov/34166410	402	Other			03-Nov-2020	19-Nov-2020	17	No		Prospective	Geneva, Switzerland	24-Jun-2021	Eight patients were excluded during the study
#01166	CT_34127046	Awake prone positioning in patients with hypoxemic respiratory failure due to COVID-19: the PROFLO multicenter randomized clinical trial	34127046	https://doi.org/10.1186/s13054-021-03602-9	https://pubmed.ncbi.nlm.nih.gov/34127046	75	Other			07-Oct-2020	07-Feb-2021	124	No	A multicenter, open-label, parallel arm, randomized clinical superiority trial		Sweden	14-Jun-2021	
#01167	CT_34225791	Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials	34225791	https://doi.org/10.1186/s40249-021-00878-5	https://pubmed.ncbi.nlm.nih.gov/34225791	73,633							Yes	A systematic review and meta-analysis		Shenzhen, China	5-Jul-2021	
#01168	CT_34207689	Elevated Procalcitonin Is Positively Associated with the Severity of COVID-19: A Meta-Analysis Based on 10 Cohort Studies	34207689	https://doi.org/10.3390/medicina57060594	https://pubmed.ncbi.nlm.nih.gov/34207689	7,716							Yes	A systematic review and meta-analysis		China	9-Jun-2021	
#01169	CT_34244723	Single-dose mRNA vaccine effectiveness against SARS-CoV-2, including Alpha and Gamma variants: a test-negative design in adults 70 years and older in British Columbia, Canada	34244723	https://doi.org/10.1093/cid/ciab616	https://pubmed.ncbi.nlm.nih.gov/34244723	16,993	Vaccine	mRNA vaccine		04-Apr-2021	01-May-2021	28	No	A test-negative study design		British Columbia, Canada	9-Jul-2021	
#01170	CT_34244681	mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar	34244681	https://doi.org/10.1038/s41591-021-01446-y	https://pubmed.ncbi.nlm.nih.gov/34244681	256,037	Vaccine	mRNA-1273 COVID-19 vaccine		01-Feb-2021	10-May-2021	99	No	Cohort study		Qatar	9-Jul-2021	
#01171	CT_34242763	Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-control study	34242763	https://doi.org/10.1016/j.ijid.2021.07.003	https://pubmed.ncbi.nlm.nih.gov/34242763	9,610				29-Apr-2020	29-May-2020	31	No	An observational, case-control study	Retrospective	Pavia, Italy	6-Jul-2021	
#01172	CT_34242245	Clinical and bioethical implications of health care interruption during the COVID-19 pandemic: A cross-sectional study in outpatients with rheumatic diseases	34242245	https://doi.org/10.1371/journal.pone.0253718	https://pubmed.ncbi.nlm.nih.gov/34242245	670	Other			24-Jun-2020	31-Oct-2020	130	No	A cross-sectional study		Mexico City, Mexico	9-Jul-2021	
#01173	CT_34242243	Characteristics of SARS-CoV-2 testing for rapid diagnosis of COVID-19 during the initial stages of a global pandemic	34242243	https://doi.org/10.1371/journal.pone.0253941	https://pubmed.ncbi.nlm.nih.gov/34242243	80,354	Other			11-Jan-2020	22-Apr-2020	103	No	Case analysis		Canada	9-Jul-2021	
#01174	CT_34241774	A cross-section observational study on the seroprevalence of antibodies to COVID-19 in patients receiving opiate agonist treatment	34241774	https://doi.org/10.1007/s11845-021-02660-w	https://pubmed.ncbi.nlm.nih.gov/34241774	103	Other						No	A cross-section observational study	Retrospective	New York, USA	9-Jul-2021	
#01175	CT_34244316	Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial	34244316	https://doi.org/10.1183/13993003.01471-2021	https://pubmed.ncbi.nlm.nih.gov/34244316	160	Plasma						No	An investigator-initiated, randomised, parallel arm, open-label, superiority clinical trial		Porto Alegre, Brazil	8-Jul-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01176	CT_34243955	Clinical features and prognosis of COVID-19 patients with metabolic syndrome: A multicenter, retrospective study	34243955	https://doi.org/10.1016/j.medcli.2021.05.014	https://pubmed.ncbi.nlm.nih.gov/34243955	233	Other			18-Jan-2020	26-Feb-2020	40	No	A multicenter, cohort study	Retrospective	China	17-Jun-2021	
#01177	CT_34243954	Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis	34243954	https://doi.org/10.1016/j.medcli.2021.06.014	https://pubmed.ncbi.nlm.nih.gov/34243954	47	Drug(s)	Tocilizumab					No	Single-center matched cohort analysis	Retrospective	Madrid, Spain	18-Jun-2020	
#01178	CT_34237554	Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials	34237554	https://doi.org/10.1016/j.dsx.2021.102186	https://pubmed.ncbi.nlm.nih.gov/34237554	1,788							Yes	A systematic review, meta-analysis, and meta-regression of randomized controlled trials		Indonesia	27-Jun-2021	
#01179	CT_34236768	Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: a multi-center, open-label, randomized controlled trial: zed controlled trial	34236768	https://doi.org/10.1111/jth.15450	https://pubmed.ncbi.nlm.nih.gov/34236768	176	Drug(s)	Enoxaparin					No	A multi-center, open-label, randomized controlled trial	Prospective	USA	8-Jul-2021	
#01180	CT_34236752	Tissue Factor upregulation is associated with SARS-CoV-2 in the lungs of COVID-19 patients	34236752	https://doi.org/10.1111/jth.15451	https://pubmed.ncbi.nlm.nih.gov/34236752	11	Other						No	Case report		USA	8-Jul-2021	
#01181	CT_34241898	Evaluation of the relationship between macrophage migration inhibitory factor level and clinical course in patients with COVID-19 pneumonia	34241898	https://doi.org/10.1002/jmv.27189	https://pubmed.ncbi.nlm.nih.gov/34241898	110	Other			15-Oct-2020	20-Jan-2021	98	No	Case study		Erzurum, Turkey	9-Jul-2021	
#01182	CT_34242377	Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study	34242377	https://doi.org/10.1371/journal.pone.0254516	https://pubmed.ncbi.nlm.nih.gov/34242377	1,232,867				30-Apr-2020	30-Sep-2020	154	No	A cross-sectional investigationl population-based survey studies	Prospective	Serbia	9-Jul-2021	
#01183	CT_34238341	Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort study	34238341	https://doi.org/10.1186/s12985-021-01617-w	https://pubmed.ncbi.nlm.nih.gov/34238341	403	Drug(s)	Arbidol | Interferon alpha-1b		11-Jan-2020	21-May-2020	132	No	Cohort study	Retrospective	Shenzhen, China	8-Jul-2021	
#01184	CT_34236244	Clinical characteristics, risk factors and cardiac manifestations of cancer patients with COVID-19	34236244	https://doi.org/10.1152/japplphysiol.00325.2021	https://pubmed.ncbi.nlm.nih.gov/34236244	1,244	Other			01-Feb-2020	31-Aug-2020	213	No	A multi-centered, cohort study	Retrospective	Wuhan, China	8-Jul-2021	
#01185	CT_34236141	Serum triglyceride levels and related factors as prognostic indicators in COVID-19 patients: A retrospective study	34236141	https://doi.org/10.1002/iid3.469	https://pubmed.ncbi.nlm.nih.gov/34236141	186	Other			09-Feb-2020	29-Feb-2020	21	No	Case study	Retrospective	Wuhan, China	8-Jul-2021	
#01186	CT_34234102	SARS-CoV-2-specific immune response in COVID-19 convalescent individuals	34234102	https://doi.org/10.1038/s41392-021-00686-1	https://pubmed.ncbi.nlm.nih.gov/34234102	171	Other						No	Cohort study		Wuhan, China	7-Jul-2021	
#01187	CT_34222849	Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial	34222849	https://doi.org/10.1016/j.eclinm.2021.100993	https://pubmed.ncbi.nlm.nih.gov/34222849	60	Drug(s) | Other	Tenofovir		20-Nov-2020	19-Mar-2021	120	No	A pilot randomized, open-label, controlled, phase 2 trial		France	26-Jun-2021	
#01188	CT_34216472	An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status	34216472	https://doi.org/10.1093/cid/ciab608	https://pubmed.ncbi.nlm.nih.gov/34216472	13,109	Vaccine	Pfizer-BioNTech vaccine | Oxford-AstraZeneca vaccine					No	An observational, longitudinal, cohort study		Oxford, UK	3-Jul-2021	
#01189	CT_34216468	Epidemiologic, immunologic, and virus characteristics in patients with paired SARS-CoV-2 serology and reverse transcription polymerase chain reaction testing	34216468	https://doi.org/10.1093/infdis/jiab349	https://pubmed.ncbi.nlm.nih.gov/34216468	592	Other			31-Aug-2020	23-Nov-2020	85	No	Cohort study	Retrospective	Georgia, USA	3-Jul-2021	
#01190	CT_34206645	SARS-CoV-2 Vaccine Willingness among Pregnant and Breastfeeding Women during the First Pandemic Wave: A Cross-Sectional Study in Switzerland	34206645	https://doi.org/10.3390/v13071199	https://pubmed.ncbi.nlm.nih.gov/34206645	2,064	Other			18-Jun-2020	12-Jul-2020	25	No	Swiss cross-sectional online study		Switzerland	22-Jun-2021	
#01191	CT_34192737	Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2	34192737	https://doi.org/10.1038/s41586-021-03739-1	https://pubmed.ncbi.nlm.nih.gov/34192737	140	Vaccine | Other	BNT162b2		14-Dec-2020	10-Feb-2020		No	Cohort study		UK	30-Jun-2021	
#01192	CT_34190148	Epidemiological study on severe acute respiratory syndrome coronavirus 2 virus transmission network in northeast China	34190148	https://doi.org/	https://pubmed.ncbi.nlm.nih.gov/34190148	125	Other						No	Epidemiological study		Jilin, China	2-Jul-2021	
#01193	CT_34135619	Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study	34135619	https://doi.org/10.2147/IJGM.S318720	https://pubmed.ncbi.nlm.nih.gov/34135619	152	Drug(s)	Quercetin					No	A Randomized, controlled, and open-label study	Prospective	Italy	8-Jun-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01194	CT_34100002	Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study	34100002	https://doi.org/10.1016/S2666-5247(21)00090-2	https://pubmed.ncbi.nlm.nih.gov/34100002	48,902	Other			06-Feb-2020	08-Jun-2020	124	No	A large multicentre, cohort study	Prospective	UK	2-Jun-2021	
#01195	CT_34099486	Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals	34099486	https://doi.org/10.1136/annrheumdis-2021-220049	https://pubmed.ncbi.nlm.nih.gov/34099486	522	Drug(s)	Janus kinase inhibitors (Baricitinib | Tofactinib)					No	Observational case series	Prospective	Moscow, Russian	10-May-2021	
#01196	CT_34125067	Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort	34125067	https://doi.org/10.1016/j.cmi.2021.03.012	https://pubmed.ncbi.nlm.nih.gov/34125067	1,137	Other			24-Jan-2020	10-Apr-2020	78	No	Cohort study	Prospective	France	10-May-2021	
#01197	CT_34107889	Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort study of SARS-CoV-2 infection and vaccination in healthcare workers	34107889	https://doi.org/10.1186/s12879-021-06233-1	https://pubmed.ncbi.nlm.nih.gov/34107889	300	Other						No	An observational, longitudinal, cohort study	Prospective	USA	9-Jun-2021	
#01198	CT_34056568	A population-based analysis of the longevity of SARS-CoV-2 antibody seropositivity in the United States	34056568	https://doi.org/10.1016/j.eclinm.2021.100902	https://pubmed.ncbi.nlm.nih.gov/34056568	39,086	Other						No	A population-based cross-sectional study		USA	24-May-2021	
#01199	CT_34020680	Intravenous immunoglobulin-based adjuvant therapy for severe COVID-19: a single-center retrospective cohort study	34020680	https://doi.org/10.1186/s12985-021-01575-3	https://pubmed.ncbi.nlm.nih.gov/34020680	113	IVIG			28-Jan-2020	25-Feb-2020	29	No	Single-center, cohort study	Retrospective	China	21-May-2021	
#01200	CT_34011059	A retrospective analysis of 12,400 SARS-CoV-2 RNA tests in patients with COVID-19 in Wuhan	34011059	https://doi.org/10.1097/MD.0000000000025916	https://pubmed.ncbi.nlm.nih.gov/34011059	6,913	Other			23-Jan-2020	03-Mar-2020	41	No	Case analysis	Retrospective	Wuhan, China	21-May-2021	
#01201	CT_34677154	Prediction of diagnosis and prognosis of COVID-19 disease by blood gas parameters using decision trees machine learning model: a retrospective observational study	34677154	https://doi.org/10.4103/2045-9912.326002	https://pubmed.ncbi.nlm.nih.gov/34677154	686				01-May-2020	01-Mar-2021	305	No	Observational study	Retrospective	Erzincan, Turkey	19-Oct-2021	
#01202	CT_34782291	Meta-analysis on the effect of combining Lianhua Qingwen with Western medicine to treat coronavirus disease 2019	34782291	https://doi.org/10.1016/j.joim.2021.10.005	https://pubmed.ncbi.nlm.nih.gov/34782291	856	Other		Combination therapy group vs single medication group respectively; -Rate of recovery from fever: 85.5% and 62.5% -Rate of recovery from cough: 56.6% and 27.9% -Recovery from shortness of breath: 68.2% and 15.4% -Rate of recovery from fatigue: 68.7% and 42.8% -Incidence of adverse reactions: 21.3% and 26.6% -Total effectiveness rate: 85.4% and 70.6%	01-Dec-2019	14-Jul-2020	227	Yes	Randomized controlled trials	Retrospective	China	2-Nov-2021	
#01203	CT_34782234	Efficacy of Bivalirudin for Therapeutic Anticoagulation in COVID-19 Patients Requiring ECMO Support	34782234	https://doi.org/10.1053/j.jvca.2021.10.026	https://pubmed.ncbi.nlm.nih.gov/34782234	42	Drug(s) | Oxygen support	Bivalirudin	Percentages of goal therapeutic aPTTs were maintained in patients with COVID-19 vs non-COVID 86%, 74% respectively	17-Jun-2019	17-Jun-2020	367	No	Case-control study	Retrospective	Indianapolis, Indiana, USA	20-Oct-2021	
#01204	CT_34782209	Convalescent Plasma for Patients Hospitalized With Coronavirus Disease 2019: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials	34782209	https://doi.org/10.1016/j.pcd.2021.10.004	https://pubmed.ncbi.nlm.nih.gov/34782209	16,608	Plasma		The study suggests the lack of benefit of CP in hospitalized COVID-19 patients	01-Dec-2019	01-Aug-2021	610	Yes	Randomized controlled trials		Singapore	10-Oct-2021	
#01205	CT_34782169	Nutritional management and clinical outcome of critically ill patients with COVID-19: A retrospective study in a tertiary hospital	34782169	https://doi.org/10.1016/j.clnu.2021.10.020	https://pubmed.ncbi.nlm.nih.gov/34782169	176	Other			01-Mar-2020	05-May-2020	66	No	Retrospective cohort study	Retrospective	Madrid, Spain	1-Nov-2021	
#01206	CT_34781984	Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19	34781984	https://doi.org/10.1186/s12959-021-00337-z	https://pubmed.ncbi.nlm.nih.gov/34781984	18	Drug(s)	Enoxaparin	The study supports intermediate-dose enoxaparin for critically ill COVID-19 patients to achieve accepted anti-FXa levels	31-Mar-2020	16-Nov-2020	231	No	Cohort study, brief report	Retrospective	Liverpool, UK	15-Nov-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01207	CT_34781981	Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial	34781981	https://doi.org/10.1186/s13063-021-05758-9	https://pubmed.ncbi.nlm.nih.gov/34781981	269	Drug(s)	Hydroxychloroquine	This trial recommends administering 400 mg of hydroxychloroquine during 4 consecutive days followed by 400 mg weekly in adults during a month				No	Multicentre, double-blind, placebo-controlled, randomized controlled study		Barcelona, Spain	15-Nov-2021	Study period: 6 months
#01208	CT_34784386	Sampling site for SARS-CoV-2 RT-PCR-An intrapatient four-site comparison from Tampere, Finland	34784386	https://doi.org/10.1371/journal.pone.0260184	https://pubmed.ncbi.nlm.nih.gov/34784386	43	Other		No significant difference in the cycle threshold values of nasopharyngeal and anterior nasal samples while saliva and oropharynx had higher cycle threshold values, the study suggests anterior nasal swabs for SARS-CoV-2 detection instead of nasopharyngeal swabs	15-Jan-2021	25-Mar-2021	70	No		Prospective	Tampere, Finland	16-Nov-2021	
#01209	CT_34783656	Efficacy of FFP3 respirators for prevention of SARS-CoV-2 infection in healthcare workers	34783656	https://doi.org/10.7554/eLife.71131	https://pubmed.ncbi.nlm.nih.gov/34783656	609	Other		changing to FFP3 respirators reduced the risk significantly (52-100% protection)	02-Nov-2020	11-Jan-2021	71	No	Observational study		UK	16-Nov-2021	
#01210	CT_34783630	Co-infections and antimicrobial use among hospitalized COVID-19 patients in Punjab, Pakistan: findings from a multicenter, point prevalence survey	34783630	https://doi.org/10.1080/20477724.2021.1999716	https://pubmed.ncbi.nlm.nih.gov/34783630	617	Drug(s)	Azithromycin | Ceftriaxone | Meropenem	85.4% antibiotics were recorded as being prescribed for 'prophylaxis				No	Multicenter, point prevalence survey		Punjab, Pakistan	16-Nov-2021	
#01211	CT_34783405	Hematological changes associated with COVID-19 infection	34783405	https://doi.org/10.1002/jcla.24064	https://pubmed.ncbi.nlm.nih.gov/34783405	714,406	Other		Critically ill patients and those with cytokine storm, neutrophilia, lymphocytopenia, elevated D-dimer, prolonged PT, and reduced fibrinogen are predictors of disease progression and adverse outcome				Yes	Meta analysis and Systematic review		Iraq	16-Nov-2021	Study conducted between December 2019 to January 2021
#01212	CT_34783218	Maternal and Neonatal Outcomes of Critically Ill Pregnant and Puerperal Patients Diagnosed with COVID-19 Disease: Retrospective Comparative Study	34783218	https://doi.org/10.3346/jkms.2021.36.e309	https://pubmed.ncbi.nlm.nih.gov/34783218	19	Other		11 patients were discharged from the ICU, 8 patients have died due to complications of COVID-19, 17 patients underwent cesarean-section (C/S), 11 preterm and 8 term deliveries, the rate of neonatal death was low and no neonatal COVID-19 occurred.				No	Single-center, observational, comparative study	Retrospective	Sakarya, Turkey	15-Nov-2021	Study carried out between March 2020 and August 2021
#01213	CT_34783049	Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers	34783049	https://doi.org/10.1002/jmv.27458	https://pubmed.ncbi.nlm.nih.gov/34783049	185	Vaccine		21 days apart 2-dose CoronaVac regimen was safe, antibody responses after two doses were comparable to the convalescent plasma but waned after 3 months				No	Cohort study	Prospective	Samut Sakhon, Thailand	15-Nov-2021	Study conducted between March and April 2021
#01214	CT_34782921	Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin	34782921	https://doi.org/10.1007/s00392-021-01970-4	https://pubmed.ncbi.nlm.nih.gov/34782921	213	Other		Raised copeptin and hs-cTnI upon admission is an independent predictor of ICU admission or 28-day mortality in hospitalized COVID-19 patients	06-Jun-2020	26-Nov-2020	174	No	Observational study	Prospective	Vienna, Austria	15-Nov-2021	
#01215	CT_34782484	External validation of the QCovid risk prediction algorithm for risk of COVID-19 hospitalisation and mortality in adults: national validation cohort study in Scotland	34782484	https://doi.org/10.1136/thoraxjnl-2021-217580	https://pubmed.ncbi.nlm.nih.gov/34782484	5,384,819	Other		Version 1 of the QCovid algorithm showed high levels of discrimination in predicting the risk of COVID-19 hospitalisations and deaths				No	Cohort study	Prospective	Scotland	15-Nov-2021	Dataset carried out for two time periods matching the original study: 1 March 2020 to 30 April 2020, and 1 May 2020 to 30 June 2020
#01216	CT_34782447	Characteristics, Comorbidities, and Outcomes of SARS-CoV-2 Infection in Patients with Autoimmune Conditions Treated with Systemic Therapies: a Population-based Study	34782447	https://doi.org/10.3899/jrheum.210888	https://pubmed.ncbi.nlm.nih.gov/34782447	315,101	Drug(s)	Tofacitinib	RA patients were at a higher risk of more severe COVID-19 for non-TNFi biologics	01-Feb-2020	09-Dec-2020	313	No	Descriptive, cohort study	Retrospective	USA	15-Nov-2021	
#01217	CT_34782400	Endovascular treatment for vaccine-induced cerebral venous sinus thrombosis and thrombocytopenia following ChAdOx1 nCoV-19 vaccination: a report of three cases	34782400	https://doi.org/10.1136/neurintsurg-2021-018238	https://pubmed.ncbi.nlm.nih.gov/34782400	3	Drug(s) | Other	Low Mwt Heparin | Argatroban | Apixaban		01-Jan-2021	20-Jul-2021	201	No	Case Report		Bristol, UK	15-Nov-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01218	CT_34782352	Acute-to-Chronic Glycemic Ratio as a Predictor of COVID-19 Severity and Mortality	34782352	https://doi.org/10.2337/dc21-1321	https://pubmed.ncbi.nlm.nih.gov/34782352	91	Other						No	Single-centered, observational cohort study		Barcelona, Spain	15-Nov-2021	Study carried out between March and April 2020
#01219	CT_34781943	Suppression of the hypothalamic-pituitary-thyroid axis is associated with the severity of prognosis in hospitalized patients with COVID-19	34781943	https://doi.org/10.1186/s12902-021-00896-2	https://pubmed.ncbi.nlm.nih.gov/34781943	235	Other			22-Jan-2020	17-Mar-2020	56	No	Observational study	Retrospective	Wuhan, China	15-Nov-2021	
#01220	CT_34796450	A retrospective cohort study of outcomes in hospitalised COVID-19 patients during the first pandemic wave in Ireland	34796450	https://doi.org/10.1007/s11845-021-02753-6	https://pubmed.ncbi.nlm.nih.gov/34796450	4,086	Other		12.8% of patients had ICU admission and 16.6% died	29-Feb-2020	31-Jul-2020	154	No	Cohort study	Retrospective	Ireland	19-Nov-2021	
#01221	CT_34796652	Some characteristics of clinical sequelae of COVID-19 survivors from Wuhan, China: A multi-center longitudinal study	34796652	https://doi.org/10.1111/irv.12943	https://pubmed.ncbi.nlm.nih.gov/34796652	715	Other		The median time interval from discharge to telephone interview was225.0 days. 19.2%, 22.7%, and 5.0% of the survivors reporting fatigue, respiratory symptoms,and cardiovascular symptoms, respectively	01-Oct-2020	01-Nov-2020	32	No	A multi-center longitudinal questionnaire-based study		Wuhan, China	19-Nov-2021	The interval time from patients discharge to the telephone follow-up initiation was more than 6 months.
#01222	CT_34796276	Serial interval of COVID-19 and the effect of Variant B.1.1.7: analyses from prospective community cohort study (Virus Watch)	34796276	https://doi.org/10.12688/wellcomeopenres.16974.1	https://pubmed.ncbi.nlm.nih.gov/34796276	24,887	Other		No evidence that B.1.1.7 variant is associated with a change in serial intervals	09-Mar-2020	22-Feb-2022	351	No	Community cohort study	Prospective	UK	9-Sep-2021	
#01223	CT_34796247	SARS-CoV-2 Blood RNA Load Predicts Outcome in Critically Ill COVID-19 Patients	34796247	https://doi.org/10.1093/ofid/ofab509	https://pubmed.ncbi.nlm.nih.gov/34796247	170	Drug(s)	Dexamethasone | Remdesivir					No	Cohort Study		Hamburg, Germany	6-Oct-2021	All patients (n=170) were hospitalized between March 2020 and March 2021
#01224	CT_34796244	Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection	34796244	https://doi.org/	https://pubmed.ncbi.nlm.nih.gov/34796244	3,349	Drug(s)	Ivermectin	Ivermectin displayed a borderline significant effect on duration of hospitalization in comparison with standard of care				Yes	Meta-analysis of Randomized Trials		UK	6-Jul-2021	
#01225	CT_34796130	Association of ABO and Rh Blood Group in Susceptibility, Severity, and Mortality of Coronavirus Disease 2019: A Hospital-Based Study From Delhi, India	34796130	https://doi.org/10.3389/fcimb.2021.767771	https://pubmed.ncbi.nlm.nih.gov/34796130	2,586	Other		Blood groups A, B, and Rh+ are more susceptible to COVID-19 infection, where blood groups O, AB, and Rh- are at a lower risk	08-Apr-2020	04-Oct-2020	180	No	Single-center, retrospective study	Retrospective	New Delhi, India	2-Nov-2021	
#01226	CT_34796000	COVID-19 in Patients with Diabetes: Clinical Course, Metabolic Status, Inflammation, and Coagulation Disorder	34796000	https://doi.org/10.17691/stm2020.12.5.01	https://pubmed.ncbi.nlm.nih.gov/34796000	64	Other		COVID-19 patients with DM is showed high severity, decreased oxygen supply, high hyperglycemia, accelerated renal dysfunction, systemic inflammation, and hypercoagulability	19-May-2020	21-Jun-2020	34	No	Cross-sectional comparative study	Prospective	Nizhny Novgorod, Russia	28-Oct-2021	
#01227	CT_34795939	Extracorporeal membrane oxygenation in patients with COVID-19: 1-year experience	34795939	https://doi.org/10.21037/jtd-21-971	https://pubmed.ncbi.nlm.nih.gov/34795939	39	Oxygen support						No	Single-center study	Retrospective	Aachen, Germany	30-Oct-2021	Data were collected at two time points (September 1, 2020 and March 21, 2021). Patients admitted to the hospital after September 1, 2020 were assigned to the second epidemic wave
#01228	CT_34795818	Frequency and factors associated with proteinuria in COVID-19 patients: a cross-sectional study	34795818	https://doi.org/10.11604/pamj.2021.40.37.29796	https://pubmed.ncbi.nlm.nih.gov/34795818	80	Other		Proteinuria is common in COVID-19 patients and is associated with age, diabetes, ferritin and ASAT	10-Mar-2020	10-Jul-2020	123	No	Cross-sectional study	Retrospective	Kinshasa, Democratic Republic of the Congo	14-Sep-2021	
#01229	CT_34795668	Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4 + T-Cell Responses	34795668	https://doi.org/10.3389/fimmu.2021.750448	https://pubmed.ncbi.nlm.nih.gov/34795668	314	Other			17-Mar-2020	29-Jan-2021	319	No	Longitudinal Study		Gothenburg, Sweden	2-Nov-2021	
#01230	CT_34795637	Blood Hemoglobin Substantially Modulates the Impact of Gender, Morbid Obesity, and Hyperglycemia on COVID-19 Death Risk: A Multicenter Study in Italy and Spain	34795637	https://doi.org/10.3389/fendo.2021.741248	https://pubmed.ncbi.nlm.nih.gov/34795637	5,345	Other		Patients with severe hyperglycemia and hemoglobin concentrations above the median had 30 times increased mortality risk	28-Feb-2020	30-Jun-2020	124	No	Multicenter, cohort Study		(Bologna and Rome) Italy and (Barcelona and Girona) Spain	2-Nov-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01231	CT_34796762	Coagulation profile and correlation between D-dimer, inflammatory markers, and COVID-19 severity in an Indonesian national referral hospital	34796762	https://doi.org/10.1177/03000605211059939	https://pubmed.ncbi.nlm.nih.gov/34796762	194	Other		Combination of CRP ≥72.65 mg/L and D-dimer ≥1250 µg/L used as marker of COVID-19 severity, with moderate accuracy				No	Cross-sectional study	Retrospective	Jakarta, Indonesia	19-Nov-2021	Study conducted at Jakarta fromMay 2020 to November 2020
#01232	CT_34796674	Epidemiology of SARS-CoV-2 infection and SARS-CoV-2 positive hospital admissions among children in South Africa	34796674	https://doi.org/10.1111/irv.12916	https://pubmed.ncbi.nlm.nih.gov/34796674	3,548,738	Other			28-Jan-2020	19-Sep-2020	236	No			Johannesburg, South Africa	18-Nov-2021	
#01233	CT_34800742	Prevalence and factors associated with symptom persistence: a prospective study of 429 mild COVID-19 outpatients	34800742	https://doi.org/10.1016/j.idnow.2021.11.003	https://pubmed.ncbi.nlm.nih.gov/34800742	429	Other		Symptoms persisted over one month in up to 44% of outpatients, most had recovered at two months.	10-Mar-2020	18-May-2020	70	No	Prospective cohort study	Prospective	Paris, France	17-Nov-2021	
#01234	CT_34800687	Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis	34800687	https://doi.org/10.1016/j.ijid.2021.11.009	https://pubmed.ncbi.nlm.nih.gov/34800687	38,821,141	Vaccine			06-Aug-2020	06-Oct-2021	427	Yes	Systematic Review and Meta-Analysis			17-Nov-2021	In total, 50 articles and 1 report were included from 14 countries including 38821141 individuals
#01235	CT_34800562	The extent of neuroradiological findings in COVID-19 shows correlation with blood biomarkers, Glasgow Coma Scale score and days in intensive care	34800562	https://doi.org/10.1016/j.neurad.2021.11.003	https://pubmed.ncbi.nlm.nih.gov/34800562	19	Other		Total intraclass correlation was 0.80				No	Prospective , single-centre cohort study	Prospective	Sweden	18-Nov-2021	Patients included from April until July 2020
#01236	CT_34800427	Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	34800427	https://doi.org/10.1016/S0140-6736(21)01825-0	https://pubmed.ncbi.nlm.nih.gov/34800427	22,560	Drug(s)	Aspirin	Patients allocated to aspirin had a slightly shorter hospitalisation, and a higher discharge from hospital alive within 28 days	01-Nov-2020	21-Mar-2021	141	No	Randomized, controlled trial	Prospective		17-Nov-2021	The trial took place at 177 hospitals in the UK, two hospitals in Indonesia, and two hospitals in Nepal
#01237	CT_34800364	Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial	34800364	https://doi.org/10.1016/S2213-2600(21)00409-4	https://pubmed.ncbi.nlm.nih.gov/34800364	15,187	Vaccine		NVX-CoV2373 vaccine efficacy in the substudy vs main study was 87.5% and 89.8%, respectively	28-Sep-2020	28-Nov-2020	62	No	Randomized, controlled trial	Prospective	UK	17-Nov-2021	
#01238	CT_34813414	Prostacyclin in Mechanically Ventilated Patients with COVID-19 and Severe Endotheliopathy: A Multicenter, Randomized, Clinical Trial	34813414	https://doi.org/10.1164/rccm.202108-1855OC	https://pubmed.ncbi.nlm.nih.gov/34813414	80	Drug(s)	Prostacyclin	Number of days alive without mechanical ventilation at 28-days was 16 vs 5 days, and 28-day mortality was 21.9% vs 43.6% in prostacyclin and placebo groups, respectively	15-Jun-2020	25-Jan-2021	225	No	Multicenter randomized controlled trial	Prospective	Copenhagen, Denmark	23-Nov-2021	
#01239	CT_34813629	Intestinal Collinsella may mitigate infection and exacerbation of COVID-19 by producing ursodeoxycholate	34813629	https://doi.org/10.1371/journal.pone.0260451	https://pubmed.ncbi.nlm.nih.gov/34813629	953	Other		The average relative abundances of Collinsella were decreased form enterotypes1 to 5 except for enterotype 2 In five enterotypes in ten countries, high Collinsella was predictive of low mortalityrates of COVID-19				No			Japan	23-Nov-2021	Data were analyzed using a machine-learning GLM to predict COVID-19 mortality rates with gut micro-biota in 953 healthy subjects in ten countries
#01240	CT_34813596	Detection of cross-reactive immunoglobulin A against the severe acute respiratory syndrome-coronavirus-2 spike 1 subunit in saliva	34813596	https://doi.org/10.1371/journal.pone.0249979	https://pubmed.ncbi.nlm.nih.gov/34813596	137	Other		Study identified SARS-CoV-2 cross-reactive IgA spike protein in saliva from individuals who did not have COVID-19. Elderly showed lower SARS--CoV-2 spike protein-CRsA than younger participants. Salivary IgA might block the binding of ACE-2 to the spike protein				No			Kanagawa, Japan	23-Nov-2021	samples were collected using Salivettes in August 2020
#01241	CT_34813037	Prior Bariatric Surgery is Associated with a Reduced Risk of Poor Outcomes in COVID-19: Propensity Matched Analysis of a Large Multi-institutional Research Network	34813037	https://doi.org/10.1007/s11695-021-05803-1	https://pubmed.ncbi.nlm.nih.gov/34813037	981,921	Surgery		Significant differences in patient demographics and co-morbidities between the BS and non-BS groups	20-Jan-2020	30-Apr-2021	467	No	Cohort study	Retrospective	USA	23-Nov-2021	
#01242	CT_34813010	Development and validation of a prediction model for estimating one-month mortality of adult COVID-19 patients presenting at emergency department with suspected pneumonia: a multicenter analysis	34813010	https://doi.org/10.1007/s11739-021-02882-x	https://pubmed.ncbi.nlm.nih.gov/34813010	1,678	Other						No	Cohort study	Retrospective	TX, USA	23-Nov-2021	Adult COVID-19 patients who were diagnosed with suspected pneumonia were included between March and November 2020

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01243	CT_34812944	**12-month SARS-CoV-2 antibody persistency in a Tyrolean COVID-19 cohort**	34812944	https://doi.org/10.1007/s00508-021-01985-x	https://pubmed.ncbi.nlm.nih.gov/34812944	29	Other		Antibody response persists against SARS-CoV-2 up to 12 months with declining concentrations except for RBD, and strong increase of all antibody concentrations after vaccination				No	Cohort study	Prospective	Innsbruck, Austria	23-Nov-2021	All cases occurred in March and April 2020 and had a positive SARS-CoV-2 antibody test
#01244	CT_34812848	**Analysis of COVID-19 Infection and Mortality Among Patients With Psychiatric Disorders, 2020**	34812848	https://doi.org/10.1001/jamanetworkopen.2021.34969	https://pubmed.ncbi.nlm.nih.gov/34812848	2,535,098	Other		The present study found that patients with schizophrenia had much increased odds of mortality by COVID-19				No	Observational cross-sectional cohort study	Retrospective	TX, USA	1-Nov-2021	The data set comprised a cohort of individuals who received a laboratory test for COVID-19 between February and December 2020
#01245	CT_34812846	**Variation in COVID-19 Mortality in the US by Race and Ethnicity and Educational Attainment**	34812846	https://doi.org/10.1001/jamanetworkopen.2021.35967	https://pubmed.ncbi.nlm.nih.gov/34812846	219,100,000	Other						No	Population-based, cross-sectional study		USA	1-Nov-2021	The data set is based on reporting by the 50 US states and the District of Columbia for the full calendar year 2020 and reported to US Centers for Disease Controland Prevention (CDC) by February 24, 2021
#01246	CT_34812845	**Seroprevalence of SARS-CoV-2 Antibodies Among Children in School and Day Care in Montreal, Canada**	34812845	https://doi.org/10.1001/jamanetworkopen.2021.35975	https://pubmed.ncbi.nlm.nih.gov/34812845	1,632	Other		The findings suggest that there was more transmission occurring in children compared with what was being detected by RT-PCR	22-Oct-2020	22-Mar-2021	152	No	Cohort study		Montreal, Canada	1-Nov-2021	
#01247	CT_34812731	**Ten months of temporal variation in the clinical journey of hospitalised patients with COVID-19: an observational cohort**	34812731	https://doi.org/10.7554/eLife.70970	https://pubmed.ncbi.nlm.nih.gov/34812731	142,540	Other			26-Jan-2020	07-Apr-2021	438	No	Observational cohort study	prospective		23-Nov-2021	complete dataset consisted of 142,540 patients admitted at 620 sites in 47 countries
#01248	CT_34812498	**New onset of smell and taste loss are common findings also in patients with symptomatic COVID-19 after complete vaccination**	34812498	https://doi.org/10.1002/lary.29964	https://pubmed.ncbi.nlm.nih.gov/34812498	153	Vaccine		Vaccination was performed with Pfizer/BioNTech (106 cases), AstraZeneca (32 cases) Moderna (12 cases) or Johnson & Johnson (3 cases) vaccines				No			Europe	23-Nov-2021	Demographic, epidemiological and clinical data were collected through medical records and online patient-reported outcome questionnaire in August and September 2021 across Europe.
#01249	CT_34812429	**Reduced antibody activity against SARS-CoV-2 B.1.617.2 Delta virus in serum of mRNA-vaccinated patients receiving Tumor Necrosis Factor-α inhibitors**	34812429	https://doi.org/10.1016/j.medj.2021.11.004	https://pubmed.ncbi.nlm.nih.gov/34812429	77	Drugs	TNF-α inhibitors | antimetabolites |antimalarial agents | anti-integrin inhibitors | NSAIDs | anti-IL-23 inhibitor | BCDT | BTKi | Nrf2 activator | SSZ | systemic steroids | anti-BLyS | S1PR mod	Longitudinal analysis showed the greatest reductions in neutralizing antibodies and Fc effector functions capacity in individuals treated with TNF-α inhibitors (TNFi). However, TNFi-treated patients receiving a third mRNA vaccine dose boosted their serum neutralizing antibody titers by more than 16-fold				No	Cohort study		Missouri, USA	18-Nov-2021	
#01250	CT_34812424	**Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial**	34812424	https://doi.org/10.1016/S2665-9913(21)00315-5	https://pubmed.ncbi.nlm.nih.gov/34812424	144	Drug(s)	Sarilumab | Remdesivir | Glucocorticoids | Anticoagulants | Tocilizumab	Sarilumab treatment did not improve early outcomes in patients with moderate-to-severe COVID-19 pneumonia	27-Mar-2020	06-Apr-2020	11	No	Open-label, randomised, controlled trial	Prospective	France	17-Nov-2021	
#01251	CT_34819555	**Usefulness of lung ultrasound for selecting asymptomatic older patients with COVID 19 pneumonia**	34819555	https://doi.org/10.1038/s41598-021-02275-2	https://pubmed.ncbi.nlm.nih.gov/34819555	110	Other		Signs of acute interstitial injury were detected by lung ultrasound in more than two-thirds of older asymptomatic patients. Moreover, mortality rate progressively raised with the increasing degree of interstitial pulmonary involvement, especially in pre-frail and frail patients.	10-Apr-2020	12-Dec-2020	247	No	Bicentric cohort study	Prospective	Italy	24-Nov-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01252	CT_34819514	Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals	34819514	https://doi.org/10.1038/s41598-021-01930-y	https://pubmed.ncbi.nlm.nih.gov/34819514	225	Vaccine						No	Observational study	Prospective	Japan	24-Nov-2021	
#01253	CT_34819387	Three-month and six-month outcomes of patients with COVID-19 associated hyperinflammation treated with short-term immunosuppressive therapy: follow-up of the CHIC study	34819387	https://doi.org/10.1136/rmdopen-2021-001906	https://pubmed.ncbi.nlm.nih.gov/34819387	118	Drug(s) | Oxygen support	Methylprednisolone | Tocilizumab | Oxygen support | Antibiotics | Chloroquine | Anticoagulation		01-Mar-2020	17-May-2020	78	No	Cohort study	Prospective	Heerlen, The Netherlands	24-Nov-2021	
#01254	CT_34819384	COVID-19 hospital activity and in-hospital mortality during the first and second waves of the pandemic in England: an observational study	34819384	https://doi.org/10.1136/thoraxjnl-2021-218025	https://pubmed.ncbi.nlm.nih.gov/34819384	374,244	Other		Mortality rates fell from 40%-50% in March 2020 to 11% in August 2020 before rising to 21% in January 2021 and declining steadily to March 2021	01-Mar-2020	31-Mar-2021	396	No	Observational study	Retrospective	London, UK	24-Nov-2021	The first wave was defined as discharges between 1 March 2020 and 31 August 2020 and the second wave as discharges between 1 September 2020 and 31 March 2021.
#01255	CT_34819329	Effect of PEP flute self-care versus usual care in early covid-19: non-drug, open label, randomised controlled trial in a Danish community setting	34819329	https://doi.org/10.1136/bmj-2021-066952	https://pubmed.ncbi.nlm.nih.gov/34819329	378	Oxygen support		PEP flute self-care had a significant, yet marginal and uncertain clinical effect on respiratory symptom severity, as measured by CAT scores	06-Oct-2020	26-Feb-2021	144	No	Randomized controlled trial	Prospective	Denmark	24-Nov-2021	
#01256	CT_: 34819290	Seroprevalence of anti-SARS-CoV-2 antibodies in women attending antenatal care in eastern Ethiopia: a facility-based surveillance	: 34819290	https://doi.org/10.1136/bmjopen-2021-055834	https://pubmed.ncbi.nlm.nih.gov/: 34819290	1,447	Other		Among1447 sera tested, 83 were positive for anti-SARS-CoV-2 antibodies	01-Apr-2020	31-Mar-2021	365	No			Harar, Ethiopia	24-Nov-2021	
#01257	CT_34819271	Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease	34819271	https://doi.org/10.1136/annrheumdis-2021-221554	https://pubmed.ncbi.nlm.nih.gov/34819271	66	Vaccine | Drugs	Rituximab	Seroconversion (78.8% vs 18.2%) and neutralising activity (80.0% vs 21.9%) was higher in non-RTX than RTX-treated patients with IMID, respectively				No	Observational cohort study	Prospective	Erlangen, Germany	24-Nov-2021	
#01258	CT_34819200	Validation of a COVID-19 self-assessment tool for the prediction of COVID-19 in a primary health care setting in Egypt	34819200	https://doi.org/10.1017/S1463423621000736	https://pubmed.ncbi.nlm.nih.gov/34819200	818	Other						No	Cohort study		Alexandria, Egypt	25-Nov-2021	Study was conducted at a PHC clinic in Alexandria between February and July 2020
#01259	CT_34819146	Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021	34819146	https://doi.org/10.1186/s13690-021-00741-x	https://pubmed.ncbi.nlm.nih.gov/34819146	1,639	Vaccine		The most commonly reported adverse events were injection site pain (91.0%), asthenia (74.3%), headache (68.7%), soreness (55.0%), and fever (47.5%).	13-Mar-2021	19-Mar-2021	7	No	Cross-sectional study		Lomé, Togo	24-Nov-2021	
#01260	CT_34819094	Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis	34819094	https://doi.org/10.1186/s12959-021-00343-1	https://pubmed.ncbi.nlm.nih.gov/34819094	28,055	Drug(s)	Anticoagulation drugs	Pooled analysis demonstrated that intermediate-to-therapeutic anticoagulation was not associated with lower in-hospital mortality and lower incidence of thrombotic events, but increased the risk of any bleeding events significantly versus prophylactic anticoagulation				Yes	Systemic review and Meta-analysis			24-Nov-2021	Review searched studies available from database inception to August 10th 2021, and included 42 studies.
#01261	CT_34818923	Oral booster probiotic bifidobacteria in SARS-COV-2 patients	34818923	https://doi.org/10.1177/20587384211059677	https://pubmed.ncbi.nlm.nih.gov/34818923	44	Probiotic		(19 / 44) patients who were administrated with oral booster-single strain probiotic were discharged with median inpatient day of 7.6 days which were significantly shorter than those without probiotic	01-Nov-2020	15-Jan-2021	76	No	Single-centered study	Retrospective	Istanbul, Turkey	25-Nov-2021	
#01262	CT_34817840	Early Transfusion of Convalescent Plasma Improves the Clinical Outcome in Severe SARS-CoV2 Infection	34817840	https://doi.org/10.1007/s40121-021-00514-7	https://pubmed.ncbi.nlm.nih.gov/34817840	267	Plasma (CCP therapy)		CCP transfusion caused a significant reduction in the overall inflammatory status of the patients, as evidenced by decreasing C-reactive protein, IL6 and ferritin levels				No	Interventional cohort study	Prospective	Budapest, Hungary	24-Nov-2021	patients hospitalized between April2020 and February 2021
#01263	CT_34817811	Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2	34817811	https://doi.org/10.1007/s12098-021-03954-8	https://pubmed.ncbi.nlm.nih.gov/34817811	65	Drug(s)	Methylprednisolone | Oxygen support | Mechanical ventilation | IV immunoglobulin					No	Cohort study		Tamil Nadu, India	24-Nov-2021	Study performed between July and October 2020

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01264	CT_34817562	Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry	34817562	https://doi.org/10.1001/jamaoncol.2021.6199	https://pubmed.ncbi.nlm.nih.gov/34817562	2,634	Anticancer therapy | Anti-COVID-19 therapy		Patients diagnosed in the first outbreak had an increased risk of death at 14 days compared to the second outbreak	27-Feb-2020	14-Feb-2021	354	No	Multi-centered, case series study	Prospective	UK, Italy, Spain, France, Belgium, and Germany	24-Nov-2021	
#01265	CT_34837648	Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial	34837648	https://doi.org/10.1007/s43440-021-00341-0	https://pubmed.ncbi.nlm.nih.gov/34837648	133	Drug(s)	Dexamethasone	Higher doses of dexamethasone failed to improve and increased the number of adverse events and worsen survival in hospitalized patients	26-Oct-2020	25-Jan-2021	92	No	Randomized-controlled Trial	Prospective	Tehran, Iran	27-Nov-2021	
#01266	CT_34837446	Clinical characteristics and hematological parameters associated with disease severity in COVID-19 positive pregnant women undergoing cesarean section: A single-center experience	34837446	https://doi.org/10.1111/jog.15108	https://pubmed.ncbi.nlm.nih.gov/34837446	110	Other		LDH values at admission are an early and powerful predictor of severe infection for pregnant women with COVID-19 undergoing a cesarean section	01-Apr-2020	01-Jun-2021	427	No	Cohort study	Retrospective	Adana, Turkey	27-Nov-2021	
#01267	CT_34837305	Chlorhexidine mouthwash reduces the salivary viral load of SARS-CoV-2: a randomized clinical trial	34837305	https://doi.org/10.1111/odi.14086	https://pubmed.ncbi.nlm.nih.gov/34837305	100	Drug(s)	Chlorhexidine	Reduction in the load of SARS-CoV-2 in 72% of the test group using chlorhexidine vs 30% in the control group	18-Dec-2020	31-Jan-2021	45	No	Randomized, double-blind, placebo-controlled trial	Prospective	Salvador, Brazil	26-Nov-2021	
#01268	CT_34851526	Worldwide prevalence of microbial agents' coinfection among COVID-19 patients: A comprehensive updated systematic review and meta-analysis	34851526	https://doi.org/10.1002/jcla.24151	https://pubmed.ncbi.nlm.nih.gov/34851526	61,547				01-Dec-2019	23-Aug-2021	632	Yes	Systematic Review and Meta-Analysis			1-Dec-2021	
#01269	CT_34851399	Factors Associated With COVID-19 Vaccine Receipt by Health Care Personnel at a Major Academic Hospital During the First Months of Vaccine Availability	34851399	https://doi.org/10.1001/jamanetworkopen.2021.36582	https://pubmed.ncbi.nlm.nih.gov/34851399	12,610	Vaccine		More than two-thirds of HCP received a COVID-19 vaccine within 4 months of vaccine availability	16-Dec-2020	16-Apr-2021	122	No	Cross-sectional study		Philadelphia, USA	1-Dec-2021	
#01270	CT_34851163	Correlation of the Commercial Anti-SARS-CoV-2 Receptor Binding Domain Antibody Test with the Chemiluminescent Reduction Neutralizing Test and Possible Detection of Antibodies to Emerging Variants	34851163	https://doi.org/10.1128/Spectrum.00560-21	https://pubmed.ncbi.nlm.nih.gov/34851163	482	Other		Both the CRNT and anti-RBD antibody tests efficiently detect immune responses convalescent COVID-19 patients				No			Toyama, Japan	1-Dec-2021	Serum samples were collected in July 2020and August 2020
#01271	CT_34851162	Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity	34851162	https://doi.org/10.1128/Spectrum.00561-21	https://pubmed.ncbi.nlm.nih.gov/34851162	740	Vaccine		The BNT162b2 vaccine produced anti-RBD antibodies, and neutraliz-ing effects against both WT SARS-CoV-2 and its emerging variants				No			Toyama, Japan	1-Dec-2021	
#01272	CT_34851137	Implementation and Accuracy of BinaxNOW Rapid Antigen COVID-19 Test in Asymptomatic and Symptomatic Populations in a High-Volume Self-Referred Testing Site	34851137	https://doi.org/10.1128/Spectrum.01008-21	https://pubmed.ncbi.nlm.nih.gov/34851137	6,099	Other			23-Dec-2020	11-Jan-2021	20	No	Cohort study	Prospective	Maryland, USA	1-Dec-2021	
#01273	CT_34851075	Cohort study: the accuracy of screening methods of COVID-19 in pregnancy	34851075	https://doi.org/10.23736/S2724-606X.21.04979-4	https://pubmed.ncbi.nlm.nih.gov/34851075	141	Other		Combined screening methods can classify pregnant women with high-risk COVID-19 before diagnosed with RT-PCR				No	Cohort study		Surabaya, Indonesia	1-Dec-2021	Prgnant women recruited from April - August 2020
#01274	CT_34850892	Gene Expression Risk Scores for COVID-19 Illness Severity	34850892	https://doi.org/10.1093/infdis/jiab568	https://pubmed.ncbi.nlm.nih.gov/34850892	53	Other			30-Apr-2020	29-Jun-2020	61	No	Cohort study		NY, USA	30-Nov-2021	
#01275	CT_34850818	COVID-19 infection risk amongst 14,104 vaccinated care home residents: a national observational longitudinal cohort study in Wales, UK, December 2020-March 2021	34850818	https://doi.org/10.1093/ageing/afab223	https://pubmed.ncbi.nlm.nih.gov/34850818	14,104	Other		90% of infections occurring within 28 days of vaccination	04-Dec-2020	04-Mar-2021	91	No	Observational longitudinal cohort study		Wales, UK	17-Nov-2021	
#01276	CT_34850576	Antibody responses to BNT162b2 mRNA vaccine: infection-naïve individuals with abdominal obesity warrant attention	34850576	https://doi.org/10.1002/oby.23353	https://pubmed.ncbi.nlm.nih.gov/34850576	1,060	Other		Between the 1st and 3rd month after vaccine dose 2, the drop in IgG-TrimericS levels was more remarkable in individuals with Abdominal Obesity compared to those without 2.44 fold vs 1.82 fold				No	Observational cohort study	Prospective	Milan, Italy	30-Nov-2021	Study started in January 2021 and lasting until March 2022
#01277	CT_34850575	Low clinical utility of testing for anti-platelet factor 4 in asymptomatic individuals after ChAdOx1 nCoV-19 vaccine	34850575	https://doi.org/10.1111/ijlh.13774	https://pubmed.ncbi.nlm.nih.gov/34850575	129	Other		No relation between the development of anti-PF4 antibodies and the immune response to the vaccine	12-Apr-2021	18-Apr-2021	7	No	Cohort study	Prospective	(Jazan & Jeddah), Saudi Arabia	30-Nov-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01278	CT_34850404	Public screening for COVID-19 in Wuhan, China and beware of the antibody positive in women and tumor patients	34850404	https://doi.org/10.1002/jmv.27483	https://pubmed.ncbi.nlm.nih.gov/34850404	21,398	Other			01-Mar-2020	30-Jun-2020	122	No	Cohort study		Wuhan, China	1-Dec-2021	
#01279	CT_34850365	Euthyroid sick syndrome as an early surrogate marker of poor outcome in mild SARS-CoV-2 disease	34850365	https://doi.org/10.1007/s40618-021-01714-1	https://pubmed.ncbi.nlm.nih.gov/34850365	506	Other			01-Apr-2020	31-May-2021	426	No	Cohort study	Prospective	Florence, Italy	1-Dec-2021	
#01280	CT_34850319	Evaluation of ECLIA antigen detection tests as screening methods for COVID-19 in comparison with molecular analysis	34850319	https://doi.org/10.1007/s11845-021-02863-1	https://pubmed.ncbi.nlm.nih.gov/34850319	110	Other						No	Observational study	Retrospective	Rome, Italy	30-Nov-2021	
#01281	CT_34850243	Severity of SARS-CoV-2 infection is linked to double-negative (CD27 - IgD -) B cell subset numbers	34850243	https://doi.org/10.1007/s00011-021-01525-3	https://pubmed.ncbi.nlm.nih.gov/34850243	106	Other						No	Cohort study		Mexico City, Mexico	30-Nov-2021	
#01282	CT_34850210	Risk factors and incidence of Long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect?	34850210	https://doi.org/10.1093/qjmed/hcab297	https://pubmed.ncbi.nlm.nih.gov/34850210	449	Other		Treatment with remdesivir leads to a 35.9% reduction in LCS rate in follow-up	10-Mar-2020	15-Jan-2021	312	No	Cohort study	Prospective	Vercelli, Italy	26-Nov-2021	
#01283	CT_34850051	Surface and air contamination with SARS-CoV-2 from hospitalized COVID-19 patients in Toronto, Canada, March-May 2020	34850051	https://doi.org/10.1093/infdis/jiab578	https://pubmed.ncbi.nlm.nih.gov/34850051	78	Other						No	Cohort study	Prospective	Toronto, Canada	27-Nov-2021	Samples were collected from March to May 2020
#01284	CT_34850034	Immune responses to the ChAdOx1 nCoV-19 and BNT162b2 vaccines and to natural COVID-19 infections over a three-month period	34850034	https://doi.org/	https://pubmed.ncbi.nlm.nih.gov/34850034	147	Other		T cell responses persisted for the 3 months in the BNT162b2 and natural infection but decreased in the ChAdOx1	05-Mar-2021	25-Mar-2021	21	No	Comparative study		Seoul, South Korea	25-Nov-2021	
#01285	CT_34850028	Infants younger than 6 months old infected by SARS-CoV-2 show the highest respiratory viral loads	34850028	https://doi.org/10.1093/infdis/jiab577	https://pubmed.ncbi.nlm.nih.gov/34850028	45,318	Other		Infants younger than 6 months old presented higher viral loads than any other age group				No	Cohort study	Retrospective	Buenos Aires, Argentina	24-Nov-2021	Ssamples were processed in the period between October 2020 and June 2021
#01286	CT_34849957	Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized COVID-19 patients: a randomized double-blind clinical trial (DISCOVER)	34849957	https://doi.org/10.1093/jac/dkab433	https://pubmed.ncbi.nlm.nih.gov/34849957	1,083	Drug(s)	Sofosbuvir | Daclatasvir	No significant effect of sofosbuvir/daclatasvir versus placebo on hospital discharge or survival in hospitalized COVID-19 patients				No	Randomized controlled trial	Prospective	Iran	28-Nov-2021	Study performed between July and October 2020
#01287	CT_34849943	Retrospective modelling of hospital bed capacities associated with the administration of remdesivir during the first wave of COVID-19 in a German metropolitan city	34849943	https://doi.org/10.1093/jac/dkab432	https://pubmed.ncbi.nlm.nih.gov/34849943	576	Drug(s)	Remedesivir		02-Mar-2020	30-Sep-2020	213	No		Retrospective	Cologne, Germany	25-Nov-2021	
#01288	CT_34849919	Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study	34849919	https://doi.org/10.1093/ibd/izab301	https://pubmed.ncbi.nlm.nih.gov/34849919	770	Vaccine	Pfizer-BioNTech | Moderna | AstraZeneca					No	Cohort study	Prospective	Prague, Czech Republic	29-Nov-2021	Vaccination underwent between January and June 2021
#01289	CT_34849680	Multisystem Inflammatory Syndrome in Adults after SARS-CoV-2 infection and COVID-19 vaccination	34849680	https://doi.org/10.1093/cid/ciab936	https://pubmed.ncbi.nlm.nih.gov/34849680	20	Other			14-Dec-2020	30-Apr-2021	138	No	Comparative study	Retrospective	USA	28-Nov-2021	
#01290	CT_34849655	A Higher Antibody Response Is Generated With a 6- to 7-Week (vs Standard) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Dosing Interval	34849655	https://doi.org/10.1093/cid/ciab938	https://pubmed.ncbi.nlm.nih.gov/34849655	186	Other		A SARS-CoV-2 vaccine dosing interval of 6–7 weeks vs standard dosing interval (<4 weeks) resulted in higher anti-spike antibodies detected in the blood of vaccinated individuals				No	Observational cohort study	Prospective	Canada	30-Nov-2021	
#01291	CT_34849615	Efficacy of Early Treatment with Favipiravir on Disease Progression among High Risk COVID-19 Patients: A Randomized, Open-Label Clinical Trial	34849615	https://doi.org/10.1093/cid/ciab962	https://pubmed.ncbi.nlm.nih.gov/34849615	500	Drug(s)	Favipiravir	Clinical progression to hypoxia occurred in (18.4%) patients on favipiravir plus standard care and (14.8%) on standard care alone				No	Randomized controlled trial	Prospective	Malaysia	19-Nov-2021	trial conducted across Malaysia from February to June 2021
#01292	CT_34849505	Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study	34849505	https://doi.org/10.1016/j.lana.2021.100134	https://pubmed.ncbi.nlm.nih.gov/34849505	705,756	Other			18-Dec-2020	30-Jun-2021	195	No	Observational cohort study	Prospective	USA	25-Nov-2021	
#01293	CT_34862422	Real world evidence of calcifediol or vitamin D prescription and mortality rate of COVID-19 in a retrospective cohort of hospitalized Andalusian patients	34862422	https://doi.org/10.1038/s41598-021-02701-5	https://pubmed.ncbi.nlm.nih.gov/34862422	15,968							No	Cohort study	Retrospective	Spain	3-Dec-2021	patients hospitalized between January and November 2020
#01294	CT_34862332	A low aldosterone/renin ratio and high soluble ACE2 associate with COVID-19 severity	34862332	https://doi.org/10.1097/HJH.0000000000003054	https://pubmed.ncbi.nlm.nih.gov/34862332	188							No	Observational study	Retrospective	The Hague, The Netherlands	1-Dec-2021	patients hospitalized between May 2020 and October 2020

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
	Count >>>	1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01295	CT_34862140	SARS-CoV-2 antibody changes in patients receiving COVID-19 convalescent plasma from normal and vaccinated donors	34862140	https://doi.org/10.1016/j.transci.2021.103326	https://pubmed.ncbi.nlm.nih.gov/34862140	25	Plasma						No	Observational study	Retrospective	IA, USA	23-Nov-2021	
#01296	CT_34862310	Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximab	34862310	https://doi.org/10.1136/rmdopen-2021-001711	https://pubmed.ncbi.nlm.nih.gov/34862310	190	Drug(s)	Infliximab | Rituximab		01-Mar-2019	29-Feb-2020	366	No	Observational cohort study	Retrospective	Geneva, Switzerland	3-Dec-2021	
#01297	CT_34861865	Nonthyroidal illness syndrome (NTIS) in severe COVID-19 patients: role of T3 on the Na/K pump gene expression and on hydroelectrolytic equilibrium	34861865	https://doi.org/10.1186/s12967-021-03163-z	https://pubmed.ncbi.nlm.nih.gov/34861865	170	Other						No			Rome, Italy	3-Dec-2021	Patients admitted from the beginning of March to the end of May 2021
#01298	CT_34887346	Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study	34887346	https://doi.org/10.1136/rmdopen-2021-001925	https://pubmed.ncbi.nlm.nih.gov/34887346	426				01-Mar-2020	13-Apr-2021	409	No	Observational, cohort study	Retrospective	Spain	9-Dec-2021	
#01299	CT_34887175	Interpretations of SARS-CoV-2 IgM and IgG antibody titers in the seroepidemiological study of asymptomatic healthy volunteers	34887175	https://doi.org/10.1016/j.jiac.2021.11.020	https://pubmed.ncbi.nlm.nih.gov/34887175	10,039	Other		(0.61%) were positive for YHLO IgM and (1.04%) for YHLO IgG	11-Jun-2020	22-Dec-2020	195	No			Tokyo, Japan	7-Dec-2021	
#01300	CT_34886916	Extracorporeal membrane oxygenation support for SARS-CoV-2: a multi-centered, prospective, observational study in critically ill 92 patients in Saudi Arabia	34886916	https://doi.org/10.1186/s40001-021-00618-3	https://pubmed.ncbi.nlm.nih.gov/34886916	1,491	Oxygen support			01-Mar-2020	30-Oct-2020	244	No	Multi-centered, observational, cohort study	Prospective	Riyadh, Saudi Arabia	9-Dec-2021	
#01301	CT_34890478	Coronavirus Disease 2019 Outcomes Among Recipients of Anti-CD20 Monoclonal Antibodies for Immune-Mediated Diseases: A Comparative Cohort Study	34890478	https://doi.org/10.1002/acr2.11386	https://pubmed.ncbi.nlm.nih.gov/34890478	673	Other		Patients who received anti-CD20 monoclonal antibodies for immune-mediated diseases prior to COVID-19 had higher mortality following COVID-19 than matched comparators	31-Jan-2020	31-Jan-2021	367	No	Comparative, cohort study	Retrospective	Massachusetts, USA	10-Dec-2021	
#01302	CT_34890441	COVID-19 symptoms at time of testing and association with positivity among outpatients tested for SARS-CoV-2	34890441	https://doi.org/10.1371/journal.pone.0260879	https://pubmed.ncbi.nlm.nih.gov/34890441	20,177	Other			16-Mar-2020	03-Sep-2020	172	No			Southeastern United States	10-Dec-2021	
#01303	CT_34890407	Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June-July 2021: A population-based cross-sectional study	34890407	https://doi.org/10.1371/journal.pmed.1003877	https://pubmed.ncbi.nlm.nih.gov/34890407	36,227	Other		Two-thirds of individuals aged ≥6 years from the general population and 85% of HCWs had antibodies against SARS-CoV-2	14-Jun-2021	06-Jul-2021	23	No	Population-based cross-sectional study		India	10-Dec-2021	
#01304	CT_34890401	A rapid real-time polymerase chain reaction-based live virus microneutralization assay for detection of neutralizing antibodies against SARS-CoV-2 in blood/serum	34890401	https://doi.org/10.1371/journal.pone.0259551	https://pubmed.ncbi.nlm.nih.gov/34890401	19	Other		13 out of 19 samples gave 100% neutralization at all dilutions				No			Karachi, Pakistan	10-Dec-2021	
#01305	CT_34889120	Nosocomial Outbreak of SARS-CoV-2 in a Non-COVID Zone of a Tertiary Care Hospital of North India: Need to Upgrade Infection Control Practices	34889120	https://doi.org/10.1177/21501327211050753	https://pubmed.ncbi.nlm.nih.gov/34889120	34	Other		The attack rate was 9.2%	19-Dec-2020	12-Jan-2021	25	No			Chandigarh, India	10-Dec-2021	
#01306	CT_34889112	N-Terminal Pro-B-Type Natriuretic Peptide as a Biomarker for the Severity and Outcomes With COVID-19 in a Nationwide Hospitalized Cohort	34889112	https://doi.org/10.1161/JAHA.121.022913	https://pubmed.ncbi.nlm.nih.gov/34889112	17,714	Other		Log-transformed NT-proBNP with other biomarkers projected a 21% increased risk of death for each 2-fold increase	23-Jan-2020	28-Nov-2020	311	No	Observational cohort study	Prospective	California, USA	10-Dec-2021	
#01307	CT_34889102	Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID-19	34889102	https://doi.org/10.1161/JAHA.121.023535	https://pubmed.ncbi.nlm.nih.gov/34889102	1,686	Drug(s)	ACEi | ARB		01-Feb-2020	01-Jun-2021	487	No	Cohort study	Prospective	Michigan, USA	10-Dec-2021	
#01308	CT_34889087	Comorbidities of Primary Care patients with COVID-19 during the first wave of the SARS-CoV-2 pandemic in the Community of Madrid	34889087	https://doi.org/10.37201/req/114.2021	https://pubmed.ncbi.nlm.nih.gov/34889087	388,446	Other			25-Feb-2020	31-May-2020	97	No	Observational study	Retrospective	Madrid, Spain	10-Dec-2021	
#01309	CT_34889010	Using NEWS2 to triage newly admitted patients with COVID-19	34889010	https://doi.org/10.1111/nicc.12739	https://pubmed.ncbi.nlm.nih.gov/34889010	200	Other		For patients with NEWS2 ≥ 4, OR was 16.4 , while for patients with NEWS2 ≥ 7, OR was 18.2	29-Jan-2020	23-Mar-2020	55	No	Single-centre, observational, case–control study	Retrospective	Wuhan, China	9-Dec-2021	
#01310	CT_34888688	Reduced magnitude and durability of humoral immune responses to COVID-19 mRNA vaccines among older adults	34888688	https://doi.org/10.1093/infdis/jiab592	https://pubmed.ncbi.nlm.nih.gov/34888688	151	Vaccine	Pfizer/BioNTech BNT162b2 | Moderna mRNA-1273					No	Longitudinal, cohort study	Prospective	British Coloumbia, Canada	9-Dec-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01311	CT_34888672	Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines	34888672	https://doi.org/10.1093/infdis/jiab593	https://pubmed.ncbi.nlm.nih.gov/34888672	1,677	Other		Relative to mRNA1273 the effectiveness of BNT162b2 was lower against infection and hospitalization; and Ad26COV2.S was lower against infection, hospitalization and death.				Yes	Meta-Analysis		Massachusetts, USA	9-Dec-2021	
#01312	CT_34888405	Factors Associated for Mortality of Older People With COVID 19: A Systematic Review and Meta-analysis	34888405	https://doi.org/10.1177/23337214211057392	https://pubmed.ncbi.nlm.nih.gov/34888405	285,650	Other						Yes	Systematic review and Meta-analysis			1-Dec-2021	
#01313	CT_34888401	US201 Study: A Phase 2, Randomized Proof-of-Concept Trial of Favipiravir for the Treatment of COVID-19	34888401	https://doi.org/10.1093/ofid/ofab563	https://pubmed.ncbi.nlm.nih.gov/34888401	50	Drug(s)	Favipiravir					No	Phase 2, randomized, controlled trial	Prospective	MA, USA	7-Dec-2021	The study was conducted from April 2020 through the end of October 2020
#01314	CT_34888396	Bamlanivimab Efficacy in Older and High-BMI Outpatients With COVID-19 Selected for Treatment in a Lottery-Based Allocation Process	34888396	https://doi.org/10.1093/ofid/ofab546	https://pubmed.ncbi.nlm.nih.gov/34888396	1,257	Drug(s)	Bamlanivimab	Patients received bamlanivimab had a statistically significant 68% reduction in the odds of hospitalization	09-Dec-2020	25-Feb-2021	79	No	Case-control study	Retrospective	USA	3-Nov-2021	
#01315	CT_34888394	A Multidimensional Cross-Sectional Analysis of Coronavirus Disease 2019 Seroprevalence Among a Police Officer Cohort: The PoliCOV-19 Study	34888394	https://doi.org/10.1093/ofid/ofab524	https://pubmed.ncbi.nlm.nih.gov/34888394	978	Other			21-Dec-2020	09-Mar-2021	79	No	Cross-sectional study		Bern, Switzerland	16-Oct-2021	
#01316	CT_34888326	Clinical Features of Early Stage COVID-19 in a Primary Care Setting	34888326	https://doi.org/10.3389/fmed.2021.764884	https://pubmed.ncbi.nlm.nih.gov/34888326	481	Other			01-Jan-2021	31-Jan-2021	31	No		Retrospective	Kamagaya, Japan	23-Nov-2021	
#01317	CT_34888318	Assessment of Sequelae of COVID-19 Nearly 1 Year After Diagnosis	34888318	https://doi.org/10.3389/fmed.2021.717194	https://pubmed.ncbi.nlm.nih.gov/34888318	120	Other			29-Jan-2020	11-Jan-2021	349	No	Cohort study	Prospective	Wuhan, China	23-Nov-2021	
#01318	CT_34888316	The MUC5B Promoter Polymorphism Associates With Severe COVID-19 in the European Population	34888316	https://doi.org/10.3389/fmed.2021.668024	https://pubmed.ncbi.nlm.nih.gov/34888316	108	Other		Carriage of the T-allele of MUC5B rs35705950 confers protection from development of severe COVID-19	19-Mar-2020	05-May-2020	48	Yes	Candidate gene case-control, cohort study	Retrospective	Netherlands	23-Nov-2021	The study also includes validation cohort from UK (COVID-19 = 436, Control=356.735), and two replication from both Italy (COVID-19 = 835, Control = 1255), Spain (Control = 775, Control 950)
#01319	CT_34894121	Circulating ubiquitous RNA, a highly predictive and prognostic biomarker in hospitalized COVID-19 patients	34894121	https://doi.org/10.1093/cid/ciab997	https://pubmed.ncbi.nlm.nih.gov/34894121	139	Other			19-Mar-2020	26-Jun-2020	100	No	Cohort study	Retrospective	Paris, France	11-Dec-2021	
#01320	CT_34893946	Case Series: Convalescent Plasma Therapy for Patients with COVID-19 and Primary Antibody Deficiency	34893946	https://doi.org/10.1007/s10875-021-01193-2	https://pubmed.ncbi.nlm.nih.gov/34893946	16	Plasma						No	Cohort study	Retrospective	USA, Germany, and Italy	10-Dec-2021	
#01321	CT_34893816	Clinical performance of a standardized SARS-CoV-2 interferon-γ release assay for simple detection of T-cell responses after infection or vaccination	34893816	https://doi.org/10.1093/cid/ciab1021	https://pubmed.ncbi.nlm.nih.gov/34893816	239	Other			15-Mar-2021	08-Jul-2021	116	No	Cross-sectional study	Prospective	Spain	10-Dec-2021	
#01322	CT_34893812	Rate and Risk Factors for Severe/Critical Disease Among Fully Vaccinated Persons with Breakthrough SARS-CoV-2 Infection in a High-risk National Population	34893812	https://doi.org/10.1093/cid/ciab1023	https://pubmed.ncbi.nlm.nih.gov/34893812	3,456	Other			15-Dec-2020	30-Jun-2021	198	No			USA	10-Dec-2021	
#01323	CT_34893611	Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England	34893611	https://doi.org/10.1038/s41467-021-27410-5	https://pubmed.ncbi.nlm.nih.gov/34893611	750	Other						No	Cohort study	Prospective	London, UK	10-Dec-2021	
#01324	CT_34893580	Endothelial dysfunction contributes to severe COVID-19 in combination with dysregulated lymphocyte responses and cytokine networks	34893580	https://doi.org/10.1038/s41392-021-00819-6	https://pubmed.ncbi.nlm.nih.gov/34893580	42	Other						No	Observational study	Prospective	Hanover, Germany	10-Dec-2021	Patients were recruited to this observational studybetween April and September 2020
#01325	CT_34893488	Severity of COVID-19 and adverse long-term outcomes: a retrospective cohort study based on a US electronic health record database	34893488	https://doi.org/10.1136/bmjopen-2021-056284	https://pubmed.ncbi.nlm.nih.gov/34893488	57,748	Other		Patients with severe COVID-19 had increased risk of new clinical conditions up to 6 months after hospital discharge	20-Feb-2020	04-Jul-2020	136	No	Cohort study	Retrospective	USA	10-Dec-2021	
#01326	CT_34893344	Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults	34893344	https://doi.org/10.1016/j.vaccine.2021.11.083	https://pubmed.ncbi.nlm.nih.gov/34893344	549	Vaccine			03-Mar-2021	24-Aug-2021	175	No	Cohort study		Bangkok, Thailand	3-Dec-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
	Count >>>	1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01327	CT_34893341	Humoral anti-SARS-CoV-2 immune response after two doses of Comirnaty vaccine in nursing home residents by previous infection status	34893341	https://doi.org/10.1016/j.vaccine.2021.11.086	https://pubmed.ncbi.nlm.nih.gov/34893341	77	Other		Between the pre-vaccination and post-vaccination periods, IgG and neutralizing antibodies increase 49 and 8-fold respectively				No	Cohort study	Prospective	Amiens, France	3-Dec-2021	
#01328	CT_34893036	Red flags of poor prognosis in pediatric cases of COVID-19: the first 6610 hospitalized children in Iran	34893036	https://doi.org/10.1186/s12887-021-03030-2	https://pubmed.ncbi.nlm.nih.gov/34893036	6,610	Other		Mortality rate in total hospitalized children was 5.3% and in children with underlying co-morbidities was 14.4%	19-Feb-2020	13-Nov-2020	269	No	Cross-sectional study		Tehran, Iran	10-Dec-2021	
#01329	CT_34893021	Impact of visceral fat on the prognosis of coronavirus disease 2019: an observational cohort study	34893021	https://doi.org/10.1186/s12879-021-06958-z	https://pubmed.ncbi.nlm.nih.gov/34893021	53	Other		Positive association of VAT/TAT with COVID-19 aggravation remained significant	01-Jan-2020	31-May-2021	517	No	Observational cohort study	Retrospective	Fukuoka, Japan	10-Dec-2021	
#01330	CT_34894631	Combination of cycle threshold time, absolute lymphocyte count and neutrophil:lymphocyte ratio is predictive of hypoxia in patients with SARS-CoV-2 infection	34894631	https://doi.org/10.1093/trstmh/trab182	https://pubmed.ncbi.nlm.nih.gov/34894631	118	Other		Ct, AL and NLR used in combination on day 3 of symptoms are predictive of hypoxia on day 7 of SARS-CoV-2 illness				No	Cohort study	Retrospective	Colombo, Sri Lanka	11-Dec-2021	Patients admitted between May 2020 and April 2021
#01331	CT_34894403	Immunogenicity after six months of BNT162b2 vaccination in frail or disabled nursing home residents: the COVID-A Study	34894403	https://doi.org/10.1111/jgs.17620	https://pubmed.ncbi.nlm.nih.gov/34894403	127	Other		Only pre-vaccination COVID-19 infection is associated with a slower rate of antibodies decrease	15-Jun-2021	02-Sep-2021	80	No	Multicenter, longitudinal, cohort study		Albacete, Spain	11-Dec-2021	
#01332	CT_34904856	SARS-CoV-2 Vaccine Antibody Response and Breakthrough Infection in Patients Receiving Dialysis	34904856	https://doi.org/10.7326/M21-4176	https://pubmed.ncbi.nlm.nih.gov/34904856	4,791	Other		Undetectable RBD response increased from 6.6% 14 to 30 days after vaccination to 20.2% 5 to 6 months after vaccination				No	Cohort study	Prospective	CA, USA	14-Dec-2021	
#01333	CT_34660144	Seroprevalence of Immunoglobulin-G Antibody Among Confirm Cases of COVID-19	34660144	https://doi.org/10.7759/cureus.17956	https://pubmed.ncbi.nlm.nih.gov/34660144	1,720	Other		Seropositivity among COVID-19 cases is 62.38%. IgG antibodies reaches its peak at around 10 weeks after diagnosis and then declines gradually				No	Cross-sectional study		Ahmedabad, India	14-Sep-2021	
#01334	CT_34904186	Complement system component dysregulation is a distinctive feature of COVID-19 disease: a prospective and comparative analysis of patients admitted to the emergency department for suspected COVID-19 disease	34904186	https://doi.org/10.1007/s11239-021-02617-x	https://pubmed.ncbi.nlm.nih.gov/34904186	80	Other			26-Mar-2020	22-May-2020	58	No	Comparative study	Prospective	Freiburg, Germany	14-Dec-2021	
#01335	CT_34904133	Low levels of CIITA and high levels of SOCS1 predict COVID-19 disease severity in children and adults	34904133	https://doi.org/10.1016/j.isci.2021.103595	https://pubmed.ncbi.nlm.nih.gov/34904133	84	Other		patients with severe disease had an elevated cytokine pattern, correlated with the IFN response with low CIITA and high SOCS1 values				No	Observational study	Prospective	Barcelona, Spain	9-Dec-2021	Patients included from March 2020 to January 2021
#01336	CT_34904132	Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial	34904132	https://doi.org/10.1016/j.jacbts.2021.09.013	https://pubmed.ncbi.nlm.nih.gov/34904132	42	Drug(s)	Crizanlizumab		15-Jul-2020	27-Nov-2020	136	No	Randomized, controlled trial	Prospective	Maryland, USA	8-Dec-2021	
#01337	CT_34904053	Hematologic and coagulopathy parameter as a survival predictor among moderate to severe COVID-19 patients in non- ICU ward: a single-center study at the main referral hospital in Surabaya, East Java, Indonesia	34904053	https://doi.org/10.12688/f1000research.53803.1	https://pubmed.ncbi.nlm.nih.gov/34904053	217	Other						No	Single-center analytical study	Retrospective	East Java, Indonesia	11-Aug-2021	Study performed between May and September, 2020
#01338	CT_34903718	Increased transmissibility of SARS-CoV-2 lineage B.1.1.7 by age and viral load	34903718	https://doi.org/10.1038/s41467-021-27202-x	https://pubmed.ncbi.nlm.nih.gov/34903718	8,093	Other		Primary cases infected with B.1.1.7 had an increased transmissibility of 1.5-1.7 times that of primary cases infected with other lineages	11-Jan-2021	07-Feb-2021	28	No	Observational study	Retrospective	Copenhagen, Denmark	13-Dec-2021	
#01339	CT_34903591	SARS-CoV-2 seroprevalence in health care workers from 10 hospitals in Quebec, Canada: a cross-sectional study	34903591	https://doi.org/10.1503/cmaj.202783	https://pubmed.ncbi.nlm.nih.gov/34903591	2,056	Other			06-Jul-2020	24-Sep-2020	81	No	Cross-sectional seroprevalence study	Retrospective	Quebec, Canada	13-Dec-2021	
#01340	CT_34903264	Lung histopathologic clusters in severe COVID-19: a link between clinical picture and tissue damage	34903264	https://doi.org/10.1186/s13054-021-03846-5	https://pubmed.ncbi.nlm.nih.gov/34903264	75	Other			29-Feb-2020	30-Jun-2020	123	No	Observational, cohort study	Retrospective	Milan, Italy	13-Dec-2021	
#01341	CT_34911722	Clinical profile and short-term outcomes of RT-PCR- positive patients with COVID-19: a cross-sectional study in a tertiary care hospital in Dhaka, Bangladesh	34911722	https://doi.org/10.1136/bmjopen-2021-055126	https://pubmed.ncbi.nlm.nih.gov/34911722	421	Other		90% of patients successfully weaned from SARS-CoV-2 infection, 3% died, and 41% reported complications after discharge	16-Apr-2020	05-Sep-2020	143	No	Single-centre, observational, case series study	Retrospective	Dhaka, Bangladesh	15-Dec-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
	Count >>>	1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01342	CT_34911691	Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study	34911691	https://doi.org/10.1136/bmj-2021-068848	https://pubmed.ncbi.nlm.nih.gov/34911691	8,153	Vaccine	mRNA-1273		01-Mar-2021	27-Jul-2021	149	No	Case-control study		California, USA	15-Dec-2021	
#01343	CT_34911366	Quantitative SARS-CoV-2 viral-load curves in paired saliva and nasal swabs inform appropriate respiratory sampling site and analytical test sensitivity required for earliest viral detection	34911366	https://doi.org/10.1128/JCM.01785-21	https://pubmed.ncbi.nlm.nih.gov/34911366	7	Other		High-analytical-sensitivity saliva testing was most reliable for earliest detection				No	Case study	Prospective	California, USA	15-Dec-2021	Study conducted between September 2020 and June 2021
#01344	CT_34911170	Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays	34911170	https://doi.org/10.1515/cclm-2021-1247	https://pubmed.ncbi.nlm.nih.gov/34911170	189	Other		Decrease in antibodies values 6 months after the first dose were 86.8% for S-RBD IgG, 82% for trimeric-S, 70.4% for VNT-Nab, 75% for PRNT50 and 75% for PRNT90				No	Cohort study	Prospective	Padova, Italy	16-Dec-2021	All subjects underwent weekly nasopharyngeal swab testingfrom March 2020 to September 202
#01345	CT_34910859	Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico	34910859	https://doi.org/10.1056/NEJMoa2116185	https://pubmed.ncbi.nlm.nih.gov/34910859	25,452	Vaccine	NVX-CoV2373	Vaccine efficacy against any variant of concern was 92.6%	27-Dec-2020	19-Apr-2021	114	No	Phase 3, randomized, observer-blinded, placebo-controlled trial	Prospective	USA, and Mexico	15-Dec-2021	
#01346	CT_34910814	High SARS-CoV-2 viral load and low CCL5 expression levels in the upper respiratory tract are associated with COVID-19 severity	34910814	https://doi.org/10.1093/infdis/jiab604	https://pubmed.ncbi.nlm.nih.gov/34910814	255	Other			09-Nov-2020	08-Mar-2021	120	No	Cohort study	Retrospective	Madrid, Spain	15-Dec-2021	
#01347	CT_34910789	National Early Warning Score 2 (NEWS2) to predict poor outcome in hospitalised COVID-19 patients in India	34910789	https://doi.org/10.1371/journal.pone.0261376	https://pubmed.ncbi.nlm.nih.gov/34910789	399	Other		Sensitivity and specificity of NEWS 2 of 5 or more in predicting poor outcomes was 93.3% and 70.7% respectively				No	Cohort study	Prospective	Puducherry, India	15-Dec-2021	Study was conducted between August and December 2020
#01348	CT_34910718	Clinical and epidemiological characterization in the follow-up of newborns with COVID-19: a descriptive study	34910718	https://doi.org/10.5867/medwave.2021.11.002141	https://pubmed.ncbi.nlm.nih.gov/34910718	34	Other			01-Jun-2020	30-Sep-2020	122	No	Observational, descriptive study	Prospective	Lima, Peru	15-Dec-2021	
#01349	CT_34519722	Clinical and epidemiological characteristics of mothers with COVID-19 and their neonates: vertical transmission	34519722	https://doi.org/10.5867/medwave.2021.07.8454	https://pubmed.ncbi.nlm.nih.gov/34519722	1,303	Other		1.7% of newborns with positive for SARS-CoV-2; and 20.1% of these neonates were hospitalized	18-Apr-2020	30-Sep-2020	166	No	Observational, descriptive, cross-sectional study	Retrospective	Trujillo, Peru	30-Aug-2021	
#01350	CT_34181675	Neutrophil-to-lymphocyte ratio, platelets-to-lymphocyte ratio, and eosinophils correlation with high-resolution computer tomography severity score in COVID-19 patients	34181675	https://doi.org/10.1371/journal.pone.0252599	https://pubmed.ncbi.nlm.nih.gov/34181675	298	Other			27-Mar-2020	30-Jun-2020	96	No	Cross-sectional study		Romania	28-Jun-2021	
#01351	CT_34211953	Prognostic Role of Neutrophil to Lymphocyte Ratio in COVID-19 Patients: Still Valid in Patients That Had Started Therapy?	34211953	https://doi.org/10.3389/fpubh.2021.664108	https://pubmed.ncbi.nlm.nih.gov/34211953	291	Other		Increase of NLR values in 49 patients with COVID-19 of the 1st wave. No significant differences of NLR between the WHO severity stage among COVID-19 patients of the IInd wave				No			Naples, Italy	15-Jun-2021	Patients admitted from March to May 2020 (1st wave) or from September 2020 to April 2021 (IInd wave)
#01352	CT_34910373	In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant	34910373	https://doi.org/10.1111/tbed.14417	https://pubmed.ncbi.nlm.nih.gov/34910373	99	Other		All vaccinated individuals presented neutralizing antibodies against B.1 and B 1.1.7 after the second dose, 14% were negative against B.1.351, and 76% had low titers (1/20-1/80).				No			Spain	15-Dec-2021	
#01353	CT_34910280	Clinical Experience with Ropeginterferon Alfa-2b in the Off-Label Use for the Treatment of COVID-19 Patients in Taiwan	34910280	https://doi.org/10.1007/s12325-021-01998-y	https://pubmed.ncbi.nlm.nih.gov/34910280	72	Drug(s)	Ropeginterferon α2β	All patients with moderate disease in the ropeginterferon alfa-2b group showed RT-PCR negative conversion within 8 days	01-May-2021	30-Jun-2021	61	No	Cohort study	Retrospective	Taipei, Taiwan	15-Dec-2021	
#01354	CT_34910128	Real-World Effectiveness Of Remdesivir In Adults Hospitalized With Covid-19: A Retrospective, Multicenter Comparative Effectiveness Study	34910128	https://doi.org/10.1093/cid/ciab1035	https://pubmed.ncbi.nlm.nih.gov/34910128	96,859	Drug(s)	Remedesvir	28-day mortality; 8.4% for remdesivir patients, & 12.5% for controls	23-Feb-2020	11-Feb-2021	355	No	Multicenter, comparative study	Retrospective	USA	15-Dec-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01355	CT_34909968	Comparison of C-reactive protein and C-reactive protein-to-albumin ratio in predicting mortality among geriatric coronavirus disease 2019 patients	34909968	https://doi.org/10.1590/1806-9282.20210811	https://pubmed.ncbi.nlm.nih.gov/34909968	404	Other		The sensitivity, specificity, and AUC values for C-reactive protein in terms of mortality were 71.01, 52.34, and 0.635%, respectively, and for C-reactive protein-to-albumin ratio were 75.74, 47.66, and 0.645%, respectively	01-Feb-2021	01-Apr-2021	60	No	Single-center, observational study	Retrospective	Turkey	13-Dec-2021	
#01356	CT_34909966	Evaluation of the cardio-ankle vascular index in COVID-19 patients	34909966	https://doi.org/10.1590/1806-9282.20210781	https://pubmed.ncbi.nlm.nih.gov/34909966	115	Other						No	Case-control study	Prospective	Trabzon, Turkey	13-Dec-2021	Study was conducted from October 2020 to April 2021
#01357	CT_34909957	Side effects and antibody response of an inactive severe acute respiratory syndrome coronavirus 2 vaccine among health care workers	34909957	https://doi.org/10.1590/1806-9282.20210755	https://pubmed.ncbi.nlm.nih.gov/34909957	94	Other		Participants who were seronegative at baseline and achieved seropositivity were 21.3 and 97.9%, respectively, overall side effects within seven days after the 1st and 2nd doses of CoronaVac were 37.2 and 28.7%	16-Dec-2020	15-Mar-2021	90	No	Cross-sectional study	Prospective	Turkey	13-Dec-2021	
#01358	CT_34909913	Use and misuse of biomarkers and the role of D-dimer and C-reactive protein in the management of COVID-19: A post-hoc analysis of a prospective cohort study	34909913	https://doi.org/10.6061/clinics/2021/e3547	https://pubmed.ncbi.nlm.nih.gov/34909913	2,478	Other			30-Mar-2020	25-Aug-2020	149	No	Single-center, observational, cohort study	Prospective	São Paulo, Brazil	8-Dec-2021	
#01359	CT_34909912	Response of patients with acute respiratory failure caused by COVID-19 to awake-prone position outside the intensive care unit based on pulmonary involvement	34909912	https://doi.org/10.6061/clinics/2021/e3368	https://pubmed.ncbi.nlm.nih.gov/34909912	48	Oxygen support		64.6% of patients were categorized as responders				No	Observational, cohort study	Prospective	São Paulo, Brazil	10-Dec-2021	Study was conducted during March and April 2021
#01360	CT_34909897	Association between thrombocytopenia and platelet profile with morbidity/mortality of severe and non-severe COVID-19 patients	34909897	https://doi.org/10.1590/1806-9282.20210720	https://pubmed.ncbi.nlm.nih.gov/34909897	1,320	Other		After 7 days of admission , increase in platelet counts was seen in non-severe patients, survivors, and severe-survivors compared with severe patients, non-survivors, and severe non-survivors, respectively	20-Feb-2020	20-May-2020	91	No	Cohort study	Retrospective	Tehran, Iran	13-Dec-2021	
#01361	CT_34909874	Chest computed tomography findings of 1271 patients with COVID-19 pneumonia and classifications with different age groups: a descriptive study from Istanbul, Turkey	34909874	https://doi.org/10.1590/1806-9282.20210150	https://pubmed.ncbi.nlm.nih.gov/34909874	1,271	Other		Normal lung computed tomography finding was (37%), followed by ground-glass opacity (31%)	11-Mar-2020	11-May-2020	62	No	Cross-sectional study	Retrospective	Istanbul, Turkey	13-Dec-2021	
#01362	CT_34916266	Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 Pneumonia: an open-label, randomised clinical trial	34916266	https://doi.org/10.1183/13993003.02518-2021	https://pubmed.ncbi.nlm.nih.gov/34916266	200	Drug(s)	Dexamethasone	(31.4%) in the low dose group and (16.3%) in the high dose group showed clinical worsening within 11 days since randomisation	15-Jan-2021	05-Jul-2021	172	No	Randomized-controlled trial	Prospective	Santiago, Spain	16-Dec-2021	
#01363	CT_34916207	SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study	34916207	https://doi.org/10.1136/bmj-2021-068665	https://pubmed.ncbi.nlm.nih.gov/34916207	4,931,775	Vaccine			01-Oct-2020	05-Oct-2021	370	No	Population based cohort study	Prospective	Denmark	16-Dec-2021	
#01364	CT_34916104	Acute unsolicited adverse events following BNT162b2 vaccine in Saudi Arabia, a real-world data	34916104	https://doi.org/10.1016/j.vaccine.2021.12.001	https://pubmed.ncbi.nlm.nih.gov/34916104	71,221	Other			01-Feb-2021	31-Mar-2021	59	No	Review	Retrospective	Riyadh, Saudi Arabia	13-Dec-2021	
#01365	CT_34915735	Role of advanced respiratory support in acute respiratory failure in clinically frail patients with COVID-19	34915735	https://doi.org/10.2217/fmb-2021-0226	https://pubmed.ncbi.nlm.nih.gov/34915735	100	Oxygen support		Overall survival rates/hospital discharge of patients still requiring ARS at 5 and 7 days post admission were 20 and 17%, respectively	01-Mar-2020	28-Feb-2021	365	No	Single-center, observational study	Retrospective	UK	17-Dec-2021	
#01366	CT_34915683	Evaluation of N/LP Ratio as a Predictor of Disease Progression and Mortality in COVID-19 Patients Admitted to the Intensive Care Unit	34915683	https://doi.org/10.5222/MMJ.2021.95676	https://pubmed.ncbi.nlm.nih.gov/34915683	134	Other		N/LP in predicting admission to the ICU was >4.18, for the need for mechanical ventilation was >5.07, and in-hospital death was 3.69				No	Observational, cohort study	Retrospective	Istanbul, Turkey	17-Dec-2021	
#01367	CT_34915675	Longitudinal SARS-CoV-2 Seroconversion Course and Antibody Levels by Blood Groups in Convalescent Plasma Donors in Turkey	34915675	https://doi.org/10.5222/MMJ.2021.00921	https://pubmed.ncbi.nlm.nih.gov/34915675	12,315	Other			07-Apr-2020	11-Dec-2020	249	No	Cohort study	Retrospective	Ankara, Turkey	17-Dec-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
	Count >>>	1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01368	CT_34915551	Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients	34915551	https://doi.org/10.1093/cid/ciab1041	https://pubmed.ncbi.nlm.nih.gov/34915551	50	Other		Only 20% and 24% of BNT162b2 recipients had detectable neutralizing antibody against the Omicron variant HKU691 and HKU344-R346K, respectively				No			Hong Kong	16-Dec-2021	
#01369	CT_34915500	Immunohistochemical and Transcriptional Analysis of SARS-CoV-2 Entry Factors and Renin-Angiotensin-Aldosterone System Components in Lethal COVID-19	34915500	https://doi.org/10.1159/000520221	https://pubmed.ncbi.nlm.nih.gov/34915500	50	Other		Higher incidence of ACE2-positivity in END (52% vs. 39%), lower positivity in ALVs (63% vs. 70%), and downregulation of ACE2 gene expression (0.25 vs. 0.55) comparing COVID-19 patients and controls, respectively				No	Cohort study	Retrospective	Switzerland	16-Dec-2021	
#01370	CT_34920375	Investigation of saliva, tongue swabs and buccal swabs as alternative specimen types to nasopharyngeal swabs for SARS-CoV-2 testing	34920375	https://doi.org/10.1016/j.jcv.2021.105053	https://pubmed.ncbi.nlm.nih.gov/34920375	260	Other		Saliva samples, tongue swabs,and buccal swabs allowed the detection of 85.3%, 67.6%, 20.8% of positive patients respectively				No	Cohort study		UK	10-Dec-2021	
#01371	CT_34920374	Antibody response to SARS-CoV-2 for more than one year - kinetics and persistence of detection are predominantly determined by avidity progression and test design	34920374	https://doi.org/10.1016/j.jcv.2021.105052	https://pubmed.ncbi.nlm.nih.gov/34920374	390	Other						No	Comparative study	Ambispective	Germany	4-Dec-2021	
#01372	CT_34920336	Prognostic role of Interleukin-6/lymphocytes ratio in SARS-CoV2 related pneumonia	34920336	https://doi.org/10.1016/j.intimp.2021.108435	https://pubmed.ncbi.nlm.nih.gov/34920336	223	Other						No	Comparative study	Retrospective	Empoli, Italy	10-Dec-2021	
#01373	CT_34920265	Performance of a rapid antigen test for SARS-CoV-2 in Kenya	34920265	https://doi.org/10.1016/j.diagmicrobio.2021.115591	https://pubmed.ncbi.nlm.nih.gov/34920265	997	Other		Ag-RDT had a sensitivity 71.5% (63.2-78.6) and specificity of 97.5% (96.2-98.5) at cycle threshold value <40	28-Dec-2020	31-Mar-2021	94	No	Cross-sectional study	Prospective	Kisumu, Kenya	1-Nov-2021	
#01374	CT_34920180	Vaccine effectiveness against COVID-19 hospitalization in adults in France: a test negative case control study	34920180	https://doi.org/10.1016/j.idnow.2021.12.002	https://pubmed.ncbi.nlm.nih.gov/34920180	853	Other		VE was 84.0% for one dose and 96.2% for two doses	21-Dec-2020	26-Jun-2021	188	No	Test negative case control study	Prospective	France	14-Dec-2021	
#01375	CT_34920122	GENOMIC CHARACTERIZATION OF SARS-CoV-2 AND ITS ASSOCIATION WITH CLINICAL OUTCOMES: A ONE-YEAR LONGITUDINAL STUDY OF THE PANDEMIC IN COLOMBIA	34920122	https://doi.org/10.1016/j.ijid.2021.12.326	https://pubmed.ncbi.nlm.nih.gov/34920122	997	Other		Lineage B.1.621 increased the need for hospitalization and lethality				No	Longitudinal study	Ambispective	Colombia	14-Dec-2021	
#01376	CT_34919937	Prognostic value of circulating calprotectin levels on the clinical course of COVID-19 differs between serum, heparin, EDTA and citrate sample types	34919937	https://doi.org/10.1016/j.cca.2021.12.011	https://pubmed.ncbi.nlm.nih.gov/34919937	176	Other		Higher cCLP levels were obtained for COVID-19 patients with i) severe/critical illness (n=70), ii) ICU admission (n=66) and iii) need for mechanical ventilation/ECMO (n=25)				No	Cohort study	Prospective	Aalst, Belgium	14-Dec-2021	patients were included between November 2020 and May 2021
#01377	CT_34919570	Potential SARS-CoV-2 infectiousness among asymptomatic healthcare workers	34919570	https://doi.org/10.1371/journal.pone.0260453	https://pubmed.ncbi.nlm.nih.gov/34919570	9,449	Other		0.2% of HCW at work were potentially infectious and pre-symptomatic and 0.17% were potentially infectious and asymptomatic				No	Cohort study		Stockholm, Sweden	17-Dec-2021	
#01378	CT_34919548	Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study	34919548	https://doi.org/10.1371/journal.pmed.1003874	https://pubmed.ncbi.nlm.nih.gov/34919548	5,542,079	Other		VE against SARS-CoV-2 infection when combining the ChAdOx1 and an mRNA vaccine was 88%	09-Feb-2021	23-Jun-2021	135	No	Population-based, observational, cohort study	Retrospective	Denmark	17-Dec-2021	
#01379	CT_34919545	Seroprevalence of SARS-CoV-2 antibodies and retrospective mortality in a refugee camp, Dagahaley, Kenya	34919545	https://doi.org/10.1371/journal.pone.0260989	https://pubmed.ncbi.nlm.nih.gov/34919545	1,206	Other		Number of infected people was estimated 67 times higher than the number of reported cases.				No	Cross-sectional study	Retrospective	Kenya	17-Dec-2021	Mortality was calculated during two periods:486 days pre-pandemic (1 January 2019 to 31 April 2020) and 326 days from the start of the pandemic (1 May 2020, to 22 March 2021)

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01380	CT_34919268	Effects of Vitamin D receptor gene polymorphisms on the prognosis of COVID-19	34919268	https://doi.org/10.1111/cen.14664	https://pubmed.ncbi.nlm.nih.gov/34919268	297	Other		Disease severity was related to Fok I Ff genotype, Taq TT genotype for ICU admission, and ApaI aa genotype was common among the patients who were died				No	Cross-sectional study		Istanbul, Turkey	17-Dec-2021	Patients admitted between April and October 2020
#01381	CT_34919259	Associations between severe pulmonary function and residual CT abnormalities in rehabilitating COVID-19 patients	34919259	https://doi.org/10.26355/eurrev_202112_27457	https://pubmed.ncbi.nlm.nih.gov/34919259	101	Other		Lung consolidation area >25% and severe-type COVID-19 were two independent risk factors for severe pulmonary dysfunction				No	Cross-sectional study	Retrospective	Wuhan, China	17-Dec-2021	
#01382	CT_34919079	The efficacy of amantadine hydrochloride in the treatment of COVID-19 - a single-center observation study	34919079	https://doi.org/	https://pubmed.ncbi.nlm.nih.gov/34919079	55	Drug(s)	Amantadine hydrochloride	Clinical stabilization was achieved in 91% of patients within 48 hours after the first dose of amantadine				No	Single-center, observational study	Retrospective	Poland	16-Dec-2021	
#01383	CT_34922398	Antiphospholipid antibodies in COVID-19-associated pneumonia patients in intensive care unit	34922398	https://doi.org/10.1080/14397595.2021.1892257	https://pubmed.ncbi.nlm.nih.gov/34922398	59	Other						No			Kayseri, Turkey	1-Mar-2021	Patients admitted from April to June 2020
#01384	CT_34910166	Minimally Invasive Tissue Sampling Findings in 12 Patients With Coronavirus Disease 2019	34910166	https://doi.org/10.1093/cid/ciab812	https://pubmed.ncbi.nlm.nih.gov/34910166	12	Other			22-Oct-2020	12-Feb-2021	114	No	Observational study	Retrospective	Barcelona, Spain	15-Dec-2021	
#01385	CT_34922338	Infection with the SARS-CoV-2 Delta Variant is Associated with Higher Recovery of Infectious Virus Compared to the Alpha Variant in both Unvaccinated and Vaccinated Individuals	34922338	https://doi.org/10.1093/cid/ciab986	https://pubmed.ncbi.nlm.nih.gov/34922338	2,644	Other		Delta variant displaced the Alpha variant to constitute 99% of the circulating lineages in the National Capital Region by August, 2021				No	Cohort study	Retrospective	USA	18-Dec-2021	Study performed between January and September 2021
#01386	CT_34922224	The effects of the antecedent use of inhaled steroid on the clinical course of COVID-19: A retrospective study of asthmatic patients	34922224	https://doi.org/10.1016/j.ijph.2021.12.003	https://pubmed.ncbi.nlm.nih.gov/34922224	275	Other			15-Mar-2020	23-Oct-2020	223	No	Cross-sectional study	Retrospective	Riyadh, Saudi Arabia	8-Dec-2021	
#01387	CT_34922160	Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19	34922160	https://doi.org/10.1016/j.thromres.2021.11.027	https://pubmed.ncbi.nlm.nih.gov/34922160	203	Other			01-Feb-2020	01-Jun-2021	487	No	Cross-sectional observational cohort study		Uden, The Netherlands	4-Dec-2021	
#01388	CT_34921756	Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial	34921756	https://doi.org/10.1016/S0140-6736(21)02392-8	https://pubmed.ncbi.nlm.nih.gov/34921756	320	Drug(s)	Rivaroxaban | Heparin		08-Oct-2020	29-Jun-2021	265	No	Open-label, multicentre, randomised trial	Prospective	Brazil	15-Dec-2021	
#01389	CT_34921684	Association between baseline use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers and death among patients tested for COVID-19	34921684	https://doi.org/10.1002/jcph.2015	https://pubmed.ncbi.nlm.nih.gov/34921684	13,880	Other						No	Observational cohort study	Retrospective	USA	18-Dec-2021	Symptomatic ED patients were accrued from January-October 2020
#01390	CT_34921683	Evaluation of Soluble Fibrin Monomer Complex in Patients in SARS-CoV-2 COVID-19 Infection Associated Coagulopathy	34921683	https://doi.org/10.1111/ejh.13738	https://pubmed.ncbi.nlm.nih.gov/34921683	108	Other		Results support the hypothesis that elevated D-dimer in COVID-19 infection is a direct consequence of endothelial damage and not overt-DIC	01-Apr-2020	14-Dec-2020	258	No	Cohort study	Retrospective	USA	18-Dec-2021	
#01391	CT_34921432	Antibody responses to COVID-19 vaccines in older adults	34921432	https://doi.org/10.1002/jmv.27531	https://pubmed.ncbi.nlm.nih.gov/34921432	81	Other			01-Mar-2021	30-Apr-2021	61	No	Cross-sectional study	Retrospective	Istanbul, Turkey	17-Dec-2021	
#01392	CT_34921080	Transmission of COVID-19 from community to healthcare agencies and back to community: a retrospective study of data from Wuhan, China	34921080	https://doi.org/10.1136/bmjopen-2021-053068	https://pubmed.ncbi.nlm.nih.gov/34921080	14,020	Other						No	Case-series study	Retrospective	Wuhan, China	17-Dec-2021	Study was conducted from December 2019 to March 2020
#01393	CT_34716320	Anti-spike antibody response to natural SARS-CoV-2 infection in the general population	34716320	https://doi.org/10.1038/s41467-021-26479-2	https://pubmed.ncbi.nlm.nih.gov/34716320	7,256	Other			26-Apr-2020	14-Jun-2021	415	No			UK	29-Oct-2021	
#01394	CT_34242356	Immune response dynamics in COVID-19 patients to SARS-CoV-2 and other human coronaviruses	34242356	https://doi.org/10.1371/journal.pone.0254367	https://pubmed.ncbi.nlm.nih.gov/34242356	280	Other						No			USA, and Pakistan	9-Jul-2021	
#01395	CT_34842924	Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial	34842924	https://doi.org/10.1001/jamanetworkopen.2021.36246	https://pubmed.ncbi.nlm.nih.gov/34842924	446	Plasma | Drug(s)	Remedesvir | Glucocorticoids | Low-molecular-weight Heparin		15-Jul-2020	08-Dec-2020	147	No	Randomized-controlled trial	Prospective	Italy	1-Nov-2021	
#01396	CT_34788233	A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia	34788233	https://doi.org/10.1172/JCI155114	https://pubmed.ncbi.nlm.nih.gov/34788233	79	Plasma | Drug(s) | Oxygen support	Remedesvir		18-May-2020	08-Jan-2021	236	No	Randomized-controlled trial	Prospective	USA	15-Dec-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01397	CT_33907251	An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients	33907251	https://doi.org/10.1038/s41598-021-88509-9	https://pubmed.ncbi.nlm.nih.gov/33907251	105	Drug(s)	Chloroquine | Hydroxychloroquine	According to these findings, the use of Clq/HClq in patients with more severe forms of COVID-19 pneumonia is strongly contraindicated	16-Apr-2020	06-Aug-2020	113	No	Randomized-controlled trial	Prospective	Curitiba, Brazil	27-Apr-2021	
#01398	CT_34145166	Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines	34145166	https://doi.org/10.1097/MJT.0000000000001402	https://pubmed.ncbi.nlm.nih.gov/34145166	3,406	Drug(s)	Ivermectin					Yes	Systematic review, meta-analysis, and trial sequential analysis	Retrospective		21-Jun-2021	
#01399	CT_34863994	The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial	34863994	https://doi.org/10.1016/j.ejphar.2021.174615	https://pubmed.ncbi.nlm.nih.gov/34863994	60	Drug(s)	Quercetin | Remedesvir | Favipiravir					No	Randomized-controlled trial	Prospective	Ahvaz, Iran	2-Dec-2021	Patients enrolled from December 2020 to January 2021
#01400	CT_34600589	Clinical characteristics and outcomes of critically ill mechanically ventilated COVID-19 patients receiving interleukin-6 receptor antagonists and corticosteroid therapy: a preliminary report from a multinational registry	34600589	https://doi.org/10.1186/s40001-021-00591-x	https://pubmed.ncbi.nlm.nih.gov/34600589	860	Drug(s)	Interleukin-6 receptor antagonists (IL-6RAs) | Steroids		01-Mar-2020	10-Jan-2021	316	No	Multicenter, observational, cohort study	Retrospective		2-Oct-2021	
#01401	CT_34026583	Tocilizumab as treatment for COVID-19: A systematic review and meta-analysis	34026583	https://doi.org/10.5662/wjm.v11.i3.95	https://pubmed.ncbi.nlm.nih.gov/34026583	13,476	Drug(s)	Tocilizumab					Yes	Systematic Review, and Meta-analysis	Prospective		20-May-2021	
#01402	CT_33609773	Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study	33609773	https://doi.org/	https://pubmed.ncbi.nlm.nih.gov/33609773	96	Drug(s)	Tocilizumab		01-Mar-2020	18-May-2020	79	No	Observational study	Retrospective	USA	1-Apr-2021	
#01403	CT_34115949	Lack of Effects of the Genetic Polymorphisms of Interleukin-10 in Clinical Outcomes of COVID-19	34115949	https://doi.org/10.1089/vim.2021.0022	https://pubmed.ncbi.nlm.nih.gov/34115949	193	Other		No evidence of an association between alleles, genotypes, or haplotypes frequencies between patient groups according to severity and outcomes				No	Cohort study		Culiacán, Mexico	12-Oct-2021	Patients were recruited between March 2020 and June 2020
#01404	CT_33121497	Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study	33121497	https://doi.org/10.1186/s12967-020-02571-x	https://pubmed.ncbi.nlm.nih.gov/33121497	901	Drug(s)	Tocilizumab	366 patients were common cases, 411 were severe, and 124 were critical				No	Cohort study	Retrospective	Wuhan, China	29-Oct-2020	
#01405	CT_32620597	Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study	32620597	https://doi.org/10.1136/annrheumdis-2020-218122	https://pubmed.ncbi.nlm.nih.gov/32620597	56	Drug(s)	Sarilumab	61% of patients treated with sarilumab clinically improved and 7% died	14-Mar-2020	02-Apr-2020	20	No	Observational, cohort study	Ambispective	Milan, Italy	3-Jul-2020	
#01406	CT_33930329	Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context	33930329	https://doi.org/10.1016/S2213-2600(21)00139-9	https://pubmed.ncbi.nlm.nih.gov/33930329	7,050	Drug(s)	Tocilizumab | Sarilumab					No	Review article			27-Apr-2021	
#01407	CT_33459964	Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19	33459964	https://doi.org/10.1007/s10875-020-00949-6	https://pubmed.ncbi.nlm.nih.gov/33459964	239	Drug(s)	Tocilizumab | Glucocorticoids	114 patients identified as having moderate disease, 54 with severe disease,and 71 with critical disease	10-Mar-2020	21-Apr-2020	43	No	Cohort study	Retrospective	Connecticut, USA	18-Jan-2021	
#01408	CT_33080002	Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19	33080002	https://doi.org/	https://pubmed.ncbi.nlm.nih.gov/33080002	3,924	Drug(s)	Tocilizumab		04-Mar-2020	12-Jun-2020	101	No	Cohort study	Retrospective	USA	1-Jan-2021	
#01409	CT_34021148	Peripheral and lung resident memory T cell responses against SARS-CoV-2	34021148	https://doi.org/10.1038/s41467-021-23333-3	https://pubmed.ncbi.nlm.nih.gov/34021148	46	Other						No	Cohort study	Prospective	Barcelona, Spain	21-May-2021	
#01410	CT_32933891	Interleukin-6 and severe COVID-19: a systematic review and meta-analysis	32933891	https://doi.org/10.1684/ecn.2020.0448	https://pubmed.ncbi.nlm.nih.gov/32933891	1,357	Other			17-Mar-2020	19-Apr-2020	34	Yes	Systematic review, and Meta-analysis		Tehran, Iran	1-Jun-2020	
#01411	CT_32721528	Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge	32721528	https://doi.org/10.1016/j.ijid.2020.07.023	https://pubmed.ncbi.nlm.nih.gov/32721528	255	Drug(s)	Tocilizumab | Sarilumab		17-Mar-2020	25-May-2020	70	No	Observational, cohort study		Massachusetts, USA	25-Jul-2020	
#01412	CT_32652164	Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis	32652164	https://doi.org/10.1016/j.jinf.2020.07.008	https://pubmed.ncbi.nlm.nih.gov/32652164	222	Drug(s)	Tocilizumab					No	Single-center analysis, comparative study	Retrospective	Milan, Italy	8-Jul-2020	
#01413	CT_32646770	Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab	32646770	https://doi.org/10.1016/j.jaut.2020.102512	https://pubmed.ncbi.nlm.nih.gov/32646770	81				01-Mar-2020	03-Apr-2020	34	No	Observational, cohort study	Retrospective	MI, USA	3-Jul-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01414	CT_32569363	Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case-controlled study	32569363	https://doi.org/10.1093/qjmed/hcaa206	https://pubmed.ncbi.nlm.nih.gov/32569363	193	Drug(s)	Tocilizumab		08-Mar-2020	25-Apr-2020	49	No	Case-control, single-center study	Retrospective	NY, USA	1-Aug-2020	
#01415	CT_32448770	Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy	32448770	https://doi.org/10.1016/j.ejim.2020.05.011	https://pubmed.ncbi.nlm.nih.gov/32448770	51	Drug(s)	Tocilizumab		10-Mar-2020	19-Apr-2020	41	No	Cohort study	Prospective	Milan, Italy	21-May-2020	
#01416	CT_32798468	Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study	32798468	https://doi.org/10.1016/S2213-2600(20)30328-3	https://pubmed.ncbi.nlm.nih.gov/32798468	83	Oxygen support			08-Mar-2020	02-May-2020	56	No	Cohort study	Retrospective	Paris, France	13-Aug-2020	
#01417	CT_32427613	Extracorporeal Membrane Oxygenation for Coronavirus Disease 2019-Induced Acute Respiratory Distress Syndrome: A Multicenter Descriptive Study	32427613	https://doi.org/10.1097/CCM.0000000000004447	https://pubmed.ncbi.nlm.nih.gov/32427613	59	Oxygen support		Decline in mortality but no significant difference; no-ECMOgroup [63.2%] vs ECMO group [57.1%]	08-Jan-2020	31-Mar-2020	84	No	A multicenter, descriptive Study	Retrospective	Wuhan, China	1-Sep-2020	
#01418	CT_34813975	Treatment of acute respiratory distress syndrome from COVID-19 with extracorporeal membrane oxygenation in obstetrical patients	34813975	https://doi.org/10.1016/j.ajogmf.2021.100537	https://pubmed.ncbi.nlm.nih.gov/34813975	10	Oxygen support		Two inpatient mortalities, 6 patients survived to discharge from ECMO, and 2 patients were still admitted				No	Case-series	Retrospective	Texas, USA	20-Nov-2021	
#01419	CT_34746170	Severe Patients With ARDS With COVID-19 Treated With Extracorporeal Membrane Oxygenation in China: A Retrospective Study	34746170	https://doi.org/10.3389/fmed.2021.699227	https://pubmed.ncbi.nlm.nih.gov/34746170	50			Twenty-one patients survived and 29 died (mortality rate: 58.0%)	03-Feb-2020	23-Jan-2021	356	No	Observational, descriptive study	Retrospective	China	20-Oct-2021	
#01420	CT_34722567	Longer Prehospitalization and Preintubation Periods in Intubated Non-survivors and ECMO Patients With COVID-19: A Systematic Review and Meta-Analysis	34722567	https://doi.org/10.3389/fmed.2021.727101	https://pubmed.ncbi.nlm.nih.gov/34722567	2,549			Prehospitalization period of intubated survivors, non-survivors, and ECMO patients was 6.15, 6.45, and 7.15 days, and preintubation period was 8.58, 9.14, and 10.54 days, respectively				Yes	Systematic Review, and Meta-analysis		Suita, Japan	15-Oct-2021	
#01421	CT_34636697	Clinical Characteristics Between Survivors and Nonsurvivors of COVID-19 Patients Requiring Extracorporeal Membrane Oxygenation (ECMO) Support: A Systematic Review and Meta-Analysis	34636697	https://doi.org/10.1177/08850666211045632	https://pubmed.ncbi.nlm.nih.gov/34636697	706			COVID-19 patients requiring ECMO support have pooled mortality rate of 40%	01-Dec-2019	01-Jun-2021	549	Yes	Systematic Review, and Meta-analysis		USA	12-Oct-2021	
#01422	CT_33902100	Multi-institutional Analysis of 100 Consecutive Patients with COVID-19 and Severe Pulmonary Compromise Treated with Extracorporeal Membrane Oxygenation: Outcomes and Trends Over Time	33902100	https://doi.org/10.1097/MAT.0000000000001434	https://pubmed.ncbi.nlm.nih.gov/33902100	100	Oxygen support		Fifty patients survived and 50 patients died				No	Multi-institutional, cohort study	Prospective	USA	1-May-2021	
#01423	CT_33236373	Role of extracorporeal membrane oxygenation in critically Ill COVID-19 patients and predictors of mortality	33236373	https://doi.org/10.1111/aor.13873	https://pubmed.ncbi.nlm.nih.gov/33236373	17	Oxygen support			01-Mar-2020	20-Apr-2020	51	No	Single-center, observational study	Retrospective	Aachen, Germany	28-Dec-2020	
#01424	CT_34242641	Multi-institutional Analysis of 200 COVID-19 Patients Treated With Extracorporeal Membrane Oxygenation: Outcomes and Trends	34242641	https://doi.org/10.1016/j.athoracsur.2021.06.026	https://pubmed.ncbi.nlm.nih.gov/34242641	200	Oxygen support		Forty-five percent of patients survived and 55% died. Survival with venovenous ECMO was (46.3%), whereas survival with venoarterial ECMO was (25%)	17-Mar-2020	01-Dec-2020	260	No	Multi-institutional, cohort study	Prospective	USA	6-Jul-2021	
#01425	CT_34452355	Detection of IFNγ-Secreting CD4 + and CD8 + Memory T Cells in COVID-19 Convalescents after Stimulation of Peripheral Blood Mononuclear Cells with Live SARS-CoV-2	34452355	https://doi.org/10.3390/v13081490	https://pubmed.ncbi.nlm.nih.gov/34452355	15	Other		Stimulation of immune cells with live SARS-CoV-2 revealed a rapid decline in the pool of effector memory CD8+, but not CD4+, T cells after recovery from COVID-19				No	Cross-sectional, cohort study		Saint Petersburg, Russia	29-Jul-2021	Study involved participants who were diagnosed with COVID-19 with the disease onset ranging from June 2020 till December 2020
#01426	CT_34193870	SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells	34193870	https://doi.org/10.1038/s41467-021-24377-1	https://pubmed.ncbi.nlm.nih.gov/34193870	101	Other		The proportion of stem cell-like memory T (TSCM) cells is peaking at approximately 120 days post-symptom onset (DPSO)				No	Cohort study		Republic of Korea	30-Jun-2021	
#01427	CT_34329696	SARS-CoV-2 specific memory T cell epitopes identified in COVID-19-recovered subjects	34329696	https://doi.org/10.1016/j.virusres.2021.198508	https://pubmed.ncbi.nlm.nih.gov/34329696	15	Other		Study identified 28 peptides from spike (S) protein and 5 peptides from nucleocapsid (N) protein as immunodominant epitopes				No	Observational study		Tennessee, USA	15-Oct-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01428	CT_32913053	Suboptimal SARS-CoV-2-specific CD8 + T cell response associated with the prominent HLA-A*02:01 phenotype	32913053	https://doi.org/10.1073/pnas.2015486117	https://pubmed.ncbi.nlm.nih.gov/32913053	35	Other						No	Cohort study		Australia	10-Sep-2020	
#01429	CT_33813122	SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay	33813122	https://doi.org/10.1016/j.cmi.2021.03.010	https://pubmed.ncbi.nlm.nih.gov/33813122	120	Other		(42.4%) unexposed donors and (97.7%) COVID-19 convalescent subjects show a positive result for at least one SARS-CoV-2 antigen				No	Cohort study	Retrospective	Italy	2-Apr-2021	
#01430	CT_34035118	SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees	34035118	https://doi.org/10.1126/sciimmunol.abj1750	https://pubmed.ncbi.nlm.nih.gov/34035118	121	Vaccine	BNT162b2 vaccine	No differences in CD4+ T-cell activation in response to variant antigens, indicating that the B.1.1.7 and B.1.351 S proteins do not escape T-cell-mediated immunity elicited by the wild type S protein				No	Cohort study	Prospective	Rotterdam, The Netherlands	25-May-2021	
#01431	CT_34107529	Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans	34107529	https://doi.org/10.1038/s41586-021-03681-2	https://pubmed.ncbi.nlm.nih.gov/34107529	32	Vaccine | Other	Ad26.COV2.S vaccine	Neutralizing antibody responses induced by Ad26.COV2.S were reduced against the B.1.351 and P.1 variants				No	Randomized, blinded, placebo controlled trial	Prospective	MA, USA	9-Jun-2021	
#01432	CT_34044428	BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans	34044428	https://doi.org/10.1038/s41586-021-03653-6	https://pubmed.ncbi.nlm.nih.gov/34044428	86	Vaccine | Other	BNT162b2 vaccine					No	Cohort study	Prospective	Germany, and USA	27-May-2021	
#01433	CT_34058265	Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-CoV-2 oncogenesis mechanism	34058265	https://doi.org/10.1016/j.virusres.2021.198464	https://pubmed.ncbi.nlm.nih.gov/34058265	547	Other						No			Washington, USA	29-May-2021	
#01434	CT_32690352	Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study	32690352	https://doi.org/10.1016/j.jaut.2020.102523	https://pubmed.ncbi.nlm.nih.gov/32690352	236	Drug(s)	Tocilizumab	Mortality rate was (12.9%)	12-Mar-2020	02-May-2020	52	No	Cohort study	Retrospective	Spain	16-Jul-2020	
#01435	CT_32482597	Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study	32482597	https://doi.org/	https://pubmed.ncbi.nlm.nih.gov/32482597	65	Drug(s)	Tocilizumab	69% of TCZ patients experienced clinical improvement compared to 61% of standard treatment patients				No	Single-centre retrospective cohort study	Retrospective	Milan, Italy	22-May-2020	
#01436	CT_32713677	Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients	32713677	https://doi.org/10.1016/j.jaut.2020.102511	https://pubmed.ncbi.nlm.nih.gov/32713677	128	Drug(s)	Tocilizumab | Hydroxychloroquine | Lopinavir | Ritonavir | Darunavir | Cobicistat | Ceftriaxone | Azithromycin | Piperacillin | Tazobactam | IV Methylprednisolone | Enoxaparin		23-Feb-2020	09-May-2020	77	No	Case-control, cohort study	Retrospective	Italy	8-Jul-2020	
#01437	CT_34611251	Tocilizumab reduces COVID-19 mortality and pathology in a dose and timing-dependent fashion: a multi-centric study	34611251	https://doi.org/10.1038/s41598-021-99291-z	https://pubmed.ncbi.nlm.nih.gov/34611251	140	Drug(s)	Tocilizumab	Mortality was reduced (4.1% vs 25.7%) when TCZ was administered at the early inflammatory stage and in doses ranging 400-800 mg in severely-ill patients	01-May-2020	01-Jul-2021	427	No	Observational, case-controlled study	Retrospective	Mexico	5-Oct-2021	
#01438	CT_32628003	Tocilizumab in patients with severe COVID-19: A single-center observational analysis	32628003	https://doi.org/10.1002/jmv.26191	https://pubmed.ncbi.nlm.nih.gov/32628003	66	Drug(s)	Tocilizumab | Steroids | Hydroxychloroquine		25-Mar-2020	24-Apr-2020	31	No	Single-center, observational study	Retrospective	PA, USA	29-Jun-2020	
#01439	CT_32918792	Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS-CoV-2	32918792	https://doi.org/10.1111/cts.12894	https://pubmed.ncbi.nlm.nih.gov/32918792	145	Drug(s)	Tocilizumab		13-Mar-2020	16-Apr-2020	35	No	Multi-center, observational study	Retrospective	USA	27-Oct-2021	
#01440	CT_34785108	Yindan Jiedu granules exhibit anti-inflammatory effect in patients with novel Coronavirus disease (COVID-19) by suppressing the NF-κB signaling pathway	34785108	https://doi.org/10.1016/j.phymed.2021.153784	https://pubmed.ncbi.nlm.nih.gov/34785108	262	Drug(s)	Traditional chinese medicine		29-Jan-2020	23-Jul-2020	177	No			Beijing, China	1-Oct-2021	
#01441	CT_34521428	Clinical outcome of patients with COVID-19 Pneumonia treated with corticosteroids and colchicine in Colombia	34521428	https://doi.org/10.1186/s12941-021-00460-9	https://pubmed.ncbi.nlm.nih.gov/34521428	301	Drug(s)	Corticosteroids | Colchicine		20-Mar-2020	07-Aug-2020	141	No	Cross-sectional study		Colombia	14-Sep-2021	
#01442	CT_33632000	A Comparison of Methylprednisolone and Dexamethasone in Intensive Care Patients With COVID-19	33632000	https://doi.org/10.1177/0885066621994057	https://pubmed.ncbi.nlm.nih.gov/33632000	262	Drug(s)	Methylprednisolone | Dexamethasone	All-cause mortalities in the usual care, methylprednisolone, and dexamethasone groups were 41.3%, 16.4% and 26.5% at 50 days, respectively	01-Mar-2020	31-Jul-2020	153	No	Cohort study	Retrospective	California, USA	25-Feb-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01443	CT_33220354	Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study	33220354	https://doi.org/10.1016/j.jaci.2020.11.006	https://pubmed.ncbi.nlm.nih.gov/33220354	120	Drug(s)	Anakinra | Methylprednisolone	At 28 days, mortality was 13.9% in treated patients and 35.6% in controls	25-Feb-2020	30-Mar-2020	35	No	Observational, cohort study	Prospective	Milan, Italy	19-Nov-2020	
#01444	CT_33020836	Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study	33020836	https://doi.org/10.1093/rheumatology/keaa587	https://pubmed.ncbi.nlm.nih.gov/33020836	112	Drug(s)	Baricitinib | Methylprednisolone		15-Mar-2020	26-Apr-2020	43	No	Observational, cohort study	Prospective	Albacete, Spain	5-Jan-2021	
#01445	CT_33219551	High-dose methylprednisolone in nonintubated patients with severe COVID-19 pneumonia	33219551	https://doi.org/10.1111/eci.13458	https://pubmed.ncbi.nlm.nih.gov/33219551	447	Drug(s)	Methylprednisolone	At 28 days, 102 patients (22.8%) had died and 115 (25.7%) received mechanical ventilation	01-Mar-2020	15-Apr-2020	46	No	Cohort study	Retrospective	NY, USA	1-Dec-2020	
#01446	CT_33326457	Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study	33326457	https://doi.org/10.1371/journal.pone.0243961	https://pubmed.ncbi.nlm.nih.gov/33326457	171	Drug(s)	Glucocorticoids | Anakinra		27-Mar-2020	10-Apr-2020	15	No	Cohort study	Prospective	Paris, France	16-Dec-2020	
#01447	CT_34153729	Intravenous methylprednisolone with or without tocilizumab in patients with severe COVID-19 pneumonia requiring oxygen support: A prospective comparison	34153729	https://doi.org/10.1016/j.jiph.2021.06.003	https://pubmed.ncbi.nlm.nih.gov/34153729	76	Drug(s)	Methylprednisolone | Tocilizumab	One patient (4.3%) in the MP group and five (18.5%) in the control arm died within 45 days				No	Randomized-controlled Trial	Prospective	Dubai, UAE	10-Jun-2021	
#01448	CT_34230996	Could pulmonary low-dose radiation therapy be an alternative treatment for patients with COVID-19 pneumonia? Preliminary results of a multicenter SEOR-GICOR nonrandomized prospective trial (IPACOVID trial)	34230996	https://doi.org/10.1007/s00066-021-01803-3	https://pubmed.ncbi.nlm.nih.gov/34230996	36	Other	Low-dose radiation therapy					No	Multi-center, non randomized trial	Prospective	Spain	6-Jul-2021	Patients enrolled between June and November 2020
#01449	CT_34473766	Possibility of deterioration of respiratory status when steroids precede antiviral drugs in patients with COVID-19 pneumonia: A retrospective study	34473766	https://doi.org/10.1371/journal.pone.0256977	https://pubmed.ncbi.nlm.nih.gov/34473766	67	Drug(s)	Favipiravir | Remdesivir | Dexamethasone					No	Single-center, observational study	Retrospective	Japan	2-Sep-2021	Patients with COVID-19 admitted between March 2020 and March 2021
#01450	CT_34605919	Association of Serum Ferritin Levels and Methylprednisolone Treatment With Outcomes in Nonintubated Patients With Severe COVID-19 Pneumonia	34605919	https://doi.org/10.1001/jamanetworkopen.2021.27172	https://pubmed.ncbi.nlm.nih.gov/34605919	380	Drug(s)	Methylprednisolone		01-Mar-2020	22-Jul-2021	509	No	Cohort study	Retrospective	NY, USA	1-Oct-2021	
#01451	CT_34542192	Comparison of pulse-dose and high-dose corticosteroids with no corticosteroid treatment for COVID-19 pneumonia in the intensive care unit	34542192	https://doi.org/10.1002/jmv.27351	https://pubmed.ncbi.nlm.nih.gov/34542192	184	Drug(s)	Methylprednisolone					No	Single-center, cohort study	Retrospective	NY, USA	28-Sep-2021	
#01452	CT_34139335	Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study	34139335	https://doi.org/10.1016/j.cmi.2021.06.008	https://pubmed.ncbi.nlm.nih.gov/34139335	101	Drug(s)	Dexamethasone	No inter-group differences in virus concentration kinetics, duration of presence of viral loads, or time from symptom onset until seroconversion				No	Observational, cohort study	Prospective	Berlin, Germany	15-Jun-2021	
#01453	CT_34622840	The effect of glucocorticoids on mortality in severe COVID-19 patients: Evidence from 13 studies involving 6612 cases	34622840	https://doi.org/10.1097/MD.0000000000027373	https://pubmed.ncbi.nlm.nih.gov/34622840	6,612	Drug(s)	Glucocorticoids	This meta-analysis found that using glucocorticoids could significantly decrease COVID-19 mortality, hazard ratio (HR) =0.60				Yes	Systematic review, and meta-analysis		Shenzhen, China	8-Oct-2021	
#01454	CT_32719045	Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study	32719045	https://doi.org/10.1136/annrheumdis-2020-218479	https://pubmed.ncbi.nlm.nih.gov/32719045	172	Drug(s)	Glucocorticoids | Tocilizumab	Treated patients had 79% higher likelihood on reaching the primary outcome (7 days earlier), 65% less mortality and 71% less invasive mechanical ventilation	07-Mar-2020	31-Mar-2020	25	No	Randomized-controlled trial	Ambispective	Limburg, The Netherlands	20-Jul-2020	
#01455	CT_33507958	High-dose corticosteroid pulse therapy increases the survival rate in COVID-19 patients at risk of hyper-inflammatory response	33507958	https://doi.org/10.1371/journal.pone.0243964	https://pubmed.ncbi.nlm.nih.gov/33507958	318	Other			04-Feb-2020	30-Apr-2020	87	No	Observational study	Prospective	Jaén, Spain	28-Jan-2021	
#01456	CT_34491575	Comparison of demographic and clinical characteristics of hospitalized COVID-19 patients with severe/critical illness in the first wave versus the second wave	34491575	https://doi.org/10.1002/jmv.27319	https://pubmed.ncbi.nlm.nih.gov/34491575	909	Other						No	Single-center, observational study	Retrospective	Istanbul, Turkey	15-Sep-2021	
#01457	CT_32876694	Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis	32876694	https://doi.org/10.1001/jama.2020.17023	https://pubmed.ncbi.nlm.nih.gov/32876694	1,703	Drug(s)	Corticosteroids		26-Feb-2020	06-Jul-2020	132	Yes	Randomized-controlled trials, and meta-analysis	Prospective		6-Oct-2020	
#01458	CT_32871238	Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study	32871238	https://doi.org/10.1016/j.jsbmb.2020.105751	https://pubmed.ncbi.nlm.nih.gov/32871238	76	Drug(s)	Calcifediol					No	Randomized, pilot, clinical study	Prospective	Córdoba, Spain	29-Aug-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01459	CT_33760094	Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19	33760094	https://doi.org/10.1001/jamanetworkopen.2021.3071	https://pubmed.ncbi.nlm.nih.gov/33760094	342	Drug(s)	Remdesivir | Corticosteroids	Addition of corticosteroids to remdesivir was not associated with a reduced hazard of death at 28 days (adjusted hazard ratio, 1.94)	04-Mar-2020	29-Aug-2020	179	No	Comparative study	Retrospective	USA	1-Mar-2021	
#01460	CT_33402303	Prediction of an increase in oxygen requirement of SARS-CoV-2 pneumonia using three different scoring systems	33402303	https://doi.org/10.1016/j.jiac.2020.12.009	https://pubmed.ncbi.nlm.nih.gov/33402303	207	Other			02-Feb-2020	31-Aug-2020	212	No	Comparative study	Retrospective	Tokyo, Japan	16-Dec-2020	
#01461	CT_32719766	Clinical Use of Short-Course and Low-Dose Corticosteroids in Patients With Non-severe COVID-19 During Pneumonia Progression	32719766	https://doi.org/10.3389/fpubh.2020.00355	https://pubmed.ncbi.nlm.nih.gov/32719766	72	Drug(s)	Corticosteroids					No	Cohort study	Retrospective	Nanjing, China	3-Jul-2020	
#01462	CT_32678530	Dexamethasone in Hospitalized Patients with Covid-19	32678530	https://doi.org/10.1056/NEJMoa2021436	https://pubmed.ncbi.nlm.nih.gov/32678530	6,425	Drug(s)	Dexamethasone	(22.9%) in the dexamethasone group and (25.7%) in the usual care group died within 28 days after randomization	19-Mar-2020	08-Jun-2020	82	No	Randomized-controlled trial	Prospective	UK	25-Feb-2021	
#01463	CT_33563218	Clinical characteristics and outcomes of critically ill COVID-19 patients in Tokyo: a single-center observational study from the first wave	33563218	https://doi.org/10.1186/s12879-021-05840-2	https://pubmed.ncbi.nlm.nih.gov/33563218	24				19-Mar-2020	26-May-2020	69	No	Observational study	Retrospective	Tokyo, Japan	9-Feb-2021	
#01464	CT_33556464	Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia	33556464	https://doi.org/10.1016/j.jaci.2021.01.024	https://pubmed.ncbi.nlm.nih.gov/33556464	128	Drug(s)	IV Anakinra | IV Methylprednisolone | Hydroxychloroquine | Azithromycin | Antivirals | Anticoagulants | Tocilizumab	Effect was similar in patients receiving anakinra alone (adjusted HR = 0.28) and anakinra plus a glucocorticoid (adjusted HR = 0.33)	26-Feb-2020	29-Apr-2020	64	No	Single-center cohort study	Retrospective	Genoa, Italy	6-Feb-2021	
#01465	CT_33172477	Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis	33172477	https://doi.org/10.1186/s13054-020-03340-4	https://pubmed.ncbi.nlm.nih.gov/33172477	382	Drug(s)	Corticosteroids		20-Jan-2020	24-Feb-2020	36	No	Single-center, observational study	Retrospective	Wuhan, China	10-Nov-2020	
#01466	CT_34022675	Role of the early short-course corticosteroids treatment in ARDS caused by COVID-19: A single-center, retrospective analysis	34022675	https://doi.org/10.1016/j.advms.2021.04.002	https://pubmed.ncbi.nlm.nih.gov/34022675	243	Drug(s)	Methylprednisolone | Dexamethasone | Hydrocortisone		09-Mar-2020	15-Jun-2020	99	No	Single-center study	Retrospective	Vercelli, Italy	24-Apr-2021	
#01467	CT_32571831	A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality	32571831	https://doi.org/10.1128/AAC.01168-20	https://pubmed.ncbi.nlm.nih.gov/32571831	463	Drug(s)	Glucocorticoid	Steroid treatment reduced mortality by 41.8% relative to the mortality with no steroid treatment	04-Mar-2020	07-Apr-2020	35	No	Controlled cohort study	Retrospective	Madrid, Spain	20-Aug-2020	
#01468	CT_34413006	Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19	34413006	https://doi.org/10.1016/j.resinv.2021.07.004	https://pubmed.ncbi.nlm.nih.gov/34413006	44	Drug(s) | Oxygen support	Baricitinib | Remdesivir | Dexamethasone					No		Retrospective	Tokyo, Japan	10-Aug-2021	
#01469	CT_32861276	Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study	32861276	https://doi.org/10.1016/S2213-2600(20)30370-2	https://pubmed.ncbi.nlm.nih.gov/32861276	301	Other			09-Mar-2020	22-Mar-2020	14	No	A multicentre, observational study	Prospective	Italy	27-Aug-2020	
#01470	CT_34283183	Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial	34283183	https://doi.org/10.1001/jama.2021.9508	https://pubmed.ncbi.nlm.nih.gov/34283183	454	Drug(s)	Canakinumab					No	Randomized, double-blind, placebo-controlled phase 3 trial	Prospective	Europe and USA	20-Jul-2021	
#01471	CT_33790049	COVID-19-induced hyperinflammation, immunosuppression, recovery and survival: how causal inference may help draw robust conclusions	33790049	https://doi.org/10.1136/rmdopen-2021-001638	https://pubmed.ncbi.nlm.nih.gov/33790049	166	Drug(s)	Methylprednisolone | Tocilizumab					No	Cohort study	Retrospective	The Netherlands	31-Mar-2021	
#01472	CT_33968298	Predictors of Mortality in Critically Ill COVID-19 Patients Demanding High Oxygen Flow: A Thin Line between Inflammation, Cytokine Storm, and Coagulopathy	33968298	https://doi.org/10.1155/2021/6648199	https://pubmed.ncbi.nlm.nih.gov/33968298	160	Other		Serum albumin, D-dimer, and IL-6 at admission to ICU were independently associated with mortality in the final multivariate analysis	23-Jun-2020	02-Oct-2020	102	No			Belgrade, Serbia	20-Apr-2021	
#01473	CT_34673895	Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial	34673895	https://doi.org/10.1001/jama.2021.18295	https://pubmed.ncbi.nlm.nih.gov/34673895	982	Drug(s)	Dexamethasone	Mortality at 28 days was 27.1% in the 12 mg of dexamethasone group vs 32.3% in the 6 mg of dexamethasone group	27-Aug-2020	20-May-2021	267	No	A multicenter, randomized clinical trial	Prospective	Europe and India	9-Nov-2021	
#01474	CT_33007478	Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19	33007478	https://doi.org/10.1016/j.cmi.2020.09.045	https://pubmed.ncbi.nlm.nih.gov/33007478	646	Drug(s)	Corticosteroids	Corticosteroid therapy was not associated with mortality difference (HR= 0.98)	29-Dec-2019	15-Feb-2020	49	No	Single-centre, cohort study	Retrospective	Wuhan, China	29-Sep-2020	
#01475	CT_33188624	Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis	33188624	https://doi.org/10.1007/s10875-020-00911-6	https://pubmed.ncbi.nlm.nih.gov/33188624	96	Drug(s)	Tocilizumab		09-Mar-2020	11-Apr-2020	34	No	Cohort study	Ambispective	Suresnes, France	14-Nov-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01476	CT_32971254	Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study	32971254	https://doi.org/10.1016/j.cmi.2020.09.014	https://pubmed.ncbi.nlm.nih.gov/32971254	513	Other			22-Feb-2020	30-Jun-2020	130	No	A multicentre observational study	Retrospective	Italy	22-Sep-2020	
#01477	CT_34275096	High-dose dexamethasone treatment for COVID-19 severe acute respiratory distress syndrome: a retrospective study	34275096	https://doi.org/10.1007/s11739-021-02800-1	https://pubmed.ncbi.nlm.nih.gov/34275096	98	Drug(s)	Dexamethasone		04-Mar-2020	01-Apr-2020	29	No	Observational study	Retrospective	Varese, Italy	17-Jul-2021	
#01478	CT_33555845	Comparison of Associations Between Glucocorticoids Treatment and Mortality in COVID-19 Patients and SARS Patients: A Systematic Review and Meta-Analysis	33555845	https://doi.org/10.1097/SHK.0000000000001738	https://pubmed.ncbi.nlm.nih.gov/33555845	45,935			Glucocorticoids treatment reduced mortality in COVID-19 and SARS patients of critical severity; however, different curative effects existed between the two diseases among subpopulations				Yes	Systematic review, and meta-analysis		Sichuan, China	1-Aug-2021	
#01479	CT_33083917	High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study	33083917	https://doi.org/10.1007/s10096-020-04078-1	https://pubmed.ncbi.nlm.nih.gov/33083917	573	Drug(s)	Methylprednisolone	High doses (HD) were associated with a higher mortality than standard doses (SD) and with an increased risk of needing MV or death				No	Single-center, observational study	Retrospective	Madrid, Spain	20-Oct-2020	
#01480	CT_33593415	Comparison of acute pneumonia caused by SARS-COV-2 and other respiratory viruses in children: a retrospective multi-center cohort study during COVID-19 outbreak	33593415	https://doi.org/10.1186/s40779-021-00306-7	https://pubmed.ncbi.nlm.nih.gov/33593415	348	Other			15-Dec-2019	15-Mar-2020	92	No	Multi-center, cohort study	Retrospective	China	16-Feb-2021	
#01481	CT_34398044	Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: A single center experience from Pune, Western India	34398044	https://doi.org/10.1097/MD.0000000000026705	https://pubmed.ncbi.nlm.nih.gov/34398044	515	Drug(s)	Tocilizumab | Steroids		02-Apr-2020	02-Nov-2020	215	No	Cohort study	Retrospective	Pune, India	23-Jul-2021	
#01482	CT_33677827	Sulodexide in the Treatment of Patients with Early Stages of COVID-19: A Randomized Controlled Trial	33677827	https://doi.org/10.1055/a-1414-5216	https://pubmed.ncbi.nlm.nih.gov/33677827	243	Drug(s)	Sulodexide	17.7% of the patients in the sulodexide group required hospitalization, compared with 29.4% in the placebo group	05-Jun-2020	30-Aug-2020	87	No	Randomized-controlled trial	Prospective	Mexico	7-Mar-2021	
#01483	CT_34937556	Ruxolitinib versus dexamethasone in hospitalized adults with COVID-19: multicenter matched cohort study	34937556	https://doi.org/10.1186/s12879-021-06982-z	https://pubmed.ncbi.nlm.nih.gov/34937556	292	Drug(s)	Ruxolitinib | Dexamethasone	Ruxolitinib therapy was associated with a better safety profile due to a reduced rate of severe cardiovascular adverse events 6.8% vs 15% for dexamethasone treatment	07-Apr-2020	09-Sep-2020	156	No	Cohort study		Russia	22-Dec-2021	
#01484	CT_34565246	Effectiveness of corticosteroids on chest high-resolution computed tomography features of COVID-19 pneumonia	34565246	https://doi.org/	https://pubmed.ncbi.nlm.nih.gov/34565246	34	Drug(s)	Corticosteroids		15-Mar-2020	15-Apr-2020	32	No	Cross-sectional, single-center, case-control study	Retrospective	Naples, Italy	25-Sep-2021	
#01485	CT_33400157	Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study	33400157	https://doi.org/10.1007/s11739-020-02600-z	https://pubmed.ncbi.nlm.nih.gov/33400157	143	Drug(s) | Other	Anakinra | Corticosteroids | Tocilizumab	Treatment with anakinra was associated with a reduced risk of mortality (adjusted hazard ratio 0.518)	15-Mar-2020	15-May-2020	62	No	Observational, cohort study	Retrospective	Granada, Spain	5-Jan-2021	
#01486	CT_34653525	Whole-lung low-dose radiation therapy (LD-RT) for non-intubated oxygen-dependent patients with COVID-19-related pneumonia receiving dexamethasone and/or remdesevir	34653525	https://doi.org/10.1016/j.radonc.2021.10.003	https://pubmed.ncbi.nlm.nih.gov/34653525	25	Drug(s)	Low-dose radiation therapy (LD-RT) | Dexamethasone | Remdesevir		11-Jun-2020	07-Dec-2020	180	No	Cohort study	Prospective	USA	13-Oct-2021	
#01487	CT_34294593	Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis	34294593	https://doi.org/10.1016/j.jmii.2021.05.009	https://pubmed.ncbi.nlm.nih.gov/34294593	197	Drug(s)	Baricitinib | Dexamethasone | Enoxaparin	Mortality was significantly lower in the baricitinib plus dexamethasone group compared to the dexamethasone monotherapy group (20.3% vs 40.5%)				No	Comparative study	Retrospective	Monterrey, Mexico	3-Jul-2021	Data collected from March 2020 through November 2020
#01488	CT_34810227	Efficacy and safety of colchicine in COVID-19: a meta-analysis of randomised controlled trials	34810227	https://doi.org/10.1136/rmdopen-2021-001746	https://pubmed.ncbi.nlm.nih.gov/34810227	16,148			The moderate quality evidence suggests no benefit of addition of colchicine to the standard care regimen in patients with COVID-19				Yes	Meta-analysis			28-Oct-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01489	CT_34640481	High-Dose Methylprednisolone Pulses for 3 Days vs. Low-Dose Dexamethasone for 10 Days in Severe, Non-Critical COVID-19: A Retrospective Propensity Score Matched Analysis	34640481	https://doi.org/10.3390/jcm10194465	https://pubmed.ncbi.nlm.nih.gov/34640481	682	Drug(s)	Methylprednisolone | Dexamethasone					No	Cohort study	Retrospective	Barcelona, Spain	28-Sep-2021	
#01490	CT_34032722	No evidence of tocilizumab treatment efficacy for severe to critical SARS-CoV2 infected patients: Results from a retrospective controlled multicenter study	34032722	https://doi.org/10.1097/MD.0000000000026023	https://pubmed.ncbi.nlm.nih.gov/34032722	54	Drug(s)	Tocilizumab	TCZ was not associated with clinical improvement as compared to SOC regarding oxygen-free status (44% vs 63%) and death (18.5% vs 22%)				No	Multicenter, observational analysis	Retrospective	Paris, France	28-May-2021	
#01491	CT_33666250	Efficacy of corticosteroid in patients with COVID-19: A multi-center retrospective study and meta-analysis	33666250	https://doi.org/10.1002/jmv.26914	https://pubmed.ncbi.nlm.nih.gov/33666250	543			Low-dose corticosteroids can significantly lower the risk of death and shorten duration of fever among patients in severe group, while prolong duration of hospitalization in non-severe group.	29-Dec-2019	17-Feb-2020	51	Yes	Multi-center, cohort study, and meta-analysis	Retrospective	Hubei, China	5-May-2021	A total of 8867 subjects were included from a meta-analysis confirming the same results
#01492	CT_32785710	Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With Coronavirus Disease 2019 (COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial	32785710	https://doi.org/10.1093/cid/ciaa1177	https://pubmed.ncbi.nlm.nih.gov/32785710	393	Drug(s)	Methylprednisolone	The mortality rates at Day 28 were not different between groups	18-Apr-2020	16-Jun-2020	60	No	A Randomized, double-blind, phase IIb, placebo-controlled trial	Prospective	Manaus, Brazil	4-May-2021	
#01493	CT_34426105	Combined Therapy of Ciclosporin Plus Favipiravir in the Management of Patients with Severe COVID-19, not Responding to Dexamethasone: A non-Controlled Prospective Trial	34426105	https://doi.org/10.1016/j.intimp.2021.108043	https://pubmed.ncbi.nlm.nih.gov/34426105	20	Drug(s)	Dexamethasone | Favipiravir | Enoxaparin | Pantoprazole | Ciclosporin	The protocol of two doses of ciclosporin with favipiravir does not have favorable effects among COVID-19 patients that do not respond to dexamethasone				No	Non-controlled clinical trial	Prospective	Tehran, Iran	4-Aug-2021	
#01494	CT_33403775	Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation	33403775	https://doi.org/10.1111/cts.12971	https://pubmed.ncbi.nlm.nih.gov/33403775	31	Drug(s)	Ruxolitinib	In the 31 patients who received ruxolitinib, symptoms improved (dyspnea scale) on day 7 in 25 of 31 patients (80.6%)				No	Pilot study		Monza, Italy	27-Jan-2021	
#01495	CT_PMC8280222	Longitudinal monitoring of laboratory markers characterizes hospitalized and ambulatory COVID-19 patients	PMC8280222	https://doi.org/10.1038/s41598-021-93950-x	https://pubmed.ncbi.nlm.nih.gov/PMC8280222	42	Other		Hospitalized patients experienced significant decreases in CRP, ferritin and IL-6 levels from admission to recovery, cardiac troponin I levels were high during the acute phase in both hospitalized and ambulatory patients				No	Longitudinal study		Germany	14-Jul-2021	
#01496	CT_34945108	Comparison between Dexamethasone and Methylprednisolone Therapy in Patients with COVID-19 Pneumonia Admitted to Non-Intensive Medical Units	34945108	https://doi.org/10.3390/jcm10245812	https://pubmed.ncbi.nlm.nih.gov/34945108	246	Drug(s)	Dexamethasone | Methylprednisolone	No statistically significant differences were found between the two groups of patients regarding 30-day mortality, complication rates, length of hospital stay, and time to viral clearance	01-Dec-2020	31-Jan-2021	62	No	Cohort study	Retrospective	Treviso, Italy	12-Dec-2021	
#01497	CT_34710097	Impact of persistent D-dimer elevation following recovery from COVID-19	34710097	https://doi.org/10.1371/journal.pone.0258351	https://pubmed.ncbi.nlm.nih.gov/34710097	129	Other		Significant lower mean pO2 and AaDO2 were observed in patients with persistent D-Dimer elevation, but the rate of ground glass opacities GGO were similar in both patient groups				No		Prospective	Vienna, Austria	28-Oct-2021	
#01498	CT_33984360	Beclin-1, an autophagy-related protein, is associated with the disease severity of COVID-19	33984360	https://doi.org/10.1016/j.lfs.2021.119596	https://pubmed.ncbi.nlm.nih.gov/33984360	129	Other		Serum BECN1 levels were increased in COVID-19 patients vs healthy controls, and significantly higher in severe vs non-severe groups. BECN1 levels showed a significantly +ve correlation with coagulation, inflammation, and biochemical markers				No	Single-center, cross-sectional study	Retrospective	Hatay, Turkey	1-Aug-2021	Study performed between September 2020 and January 2021

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01499	CT_35071683	Persistence of Robust Humoral Immune Response in Coronavirus Disease 2019 Convalescent Individuals Over 12 Months After Infection	35071683	https://doi.org/10.1093/ofid/ofab626	https://pubmed.ncbi.nlm.nih.gov/35071683	497	Other		Antibody titers of NP-IgG, RBD-IgG, and nAbs were higher in severe and moderate cases than in mild cases at 12 months after onset				No			Japan	10-Dec-2021	Study carried out between January and August 2020
#01500	CT_35072166	The antibody response to SARS-CoV-2 infection persists over at least 8 months in symptomatic patients	35072166	https://doi.org/10.1038/s43856-021-00032-0	https://pubmed.ncbi.nlm.nih.gov/35072166	4,735	Other		The antibody response persists for at least 8-10 months				No	Observational, cohort study	Prospective	Milano, Italy	17-Sep-2021	
#01501	CT_35076497	Epidemiological Characteristics of Hospitalized Patients with Moderate versus Severe COVID-19 Infection: A Retrospective Cohort Single Centre Study	35076497	https://doi.org/10.3390/diseases10010001	https://pubmed.ncbi.nlm.nih.gov/35076497	1,002	Other			03-Mar-2020	09-Sep-2020	191	No	Single-centre, cohort study	Retrospective	Muscat, Oman	23-Dec-2021	
#01502	CT_35070667	Pattern of ocular manifestations and the prevalence of severe acute respiratory syndrome coronavirus-2 in tears of hospitalized coronavirus disease 2019 patients	35070667	https://doi.org/10.4103/tjo.tjo_40_21	https://pubmed.ncbi.nlm.nih.gov/35070667	804	Other		(38.4%) patients were identified with ocular manifestations	15-Sep-2020	15-Nov-2020	62	No	Population-based, observational study	Prospective	India	6-Dec-2021	
#01503	CT_35071229	5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Early Warning Biomarkers for COVID-19 Progression and Myocardial Injury	35071229	https://doi.org/10.3389/fcell.2021.781267	https://pubmed.ncbi.nlm.nih.gov/35071229	256	Other						No	Multi-center, cohort study	Prospective	Wuhan, China	6-Jan-2022	
#01504	CT_35071250	Red Blood Cell Distribution Width in Hospitalized COVID-19 Patients	35071250	https://doi.org/10.3389/fmed.2021.582403	https://pubmed.ncbi.nlm.nih.gov/35071250	294	Other		Prevalence of increased red blood cell distribution width (RDW) was 49.7%. RDW was associated with increased risk of in-hospital mortality and septic shock	20-Jan-2020	25-Apr-2020	97	No	Descriptive study	Retrospective	New York, USA	7-Jan-2022	
#01505	CT_35071263	The Prognostic Capacity of the Radiographic Assessment for Lung Edema Score in Patients With COVID-19 Acute Respiratory Distress Syndrome-An International Multicenter Observational Study	35071263	https://doi.org/10.3389/fmed.2021.772056	https://pubmed.ncbi.nlm.nih.gov/35071263	139	Other			01-Dec-2019	31-May-2020	183	No	An international, multicenter, observational study	Retrospective	The Netherlands, Italy, Belgium, and Thailand	5-Jan-2022	
#01506	CT_35071267	Genome Sequencing Reveals a Mixed Picture of SARS-CoV-2 Variant of Concern Circulation in Eastern Uttar Pradesh, India	35071267	https://doi.org/10.3389/fmed.2021.781287	https://pubmed.ncbi.nlm.nih.gov/35071267	87	Other			18-Mar-2020	31-Jul-2021	501	No			Uttar Pradesh, India	7-Jan-2022	
#01507	CT_35071291	Malnutrition Contributes to Low Lymphocyte Count in Early-Stage Coronavirus Disease-2019	35071291	https://doi.org/10.3389/fnut.2021.739216	https://pubmed.ncbi.nlm.nih.gov/35071291	101	Other		(58.4%) of the patients showed low total lymphocyte count (TLC), 41 (40.6%) were at risk for malnutrition, and 18 of them were malnourished.	06-Feb-2020	20-Mar-2020	44	No	Observational study	Prospective	Wuhan, China	6-Jan-2022	
#01508	CT_35071343	Frequent Constriction-Like Echocardiographic Findings in Elite Athletes Following Mild COVID-19: A Propensity Score-Matched Analysis	35071343	https://doi.org/10.3389/fcvm.2021.760651	https://pubmed.ncbi.nlm.nih.gov/35071343	214	Other						No	Cohort study	Prospective	Budapest, Hungary	5-Jan-2022	
#01509	CT_35083423	Evaluation of I-TAC as a potential early plasma marker to differentiate between critical and non-critical COVID-19	35083423	https://doi.org/10.15698/cst2022.01.262	https://pubmed.ncbi.nlm.nih.gov/35083423	39	Other		I-TAC levels were significantly higher in critical patients when compared with moderate (p = 0.04), severe (p = 0.03) or the combined non-critical (p = 0.02) group	17-Apr-2020	18-Dec-2020	246	No	Cohort study		OK, USA	21-Dec-2021	
#01510	CT_34476717	Favipiravir treatment does not influence disease progression among adult patients hospitalized with moderate-to-severe COVID-19: a prospective, sequential cohort study from Hungary	34476717	https://doi.org/10.1007/s11357-021-00452-9	https://pubmed.ncbi.nlm.nih.gov/34476717	150	Drug(s)	Favipiravir	The use of favipiravir was not statistically significant as a protective factor against disease progression				No	Sequential cohort study	Prospective	Budapest, Hungary	3-Sep-2021	Study was performed between March and August 2020
#01511	CT_33128482	Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19	33128482	https://doi.org/10.1111/jcpt.13305	https://pubmed.ncbi.nlm.nih.gov/33128482	107	Drug(s)	Favipiravir | Lopinavir/Ritonavir	The length of hospital stay was significantly lower in the FVP group compared to the LPV/r group among patients discharged from the ICU	19-Mar-2020	30-May-2020	73	No	Observational study	Retrospective	Sakarya, Turkey	31-Oct-2020	
#01512	CT_32876695	Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial	32876695	https://doi.org/10.1001/jama.2020.17021	https://pubmed.ncbi.nlm.nih.gov/32876695	299	Drug(s)	Dexamethasone	The use of IV dexamethasone + SOC compared with SOC alone resulted in a statistically significant increase in the number of ventilator-free days	17-Apr-2020	21-Jul-2020	96	No	Randomized clinical trial	Prospective	Brazil	6-Oct-2020	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01513	CT_33930706	Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial	33930706	https://doi.org/10.1016/j.intimp.2021.107702	https://pubmed.ncbi.nlm.nih.gov/33930706	55	Drug(s)	Favipiravir	The proportion of virus shedding in favipiravir group was higher than control group (80.6% vs 52.6%, p = 0.030)	27-Mar-2020	09-May-2020	44	No	Multicenter, open-label, randomized controlled trial	Prospective	China	21-Apr-2021	
#01514	CT_34464921	Favipiravir versus standard of care in patients with severe COVID-19 infections: A retrospective comparative study	34464921	https://doi.org/10.1016/j.jiph.2021.08.022	https://pubmed.ncbi.nlm.nih.gov/34464921	226	Drug(s)	Favipiravir	Overall mortality was not statistically significant between cohorts	18-Apr-2020	27-Oct-2020	193	No	Comparative study	Retrospective	Alahsa, Saudi Arabia	24-Aug-2021	
#01515	CT_34111191	Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study	34111191	https://doi.org/10.1371/journal.pone.0252984	https://pubmed.ncbi.nlm.nih.gov/34111191	222	Drug(s) | Others	Interferon beta-1b | Lopinavir/Ritonavir | Ribavirin | Favipiravir	Early IFN-based triple therapy showed lower 28-days mortality as compared to FPV	01-May-2020	30-Sep-2020	153	No	Single center, observational, comaparative study	Prospective	Riyadh, Saudi Arabia	10-Jun-2021	
#01516	CT_34426106	Evaluation of adalimumab effects in managing severe cases of COVID-19: A randomized controlled trial	34426106	https://doi.org/10.1016/j.intimp.2021.107961	https://pubmed.ncbi.nlm.nih.gov/34426106	68	Drug(s) | Oxygen support	Adalimumab | Remdesvir | Dexamethasone	Results did not support the use of adalimumab in combination with remdesivir and dexamethasone in the treatment of severe COVID-19 cases				No	Randomized controlled trial	Prospective	Tehran, Iran	7-Jul-2021	
#01517	CT_34034765	Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case-control study	34034765	https://doi.org/10.1186/s12985-021-01577-1	https://pubmed.ncbi.nlm.nih.gov/34034765	144			FPV treatment had an impact on PCR negativity and disease progression. However, it did not have a positive effect on the estimated survival time				No	Observational, case-controlled, cohort study	Retrospective	Eskişehir, Turkey	25-May-2021	Study was performed between March 2020 and September 2020
#01518	CT_33962885	Effects on mortality of early vs late administration of convalescent plasma in the treatment of Covid-19	33962885	https://doi.org/10.1016/j.transci.2021.103148	https://pubmed.ncbi.nlm.nih.gov/33962885	141	Plasma			01-May-2020	30-Sep-2020	153	No	Comparative study	Retrospective	Sakarya, Turkey	24-Apr-2021	
#01519	CT_33631512	Serum cytokine levels of COVID-19 patients after 7 days of treatment with Favipiravir or Kaletra	33631512	https://doi.org/10.1016/j.intimp.2021.107407	https://pubmed.ncbi.nlm.nih.gov/33631512	48	Drug(s) | Other	Favipiravir | Lopinavir/Ritonavir	Antiviral treatments did not suppress the inflammatory phase of COVID-19 after 7 days treatment	10-Apr-2020	09-May-2020	30	No	Observational study	Retrospective	Tehran, Iran	22-Jan-2021	
#01520	CT_33890544	Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis	33890544	https://doi.org/10.1080/03007995.2021.1920900	https://pubmed.ncbi.nlm.nih.gov/33890544	457	Drug(s)	Favipiravir	No overall mortality benefits were displayed using FPV across the severity spectrum				No	Observational study	Retrospective	Riyadh, Saudi Arabia	19-May-2021	
#01521	CT_33947344	Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients	33947344	https://doi.org/10.1186/s12879-021-06104-9	https://pubmed.ncbi.nlm.nih.gov/33947344	60	Drug(s)	Ivermectin					No	Randomized, controlled, single-blind phase 3 study	Prospective	Turkey	4-May-2021	Trial conducted between May–September 2020
#01522	CT_33726482	The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment	33726482	https://doi.org/10.3906/sag-2012-189	https://pubmed.ncbi.nlm.nih.gov/33726482	204	Drug(s)	Favipiravir | Lopinavir/Ritonavir	Favipiravir was more effective than LPV/RTV in reducing mortality with COVID-19	30-Mar-2020	30-Sep-2020	185	No	Comparative study	Retrospective	Turkey	30-Aug-2021	
#01523	CT_35089113	Delayed inflammation decrease is associated with mortality in Tocilizumab-treated critically ill SARS-CoV-2 patients: A retrospective matched-cohort analysis	35089113	https://doi.org/10.1177/17534259211064602	https://pubmed.ncbi.nlm.nih.gov/35089113	63	Drug(s)	Tocilizumab		01-Mar-2020	15-Apr-2020	46	No	Matched-cohort analysis	Retrospective	Paris, France	28-Jan-2022	
#01524	CT_35087533	A Differential Signature of Circulating miRNAs and Cytokines Between COVID-19 and Community-Acquired Pneumonia Uncovers Novel Physiopathological Mechanisms of COVID-19	35087533	https://doi.org/10.3389/fimmu.2021.815651	https://pubmed.ncbi.nlm.nih.gov/35087533	123	Other		Significant difference in cytokine signature was detected between COVID-19 and CAP that included EGFR, CXCL12 and IL-10	10-Mar-2020	21-Apr-2020	43	No	Cohort study	Retrospective	Madrid, Spain	11-Jan-2022	
#01525	CT_35088494	A possible dose-response equation: Viral load after plasma infusion in COVID-19 patients and anti-SARS-CoV-2 antibody titers in convalescent plasma	35088494	https://doi.org/10.1111/tme.12852	https://pubmed.ncbi.nlm.nih.gov/35088494	38	Plasma			01-Mar-2020	30-Mar-2020	30	No			Hubei, China	27-Jan-2022	
#01526	CT_35096202	The Prognostic Role of Metabolic and Endocrine Parameters for the Clinical Severity of COVID-19	35096202	https://doi.org/10.1155/2022/5106342	https://pubmed.ncbi.nlm.nih.gov/35096202	70	Other		Longer duration of hospitalization and higher WBC count are associated with poor outcomes in COVID-19 patients				No	Cross-sectional study	Retrospective	Mashhad, Iran	20-Jan-2022	
#01527	CT_35096288	Evidence of a SARS-CoV-2 double Spike mutation D614G/S939F potentially affecting immune response of infected subjects	35096288	https://doi.org/10.1016/j.csbj.2022.01.021	https://pubmed.ncbi.nlm.nih.gov/35096288	16	Other						No		Retrospective	Rome, Italy	21-Jan-2022	
#01528	CT_35096716	COVID-19 in Pediatrics: Demographic, Clinical, Laboratory, and Radiological Characteristics of Infected Patients With SARS-CoV-2	35096716	https://doi.org/10.3389/fped.2021.808187	https://pubmed.ncbi.nlm.nih.gov/35096716	91	Other		(17.5%) cases were hospitalized in ICU, and (8.8%) deceased	14-Mar-2020	24-Feb-2021	348	No		Retrospective	Gorgan, Iran	13-Jan-2022	
#01529	CT_35096725	Evaluation of Rapid Antigen Tests Using Nasal Samples to Diagnose SARS-CoV-2 in Symptomatic Patients	35096725	https://doi.org/10.3389/fpubh.2021.728969	https://pubmed.ncbi.nlm.nih.gov/35096725	4,183	Other		Calculated sensitivity and specificity of the rapid antigen detection test was 82.1 and 99.1%, respectively				No	Cross-sectional study		Bahrain	14-Jan-2022	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01530	CT_35096849	Pulmonary Sequelae in Patients After Recovery From Coronavirus Disease 2019: A Follow-Up Study With Chest CT	35096849	https://doi.org/10.3389/fmed.2021.686878	https://pubmed.ncbi.nlm.nih.gov/35096849	273	Other		The most common CT findings were ground-glass opacity and parenchymal band; (55.3%) and (38.2%) at 3 months follow-up, and (48.2%) and (44.7%) at 6 months follow-up, respectively	03-Feb-2020	03-May-2020	91	No	Comparative study	Ambispective	Shenzhen, China	13-Jan-2022	
#01531	CT_35096891	The Positive Rate of Nucleic Acid Testing and the Epidemiological Characteristics of COVID-19 in Chongqing	35096891	https://doi.org/10.3389/fmed.2021.802708	https://pubmed.ncbi.nlm.nih.gov/35096891	7,118	Other			20-Jan-2020	26-Mar-2020	67	No	Observational study	Retrospective	Chongqing, China	14-Jan-2022	
#01532	CT_35096894	The Prevalence and Clinical Implications of Rectal SARS-CoV-2 Shedding in Danish COVID-19 Patients and the General Population	35096894	https://doi.org/10.3389/fmed.2021.804804	https://pubmed.ncbi.nlm.nih.gov/35096894	274	Other			12-Jun-2020	28-Feb-2021	262	No			Denmark	13-Jan-2022	
#01533	CT_35096906	Lung Ultrasound as a First-Line Test in the Evaluation of Post-COVID-19 Pulmonary Sequelae	35096906	https://doi.org/10.3389/fmed.2021.815732	https://pubmed.ncbi.nlm.nih.gov/35096906	352	Other			03-Mar-2020	21-Sep-2020	203	No	Single-center, observational study	Prospective	Barcelona, Spain	13-Jan-2022	
#01534	CT_35096923	Oral Bacteriotherapy Reduces the Occurrence of Chronic Fatigue in COVID-19 Patients	35096923	https://doi.org/10.3389/fnut.2021.756177	https://pubmed.ncbi.nlm.nih.gov/35096923	58	Drug(s) | Other	Hydroxychloroquine | Azithromycin | Lopinavir/Ritonavir | Darunavir/Cobicistat | LMWH | Tocilizumab | Oral Bacteriotherapy		01-Mar-2020	30-Apr-2020	61	No	Observational study	Retrospective	Rome, Italy	12-Jan-2022	
#01535	CT_35097067	Methylprednisolone accelerate chest computed tomography absorption in COVID-19: A three-centered retrospective case control study from China	35097067	https://doi.org/10.12998/wjcc.v10.i2.426	https://pubmed.ncbi.nlm.nih.gov/35097067	70	Drug(s) | Oxygen support	Methylprednisolone	CT obvious absorption rate were 89.47%, 12.5% for corticosteroid group vs control group, respectively	27-Jan-2020	30-Mar-2020	64	No	Case-control study	Retrospective	China	14-Jan-2022	
#01536	CT_35097117	Seropositivity of SARS-CoV-2 IgG Antibody among People in Dhaka City during the Prevaccination Period	35097117	https://doi.org/10.1155/2022/4451144	https://pubmed.ncbi.nlm.nih.gov/35097117	239	Other						No			Dhaka, Bangladesh	27-Jan-2022	Study performed between October 2020 and February 2021
#01537	CT_35098172	SARS-CoV-2 infections in patients with autoimmune blistering disorders: a case series and retrospective analysis	35098172	https://doi.org/10.1016/j.jdin.2022.01.003	https://pubmed.ncbi.nlm.nih.gov/35098172	10	Other			01-Mar-2020	31-Aug-2021	549	No	Case series study	Retrospective	North Carolina, USA	24-Jan-2022	
#01538	CT_35098177	Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial	35098177	https://doi.org/10.1016/S2666-5247(21)00280-9	https://pubmed.ncbi.nlm.nih.gov/35098177	120	Vaccine			30-Oct-2020	02-Dec-2020	34	No	A randomised, double-blind, placebo-controlled, phase 1 trial	Prospective	Hangzhou, China	24-Jan-2022	
#01539	CT_35098386	Evaluation serum levels of Insulin Growth Factor-1 (IGF-1) and its association with clinical parameters in severe COVID-19	35098386	https://doi.org/10.1007/s10787-021-00908-6	https://pubmed.ncbi.nlm.nih.gov/35098386	114	Other		Serum levels of IGF-1 had no significant difference in COVID-19 patients compared to the healthy subjects (p = 0.359)				No	Observational study	Retrospective	Iran	31-Jan-2022	
#01540	CT_35162195	Effect of a Nutritional Support System to Increase Survival and Reduce Mortality in Patients with COVID-19 in Stage III and Comorbidities: A Blinded Randomized Controlled Clinical Trial	35162195	https://doi.org/10.3390/ijerph19031172	https://pubmed.ncbi.nlm.nih.gov/35162195	80	Other						No	A blinded, randomized, controlled clinical trial	Prospective	Mexico	21-Jan-2022	Study started in September 2020, and ended inApril 2021
#01541	CT_35140702	Is There a Crucial Link Between Vitamin D Status and Inflammatory Response in Patients With COVID-19?	35140702	https://doi.org/10.3389/fimmu.2021.745713	https://pubmed.ncbi.nlm.nih.gov/35140702	93	Drug(s)	Vitamin D					No	Observational study	Retrospective	Pisa, Italy	24-Jan-2022	
#01542	CT_35138402	Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19: A Phase 2 Randomized Clinical Trial	35138402	https://doi.org/10.1001/jamanetworkopen.2021.44942	https://pubmed.ncbi.nlm.nih.gov/35138402	73	Drug(s)	Niclosamide	No significant difference in oropharyngeal clearance of SARS-CoV-2 at day 3 between placebo and niclosamide groups	01-Oct-2020	20-Apr-2021	202	No	A phase 2 randomized clinical trial	Prospective	Massachusetts, USA	1-Feb-2022	
#01543	CT_35107188	Efficacy and safety of colchicine treatment in patients with COVID-19: A prospective, multicenter, randomized clinical trial	35107188	https://doi.org/10.1002/ptr.7319	https://pubmed.ncbi.nlm.nih.gov/35107188	202	Drug(s)	Colchicine		26-Mar-2020	30-Sep-2020	189	No	Multicenter, randomized clinical trial	Prospective	Iran	2-Feb-2022	
#01544	CT_35093205	Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial	35093205	https://doi.org/10.1016/S0140-6736(22)00101-5	https://pubmed.ncbi.nlm.nih.gov/35093205	579	IVIG			08-Oct-2020	10-Feb-2021	126	No	International randomised, double-blind, placebo-controlled, phase 3 trial	Prospective		28-Jan-2022	
#01545	CT_35085462	Tocilizumab-Induced Unexpected Increase of Several Inflammatory Cytokines in Critically Ill COVID-19 Patients: The Anti-Inflammatory Side of IL-6	35085462	https://doi.org/10.1089/vim.2021.0111	https://pubmed.ncbi.nlm.nih.gov/35085462	23	Drug(s)	Tocilizumab		18-Mar-2020	06-May-2020	50	No	Cohort study		Brussels, Belgium	27-Jan-2022	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01546	CT_35075175	Matrix metalloproteinases (MMP) 3 and 9 as biomarkers of severity in COVID-19 patients	35075175	https://doi.org/10.1038/s41598-021-04677-8	https://pubmed.ncbi.nlm.nih.gov/35075175	156	Other		MMP9 was positively correlated with serum interleukin-6, myeloperoxidase, and circulating neutrophils and monocytes number				No			Naples, Italy	24-Jan-2022	
#01547	CT_PMC8782575	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study	PMC8782575	https://doi.org/10.1016/S0140-6736(22)00094-0	https://pubmed.ncbi.nlm.nih.gov/PMC8782575	1,205	Vaccine			16-Aug-2021	01-Sep-2021	17	No	A phase 4, non-inferiority, single blind, randomised study	Prospective	São Paulo, Brazil	21-Jan-2022	
#01548	CT_35046397	A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19	35046397	https://doi.org/10.1038/s41467-022-28064-7	https://pubmed.ncbi.nlm.nih.gov/35046397	80	Plasma		In severe COVID-19 patients with mild or moderate ARDS no significant clinical benefit was registered with convalescent plasma therapy	31-May-2020	12-Oct-2020	135	No	A phase 2, single-centered, open label, randomised control trial	Prospective	India	19-Jan-2022	
#01549	CT_35045362	Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study	35045362	https://doi.org/10.1016/j.ebiom.2021.103810	https://pubmed.ncbi.nlm.nih.gov/35045362	90	Vaccine			10-Aug-2020	13-Oct-2020	65	No	A randomized, placebo-controlled, phase I study	Prospective	France, and Belgium	16-Jan-2022	
#01550	CT_35042081	Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial	35042081	https://doi.org/10.1016/j.ebiom.2021.103811	https://pubmed.ncbi.nlm.nih.gov/35042081	231	Vaccine			27-Aug-2020	01-Dec-2020	97	No	A phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial	Prospective	USA, Austria, and Belgium	15-Jan-2022	
#01551	CT_35029629	Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial	35029629	https://doi.org/10.1001/jama.2021.24939	https://pubmed.ncbi.nlm.nih.gov/35029629	314	Drug(s)	Casirivimab | Imdevimab		13-Jul-2020	11-Mar-2021	242	No	Randomized, double-blind, placebo-controlled, phase 3 trial	Prospective	USA, Romania, and Moldova	1-Feb-2022	
#01552	CT_35023260	Effect of nanocurcumin supplementation on the severity of symptoms and length of hospital stay in patients with COVID-19: A randomized double-blind placebo-controlled trial	35023260	https://doi.org/10.1002/ptr.7374	https://pubmed.ncbi.nlm.nih.gov/35023260	44	Nanocurcumin						No	A randomized, double-blind, placebo-controlled trial	Prospective	Tehran, Iran	12-Jan-2022	
#01553	CT_35014600	Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial	35014600	https://doi.org/10.1080/19490976.2021.2018899	https://pubmed.ncbi.nlm.nih.gov/35014600	293	Probiotic			26-Aug-2020	10-Dec-2020	107	No	A randomized, quadruple-blinded, placebo-controlled trial	Prospective	Mexico	11-Jan-2022	
#01554	CT_34999239	High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial	34999239	https://doi.org/10.1016/j.ijantimicag.2021.106516	https://pubmed.ncbi.nlm.nih.gov/34999239	93	Drug(s)	Ivermectin		31-Jul-2020	29-Jun-2021	334	No	A randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial	Prospective	Italy	6-Jan-2022	
#01555	CT_34975830	The Effect of Vitamin C on Pathological Parameters and Survival Duration of Critically Ill Coronavirus Disease 2019 Patients: A Randomized Clinical Trial	34975830	https://doi.org/10.3389/fimmu.2021.717816	https://pubmed.ncbi.nlm.nih.gov/34975830	120	Drug(s)	Vitamin C					No	Randomized controlled trial	Prospective	Iran	15-Dec-2021	Randomized clinical trial carried out from May to July 2020
#01556	CT_34928990	Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study	34928990	https://doi.org/10.1371/journal.pone.0261113	https://pubmed.ncbi.nlm.nih.gov/34928990	75	Drug(s)	Eculizumab					No	Single-centre, academic, unblinded study	Retrospective	Bergamo, Italy	20-Dec-2021	Study performed from February 2020 to April 2020
#01557	CT_34964849	Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19: A Randomized Clinical Trial	34964849	https://doi.org/10.1001/jamanetworkopen.2021.41328	https://pubmed.ncbi.nlm.nih.gov/34964849	1,279	Drug(s)	Colchicine		17-Apr-2020	28-Mar-2021	346	No	A multicenter, open-label, randomized clinical trial	Prospective	Argentina	1-Dec-2021	
#01558	CT_34963099	Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial	34963099	https://doi.org/10.1016/j.ebiom.2021.103789	https://pubmed.ncbi.nlm.nih.gov/34963099	100	Other		17.9% of patients in the MSC group had normal CT images at month 12, but none in placebo group (p = 0.013), MSC group improved in whole-lung lesion volume than placebo p = 0.03	08-Apr-2020	31-Mar-2021	358	No	A randomized, double-blind, placebo-controlled trial	Prospective	Hubei, China	25-Dec-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01559	CT_34956222	Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together	34956222	https://doi.org/10.3389/fimmu.2021.790469	https://pubmed.ncbi.nlm.nih.gov/34956222	568	Drug(s)	Bamlanivimab | Etesevimab	N-terminal domain (Spike-NTD) and nucleocapsid protein (NCP) epitopes were 1.4 to 4.1 fold lower at day 15-85 in mAb recipients than placebo.				No	Cohort study		USA	9-Dec-2021	
#01560	CT_34937145	Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients	34937145	https://doi.org/10.1056/NEJMoa2116846	https://pubmed.ncbi.nlm.nih.gov/34937145	562	Drug(s)	Remdesivir		18-Sep-2020	08-Apr-2021	203	No	Randomized controlled trial	Prospective	USA	22-Dec-2021	
#01561	CT_34929493	Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants	34929493	https://doi.org/10.1016/j.ebiom.2021.103761	https://pubmed.ncbi.nlm.nih.gov/34929493	26	Other						No	Comparative, cohort study	Retrospective	Ulm, Germany	17-Dec-2021	
#01562	CT_34907003	Hyperbaric oxygen as an adjuvant treatment for patients with COVID-19 severe hypoxaemia: a randomised controlled trial	34907003	https://doi.org/10.1136/emermed-2021-211253	https://pubmed.ncbi.nlm.nih.gov/34907003	39	Oxygen support		Time to correct hypoxaemia was shorter in treatment group versus control group; median 3 days vs median 9 days , respectively (p<0.010)				No	Randomized controlled trial	Prospective	Buenos Aires, Argentina	14-Dec-2021	Study performed from July to November 2020
#01563	CT_34901997	Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial	34901997	https://doi.org/10.1001/jamainternmed.2021.6850	https://pubmed.ncbi.nlm.nih.gov/34901997	926	Plasma			17-Apr-2020	15-Mar-2021	333	No	Randomized controlled trial	Prospective	USA	1-Feb-2022	
#01564	CT_34883053	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial	34883053	https://doi.org/10.1016/S0140-6736(21)02718-5	https://pubmed.ncbi.nlm.nih.gov/34883053	1,072	Vaccine			19-Apr-2021	05-Oct-2021	170	No	A single-blind, randomised, phase 2, non-inferiority trial	Prospective	UK	6-Dec-2021	
#01565	CT_34874419	Effect of High-Flow Oxygen Therapy vs Conventional Oxygen Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients With Severe COVID-19: A Randomized Clinical Trial	34874419	https://doi.org/10.1001/jama.2021.20714	https://pubmed.ncbi.nlm.nih.gov/34874419	199	Oxygen support		High-flow oxygen through a nasal cannula significantly decreased need for mechanical ventilation and time to recovery than conventional low-flow oxygen therapy	13-Aug-2020	10-Feb-2021	182	No	Randomized controlled trial	Prospective	Colombia	7-Dec-2021	
#01566	CT_34871182	Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome	34871182	https://doi.org/10.1172/JCI153173	https://pubmed.ncbi.nlm.nih.gov/34871182	62	Drug(s)	CERC-002	Patients remained alive and free of respiratory failure through day 28 after receiving CERC-002 (83.9%) versus placebo (64.5%; P = 0.044)	17-Jul-2020	19-Jan-2021	187	No	A randomized, double-blind, multicenter, proof-of-concept trial	Prospective	USA	1-Feb-2022	
#01567	CT_34863304	Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden	34863304	https://doi.org/10.1186/s13104-021-05847-7	https://pubmed.ncbi.nlm.nih.gov/34863304	31	Plasma						No	A randomized, controlled, open-label study	Prospective	Sweden	4-Dec-2021	Study carried out between June 2020 and January 2021
#01568	CT_34858404	Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine	34858404	https://doi.org/10.3389/fimmu.2021.747830	https://pubmed.ncbi.nlm.nih.gov/34858404	18	Vaccine						No	A phase 3 clinical trial	Prospective	Chile	9-Nov-2021	
#01569	CT_34852148	Effect of a Single High-Dose Vitamin D3 on the Length of Hospital Stay of Severely 25-Hydroxyvitamin D-Deficient Patients with COVID-19	34852148	https://doi.org/10.6061/clinics/2021/e3549	https://pubmed.ncbi.nlm.nih.gov/34852148	32	Drug(s)	Vitamin D3	200.000 IU of vitamin D3 did not significantly reduce the length of hospital stay of patients with severe 25-hydroxyvitamin D deficiency and COVID-19				No	A multicenter, double-blinded, randomized, placebo-controlled trial	Prospective	São Paulo, Brazil	26-Nov-2021	
#01570	CT_34844191	Next generation plasma proteome profiling of COVID-19 patients with mild to moderate symptoms	34844191	https://doi.org/10.1016/j.ebiom.2021.103723	https://pubmed.ncbi.nlm.nih.gov/34844191	50	Other						No	Randomized controlled trial	Ambispective	Istanbul, Turkey	27-Nov-2021	Study conducted from September 2020 to January 2021
#01571	CT_35201518	Inflawell ® improves neutrophil-to-lymphocyte ratio and shortens hospitalization in patients with moderate COVID-19, in a randomized double-blind placebo-controlled clinical trial	35201518	https://doi.org/10.1007/s10787-022-00928-w	https://pubmed.ncbi.nlm.nih.gov/35201518	47	Drug(s)	Inflawell (Boswellia extract)		25-Jan-2021	05-Mar-2021	40	No	A phase II randomized, double-blind, placebo-controlled parallel trial		Tehran, Iran	24-Feb-2022	
#01572	CT_34882589	Inactivated Whole-virus Vaccine Triggers Low Response Against SARS-CoV-2 Infection Among Renal Transplant Patients: Prospective Phase 4 Study Results	34882589	https://doi.org/10.1097/TP.0000000000004036	https://pubmed.ncbi.nlm.nih.gov/34882589	3,371	Vaccine	CoronaVac		20-Mar-2021	22-Aug-2021	156	No	Phase 4, nonrandomized, single-center interventional study	Prospective	São Paulo, Brazil	24-Mar-2022	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01573	CT_35073571	Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study	35073571	https://doi.org/10.1182/bloodadvances.2021006627	https://pubmed.ncbi.nlm.nih.gov/35073571	36	Vaccine | Other						No	Cohort study	Prospective	Massachusetts, USA	14-Mar-2022	Study was conducted between August 2020 and August 2021
#01574	CT_35177302	A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report	35177302	https://doi.org/10.1016/j.vaccine.2022.02.030	https://pubmed.ncbi.nlm.nih.gov/35177302	200	Vaccine	mRNA-1273/TAK-919					No	Phase 1/2, randomised, observer-blind, placebo-controlled trial		Japan	8-Feb-2022	The participants are to be followed up for 12 months after the second dose
#01575	CT_35164986	A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity	35164986	https://doi.org/10.1016/j.vaccine.2022.02.029	https://pubmed.ncbi.nlm.nih.gov/35164986	60	Vaccine						No	Phase I, randomized, double-blind clinical trial		Havana, Cuba	8-Feb-2022	
#01576	CT_35081293	Homologous and Heterologous Covid-19 Booster Vaccinations	35081293	https://doi.org/10.1056/NEJMoa2116414	https://pubmed.ncbi.nlm.nih.gov/35081293	457	Vaccine			29-May-2021	13-Sep-2021	108	No	Phase 1-2, open-label, nonrandomized, adaptive-design clinical trial		USA	26-Jan-2022	
#01577	CT_35210118	Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial	35210118	https://doi.org/10.1016/j.vaccine.2022.02.019	https://pubmed.ncbi.nlm.nih.gov/35210118	125	Vaccine	ChAdOx1 nCoV-19/AZD1222					No	Single-center, non-inferiority, randomized controlled trial		Thailand	21-Feb-2022	
#01578	CT_35045226	Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming	35045226	https://doi.org/10.1056/NEJMoa2116747	https://pubmed.ncbi.nlm.nih.gov/35045226	434	Vaccine | Other	Ad26.COV2.S | mRNA-1273 | BNT162b2					No	Single-blind, multicenter, randomized, controlled trial		The Netherlands	19-Jan-2022	
#01579	CT_35114690	Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients	35114690	https://doi.org/10.1182/bloodadvances.2021006917	https://pubmed.ncbi.nlm.nih.gov/35114690	723	Other						No	Observational, multicenter, cohort study	Prospective	The Netherlands	4-Mar-2022	
#01580	CT_35139271	Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S	35139271	https://doi.org/10.1056/NEJMoa2117608	https://pubmed.ncbi.nlm.nih.gov/35139271	8,940	Other			21-Sep-2020	09-Jul-2021	292	No	Double-blinded portion of phase 3 multinational, randomized, placebo-controlled trial			9-Feb-2022	
#01581	CT_35150610	High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial	35150610	https://doi.org/10.1016/S2213-2600(21)00545-2	https://pubmed.ncbi.nlm.nih.gov/35150610	376	Plasma			10-Nov-2020	28-Jul-2021	261	No	A multicentre, double-blind, randomised, placebo-controlled trial	Prospective	Catalonia, Spain	10-Mar-2022	
#01582	CT_35131133	Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial	35131133	https://doi.org/10.1016/j.vaccine.2021.12.046	https://pubmed.ncbi.nlm.nih.gov/35131133	3,813	Vaccine | Other	BNT162b2					No	Randomized, placebo-controlled, observer-blinded global phase 3 clinical trial		USA	24-Dec-2021	
#01583	CT_34863332	A phase 3, randomised, double-blind, placebo-controlled trial	34863332	https://doi.org/10.1016/S2213-2600(21)00494-X	https://pubmed.ncbi.nlm.nih.gov/34863332	528	Drug(s)	Lenzilumab		05-May-2020	27-Jan-2021	268	No			USA, and Brazil	1-Dec-2021	
#01584	CT_34826383	Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study	34826383	https://doi.org/10.1016/S1473-3099(21)00674-5	https://pubmed.ncbi.nlm.nih.gov/34826383	2,136	Vaccine | Other			15-Apr-2021	15-May-2021	31	No	A test-negative, case-control study		India	23-Nov-2021	
#01585	CT_34826381	Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial	34826381	https://doi.org/10.1016/S1473-3099(21)00677-0	https://pubmed.ncbi.nlm.nih.gov/34826381	39,680	Vaccine	CVnCoV		11-Dec-2020	12-Apr-2021	123	No	A randomised, observer-blinded, placebo-controlled, phase 2b/3 trial		Europe and Latin America	23-Nov-2021	
#01586	CT_35192617	Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients	35192617	https://doi.org/10.1371/journal.pone.0261979	https://pubmed.ncbi.nlm.nih.gov/35192617	52	Other						No	Cohort study	Prospective	Bergen, Norway	22-Feb-2022	
#01587	CT_35151397	Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	35151397	https://doi.org/10.1016/S0140-6736(22)00163-5	https://pubmed.ncbi.nlm.nih.gov/35151397	9,785	Drug(s)	Casirivimab | Imdevimab		18-Sep-2020	22-May-2021	247	No	A randomised, controlled, open-label platform trial		UK	12-Feb-2022	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
	Count >>>	1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01588	CT_35136139	Development of SARS-CoV2 humoral response including neutralizing antibodies is not sufficient to protect patients against fatal infection	35136139	https://doi.org/10.1038/s41598-022-06038-5	https://pubmed.ncbi.nlm.nih.gov/35136139	187	Other						No	Cohort study		Brussels, Belgium	8-Feb-2022	
#01589	CT_35087233	Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial	35087233	https://doi.org/10.1038/s41591-021-01677-z	https://pubmed.ncbi.nlm.nih.gov/35087233	293	Vaccine						No	A single-center, randomized, controlled, observer-blinded trial	Prospective	China	27-Jan-2022	
#01590	CT_34928302	Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial	34928302	https://doi.org/10.1001/jamainternmed.2021.7372	https://pubmed.ncbi.nlm.nih.gov/34928302	197	Vaccine	BNT162b2 | mRNA-1273 | Ad26COVS1		15-Jun-2021	16-Aug-2021	63	No	An investigator-initiated, single center, single-blinded, 1:1 randomized clinical trial		Vienna, Austria	20-Dec-2021	
#01591	CT_34807716	Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine : Secondary Analysis of a Randomized Trial	34807716	https://doi.org/10.7326/M21-3480	https://pubmed.ncbi.nlm.nih.gov/34807716	117	Vaccine | Other						No	Secondary analysis of a randomized, double-blind, controlled trial		Ontario, Canada	23-Nov-2021	
#01592	CT_34775604	Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid-organ cancers	34775604	https://doi.org/10.1111/imm.13433	https://pubmed.ncbi.nlm.nih.gov/34775604	299	Other			01-Feb-2021	01-Apr-2021	60	No	Cohort study		Cardiff, UK	6-Dec-2021	
#01593	CT_34536349	Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial	34536349	https://doi.org/10.1016/S1473-3099(21)00462-X	https://pubmed.ncbi.nlm.nih.gov/34536349	288	Vaccine	BBIBP-CorV		14-Aug-2021	24-Sep-2021	42	No	A randomised, double-blind, dose-escalation, controlled phase 1/2 trial		Henan, China	15-Sep-2021	
#01594	CT_35065705	Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial	35065705	https://doi.org/10.1016/S0140-6736(22)00055-1	https://pubmed.ncbi.nlm.nih.gov/35065705	30,128	Vaccine			24-Mar-2021	10-Aug-2021	140	No	Ongoing phase 2 and 3 double-blind, placebo-controlled trial		Belgium, Brazil, Colombia, Philippines, and South Africa	20-Jan-2022	
#01595	CT_35042847	Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naive patients	35042847	https://doi.org/10.1038/s41408-022-00608-6	https://pubmed.ncbi.nlm.nih.gov/35042847	189	Other			01-Mar-2020	01-Apr-2021	397	No	Multicenter cross-sectional cohort study		Italy	18-Jan-2022	
#01596	CT_34953526	Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial	34953526	https://doi.org/10.1016/S0140-6736(21)02753-7	https://pubmed.ncbi.nlm.nih.gov/34953526	3,152	Vaccine			22-Sep-2020	15-Jan-2021	116	No	Double-blind, randomised, international, placebo-controlled, endpoint-case driven, phase 3, clinical trial		Argentina, Chile, Mexico, Pakistan, and Russia	23-Dec-2021	
#01597	CT_34824035	Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV	34824035	https://doi.org/10.1016/j.intimp.2021.108383	https://pubmed.ncbi.nlm.nih.gov/34824035	48	Vaccine | Other						No	Cohort study		China	18-Nov-2021	
#01598	CT_34688944	Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial	34688944	https://doi.org/10.1016/j.ijid.2021.10.030	https://pubmed.ncbi.nlm.nih.gov/34688944	256	Vaccine	ChAdOx1 nCoV-19					No	Phase 1/2, randomized, double-blind, parallel-group, placebo-controlled trial		Japan	22-Oct-2021	
#01599	CT_34933684	Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial	34933684	https://doi.org/10.1186/s40249-021-00924-2	https://pubmed.ncbi.nlm.nih.gov/34933684	809	Vaccine						No	An ongoing randomized, parallel, controlled phase IV trial		China	22-Dec-2021	Study was conducted between Jan 2021 and May 2021
#01600	CT_34863358	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial	34863358	https://doi.org/10.1016/S0140-6736(21)02717-3	https://pubmed.ncbi.nlm.nih.gov/34863358	2,878	Vaccine	ChAdOx1 nCov-19 | BNT162b2		01-Jun-2021	30-Jun-2021	30	No	A multicentre, randomised, controlled, phase 2 trial		UK	18-Dec-2021	
#01601	CT_34774197	Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial	34774197	https://doi.org/10.1016/S0140-6736(21)02329-1	https://pubmed.ncbi.nlm.nih.gov/34774197	679	Vaccine	ChAdOx1 | BNT162b2		01-Apr-2021	26-Jun-2021	87	No	A multicentre, randomised, controlled, phase 4 trial		UK	18-Dec-2021	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01602	CT_34587382	Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine	34587382	https://doi.org/10.1056/NEJMoa2105290	https://pubmed.ncbi.nlm.nih.gov/34587382	32,451	Vaccine	ChAdOx1 nCoV-19		28-Aug-2020	15-Jan-2021	141	No	Double-blind, randomized, placebo-controlled, phase 3 clinical trial			29-Sep-2021	
#01603	CT_34774196	Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial	34774196	https://doi.org/10.1016/S0140-6736(21)02000-6	https://pubmed.ncbi.nlm.nih.gov/34774196	25,798	Vaccine	BBV152		16-Nov-2020	07-Jan-2021	53	No	A randomised, double-blind, placebo-controlled, multicentre, phase 3		India	11-Nov-2021	
#01604	CT_34950155	CD19+IgD+CD27- Naïve B Cells as Predictors of Humoral Response to COVID 19 mRNA Vaccination in Immunocompromised Patients	34950155	https://doi.org/10.3389/fimmu.2021.803742	https://pubmed.ncbi.nlm.nih.gov/34950155	199	Other						No	Case report			7-Dec-2021	
#01605	CT_35363644	Impact of Gestational COVID-19 on Neonatal Outcomes: Is Vertical Infection Possible?	35363644	https://doi.org/10.1097/INF.0000000000003518	https://pubmed.ncbi.nlm.nih.gov/35363644	351	Other		5.1% were considered to have SARS-CoV-2 infection in the neonatal period, with 1.7% considered intrauterine and 3.4% intrapartum or early postnatal transmission cases.	15-Mar-2020	30-Nov-2020	261	No	Observational, descriptive, multicentric study	Prospective	Spain	30-Mar-2022	
#01606	CT_35363626	Patterns of Inflammatory Cell Infiltration and Expression of STAT6 in the Lungs of Patients With COVID-19: An Autopsy Study	35363626	https://doi.org/10.1097/PAI.0000000000001023	https://pubmed.ncbi.nlm.nih.gov/35363626	18	Other		STAT6 expression was increased in pneumocytes and lymphocytes in the lungs of patients with COVID-19				No	Autopsy Study		USA	4-Apr-2022	
#01607	CT_35363202	Prognostic value of serum amyloid A in COVID-19: A meta-analysis	35363202	https://doi.org/10.1097/MD.0000000000028880	https://pubmed.ncbi.nlm.nih.gov/35363202	4,248	Other			01-Dec-2019	19-Dec-2020	385	Yes	Meta-analysis	Retrospective	China	18-Feb-2022	
#01608	CT_35363187	The association of clinical features and laboratory findings of COVID-19 infection with computed pneumonia volume	35363187	https://doi.org/10.1097/MD.0000000000028856	https://pubmed.ncbi.nlm.nih.gov/35363187	66	Other			23-Jan-2020	20-Feb-2020	29	No	Observational study	Retrospective	China	18-Feb-2022	
#01609	CT_35363081	The Age-Dependent Role of Th22, Tc22, and Tc17 Cells in the Severity of Pneumonia in COVID-19 Immunopathogenesis	35363081	https://doi.org/10.1089/vim.2021.0132	https://pubmed.ncbi.nlm.nih.gov/35363081	210	Other						No	Cohort study		Bursa, Turkey	31-Mar-2022	
#01610	CT_35362857	Treatments, resource utilization, and outcomes of COVID-19 patients presenting to emergency departments across pandemic waves: an observational study by the Canadian COVID-19 Emergency Department Rapid Response Network (CCEDRRN)	35362857	https://doi.org/10.1007/s43678-022-00275-3	https://pubmed.ncbi.nlm.nih.gov/35362857	9,967				01-Mar-2020	31-Dec-2020	306	No	Observational study	Retrospective	Canada	1-Apr-2022	
#01611	CT_35362530	Clinical and virological characteristics of SARS-CoV-2 B.1.617.2 (Delta) variant: a prospective cohort study	35362530	https://doi.org/10.1093/cid/ciac239	https://pubmed.ncbi.nlm.nih.gov/35362530	141	Other		Delta variant exhibited prolonged viable viral shedding with more severe symptoms non-delta variants				No	Observational, cohort study	Prospective	Seoul, South Korea	1-Apr-2022	Study performed between July and August 2021
#01612	CT_35362405	Seroprevalence of antibodies against SARS-CoV-2 in the adult population during the pre-vaccination period, Norway, winter 2020/21	35362405	https://doi.org/10.2807/1560-7917.ES.2022.27.13.2100376	https://pubmed.ncbi.nlm.nih.gov/35362405	27,700	Other						No	Population-based, cross-sectional study		Norway	31-Mar-2022	
#01613	CT_35362306	Timeline of critically ill 2019 SARS-CoV-2 cases after onset of illness: Intensive care data from Turkey	35362306	https://doi.org/10.5578/tt.20229908	https://pubmed.ncbi.nlm.nih.gov/35362306	213	Other						No	Observational study	Retrospective	Turkey	10-Feb-2022	Study included between March 2020 and March 2021
#01614	CT_35362143	Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma	35362143	https://doi.org/10.1111/iju.14882	https://pubmed.ncbi.nlm.nih.gov/35362143	145	Other			21-Jun-2021	01-Nov-2021	134	No	Cohort study	Retrospective	Japan	31-Mar-2022	Study conduced between June 21 and November 1, 2021
#01615	CT_35361992	Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults	35361992	https://doi.org/10.1038/s41591-022-01780-9	https://pubmed.ncbi.nlm.nih.gov/35361992	36	Other						No	Cohort study	Retrospective	UK	31-Mar-2022	
#01616	CT_35361913	Serum IL-28A/IFN-λ2 is linked to disease severity of COVID-19	35361913	https://doi.org/10.1038/s41598-022-09544-8	https://pubmed.ncbi.nlm.nih.gov/35361913	257	Other			21-Mar-2020	31-Mar-2021	376	No	Observational, cohort study	Retrospective	Tokyo, Japan	31-Mar-2022	
#01617	CT_35361888	Absence of SARS-CoV-2 Spike glycoprotein expression in placentas from individuals after mRNA SARS-CoV-2 vaccination	35361888	https://doi.org/10.1038/s41379-022-01061-3	https://pubmed.ncbi.nlm.nih.gov/35361888	48	Other			01-Jan-2021	01-Dec-2021	335	No	Cohort study	Prospective	USA	31-Mar-2022	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01618	CT_35361691	**Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy**	35361691	https://doi.org/10.1136/rmdopen-2021-002166	https://pubmed.ncbi.nlm.nih.gov/35361691	91	Vaccine | Other	BNT162b2 | mRNA-1273		26-Apr-2021	30-Jun-2021	66	No	Single-centre, open-label, case–control study		Bern, Switzerland	31-Mar-2022	
#01619	CT_35361651	**Prediction of the need for intensive oxygen supplementation during hospitalisation among subjects with COVID-19 admitted to an academic health system in Texas: a retrospective cohort study and multivariable regression model**	35361651	https://doi.org/10.1136/bmjopen-2021-058238	https://pubmed.ncbi.nlm.nih.gov/35361651	329	Other		The multivariable regression model found that lactate dehydrogenase (OR 2.36), Quick Sequential Organ Failure Assessment score (OR 2.26) and neutrophil to lymphocyte ratio (OR 1.15) were significant predictors of severe disease	19-Mar-2020	30-Jun-2020	104	No	Cohort study	Retrospective	Texas, USA	31-Mar-2022	
#01620	CT_35361632	**Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia, A double-blind, randomised, placebo-controlled trial**	35361632	https://doi.org/10.1183/13993003.00025-2022	https://pubmed.ncbi.nlm.nih.gov/35361632	301	Drug(s)	Methylprednisolone | Dexamethasone	No significant differences between pulse methylprednisolone and placebo arms were observed in terms of admission to ICU with orotracheal intubation or death, or overall mortality	21-Dec-2020	10-Mar-2021	80	No	Multicenter, randomised, double-blind, placebo-controlled trial,	Prospective	Italy	31-Mar-2022	
#01621	CT_35361536	**Adverse reactions to the first and second doses of Pfizer-BioNTech COVID-19 vaccine among healthcare workers**	35361536	https://doi.org/10.1016/j.jiac.2022.03.015	https://pubmed.ncbi.nlm.nih.gov/35361536	374	Vaccine	Pfizer-BioNTech		08-Mar-2021	09-Jul-2021	124	No		Prospective	Kyoto, Japan	25-Mar-2022	
#01622	CT_35361531	**Prevalence and prognosis of increased pancreatic enzymes in patients with COVID-19: A systematic review and meta-analysis**	35361531	https://doi.org/10.1016/j.pan.2022.03.014	https://pubmed.ncbi.nlm.nih.gov/35361531	36,496							Yes	Systematic review and meta-analysis			25-Mar-2022	
#01623	CT_35361161	**Demographics, clinical characteristics, and outcomes of 27,256 hospitalized COVID-19 patients in Kermanshah Province, Iran: a retrospective one-year cohort study**	35361161	https://doi.org/10.1186/s12879-022-07312-7	https://pubmed.ncbi.nlm.nih.gov/35361161	27,256	Other			20-Feb-2020	19-Feb-2021	366	No	Multicenter, cohort study	Retrospective	Kermanshah, Iran	31-Mar-2022	
#01624	CT_35361140	**A cohort study measuring SARS-CoV-2 seroconversion and serial viral testing in university students**	35361140	https://doi.org/10.1186/s12879-022-07314-5	https://pubmed.ncbi.nlm.nih.gov/35361140	107	Other			01-Sep-2020	15-Nov-2020	76	No	Cohort study		USA	31-Mar-2022	
#01625	CT_35361071	**SOD2 rs4880 and GPX1 rs1050450 polymorphisms do not confer risk of COVID-19, but influence inflammation or coagulation parameters in Serbian cohort**	35361071	https://doi.org/10.1080/13510002.2022.2057707	https://pubmed.ncbi.nlm.nih.gov/35361071	458	Other		Only GSTP1 haplotype was associated with COVID-19 risk (p = 0.009)				No	Cohort study		Serbia	31-Mar-2022	Samples were collected between March and June 2021
#01626	CT_35360973	**Incidence and Clinical Features of Pneumomediastinum and Pneumothorax in COVID-19 Pneumonia**	35360973	https://doi.org/10.1177/08850666221091441	https://pubmed.ncbi.nlm.nih.gov/35360973	3,377	Other		Air leak occurred with 0.56%	01-Mar-2020	28-Feb-2021	365	No	Obsrvational study	Retrospective	Watford, UK	31-Mar-2022	
#01627	CT_35360970	**Acute Myocardial Injury Assessed by High-Sensitive Cardiac Troponin Predicting Severe Outcomes and Death in Hospitalized Patients with COVID-19 Infection**	35360970	https://doi.org/10.1177/10760296221090227	https://pubmed.ncbi.nlm.nih.gov/35360970	298	Other		Cox proportional hazards regression analysis shows a significantly increased risk of death among cardiac-injured COVID-19-patients	01-Oct-2020	01-Dec-2020	62	No	Cohort study	Retrospective	Oujda, Morocco	31-Mar-2022	
#01628	CT_35360793	**Chest radiographic findings and their correlation with disease progression in COVID-19 patients in northern India**	35360793	https://doi.org/10.4103/jfmpc.jfmpc_398_21	https://pubmed.ncbi.nlm.nih.gov/35360793	500	Other		Fever and cough were the most common symptoms but significant correlation of an abnormal CXR was found with dyspnoea	15-Mar-2020	01-Jul-2020	109	No	Obsrvational study	Retrospective	Pradesh, India	16-Feb-2022	
#01629	CT_35360736	**Comparison of SARS-CoV-2 Variants of Concern Alpha (B.1.1.7) vs. Beta (B.1.351) in Critically Ill Patients: A Multicenter Cohort Study**	35360736	https://doi.org/10.3389/fmed.2022.828402	https://pubmed.ncbi.nlm.nih.gov/35360736	333	Other		Alpha and Beta groups did not differ significantly in terms of 60-day mortality (19 vs. 23%), 28-day mortality (17 vs. 20%), need for mechanical ventilation (60 vs. 61%), mechanical ventilation duration (14 vs. 15 days), patient demographic variables, comorbidities, or clinical variables on ICU admission	09-Jan-2021	15-May-2021	127	No	Multicenter, cohort study	Ambispective	France	10-Mar-2022	
#01630	CT_35360719	**The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study**	35360719	https://doi.org/10.3389/fmed.2022.850858	https://pubmed.ncbi.nlm.nih.gov/35360719	358	Other		The overall prevalence of anti-SARS-CoV-2 antibodies was (18.4%)				No	Cohort study		Milan, Italy	11-Mar-2022	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01631	CT_35360197	Long-term Outcomes and Recovery of Patients who Survived COVID-19: LUNG INJURY COVID-19 Study	35360197	https://doi.org/10.1093/ofid/ofac098	https://pubmed.ncbi.nlm.nih.gov/35360197	305				23-Mar-2020	20-Aug-2020	151	No	Observational, cohort study	Prospective	Madrid, Spain	25-Feb-2022	
#01632	CT_35360196	Clinical Outcomes in Hospitalized Vaccine-Breakthrough Coronavirus Disease 2019 Cases Compared With Contemporary Unvaccinated Hospitalized Adults	35360196	https://doi.org/10.1093/ofid/ofac122	https://pubmed.ncbi.nlm.nih.gov/35360196	767	Other			27-Mar-2021	31-Aug-2021	158	No	Report		Santiago, Chile	13-Mar-2022	
#01633	CT_35360195	Characteristics and Risk Factors for Mortality by Coronavirus Disease 2019 Pandemic Waves in Fulton County, Georgia: A Cohort Study March 2020-February 2021	35360195	https://doi.org/10.1093/ofid/ofac101	https://pubmed.ncbi.nlm.nih.gov/35360195	75,289	Other		Cases with any disability, chronic renal disease, and cardiovascular disease were more likely to die in each wave compared with those without these comorbidities	02-Mar-2020	28-Feb-2021	364	No	Cohort study	Retrospective	Georgia, USA	3-Mar-2022	
#01634	CT_35360017	Meta-Analysis and Systematic Review of Coagulation Disbalances in COVID-19: 41 Studies and 17,601 Patients	35360017	https://doi.org/10.3389/fcvm.2022.794092	https://pubmed.ncbi.nlm.nih.gov/35360017	17,601	Other		Hemostatic laboratory parameters, with exception of platelets, are significantly elevated in patients with severe COVID-19				Yes	Meta-analysis and systematic review	Retrospective		11-Mar-2022	
#01635	CT_35359969	Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern	35359969	https://doi.org/10.3389/fimmu.2022.863039	https://pubmed.ncbi.nlm.nih.gov/35359969	46	Other			26-Mar-2020	31-Jul-2020	128	No	Cohort study	Prospective	Hannover, Germany	14-Mar-2022	
#01636	CT_35359967	SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity	35359967	https://doi.org/10.3389/fimmu.2022.840126	https://pubmed.ncbi.nlm.nih.gov/35359967	5	Other						No	Cohort study		Berlin, Germany	10-Mar-2022	
#01637	CT_35359947	Impact of Hypogammaglobulinemia on the Course of COVID-19 in a Non-Intensive Care Setting: A Single-Center Retrospective Cohort Study	35359947	https://doi.org/10.3389/fimmu.2022.842643	https://pubmed.ncbi.nlm.nih.gov/35359947	374	Other			01-Dec-2020	31-Jan-2021	62	No	Single-center, cohort study	Retrospective	Treviso, Italy	10-Mar-2022	
#01638	CT_35359931	Disease Severity in Moderate-to-Severe COVID-19 Is Associated With Platelet Hyperreactivity and Innate Immune Activation	35359931	https://doi.org/10.3389/fimmu.2022.844701	https://pubmed.ncbi.nlm.nih.gov/35359931	87	Other		Severe inflammatory response, platelet hyperreactivity associated to a worse clinical outcome in patients with COVID-19				No	Cohort study	Retrospective	Berlin, Germany	11-Mar-2022	Patients were recruited between May 2020 and May 2021
#01639	CT_35359885	Evaluation of Clinical Findings and Treatment Results of Coronavirus Disease 2019 (COVID-19) in Pediatric Cancer Patients: A Single Center Experience	35359885	https://doi.org/10.3389/fped.2022.848379	https://pubmed.ncbi.nlm.nih.gov/35359885	45	Other						No	Obsrvational study	Retrospective	Adana, Turkey	10-Mar-2022	Pediatric cancer patients with COVID-19 admitted from October 2020 to October 2021
#01640	CT_35359732	Inactivated Vaccines Against SARS-CoV-2: Neutralizing Antibody Titers in Vaccine Recipients	35359732	https://doi.org/10.3389/fmicb.2022.816778	https://pubmed.ncbi.nlm.nih.gov/35359732	1,335	Vaccine | Other	Sinovac vaccine | WIV04 vaccine | HB02 vaccine	NAb positivity rate was the highest at the first and second month after the second dose of vaccine, and gradually decreased over time. With a 21-day interval between two doses, neutralizing antibody levels persisted for only 6 months after the second dose .	19-Jan-2021	23-Jun-2021	156	No	Cohort study		Beijing, China	10-Mar-2022	
#01641	CT_35359698	Comparison of patients with severe COVID-19 admitted to an intensive care unit in South Africa during the first and second wave of the COVID-19 pandemic	35359698	https://doi.org/10.7196/AJTCCM.2021.v27i4.185	https://pubmed.ncbi.nlm.nih.gov/35359698	490	Other			27-Mar-2020	10-Feb-2021	321	No	Single-centre, descriptive study	Prospective	Cape Town, South Africa	31-Dec-2021	
#01642	CT_35359407	Outcomes of Patients With Active Cancer and COVID-19 in the Intensive-Care Unit: A Multicenter Ambispective Study	35359407	https://doi.org/10.3389/fonc.2022.858276	https://pubmed.ncbi.nlm.nih.gov/35359407	409	Other			12-Mar-2020	08-Mar-2021	362	No	Cohort study	Ambispective	France	10-Mar-2022	
#01643	CT_35359168	Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia	35359168	https://doi.org/10.1007/s00134-022-06677-2	https://pubmed.ncbi.nlm.nih.gov/35359168	924	Drug(s)	Dexamethasone	At 180 days, patients (33.7%) had died in the 12 mg group versus (38.6%) in the 6 mg group				No				31-Mar-2022	
#01644	CT_35359137	Barotrauma in critically ill COVID-19 patients: a retrospective case-control study	35359137	https://doi.org/10.5114/ait.2022.114034	https://pubmed.ncbi.nlm.nih.gov/35359137	60	Other		Barotrauma in the COVID-19 ICU is associated with prolonged ICU stay, higher odds of mortality and longer duration spent on mechanical ventilation and a high-flow nasal cannula	01-Oct-2020	31-Dec-2020	92	No	Case-control study	Retrospective	India	16-Mar-2022	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01645	CT_35359136	Predicting the effectiveness of high-flow oxygen therapy in COVID-19 patients: a single-centre observational study	35359136	https://doi.org/10.5114/ait.2022.113738	https://pubmed.ncbi.nlm.nih.gov/35359136	16	Oxygen support			16-Mar-2020	03-Jun-2020	80	No	Observational study	Retrospective	Gauting, Germany	16-Mar-2022	
#01646	CT_35358723	Serological surveillance of healthcare workers to evaluate natural infection- and vaccine-derived immunity to SARS-CoV-2 during an outbreak in Dili, Timor-Leste	35358723	https://doi.org/10.1016/j.ijid.2022.03.043	https://pubmed.ncbi.nlm.nih.gov/35358723	324	Other			07-Apr-2021	08-Sep-2021	155	No	Longitudinal study	Prospective	Dili, Timor-Leste	28-Mar-2022	
#01647	CT_35358722	Role of procalcitonin as a predictor of clinical outcomes in hospitalized patients with COVID-19	35358722	https://doi.org/10.1016/j.ijid.2022.03.044	https://pubmed.ncbi.nlm.nih.gov/35358722	223	Other		Study results demonstrate statistically significant correlation between PCT ≤ 0.25 ng/ml and admission APACHE II score and CRP levels	01-Mar-2020	10-Jul-2020	132	No	Cohort study	Retrospective	Nebraska, USA	28-Mar-2022	
#01648	CT_35358491	Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England	35358491	https://doi.org/10.1016/S2352-4642(22)00059-1	https://pubmed.ncbi.nlm.nih.gov/35358491	690,761	Other			27-Jan-2020	31-Jul-2021	552	No	National surveillance study	Prospective	England	28-Mar-2022	
#01649	CT_35358307	Cellular and humoral immune responses to SARS-CoV-2 vaccination in inflammatory bowel disease patients	35358307	https://doi.org/10.1093/ecco-jcc/jjac048	https://pubmed.ncbi.nlm.nih.gov/35358307	90	Other						No	A non-interventional, observational trial		Czech Republic	31-Mar-2022	
#01650	CT_35358238	Clinical characteristics, systemic complications, and in-hospital outcomes for patients with COVID-19 in Latin America. LIVEN-Covid-19 study: A prospective, multicenter, multinational, cohort study	35358238	https://doi.org/10.1371/journal.pone.0265529	https://pubmed.ncbi.nlm.nih.gov/35358238	3,008	Other						No	Observational cohort study	Prospective	Latin America	31-Mar-2022	Subjects admitted to 22 hospitals due to SARS-CoV-2 infection in eight countries in Latin America between March 2020 and January 2021
#01651	CT_35358185	High-altitude is associated with better short-term survival in critically ill COVID-19 patients admitted to the ICU	35358185	https://doi.org/10.1371/journal.pone.0262423	https://pubmed.ncbi.nlm.nih.gov/35358185	230	Other			15-Mar-2020	15-Jul-2020	123	No	Two-center cohort study	Prospective	Ecuador	31-Mar-2022	
#01652	CT_35358170	Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022	35358170	https://doi.org/10.15585/mmwr.mm7113e2	https://pubmed.ncbi.nlm.nih.gov/35358170	105,531							No	Multivariate analysis			1-Apr-2022	
#01653	CT_35357792	The study of serum hsCRP, ferritin, IL-6 and plasma D-dimer in COVID-19: a retrospective study	35357792	https://doi.org/10.1515/hmbci-2021-0088	https://pubmed.ncbi.nlm.nih.gov/35357792	400	Other						No	Cross-sectional study	Retrospective	India	31-Mar-2022	
#01654	CT_35357255	Immunohistochemical Expression of VDR in Myocardium: Postmortem Evaluation of COVID-19 Patients	35357255	https://doi.org/10.1369/00221554221089916	https://pubmed.ncbi.nlm.nih.gov/35357255	48	Other						No			Russia	31-Mar-2022	Autopsy sampling was carried out during period from February to May 2021
#01655	CT_35357022	Effect of elevated fasting blood glucose level on the one-year mortality and sequelae in hospitalized COVID-19 patients: a bidirectional cohort study	35357022	https://doi.org/10.1002/jmv.27737	https://pubmed.ncbi.nlm.nih.gov/35357022	2,545	Other			01-Jan-2020	17-Mar-2021	442	No	Bidirectional, cohort study		Hubei, China	31-Mar-2022	
#01656	CT_35356660	BNT162b2 and ChAdOx1 nCoV-19 vaccinations, incidence of SARS-CoV-2 infections and COVID-19 hospitalisations in Scotland in the Delta era	35356660	https://doi.org/10.7189/jogh.12.05008	https://pubmed.ncbi.nlm.nih.gov/35356660	4,183,022	Other			01-May-2021	23-Oct-2021	176	No	Cohort study	Retrospective	Scotland	26-Mar-2022	
#01657	CT_35356088	Mortality Predictive Value of APACHE II and SOFA Scores in COVID-19 Patients in the Intensive Care Unit	35356088	https://doi.org/10.1155/2022/5129314	https://pubmed.ncbi.nlm.nih.gov/35356088	204	Other		SOFA was a better mortality predictor than the APACHE II in critically ill COVID-19 patients. But they could not predict death with high accuracy				No	Cohort study	Retrospective	Tehran, Iran	28-Mar-2022	
#01658	CT_35355988	Heterologous Immune Responses of Serum IgG and Secretory IgA Against the Spike Protein of Endemic Coronaviruses During Severe COVID-19	35355988	https://doi.org/10.3389/fimmu.2022.839367	https://pubmed.ncbi.nlm.nih.gov/35355988	60	Other						No	Cohort study	Retrospective	Utrecht, Netherlands	9-Mar-2022	
#01659	CT_35355776	Importance of Vitamin D3 in COVID-19 Patients	35355776	https://doi.org/10.22092/ari.2021.356070.1769	https://pubmed.ncbi.nlm.nih.gov/35355776	180	Drug(s)	Vitamin D3	Patients who received Vit D3 were recovered from hospital 5 days on average sooner than those in the group (B)				No			Najaf, Iraq	30-Nov-2021	
#01660	CT_35355770	Measurement of SARS-CoV-2-Specific Humoral and Cellular Immunity in Coronavirus Disease 2019 Convalescent Health Care Workers in Iraq	35355770	https://doi.org/10.22092/ari.2021.356135.1785	https://pubmed.ncbi.nlm.nih.gov/35355770	191	Other						No			Baghdad, Iraq	30-Nov-2021	
#01661	CT_35355659	Humoral immune response in healthcare workers after two doses of a BNT162b2 mRNA vaccine in Yucatan, Mexico	35355659	https://doi.org/10.1002/rcr2.920	https://pubmed.ncbi.nlm.nih.gov/35355659	79	Other			13-Jan-2021	17-Feb-2021	36	No	Case-series study		Yucatan, Mexico	22-Mar-2022	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01662	CT_35355604	Immunogenicity and Safety of COVID-19 Vaccines in Patients Receiving Renal Replacement Therapy: A Systematic Review and Meta-Analysis	35355604	https://doi.org/10.3389/fmed.2022.827859	https://pubmed.ncbi.nlm.nih.gov/35355604	4,264			Patients on RRT (Renal Replacement Therapy) had significantly reduced antibody response after two-dosed COVID-19 vaccination.				Yes	Systematic review and meta-analysis	Prospective	China	9-Mar-2022	
#01663	CT_35355599	Angiotensin System Autoantibodies Correlate With Routine Prognostic Indicators for COVID-19 Severity	35355599	https://doi.org/10.3389/fmed.2022.840662	https://pubmed.ncbi.nlm.nih.gov/35355599	50	Other		A decrease in one unit of hemoglobin, an increase in 0.25 units of procalcitonin, or an increase in 100 units of lactate dehydrogenase increased the severity of the disease by 35.27, 69.25, and 3.2%, respectively				No	Observational study	Ambispective	Spain	9-Mar-2022	Patients recruited from April 2020 to December 2020
#01664	CT_35355308	Loss of mitochondrial membrane potential (ΔΨ m) in leucocytes as post-COVID-19 sequelae	35355308	https://doi.org/10.1002/JLB.3MA0322-279RRR	https://pubmed.ncbi.nlm.nih.gov/35355308	123	Other						No			Mexico	31-Mar-2022	
#01665	CT_35355295	Impact of the "atherosclerotic pabulum" on in-hospital mortality for SARS-CoV-2 infection. Is calcium score able to identify at-risk patients?	35355295	https://doi.org/10.1002/clc.23809	https://pubmed.ncbi.nlm.nih.gov/35355295	284	Other		Patients with CAC had a higher inflammatory burden at admission (d-dimer, p = .002; C-reactive protein, p = .002; procalcitonin, p = .016) and a higher high-sensitive cardiac troponin I (HScTnI, p = <.001) at admission and at peak, higher incidence of bilateral infiltration (p = .043) and higher in-H mortality (p = .048).				No		Retrospective	Padua, Italy	30-Mar-2022	
#01666	CT_35355294	Cycle Threshold Values and SARS-CoV-2: Relationship to Demographic Characteristics and Disease Severity	35355294	https://doi.org/10.1002/jmv.27752	https://pubmed.ncbi.nlm.nih.gov/35355294	256	Other		No significant differences in Ct value by demographic characteristics including age, sex, race or ethnicity, increasing Ct was associated with increased odds of severe disease	20-Mar-2020	13-Jul-2020	116	No	Observational study	Retrospective	Boston, USA	31-Mar-2022	
#01667	CT_35355290	A risk score for predicting death in COVID-19 in-hospital infection: A Brazilian single-center study	35355290	https://doi.org/10.1002/jcu.23195	https://pubmed.ncbi.nlm.nih.gov/35355290	111	Other						No	Single-center, observational study	Prospective	São Paulo, Brazil	30-Mar-2022	
#01668	CT_35355242	COVID-19 as an effect modifier of the relationship between age and in-hospital survival in older patients admitted to an Italian Emergency Department	35355242	https://doi.org/10.1007/s40520-022-02115-x	https://pubmed.ncbi.nlm.nih.gov/35355242	896				24-Feb-2020	11-Apr-2020	48	No	Observational study	Retrospective	Brescia, Italy	30-Mar-2022	
#01669	CT_35355237	Obesity and lipid metabolism disorders determine the risk for development of long COVID syndrome: a cross-sectional study from 50,402 COVID-19 patients	35355237	https://doi.org/10.1007/s15010-022-01784-0	https://pubmed.ncbi.nlm.nih.gov/35355237	50,402			Lipid metabolism disorders and obesity represent age-independent risk factors for the development of long COVID syndrome	01-Mar-2020	31-Mar-2021	396	No	Cross-sectional study	Retrospective	Germany	30-Mar-2022	
#01670	CT_35355236	Efficacy of different anticoagulant doses for patients with COVID-19: a systematic review and network meta-analysis	35355236	https://doi.org/10.1007/s15010-022-01809-8	https://pubmed.ncbi.nlm.nih.gov/35355236	34,045							Yes	Systematic review and meta-analysis		Japan	30-Mar-2022	
#01671	CT_35354828	A risk scoring system to predict progression to severe pneumonia in patients with Covid-19	35354828	https://doi.org/10.1038/s41598-022-07610-9	https://pubmed.ncbi.nlm.nih.gov/35354828	561	Other		In the development cohort, the sensitivity and specificity were 83.8% and 78.9%. In the validation cohort, the sensitivity and specificity were 70.8% and 79.3%, respectively. The C-statistics was 0.884 (95% CI 0.833-0.934) in the development cohort and 0.828 (95% CI 0.733-0.923) in the validation cohort.	21-Feb-2020	26-Apr-2020	66	No	Randomized clinical trial	Prospective	Daegu, South Korea	30-Mar-2022	
#01672	CT_35354854	Detection and quantification of infectious severe acute respiratory coronavirus-2 in diverse clinical and environmental samples	35354854	https://doi.org/10.1038/s41598-022-09218-5	https://pubmed.ncbi.nlm.nih.gov/35354854	75	Other			22-Apr-2020	31-Mar-2021	344	No			Alberta (AB), Canada	30-Mar-2022	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01673	CT_35354702	PERFORMANCE EVALUATION OF SIX DIFFERENT SARS-CoV-2 ANTIBODY IMMUNOASSAYS: DISEASE SEVERITY AND SERUM SAMPLING TIME AFFECT THE SENSITIVITY	35354702	https://doi.org/10.7883/yoken.JJID.2021.636	https://pubmed.ncbi.nlm.nih.gov/35354702	143	Other						No			Turkey	31-Mar-2022	
#01674	CT_35354229	Discharge from the emergency department and early hospital revaluation in patients with COVID-19 pneumonia: a prospective study	35354229	https://doi.org/10.15441/ceem.21.131	https://pubmed.ncbi.nlm.nih.gov/35354229	84				15-Nov-2020	10-Jan-2021	57	No	Single-center, cohort study	Prospective	Italy	31-Mar-2022	
#01675	CT_35353979	Effect of Early Treatment with Ivermectin among Patients with Covid-19	35353979	https://doi.org/10.1056/NEJMoa2115869	https://pubmed.ncbi.nlm.nih.gov/35353979	3,515	Drug(s)	Ivermectin | Hydroxychloroquine | Lopinavir / Ritonavir | Metformin | Doxazosin | Interferon lambda | Fluvoxamine		02-Jun-2020	06-Aug-2021	431	No	Double-blind, randomized, placebo-controlled, adaptive platform trial	Prospective	Brazil	30-Mar-2022	
#01676	CT_35353976	BNT162b2 Protection against the Omicron Variant in Children and Adolescents	35353976	https://doi.org/10.1056/NEJMoa2202826	https://pubmed.ncbi.nlm.nih.gov/35353976	2,812				01-Jul-2021	17-Feb-2022	232	No	Case-control study		USA	30-Mar-2022	
#01677	CT_35353960	Early Outpatient Treatment for Covid-19 with Convalescent Plasma	35353960	https://doi.org/10.1056/NEJMoa2119657	https://pubmed.ncbi.nlm.nih.gov/35353960	1,225	Plasma			03-Jun-2020	01-Oct-2021	486	No	Multicenter, double-blind, randomized, controlled trial	Prospective	USA	30-Mar-2022	
#01678	CT_35353030	Inflammation parameters predict fatal outcome in male COVID-19 patients in a low case-fatality area - a population-based registry study	35353030	https://doi.org/10.1080/23744235.2022.2055786	https://pubmed.ncbi.nlm.nih.gov/35353030	585	Other			27-Feb-2020	21-Jun-2020	116	No	Observational population-based quality registry study	Retrospective	Helsinki, Finland	30-Mar-2022	
#01679	CT_35352914	Diagnostic value of chest CT scanning for determination of Covid-19 severity in individual lung lobes	35352914	https://doi.org/10.26444/aaem/144842	https://pubmed.ncbi.nlm.nih.gov/35352914	124	Other						No	Observational study	Retrospective	Poland	21-Mar-2022	
#01680	CT_35352674	Association between benzodiazepine receptor agonist use and mortality in patients hospitalised for COVID-19: a multicentre observational study	35352674	https://doi.org/10.1017/S2045796021000743	https://pubmed.ncbi.nlm.nih.gov/35352674	14,381	Drug(s)	Benzodiazepine					No	Multicentre, observational, cohort study	Retrospective	Paris, France	30-Mar-2022	
#01681	CT_35352489	Associations between cardiometabolic disease severity, social determinants of health (SDoH) and poor COVID-19 outcomes	35352489	https://doi.org/10.1002/oby.23440	https://pubmed.ncbi.nlm.nih.gov/35352489	2,873	Other						No	Longitudinal study	Retrospective	Alabama, USA	29-Mar-2022	
#01682	CT_35352478	Low-density lipoprotein apheresis is associated with removal of SARS-CoV-2 antibodies	35352478	https://doi.org/10.1111/1744-9987.13842	https://pubmed.ncbi.nlm.nih.gov/35352478	76	Other						No		Retrospective	Germany	29-Mar-2022	
#01683	CT_35352210	Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab	35352210	https://doi.org/10.1007/s10238-022-00809-0	https://pubmed.ncbi.nlm.nih.gov/35352210	71	Drug(s)	Ibrutinib | Rituximab					No	Cohort study	Retrospective	Prague, Czech Republic	29-Mar-2022	Subjects were recruited into the study between May 2021 and August 2021
#01684	CT_35351942	Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study	35351942	https://doi.org/10.1038/s41598-022-09170-4	https://pubmed.ncbi.nlm.nih.gov/35351942	360	Drug(s) | Other	Remedesivir	201 patients treated with remdesivir (177 recovered from COVID-19), and 159 did not receive remdesivir treatment . Increased pancreatic enzyme levels of grade 3 or higher or acute pancreatitis developed in (23 / 201) and (3 / 159) patients	05-Feb-2020	20-Mar-2021	410	No	Single-center, observational study	Retrospective	Kanagawa, Japan	29-Mar-2022	
#01685	CT_35351217	Effectiveness of two COVID-19 vaccines (viral vector and inactivated viral vaccine) against SARS-CoV-2 infection in a cohort of healthcare workers	35351217	https://doi.org/10.1017/ice.2022.50	https://pubmed.ncbi.nlm.nih.gov/35351217	13,813	Vaccine	CoronaVac vaccine | ChAdOx1 vaccine		01-Jan-2021	03-Aug-2021	215	No	Cohort study	Retrospective	Sao Paulo, Brazil	30-Mar-2022	
#01686	CT_35351135	Recovery of serum testosterone levels is an accurate predictor of survival from COVID-19 in male patients	35351135	https://doi.org/10.1186/s12916-022-02345-w	https://pubmed.ncbi.nlm.nih.gov/35351135	497	Other		Longitudinal analyses in a subcohort of male COVID-19 patients identified serum testosterone trajectories as the strongest predictor of survival (AUC of ROC = 92.8%, p < 0.0001)	01-May-2020	30-Jun-2020	61	No	Longitudinal study	Retrospective	Barcelona, Spain	29-Mar-2022	
#01687	CT_35351083	Swab test in biological fluids as predictor of COVID-19 transmission risk during surgery: a prospective cross-sectional study from an Italian COVID center	35351083	https://doi.org/10.1186/s12893-022-01571-6	https://pubmed.ncbi.nlm.nih.gov/35351083	8	Other		All 20 swabs performed from biological fluids resulted negative for SARS-CoV-2 RNA detection.				No	Single-center, cross-sectional study	Prospective	Ferrara, Italy	30-Mar-2022	COVID-19 patients underwent emergency surgery from February 2020 to May 2021

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01688	CT_35350884	Evasion of vaccine-induced humoral immunity by emerging sub-variants of SARS-CoV-2	35350884	https://doi.org/10.2217/fmb-2022-0025	https://pubmed.ncbi.nlm.nih.gov/35350884	19	Other		Beta+R346K, exhibited the highest vaccine resistance among the tested mutants. Mu+K417N mutant exhibited almost no decrease in neutralization.				No			Kanagawa, Japan	30-Mar-2022	
#01689	CT_35350852	Copeptin: a neuroendocrine biomarker of COVID-19 severity	35350852	https://doi.org/10.2217/bmm-2021-1100	https://pubmed.ncbi.nlm.nih.gov/35350852	160	Other		Severe COVID-19 patients showed higher serum copeptin level in comparison to mild to moderate cases				No	Cohort study	Prospective	Cairo, Egypt	30-Mar-2022	
#01690	CT_35350784	Kinetics of Severity Biomarkers and Immunological Features of Methylprednisolone Therapy for Severe COVID-19 Patients	35350784	https://doi.org/10.3389/fimmu.2022.758946	https://pubmed.ncbi.nlm.nih.gov/35350784	38	Drug(s)	Methylprednisolone					No	Longitudinal study	Retrospective	Guangzhou, China	8-Mar-2022	
#01691	CT_35350713	Identifying SARS-CoV-2 Lineage Mutation Hallmarks and Correlating Them With Clinical Outcomes in Egypt: A Pilot Study	35350713	https://doi.org/10.3389/fmolb.2022.817735	https://pubmed.ncbi.nlm.nih.gov/35350713	35	Other						No	Pilot study	Retrospective	Cairo, Egypt	8-Mar-2022	Study performed between April 2020 and August 2020
#01692	CT_35350438	Unvaccinated Children Are an Important Link in the Transmission of SARS-CoV-2 Delta Variant (B1.617.2): Comparative Clinical Evidence From a Recent Community Surge	35350438	https://doi.org/10.3389/fcimb.2022.814782	https://pubmed.ncbi.nlm.nih.gov/35350438	226	Other			10-Sep-2021	20-Oct-2021	41	No	Comparative study		Fuzhou, China	8-Mar-2022	
#01693	CT_35350104	The Longitudinal Evolution of Post-COVID-19 Outcomes Among Hemodialysis Patients in Turkey	35350104	https://doi.org/10.1016/j.ekir.2022.03.017	https://pubmed.ncbi.nlm.nih.gov/35350104	1,223	Other		28th day mortality and mortality between 28th day-90th day were higher in the COVID-19 group than non-COVID group [19 (3.0%) patients vs. none (0%); 15 (2.4%) patients vs. 4 (0.7%) patients, respectively].	21-Apr-2021	11-Jun-2021	52	No	National, multicenter, observational study	Retrospective	Turkey	25-Mar-2022	
#01694	CT_35350097	Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group	35350097	https://doi.org/10.1016/j.eclinm.2022.101362	https://pubmed.ncbi.nlm.nih.gov/35350097	450	Drug(s)	Tocilizumab | Dexamethasone	Mechanical ventilation need and mortality were not improved with TCZ+DEX compared with DEX alone. The safety of both treatments was similar.	24-Jul-2020	18-May-2021	299	No	Randomized controlled trial	Prospective	France	25-Mar-2022	
#01695	CT_35349967	Clinical characteristics, respiratory management, and determinants of oxygenation in COVID-19 ARDS: A prospective cohort study	35349967	https://doi.org/10.1016/j.jcrc.2022.154021	https://pubmed.ncbi.nlm.nih.gov/35349967	1,525	Other			20-Mar-2020	31-Oct-2020	226	No	Multicenter, cohort study	Prospective	Argentina	26-Mar-2022	
#01696	CT_35349827	T cell response against SARS-CoV-2 persists after one year in patients surviving severe COVID-19	35349827	https://doi.org/10.1016/j.ebiom.2022.103967	https://pubmed.ncbi.nlm.nih.gov/35349827	31	Other						No	Observational study		Lyon, France	26-Mar-2022	
#01697	CT_35349755	Blood myxovirus resistance protein-1 measurement in the diagnostic work-up of suspected COVID-19 infection in the emergency department	35349755	https://doi.org/10.1002/iid3.609	https://pubmed.ncbi.nlm.nih.gov/35349755	100	Other		Median MxA level was significantly higher ($p < .001$) in COVID-19 patients compared to non-COVID-19 patients, respectively 1933 and 0.1 ng/ml.				No	Single-center, observational, cohort study	Prospective	Rotterdam, The Netherlands	29-Mar-2022	Study conducted between March and June 2021
#01698	CT_35349749	Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals	35349749	https://doi.org/10.1002/iid3.592	https://pubmed.ncbi.nlm.nih.gov/35349749	374	Other			29-Jan-2021	04-Aug-2021	188	No	Cohort study	Prospective	Sri Lanka	22-Mar-2022	
#01699	CT_35349483	IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function	35349483	https://doi.org/10.1172/jci.insight.158362	https://pubmed.ncbi.nlm.nih.gov/35349483	118	Other						No	Cohort study		USA	29-Mar-2022	
#01700	CT_35349521	Extracorporeal Membrane Oxygenation in Pregnant Women With COVID-19	35349521	https://doi.org/10.1097/MAT.0000000000001646	https://pubmed.ncbi.nlm.nih.gov/35349521	10	Oxygen support		9 / 10 patients survived ICU discharge after a gradual recovery of pulmonary function				No	Observational study	Prospective	Al Jahra, Kuwait	1-Apr-2022	Patients admitted from September 2020 until May 2021
#01701	CT_35239462	COVID-19 vaccine uptake and effectiveness in adults aged 50 years and older in Wales UK: a 1.2m population data-linkage cohort approach	35239462	https://doi.org/10.1080/21645515.2022.2031774	https://pubmed.ncbi.nlm.nih.gov/35239462	1,262,689	Other						No	Population data-linkage cohort approach	Retrospective	Wales, UK	3-Mar-2022	
#01702	CT_35349005	High-dose intravenous vitamin C decreases rates of mechanical ventilation and cardiac arrest in severe COVID-19	35349005	https://doi.org/10.1007/s11739-022-02954-6	https://pubmed.ncbi.nlm.nih.gov/35349005	100	Drug(s)	Vitamin C		24-Mar-2020	02-Jul-2020	101	No	Observational, cohort study	Retrospective	MI, USA	29-Mar-2022	
#01703	CT_35348610	Extracorporeal Membrane Oxygenation for Respiratory Failure Related to COVID-19: A Nationwide Cohort Study	35348610	https://doi.org/10.1097/ALN.0000000000004168	https://pubmed.ncbi.nlm.nih.gov/35348610	429	Oxygen support			21-Apr-2020	25-Oct-2020	188	No	A nationwide, cohort study	Ambispective	France	29-Mar-2022	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01704	CT_35348444	CD4 + T Cell Dysfunction in Severe COVID-19 Disease is TNFα/TNFRI-Dependent	35348444	https://doi.org/10.1164/rccm.202111-2493OC	https://pubmed.ncbi.nlm.nih.gov/35348444	148	Other						No	Observational study		PA, USA	29-Mar-2022	
#01705	CT_35348379	Chest CT of Lung Injury 1 Year after COVID-19 Pneumonia: The CovILD Study	35348379	https://doi.org/10.1148/radiol.211670	https://pubmed.ncbi.nlm.nih.gov/35348379	91	Other						No	Multicenter, observational, cohort study	Prospective	Austria	29-Mar-2022	
#01706	CT_35347523	Role of triggering receptor expressed on myeloid cells-1 (TREM-1) in COVID-19 and other viral pneumonias: a systematic review and meta-analysis of clinical studies	35347523	https://doi.org/10.1007/s10787-022-00972-6	https://pubmed.ncbi.nlm.nih.gov/35347523	366							Yes	Systematic review and meta-analysis		Brazil	28-Mar-2022	
#01707	CT_35347208	Seroconversion dynamic and SARS-CoV-2 seropositivity in unvaccinated population during the first and second outbreaks in Mexico	35347208	https://doi.org/10.1038/s41598-022-09395-3	https://pubmed.ncbi.nlm.nih.gov/35347208	522,690	Other			05-Jul-2020	31-Dec-2020	180	No	Cross-sectional study	Retrospective	Mexico	28-Mar-2022	
#01708	CT_35347166	C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19	35347166	https://doi.org/10.1038/s41598-022-08882-x	https://pubmed.ncbi.nlm.nih.gov/35347166	3,218	Drug(s)	Tocilizumab | Dexamethasone					No	Observational, cohort study	Retrospective	Barcelona, Spain	28-Mar-2022	Patients admitted from February 2020 to February 2021
#01709	CT_35346565	Lung Opacity and Coronary Artery Calcium Score: A Combined Tool for Risk Stratification and Outcome Prediction in COVID-19 Patients	35346565	https://doi.org/10.1016/j.acra.2022.02.019	https://pubmed.ncbi.nlm.nih.gov/35346565	142	Other						No		Retrospective	Germany	28-Feb-2022	
#01710	CT_35346536	IgG antibody production and persistence to 6 months following SARS-CoV-2 vaccination: A Northern Ireland observational study	35346536	https://doi.org/10.1016/j.vaccine.2022.02.087	https://pubmed.ncbi.nlm.nih.gov/35346536	111	Other						No	Observational study		Belfast, Northern Ireland	3-Mar-2022	
#01711	CT_35346319	Factors for success of awake prone positioning in patients with COVID-19-induced acute hypoxemic respiratory failure: analysis of a randomized controlled trial	35346319	https://doi.org/10.1186/s13054-022-03950-0	https://pubmed.ncbi.nlm.nih.gov/35346319	430	Other						No	Randomized controlled trial	Prospective		28-Mar-2022	
#01712	CT_35324471	A population-based cohort approach to assess excess mortality due to the spread of COVID-19 in Italy, January-May 2020	35324471	https://doi.org/10.4415/ANN_22_01_04	https://pubmed.ncbi.nlm.nih.gov/35324471	57,204,501				01-Jan-2020	31-May-2020	152	No	Population-based, cohort study	Retrospective	Italy	24-Mar-2022	
#01713	CT_35324045	Antibody response to mRNA SARS-CoV-2 vaccination in 182 patients after allogeneic hematopoietic cell transplantation	35324045	https://doi.org/10.1111/tid.13828	https://pubmed.ncbi.nlm.nih.gov/35324045	182	Other			23-Mar-2021	01-Sep-2021	163	No	Cohort study	Retrospective	Switzerland	24-Mar-2022	
#01714	CT_35327350	The Role of Genetic Factors in the Development of Acute Respiratory Viral Infection COVID-19: Predicting Severe Course and Outcomes	35327350	https://doi.org/10.3390/biomedicines10030549	https://pubmed.ncbi.nlm.nih.gov/35327350	397	Other						No			Moscow, Russia	25-Feb-2022	
#01715	CT_35329962	Chest X-ray Does Not Predict the Risk of Endotracheal Intubation and Escalation of Treatment in COVID-19 Patients Requiring Noninvasive Respiratory Support	35329962	https://doi.org/10.3390/jcm11061636	https://pubmed.ncbi.nlm.nih.gov/35329962	142							No	Cohort study	Retrospective	Padua, Italy	16-Mar-2022	
#01716	CT_35343397	Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis	35343397	https://doi.org/10.1080/22221751.2022.2059405	https://pubmed.ncbi.nlm.nih.gov/35343397	8,614			Tocilizumab treatment showed promising results in reducing 28-day mortality and progression to mechanical ventilation in patients with moderate-to-severe COVID-19	10-Aug-2021	10-Feb-2022	185	Yes	Systematic review and meta-analysis		Republic of Korea	18-Apr-2022	
#01717	CT_35343243	Homocysteine as a marker for predicting disease severity in patients with COVID-19	35343243	https://doi.org/10.2217/bmm-2021-0688	https://pubmed.ncbi.nlm.nih.gov/35343243	151	Other			01-May-2020	01-Jul-2020	62	No	Randomized controlled trial	Ambispective	Turkey	28-Mar-2022	
#01718	CT_35342933	The prognostic role of interatrial block among COVID-19 patients hospitalized in medicine wards	35342933	https://doi.org/10.1111/eci.13781	https://pubmed.ncbi.nlm.nih.gov/35342933	300	Other						No	Observational study	Retrospective	Italy	28-Mar-2022	
#01719	CT_35342931	Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19	35342931	https://doi.org/10.1111/eci.13776	https://pubmed.ncbi.nlm.nih.gov/35342931	60	Drug(s)	Aprotinin		20-May-2020	20-Oct-2021	519	No	Randomized controlled trial	Prospective	Spain	28-Mar-2022	
#01720	CT_35346253	Characteristics of lymphocyte subsets and cytokine profiles of patients with COVID-19	35346253	https://doi.org/10.1186/s12985-022-01786-2	https://pubmed.ncbi.nlm.nih.gov/35346253	214	Other		No statistical differences among all tested indicators of lymphocyte subsets and cytokines between severe group (n = 38) and critical group (n = 15) on hospital admission or ICU admission	19-Jan-2020	30-Apr-2020	103	No	Cohort study	Retrospective	Chongqing, China	28-Mar-2022	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01721	CT_35346184	AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2	35346184	https://doi.org/10.1186/s12916-022-02342-z	https://pubmed.ncbi.nlm.nih.gov/35346184	52	Vaccine	ChAdOx nCov-19					No	Cohort study	Prospective	Blantyre, Malawi	28-Mar-2022	
#01722	CT_35346080	Performances of clinical characteristics and radiological findings in identifying COVID-19 from suspected cases	35346080	https://doi.org/10.1186/s12880-022-00780-y	https://pubmed.ncbi.nlm.nih.gov/35346080	239	Other		COVID-19 group are more likely to have fever (OR 4.22), contact history (OR 284.73), lower WBC count (OR 0.63), left lower lobe involvement (OR 9.42), multifocal lesions (OR 8.98), pleural thickening (OR 5.59), peripheral distribution (OR 0.09), and less mediastinal lymphadenopathy (OR 0.037)	21-Jan-2020	05-Mar-2020	45	No	Cohort study	Retrospective	China	26-Mar-2022	
#01723	CT_35345821	Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS	35345821	https://doi.org/10.2147/CLEP.S323292	https://pubmed.ncbi.nlm.nih.gov/35345821	4,537,153							No	Descriptive study	Retrospective	USA, Europe, Asia	22-Mar-2022	
#01724	CT_35345814	Hematological Changes in the Second Wave of SARS-CoV-2 in North India	35345814	https://doi.org/10.7759/cureus.23495	https://pubmed.ncbi.nlm.nih.gov/35345814	100	Other						No	Descriptive study		Lucknow, India	25-Mar-2022	Study was done from Mayto June 2021
#01725	CT_35345731	Immunoglobulin G Antibodies to SARS-CoV-2 Among Healthcare Workers at a Tertiary Care Center in South India	35345731	https://doi.org/10.7759/cureus.22520	https://pubmed.ncbi.nlm.nih.gov/35345731	550	Other						No	Cross-sectional study	Prospective	India	23-Feb-2022	
#01726	CT_35345649	Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study	35345649	https://doi.org/10.1016/j.lana.2022.100228	https://pubmed.ncbi.nlm.nih.gov/35345649	152	Drug(s)	Tocilizumab | Dexamethasone		01-Aug-2020	24-Jun-2021	328	No	Cohort study	Retrospective	Vancouver, Canada	23-Mar-2022	
#01727	CT_35345420	New domiciliary supplemental oxygen therapy after hospitalisation for COVID-19 in metropolitan Chicago	35345420	https://doi.org/10.1183/23120541.00577-2021	https://pubmed.ncbi.nlm.nih.gov/35345420	65	Oxygen support						No	Cohort study	Retrospective	IL, USA	21-Mar-2022	
#01728	CT_35345417	SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study	35345417	https://doi.org/10.1016/S2666-5247(22)00036-2	https://pubmed.ncbi.nlm.nih.gov/35345417	1,096	Other			07-Jan-2020	27-Jan-2021	387	No	Longitudinal, cohort study	Prospective	Wuhan, China	23-Mar-2022	
#01729	CT_35344951	Implications of COVID-19 on Thrombotic Profile of Severely Affected Patients	35344951	https://doi.org/10.1159/000522543	https://pubmed.ncbi.nlm.nih.gov/35344951	70	Other						No	Comparative study	Retrospective	Delhi, India	28-Mar-2022	
#01730	CT_35350262	Comparison of COVID-19 characteristics in Egyptian patients according to their Toll-Like Receptor-4 (Asp299Gly) polymorphism	35350262	https://doi.org/10.53854/liim-3001-11	https://pubmed.ncbi.nlm.nih.gov/35350262	145	Other						No	Cross-sectional study		Cairo, Egypt	1-Mar-2022	
#01731	CT_35342777	Seroprevalence of SARS-CoV-2 Antibodies in Children and Adolescents: Results From a Population-Based Survey in 10 Colombian Cities	35342777	https://doi.org/10.1177/2333794X221085385	https://pubmed.ncbi.nlm.nih.gov/35342777	3,124	Other						No	Population-based, cross-sectional study		Colombia	21-Mar-2022	
#01732	CT_35342692	Cardiometabolic Morbidity and Other Prognostic Factors for Mortality in Adult Hospitalized COVID-19 Patients in North Jakarta, Indonesia	35342692	https://doi.org/10.5334/gh.1019	https://pubmed.ncbi.nlm.nih.gov/35342692	243	Other			20-Mar-2020	31-Jul-2020	134	No	Cohort study	Retrospective	Jakarta, Indonesia	18-Feb-2022	
#01733	CT_35342664	Troponin Levels and the Severity of COVID-19 Pneumonia	35342664	https://doi.org/10.7759/cureus.23193	https://pubmed.ncbi.nlm.nih.gov/35342664	214	Other						No		Retrospective	Dammam, Saudi Arabia	15-Mar-2022	
#01734	CT_35342138	Anti-SARS CoV-2 IgG in COVID-19 Patients with Hematological Diseases: A Single-center, Retrospective Study in Japan	35342138	https://doi.org/10.2169/internalmedicine.9209-21	https://pubmed.ncbi.nlm.nih.gov/35342138	77	Other			25-Mar-2020	14-May-2020	51	No	Observational study	Retrospective	Japan	26-Mar-2022	
#01735	CT_35342082	Endothelial glycocalyx damage in patients with severe COVID-19 on mechanical ventilation - a prospective observational pilot study	35342082	https://doi.org/10.3233/CH-221401	https://pubmed.ncbi.nlm.nih.gov/35342082	28	Other						No	Observational, pilot study	Prospective	Czech Republic	21-Mar-2022	
#01736	CT_35341958	Accuracy of clustered regularly interspaced short palindromic repeats (CRISPR) to diagnose COVID-19, a meta-analysis	35341958	https://doi.org/10.1016/j.micpath.2022.105498	https://pubmed.ncbi.nlm.nih.gov/35341958	5,857							Yes	Meta-analysis		China	25-Mar-2022	
#01737	CT_35341944	Aromatherapy blend of thyme, orange, clove bud, and frankincense boosts energy levels in post-COVID-19 female patients: A randomized, double-blinded, placebo controlled clinical trial	35341944	https://doi.org/10.1016/j.ctim.2022.102823	https://pubmed.ncbi.nlm.nih.gov/35341944	44	Other						No	Randomized-controlled trial	Prospective	USA	25-Mar-2022	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01738	CT_35341647	A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines	35341647	https://doi.org/10.1016/j.vaccine.2022.03.036	https://pubmed.ncbi.nlm.nih.gov/35341647	422	Vaccine	ChAdOx1 nCoV-19 vaccine					No	Randomized-controlled trial	Prospective	Thailand	24-Mar-2022	
#01739	CT_35341646	Effectiveness of the Comirnaty and the Vaxzevria vaccines in preventing SARS-CoV-2 infection among residents in Lazio region (Italy)	35341646	https://doi.org/10.1016/j.vaccine.2022.02.063	https://pubmed.ncbi.nlm.nih.gov/35341646	371,423	Vaccine	Comirnaty | Vaxzevria		27-Dec-2020	11-Apr-2021	106	No	Cohort study	Retrospective	Italy	22-Mar-2022	
#01740	CT_35341332	Clinical and hematological characteristics of 300 COVID-19 patients in Erbil, Kurdistan Region, Iraq	35341332	https://doi.org/10.1177/03946320221085465	https://pubmed.ncbi.nlm.nih.gov/35341332	300	Other			15-Sep-2020	02-Feb-2021	141	No	Cohort study	Retrospective	Erbil, Iraq	27-Mar-2022	
#01741	CT_35341072	Multicenter STudy of tissue plasminogen activator (alteplase) use in COVID-19 severe respiratory failure (MUST COVID): A retrospective cohort study	35341072	https://doi.org/10.1002/rth2.12669	https://pubmed.ncbi.nlm.nih.gov/35341072	79	Other			01-Mar-2020	03-Mar-2021	368	No	Observational, cohort study	Retrospective	USA	21-Mar-2022	
#01742	CT_35341058	The dynamics of circulating SARS-CoV-2 lineages in Bogor and surrounding areas reflect variant shifting during the first and second waves of COVID-19 in Indonesia	35341058	https://doi.org/10.7717/peerj.13132	https://pubmed.ncbi.nlm.nih.gov/35341058	202	Other						No			Indonesia	22-Mar-2022	
#01743	CT_35340920	COVID-19 Mortality in Children: A Referral Center Experience from Iran (Mofid Children's Hospital, Tehran, Iran)	35340920	https://doi.org/10.1155/2022/2737719	https://pubmed.ncbi.nlm.nih.gov/35340920	59	Other						No	Cross-sectional study	Retrospective	Tehran, Iran	16-Mar-2022	
#01744	CT_35340816	Oral manifestations associated with COVID-19 disease: An observational cross sectional study	35340816	https://doi.org/10.1016/j.jobcr.2022.03.008	https://pubmed.ncbi.nlm.nih.gov/35340816	367	Other						No	Observational, cross-sectional study		India	19-Mar-2022	
#01745	CT_35335080	Fever after Vaccination against SARS-CoV-2 with mRNA-Based Vaccine Associated with Higher Antibody Levels during 6 Months Follow-Up	35335080	https://doi.org/10.3390/vaccines10030447	https://pubmed.ncbi.nlm.nih.gov/35335080	383	Vaccine	BNT162b2 mRNA		27-Jan-2021	13-Jun-2021	138	No	Cohort study	Prospective	Hungary	14-Mar-2022	
#01746	CT_35335084	Systemic Adverse Effects Induced by the BNT162b2 Vaccine Are Associated with Higher Antibody Titers from 3 to 6 Months after Vaccination	35335084	https://doi.org/10.3390/vaccines10030451	https://pubmed.ncbi.nlm.nih.gov/35335084	378	Other						No	Single-center, observational study	Prospective	Japan	15-Mar-2022	
#01747	CT_35443106	Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19	35443106	https://doi.org/10.1056/NEJMoa2116620	https://pubmed.ncbi.nlm.nih.gov/35443106	5,197	Drug(s)	Tixagevimab/Cilgavimab		21-Nov-2020	22-Mar-2021	122	No	Randomized controlled trial	Prospective		20-Apr-2022	
#01748	CT_35340743	Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort	35340743	https://doi.org/10.1016/S2666-7568(22)00035-6	https://pubmed.ncbi.nlm.nih.gov/35340743	2,828,294				11-Mar-2021	26-Oct-2021	230	No	Population-based, match-paired cohort study	Retrospetcive	Colombia	21-Mar-2022	
#01749	CT_35350255	Differential mortality with COVID-19 and invasive mechanical ventilation between high-income and low-and middle-income countries: a systematic review, meta-analysis, and meta-regression	35350255	https://doi.org/10.53854/liim-3001-6	https://pubmed.ncbi.nlm.nih.gov/35350255	243,835				01-Dec-2019	15-Jul-2021	593	Yes	Systematic review, and meta-analysis			1-Mar-2022	
#01750	CT_35350866	Novel biomarker-based score (SAD-60) for predicting mortality in patients with COVID-19 pneumonia: a multicenter retrospective cohort of 1013 patients	35350866	https://doi.org/10.2217/bmm-2021-1085	https://pubmed.ncbi.nlm.nih.gov/35350866	1,013	Other						No	Cohort study	Retrospective	Istanbul, Turkey	30-Mar-2022	
#01751	CT_34525277	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months	34525277	https://doi.org/10.1056/NEJMoa2110345	https://pubmed.ncbi.nlm.nih.gov/34525277	44,047	Vaccine	BNT162b2		15-Oct-2020	13-Mar-2021	150	No	An ongoing, randomized, placebo-controlled, observe-rblinded, multinational, phase 1–2–3 trial		Worldwide	15-Sep-2021	
#01752	CT_35368622	Immunogenicity and clinical features relating to BNT162b2 messenger RNA COVID-19 vaccine, Ad26.COV2.S and ChAdOx1 adenoviral vector COVID-19 vaccines: a systematic review of non-interventional studies	35368622	https://doi.org/10.1186/s43094-022-00409-5	https://pubmed.ncbi.nlm.nih.gov/35368622	397				01-Nov-2020	31-May-2021	212	Yes	Systematic review, and meta-analysis		Nigeria	26-Mar-2022	
#01753	CT_35383273	Relationship of anti-SARS-CoV-2 IgG antibodies with Vitamin D and inflammatory markers in COVID-19 patients	35383273	https://doi.org/10.1038/s41598-022-09785-7	https://pubmed.ncbi.nlm.nih.gov/35383273	69	Other						No			Kosovo	5-Apr-2022	
#01754	CT_35386106	Clinical characteristics and predictors of death among hospitalized patients infected with SARS-CoV-2 in Sicily, Italy: A retrospective observational study	35386106	https://doi.org/10.3892/br.2022.1517	https://pubmed.ncbi.nlm.nih.gov/35386106	421	Other			01-Mar-2020	18-May-2020	79	No	Observational study	Retrospective	Italy	1-Mar-2022	
#01755	CT_35395678	Corticosteroid therapy in COVID-19 associated with in-hospital mortality in geriatric patients: a propensity matched cohort study	35395678	https://doi.org/10.1093/gerona/glac084	https://pubmed.ncbi.nlm.nih.gov/35395678	1,579	Drug(s)	Corticosteroids					No	Cohort study	Retrospective	Paris, France	8-Apr-2022	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01756	CT_35398491	Effect of the coronavirus disease 2019 pandemic on morbidity among children hospitalized for an asthma exacerbation	35398491	https://doi.org/10.1016/j.anai.2022.03.033	https://pubmed.ncbi.nlm.nih.gov/35398491	293	Other						No	Case-control study	Retrospective	WA, USA	8-Apr-2022	
#01757	CT_35398519	Immune evasion and chronological decrease in titer of neutralizing antibody against SARS-CoV-2 and its variants of concerns in COVID-19 patients	35398519	https://doi.org/10.1016/j.clim.2022.108999	https://pubmed.ncbi.nlm.nih.gov/35398519	146	Other		Titers against Wuhan-hu-1 decreased by 23%, and those to Delta variant decreased by 70%.				No	Observational study		Tokyo, Japan	7-Apr-2022	
#01758	CT_35412018	Age-adjusted mortality and predictive value of liver chemistries in a Viennese cohort of COVID-19 patients	35412018	https://doi.org/10.1111/liv.15274	https://pubmed.ncbi.nlm.nih.gov/35412018	900	Other						No	Cohort study	Retrospective	Vienna, Austria	12-Apr-2022	
#01759	CT_35412029	Reactogenicity of the mRNA SARS-CoV-2 Vaccines Associates with Immunogenicity in Patients with Autoimmune and Inflammatory Disease	35412029	https://doi.org/10.1002/acr.24894	https://pubmed.ncbi.nlm.nih.gov/35412029	441	Vaccine | Other	mRNA SARS-CoV-2 vaccines					No	Longitudinal, observational study	Prospective	USA	12-Apr-2022	
#01760	CT_35414616	COVID-19 in pregnant women: An evaluation of clinical symptoms and laboratory parameters based on the 3 trimesters	35414616	https://doi.org/10.15537/smj.2022.43.4.20210904	https://pubmed.ncbi.nlm.nih.gov/35414616	175	Other		No significant relationship was found between pregnancy trimesters and the need for ICU admission. Shortness of breath at the first admission increased the need for ICU by 6.95 times, and a 1 unit increase in C-reactive protein (CRP) level increased the risk of ICU by 1.003 times.				No	Cohort study	Retrospective	Turkey	1-Apr-2022	
#01761	CT_35414617	Side-effects of COVID-19 vaccines among the Saudi population: A cross-sectional study	35414617	https://doi.org/10.15537/smj.2022.43.4.20210905	https://pubmed.ncbi.nlm.nih.gov/35414617	2,530							No	Cross-sectional study		Hail, Saudi Arabia	1-Apr-2022	
#01762	CT_35421120	Dysregulation of the leukocyte signaling landscape during acute COVID-19	35421120	https://doi.org/10.1371/journal.pone.0264979	https://pubmed.ncbi.nlm.nih.gov/35421120	63	Other						No			MO, USA	14-Apr-2022	
#01763	CT_35411681	Humoral antibody response to the first dose of the ChAdOx1 nCoV-19 vaccine in Asian patients undergoing hemodialysis	35411681	https://doi.org/10.1111/hdi.13011	https://pubmed.ncbi.nlm.nih.gov/35411681	434	Other		22 days from vaccination, 56% of the participants were seropositive. (88%) had low antibody titers (< 15 U/ml).				No	Cohort study	Prospective	New Taipei City, Taiwan	11-Apr-2022	
#01764	CT_35411627	Remdesivir treatment in hospitalized patients affected by COVID-19 pneumonia: A case-control study	35411627	https://doi.org/10.1002/jmv.27768	https://pubmed.ncbi.nlm.nih.gov/35411627	566	Drug(s)	Remdesivir					No	Observational study	Retrospective	Italy	11-Apr-2022	
#01765	CT_35412591	Associations between SARS-CoV-2 variants and risk of COVID-19 hospitalization among confirmed cases in Washington State: a retrospective cohort study	35412591	https://doi.org/10.1093/cid/ciac279	https://pubmed.ncbi.nlm.nih.gov/35412591	58,848	Other			01-Dec-2020	14-Jan-2022	410	No	Cohort study	Retrospective	WA, USA	12-Apr-2022	
#01766	CT_35412385	Changing Patterns of SARS-CoV-2 Seroprevalence among Canadian Blood Donors during the Vaccine Era	35412385	https://doi.org/10.1128/spectrum.00339-22	https://pubmed.ncbi.nlm.nih.gov/35412385	149,522	Other			01-Jan-2021	24-Nov-2021	328	No			Canada	27-Apr-2022	
#01767	CT_35419319	SARS-CoV-2 Positivity in Early Infancy: A National Cohort From Saudi Arabia	35419319	https://doi.org/10.3389/fped.2022.849659	https://pubmed.ncbi.nlm.nih.gov/35419319	898	Other						No	Cohort study	Ambispective	Riyadh, Saudi Arabia	28-Mar-2022	
#01768	CT_35419104	Clinical and biochemical profile of COVID-19 patients admitted in a tertiary care hospital in Visakhapatnam, India during post unlock 2.0 - a retrospective study	35419104	https://doi.org/10.25122/jml-2021-0341	https://pubmed.ncbi.nlm.nih.gov/35419104	558	Other			02-Aug-2020	31-Aug-2020	30	No	Observational study	Retrospective	Visakhapatnam, India	1-Feb-2022	
#01769	CT_35417912	Association Between Endocrine Disorders and Severe COVID-19 Disease in Pediatric Patients	35417912	https://doi.org/10.1159/000524595	https://pubmed.ncbi.nlm.nih.gov/35417912	390	Other						No	Cross-sectional study	Retrospective	MO, USA	13-Apr-2022	
#01770	CT_35413587	Clinical characterization of COVID-19 breakthrough infections, Philippines	35413587	https://doi.org/10.1016/j.jcv.2022.105157	https://pubmed.ncbi.nlm.nih.gov/35413587	182	Other			01-Mar-2021	15-Jul-2021	137	No			Philippines	6-Apr-2022	
#01771	CT_35413588	Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan	35413588	https://doi.org/10.1016/j.jcv.2022.105156	https://pubmed.ncbi.nlm.nih.gov/35413588	945	Vaccine	ChAdOx1-S | mRNA-1273					No	Multiple-center study	Prospective	Taiwan	6-Apr-2022	
#01772	CT_35413107	Investigation of A SARS-CoV-2 Delta (B.1.617.2) Variant Outbreak Among Residents of a Skilled Nursing Facility and Vaccine Effectiveness Analysis - Maricopa County, Arizona, June-July 2021	35413107	https://doi.org/10.1093/cid/ciac240	https://pubmed.ncbi.nlm.nih.gov/35413107	109	Other			10-Jun-2021	23-Jul-2021	44	No			AZ, USA	12-Apr-2022	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01773	CT_35413071	Evidence of SARS-CoV-2 in nasal brushings and olfactory mucosa biopsies of COVID-19 patients	35413071	https://doi.org/10.1371/journal.pone.0266740	https://pubmed.ncbi.nlm.nih.gov/35413071	25	Other						No			Milan, Italy	12-Apr-2022	
#01774	CT_35416467	Older adults with severe coronavirus disease 2019 admitted to intensive care unit: prevalence, characteristics and risk factors for mortality	35416467	https://doi.org/10.23736/S0375-9393.22.16387-X	https://pubmed.ncbi.nlm.nih.gov/35416467	458	Other						No			Greece	13-Apr-2022	
#01775	CT_35412409	COVID-19 breakthrough infections and humoral immune response among BNT162b2 vaccinated healthcare workers in Malaysia	35412409	https://doi.org/10.1080/22221751.2022.2065936	https://pubmed.ncbi.nlm.nih.gov/35412409	551	Vaccine	BNT162b2					No	Cohort study	Prospective	Malaysia	3-May-2022	
#01776	CT_35412597	Exposure and Outcome in practice: a retrospective cohort study between fibrinolytic suppression and hypercoagulability, the severity of hypoxemia, and mortality in COVID-19 patients	35412597	https://doi.org/10.1097/ALN.0000000000004239	https://pubmed.ncbi.nlm.nih.gov/35412597	55	Other						No	Cohort study	Retrospective		11-Apr-2022	
#01777	CT_35412625	Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19	35412625	https://doi.org/10.1001/jamanetworkopen.2022.6920	https://pubmed.ncbi.nlm.nih.gov/35412625	1,959	Drug(s)	Casirivimab | Imdevimab					No	Cohort study	Prospective	USA	1-Apr-2022	
#01778	CT_35412626	Immunogenicity and Risk Factors Associated With Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ Transplant: A Systematic Review and Meta-Analysis	35412626	https://doi.org/10.1001/jamanetworkopen.2022.6822	https://pubmed.ncbi.nlm.nih.gov/35412626	11,713							Yes	Systematic review, and meta-analysis		Thailand	1-Apr-2022	
#01779	CT_35419860	The kinetics and predictors of anti-SARS-CoV-2 antibodies up to 8 months after symptomatic COVID-19: A Czech cross-sectional study	35419860	https://doi.org/10.1002/jmv.27784	https://pubmed.ncbi.nlm.nih.gov/35419860	662	Other						No	Cross-sectional study		Czech Republic	14-Apr-2022	
#01780	CT_35419822	Anti-IFN-α/-ω neutralizing antibodies from COVID-19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severity	35419822	https://doi.org/10.1002/eji.202249824	https://pubmed.ncbi.nlm.nih.gov/35419822	360	Other						No			Rome, Italy	13-Apr-2022	
#01781	CT_35422642	The Association Between the Albumin and Viral Negative Conversion Rate in Patients Infected with Novel Coronavirus Disease 2019 (COVID-19)	35422642	https://doi.org/10.2147/IDR.S353091	https://pubmed.ncbi.nlm.nih.gov/35422642	190	Other			04-Feb-2020	14-Apr-2020	71	No	Cohort study	Retrospective	Hubei, China	8-Apr-2022	
#01782	CT_35422702	Pulmonary Inflammatory Response in Lethal COVID-19 Reveals Potential Therapeutic Targets and Drugs in Phases III/IV Clinical Trials	35422702	https://doi.org/10.3389/fphar.2022.833174	https://pubmed.ncbi.nlm.nih.gov/35422702	19	Other						No				29-Mar-2022	
#01783	CT_35419650	Efficacy and Safety of ELOM-080 as Add-On Therapy in COVID-19 Patients with Acute Respiratory Insufficiency: Exploratory Data from the Prospective Placebo-Controlled COVARI Trial	35419650	https://doi.org/10.1007/s12325-022-02135-z	https://pubmed.ncbi.nlm.nih.gov/35419650	35	Drug(s)	ELOM-080					No	Randomized controlled trial	Prospective	Germany	13-Apr-2022	
#01784	CT_35434060	Mortality in patients with COVID-19 requiring extracorporeal membrane oxygenation: A meta-analysis	35434060	https://doi.org/10.12998/wjcc.v10.i8.2457	https://pubmed.ncbi.nlm.nih.gov/35434060	1,494	Oxygen support						Yes	Systematic review, and meta-analysis		Zhejiang, China	16-Mar-2022	
#01785	CT_35434405	Rehabilitation Characteristics of Acute-stage COVID-19 Survivors Managed with Extracorporeal Membrane Oxygenation in the Intensive Care Unit	35434405	https://doi.org/10.2490/prm.20220015	https://pubmed.ncbi.nlm.nih.gov/35434405	20	Oxygen support | Drugs	Remdesivir | Dexamethasone | Baricitinib		21-Apr-2020	20-Aug-2021	487	No	Observational study	Retrospective	Tokyo, Japan	31-Mar-2022	
#01786	CT_35431952	The Use of Oral Anticoagulation Is Not Associated With a Reduced Risk of Mortality in Patients With COVID-19: A Systematic Review and Meta-Analysis of Cohort Studies	35431952	https://doi.org/10.3389/fphar.2022.781192	https://pubmed.ncbi.nlm.nih.gov/35431952	30,646	Drug(s)	Anticoagulants					Yes	Systematic review, and meta-analysis		China	31-Mar-2022	
#01787	CT_35430106	Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers	35430106	https://doi.org/10.1016/j.vaccine.2022.04.020	https://pubmed.ncbi.nlm.nih.gov/35430106	50	Vaccine | Other	BNT162b2					No	Observational study	Prospective	Thailand	13-Apr-2022	
#01788	CT_35430141	The current status of thrombosis and anticoagulation therapy in patients with COVID-19 in Japan: From the CLOT-COVID study	35430141	https://doi.org/10.1016/j.jjcc.2022.03.015	https://pubmed.ncbi.nlm.nih.gov/35430141	2,894	Other						No	Cohort study	Retrospective	Japan	5-Apr-2022	
#01789	CT_35427999	High T-cell response rate after COVID-19 vaccination in belimumab and rituximab recipients	35427999	https://doi.org/10.1016/j.jaut.2022.102827	https://pubmed.ncbi.nlm.nih.gov/35427999	41	Drug(s)	Belimumab | Rituximab					No	Cohort study		Udine, Italy	11-Apr-2022	
#01790	CT_35422381	Outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs	35422381	https://doi.org/10.1016/j.jiac.2022.04.006	https://pubmed.ncbi.nlm.nih.gov/35422381	78	Drug(s)	Remdesivir | Favipiravir | Corticosteroids		01-Feb-2020	31-Mar-2021	425	No	Cohort study	Retrospective	Kanagawa, Japan	11-Apr-2022	

Table summarizing publications reporting on clinical and epidemiological studies (1800 publications listed, updated 24 June 2022), by Mahmoud Faheem, Yasmine Saied, Shaimaa Hegazy, Ramy K. Aziz. https://host-pathogen.net/covid/coctail.html

Serial #	Unique ID	Publication Title	PMID	DOI (if no PMID)	Link to NCBI	Number of patients	Type of intervention (Drug/ Vaccine/ other?)	Drug(s)/ treatment	Outcome (if available)	Start date (if known)	End date (if known)	Duration (in days)	Meta-analysis (Y/N)	Type of trial	Retrospective/ Prospective	Geographic location	Date of publication	Notes
Count >>>		1800	1799	1404	1800	1799	1578	548	401	1182	1182	1520	1800	1537	1141	1748	1800	99
#01791	CT_35422374	**Interleukin-6 inhibitors reduce mortality in coronavirus disease-2019: An individual patient data meta-analysis from randomized controlled trials**	35422374	https://doi.org/10.1016/j.ejim.2022.04.004	https://pubmed.ncbi.nlm.nih.gov/35422374	7,467	Drug(s)	IL-6 inhibitors					Yes	Systematic review, and meta-analysis from randomized controlled trials			7-Apr-2022	
#01792	CT_35436611	**Safety and immunogenicity of SpikoGen®, an advax-cpg55.2-adjuvanted sars-cov-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations**	35436611	https://doi.org/10.1016/j.cmi.2022.04.004	https://pubmed.ncbi.nlm.nih.gov/35436611	400	Vaccine	SpikoGen®					No	Randomized controlled trial	Prospective	Tehran, Iran	15-Apr-2022	
#01793	CT_35436751	**Assessment of changes in immune status linked to COVID-19 convalescent and its clinical severity in patients and uninfected exposed relatives**	35436751	https://doi.org/10.1016/j.imbio.2022.152216	https://pubmed.ncbi.nlm.nih.gov/35436751	339	Other			11-Mar-2020	11-Jun-2020	93	No	Cross-sectional study		Havana, Cuba	12-Apr-2022	
#01794	CT_35501178	**Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial**	35501178	https://doi.org/10.1016/j.vaccine.2022.04.035	https://pubmed.ncbi.nlm.nih.gov/35501178	200	Vaccine	NVX-CoV2373		21-Feb-2021	17-Mar-2021	25	No	Phase 1/2, randomized, observer-blind, placebo-controlled trial		Japan	29-Apr-2022	
#01795	CT_34958382	**Immunogenicity and Safety of a 3-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial**	34958382	https://doi.org/10.1093/infdis/jiab627	https://pubmed.ncbi.nlm.nih.gov/34958382	500	Vaccine						No	Phase 2 randomized, double-blind, placebo-controlled trial		China	27-Dec-2021	
#01796	CT_35489376	**Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial**	35489376	https://doi.org/10.1016/S2352-3018(22)00041-8	https://pubmed.ncbi.nlm.nih.gov/35489376	4,408	Vaccine	NVX-CoV2373		17-Aug-2020	25-Nov-2020	101	No	Randomised, observer-blinded, multicentre, placebo-controlled phase 2A/B trial		South Africa	27-Apr-2022	
#01797	CT_35015969	**A Randomized Clinical Trial Using CoronaVac or BNT162b2 Vaccine as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac**	35015969	https://doi.org/10.1164/rccm.202111-2655LE	https://pubmed.ncbi.nlm.nih.gov/35015969	360	Vaccine	CoronaVac | BNT162b2		18-Aug-2021	26-Oct-2021	70	No	Randomized clinical trial		Hong Kong, China	11-Jan-2022	
#01798	CT_35274326	**Survival of the hospitalized patients with COVID-19 receiving atorvastatin: A randomized clinical trial**	35274326	https://doi.org/10.1002/jmv.27710	https://pubmed.ncbi.nlm.nih.gov/35274326	154	Other			20-Apr-2021	20-May-2021	31	No	Single-blind, randomized clinical trial		Bojnurd, Iran	22-Mar-2022	
#01799	CT_35292989	**Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trial**	35292989	https://doi.org/10.1002/jmv.27724	https://pubmed.ncbi.nlm.nih.gov/35292989	63	Drug(s) | Other	Favipiravir | Interferon | Lopinavir/ritonavir					No	A randomized clinical trial		Bandar Abbas, Iran	24-Mar-2022	
#01800	CT_35320659	**Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine**	35320659	https://doi.org/10.1056/NEJMoa2200674	https://pubmed.ncbi.nlm.nih.gov/35320659	10,125	Vaccine	BNT162b2		01-Jul-2021	10-Aug-2021	41	No	An ongoing, placebo-controlled, randomized, phase 3 trial,	Prospective	USA	23-Mar-2022	